ANNUAL REPORT 2009-10 CONTENTS
ABOUT QIMR 1 RESEARCH DIVISIONS 14
QIMR at a glance 2 Cancer and Cell Biology 16
Research highlights 4 Genetics and Population Health 27
Awards and achievements 6 Immunology 43
Chairman’s report 8 Infectious Diseases 56
Members of Council 9 Mental Health 72
Director’s report 11 Joint Research 74
Cover: Tissue culture plate courtesy of phototonyphillips.com | Inside Cover: Aedan Roberts, PhD student, Familial Cancer Laboratory ABOUT US OUR QIMR is one of Australia’s largest and most successful PHILOSOPHY medical research institutes. Our researchers are investigating the genetic and environmental causes QIMR supports scientists who perform world-class of more than 40 diseases as well as developing new medical research aimed at improving the health and diagnostics, better treatments and prevention strategies. well-being of all people. The Institute’s diverse research program extends from tropical diseases to cancers to Indigenous health, mental health, obesity, HIV and asthma.
OUR VISION OUR LOGO To be a world renowned medical research institution. The QIMR logo is comprised of superimposed benzene rings which symbolise one of the fundamental molecular
arrangements of the chemicals which make up living things.
OUR MISSION Director – Professor Michael Good AO Deputy Director – Professor Adèle Green AC Better health through medical research. Patron – Her Excellency Ms Penelope Wensley AO www.qimr.edu.au | [email protected]
CORPORATE DIVISION 78 Patents 93
Trust report 83 Offi cial Committees 94
Members of Trust 84 Publications 96
POSTGRADUATE TRAINING 85 Lectures 108
Completed students 87 Staff 117
Student awards 88 Students 124
AWARDS 89 Visiting Scientists 125
Grants and funding 91 Organisational Structure 128
QIMR Annual Report 2009/10 1
100713_QIMR_AR10_FINAL.indd 1 22/09/10 10:04 AM QIMR AT A GLANCE
Supporting scientists who perform world-class medical research aimed at improving the health and well-being of all people.
PATENT PORTFOLIO BY CATEGORY RESEARCH AGREEMENTS
New treatment patents Research service agreements Vaccine patents Clinical trial agreements Delivery platform patents Commercialisation agreements Diagnostic patents Intellectual property agreements Drug target patents License agreements Others
2 QIMRQIMR Annual ReportReport 20092009/10/10 NHMRC GRANTS
$ Millions 20
16
12
8
4
0 2004 2005 2006 2007 2008 2009 2010
Grants Fellowships
FUNDRAISING REVENUE SCIENTIFIC PUBLICATIONS $ Millions 450 8.0 7.0 350 6.0 5.0 250 4.0 3.0 150 2.0 50 1.0 0 0 2004 2005 2006 2007 2008 2009 2010 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 Articles High Impacts Bequests/Gifts in Kind Sponsorship Event Revenue Donations & Gifts
STAFF NUMBERS QIMR TRUST RESEARCH FUNDING $ Millions 700 7.0 600 6.0 500 5.0 400 4.0 300 3.0 200 2.0 100 1.0 0 0 2006 2007 2008 2009 2010
Staff Students 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10
3 RESEARCH HIGHLIGHTS
• Identifi ed a new gene linked to schizophrenia and bipolar • Developed a more effective treatment against visceral disorder. leishmaniasis, using an antibody which stimulates the • Used an experimental immunotherapy treatment to help a immune system. bone marrow transplant patient overcome a life threatening • Discovered strong period pain and excess weight in infection. childhood doubles risk of endometriosis. • Effectively prevented mosquitoes from spreading dengue • Developed a simple blood test to monitor risk of contracting fever by infecting them with a naturally occurring bacterium, cytomegalovirus which is one of the leading causes of death Wolbachia. for transplant patients. • Assisted the World Health Organization identify the best • Identifi ed and successfully treated a previously undiagnosed malaria rapid diagnostic tests to control malaria. condition, an immune defect that leads to fulminant • Found two new genes that increase the risk of late onset infectious mononucleosis. Alzheimer’s disease. • Discovered the cumulative effect of lots of small genetic • Proved the consumption of moderate amounts of alcohol variations in many of our genes determine complex traits during pregnancy affects the expression of genes in the such as height. developing fetus and that these changes last into adulthood. • Identifi ed a new variant of a gene that helps regulate iron and • Identifi ed a potential new target for future anti-malarial drugs, haemoglobin levels. an enzyme used by the malaria parasite to obtain nutrients. • Commenced human clinical trials using live malaria to develop a method to test future anti-malarial drugs.
4 QIMR Annual Report 2009/10 CANCER RELATED RESEARCH Dr Kelly Landers, Conjoint Endocrine Laboratory HIGHLIGHTS
• Identifi ed two gene variants that double the risk of • Found that women who eat processed meat several times developing melanoma. a week increase their risk of developing ovarian cancer by 20%. • Discovered that missense mutations in DNA have a greater impact on breast cancer risk than previously thought. • Discovered the bacteria that cause stomach ulcers dramatically reduce the risk of oesophageal cancer. • Discovered the human liver fl uke (Opisthorchis viverrini) contributes to the development of liver cancer by secreting • Developed a compound from the rainforest that has granulin. shown signifi cant anti-cancer activity in animal cancers. • Identifi ed a gene variant associated with increased survival • Demonstrated increased risk of cancer risk in in breast cancer patients. haemochromatosis patients. • Found that drinking more than four cups a day of black, green or herbal tea reduces ovarian cancer risk by almost 30%.
5 AWARDS AND ACHIEVEMENTS
• QIMR received its largest-ever number of project grants • Professor Peter Visscher, head of QIMR’s Queensland from the National Health and Medical Research Council Statistical Genetics Laboratory, was honoured by being (NHMRC) with 26 successful applications representing elected to the Australian Academy of Science. a 41% success rate. This is signifi cantly higher than the • Associate Professor Maher Gandhi, head of Clinical national average of 23%. Immunohaematology won the Australian Society for • Professor Michael Good, QIMR Director received an Medical Research's (ASMR) Research Week Clinical Australia Fellowship providing $4 million over fi ve years Researcher Award for his work investigating the to continue his lifesaving work into combating malaria immunobiology of lymphoma. and streptococcus A – two of the world’s biggest killers. • Kimberley Jones, from the same laboratory won the Professor Good was also awarded the 2009 CSIRO Eureka Postgraduate Student Award. Prize for Leadership in Science and selected as a 2010 Queensland Great. • Dr Michelle Wykes was awarded a $300,000 Queensland Government Smart Futures Fellowship for research on the body’s immune response to malaria infection.
6 QIMR Annual Report 2009/10 Jatin Patel, PhD student, Conjoint Endocrine Laboratory
• Associate Professor Gail Garvey won the Our Women, • Dr Daniel Worthley was awarded the NHMRC RG Our State Award for Promoting Indigenous Women in Menzies Fellowship which is awarded to the highest recognition of QIMR’s Spotlighting Careers in Indigenous ranked postdoctoral fellowship application and a NHMRC Heath and Science Program. CJ Martin Postdoctoral Training Fellowship to undertake further research in the USA. • Dr Manuel Ferreira won the QIMR Post-doctoral award and was a fi nalist in the ASMR 2010 Post-doctoral awards. • Dr Stuart MacGregor won the prestigious Ruth Stephens Dr Ferreira was also successful in securing NHMRC funding Gani Medal of the Australian Academy of Science. to embark on Australia’s largest genetic asthma study. • Dr Li Yuesheng was awarded a Future Fellowship by • Dr Alberto Pinzón-Charry, won a 2009 Queensland Australian Research Council (ARC) and is the only scientist Young Tall Poppy Science Award for excellence in research from Queensland to receive the Howard Hughes Medical and public engagement. Institute Fellowship which has been extended until 2011.
7 CHAIRMAN'S REPORT
I was honoured when approached by the Premier of Queensland. The Honourable Anna Bligh, in 2009 to take up the position of Chair of the QIMR Council. As Vice Chancellor of The University of Queensland from 1996 to 2007, I have been involved in the development of many major new research institutes including the Institute for Molecular Bioscience and the Queensland Brain Institute and am aware of the challenges facing a growing QIMR.
The last 12 months has seen QIMR move into a period of signifi cant growth with construction commencing on the Smart State Medical Research Centre, a 13 fl oor research facility due for completion in 2012. The fi rst sod was turned by Premier Bligh on 9 February 2010.
The state-of-the-art facility Professor John Hay AC - QIMR Council Chair will accommodate 20 new Our research program, publications and competitive funding research laboratories, continues to grow and attract world-class researchers and students from around the globe.
increasing QIMR’s staff During his time as Director, Michael was instrumental in securing funding for the new building; established QIMR’s capacity by more than 60 Indigenous Health Research Program, and a new Division of Mental Health Research. The Institute’s successful education percent to around 1,200. program is testament to his commitment to inspiring the scientists of tomorrow. The project is not only an important asset to QIMR, but also The past year also saw the departure of the General to the wider community with the research completed within its Manager, Dr Julie-Anne Tarr who after two years at QIMR walls benefi ting the health and well-being of all. took up a position with the Queensland University of The Queensland Government has shown its long term Technology. During her time at QIMR, Dr Tarr was heavily commitment to our endeavours by substantially increasing our involved in securing funding for the construction of the new core fi nancial support. This generous commitment will allow $180 million Smart State Medical Research Centre and the recruitment of fi rst class scientists and the establishment of overseeing the re-organisation of the Corporate Division. additional innovative projects. The QIMR Council is grateful for the continued support of the It has also been a time of change as we search for a new QIMR Trust and the many volunteers and supporters in the Director to take over the leadership of the Institute following the community. resignation of Professor Michael Good. Michael leaves after ten years as Director to take up a prestigious Australia Fellowship I look forward to working with Council members and our at Griffi th University and return to the Laboratory bench to dedicated staff in order to continue to build on QIMR’s follow his passion and life time work – developing vaccines for achievements as one of the world’s leading medical research malaria and streptococcus A. institutes. I would like to take this opportunity of thanking Michael whose QIMR Council Chair leadership helped position QIMR as a global research leader. Professor John Hay AC
8 QIMR Annual Report 2009/10 COUNCIL MEMBERS
Professor John Hay Professor Emeritus Bryan Campbell BA (Hons) (Western Australia and Cambridge), MA (Cambridge), AM MD BS FRACP FRACMA PhD (Western Australia), Hon LittD Professor Campbell was formerly (Deakin), Hon DLitt. (UWA); Hon Chief Health Offi cer Queensland DU (QUT); Hon LLD (Queensland); and Head of The University of FAHA; FACE; FAIM; FQA (Chair from Queensland Medical School. He 24/09/09) has been a Councillor of the Royal Professor Hay was Vice-Chancellor of The University Australasian College of Physicians, the Royal Australian of Queensland from 1996-2007. In that time he led the College of Medical Administrators and a member of the development of many major new research institutes including National Health and Medical Research Council. He was Deputy the Institute for Molecular Bioscience, the Australian Institute Chair of the Australian Health Ethics Committee and a member of Bioengineering and Nanotechnology and the Queensland of the NHMRC Embryo Research Licensing Committee. Brain Institute. He was also instrumental in securing funding for Professor Campbell has been a member of the Queensland the Translational Research Institute to be built at the Princess Institute of Medical Research Council for over 20 years. Alexandra Hospital. He has led both Deakin University and Professor Campbell is also a member of the QIMR Finance The University of Queensland to be named Australian University and Audit Committee. of the Year by the Good Universities Guide. Professor Hay is Chair of nine boards, including QIMR to which he was appointed by the Queensland Government in September 2009. Professor Judith Clements BAppSc MAppSc PhD Mr Christopher Coyne Professor Clements has over 20 years experience as a basic LLB (Acting Chair to 23/09/09) researcher in biomedical research, Christopher Coyne is a solicitor of primarily in the general fi eld of the Supreme Court of Queensland, molecular endocrinology. Her an accredited specialist in the fi eld of current research seeks understanding of the molecular basis Commercial Litigation, specialising in of hormone dependent and urogenital cancers such as insurance law, health law, corporate prostate, breast, ovarian and endometrial carcinoma. She is governance and risk management. Following his admission currently Scientifi c Director of the Australian Prostate Cancer as a solicitor in 1979 he practised law in Brisbane and was a Research Centre−Queensland and Program Leader of the partner in the national law fi rm Clayton Utz from 1984 to 2004. Hormone-Dependent Cancer Program within the Institute of Chris now practices on his own account. He was appointed Health and Biomedical Innovation at the Queensland University an Adjunct Professor of The University of Queensland School of Technology. She is also an NHMRC Principal Research of Law in 2002. Chris is Board Chairman of Lexon Insurance Fellow and NHMRC Academy member (2009-2010). In 2007 Ltd (Queensland Law Society, Singapore Captive Insurer), a Professor Clements was awarded the prestigious international Director of the Incorporated Council of Law Reporting for the Frey-Werle Foundation Gold Medal for her signifi cant State of Queensland, Past President Medico-Legal Society of contributions to the kallikrein protease fi eld. Professor Queensland and Australian Insurance Law Association and Clements is Chair of the QIMR Appointment and Promotions former legal member Australian Health Ethics Committee. Committee. Chris is a sessional member of the Queensland Civil and Administrative Tribunal. Chris is also a member of the QIMR Personnel Administration Committee.
9 COUNCIL MEMBERS (CONTINUED)
Mr Paul Fennelly Associate Professor Paula Marlton BA LLB MB BS (Hons I) FRACP FRCPA Paul Fennelly has wide experience Paula Marlton is the Head of in fi nancial management, business Leukaemia and Lymphoma Services and public administration. He is at the Princess Alexandra Hospital an executive with Hastings Funds where she is also Deputy Director Management which is a member of Haematology. Her previous of the Westpac Group. His focus is appointments include three years on major equity investments, primarily in social and economic at the MD Anderson Cancer Centre in Houston, Texas. infrastructure. From 2002 - 2006 Mr Fennelly was Director- She has extensive experience in clinical research including General of the then Department of State Development; the role of principal investigator for national multi-centre concurrently he served as Queensland's Co-ordinator-General. trials and supervisor of molecular translational research Prior to joining the Queensland Government he was Victorian associated with trials. She was the founding Chair of the Director of the Australian Industry Group which is the nation's Australasian Leukaemia and Lymphoma Group Laboratory largest industry association. Mr Fennelly is the Chair of the Science Committee and has established and continues to QIMR Finance and Audit Committee and Chair of the QIMR direct the PwC Leukaemia and Lymphoma Tissue Bank. Her Personnel Administration Committee. other professional roles include Medical Advisor and Board member of the Leukaemia Foundation, member of several Drug Advisory Boards and Government and College Advisory Professor Lyn Griffi ths Committees as well as a wide range of academic and clinical service roles. BSc (Hons) PhD Professor Griffi ths is Director of the Griffi th Health Institute and Dr Jeannette Young the Genomics Research Centre at MB BS FRACMA MBA AFACHSE Griffi th University. She has expertise in human molecular genetics, Dr Jeannette Young is the Chief undertaking research to map and Health Offi cer for Queensland, a role identify genes involved in common complex human disorders, she has fi lled since August 2005. including studies on migraine, cardio-vascular disease risk, Prior to this, she held the position multiple sclerosis and certain types of cancer. Her research of Executive Director of Medical has been well funded by national competitive grants and Services at the Princess Alexandra industry and she has authored 176 peer-reviewed publications Hospital. Today she is responsible for such matters as disaster to date in molecular genetics international journals as well as planning and response, retrieval services, licensing of Private supervising 24 PhD students to completion. She is a current Hospitals, organ and tissue donation services, offender health Queensland President Human Genetics Society Australasia, services, population health services and mental health policy past Australian Society of Medical Research Director, current and legislation. Dr Young is a member of numerous State Member and past Chair of the Scientifi c Program Committee and National committees and Boards, some of which include for the International Congress of Human Genetics and has the Queensland Board of the Medical Board of Australia, the been awarded the Centenary Medal for Distinguished Service NHMRC and the Australian Health Protection Committee. to Education and Medical Research.
10 QIMRR Annual Report 202009/1009/10 Sod turning ceremony of the Smart State Medical Research Centre with the Premier of Queensland, The Honourable Anna Bligh MP, Professor John Hay and Professor Michael Good.
DIRECTOR'S REPORT
As this is my last report as Director, I thought it appropriate to Manufacturing Practice facility, Q-Gen, charged with making refl ect on some of the changes at the Institute and some of therapies for experimental human use. With the establishment the great contributions made by QIMR staff and students. It of the clinical trials company, Q-Pharm, clinical research has been an enormous honour and privilege to lead so many received a signifi cant boost and made us far more competitive dedicated and brilliant scientists, support staff and students in translational research. over the last ten years. I thank them all for the very generous The opening of the Clive Berghofer Cancer Research Centre support and friendship they have shown me, not just over the (CBCRC) also coincided with the establishment of our decade during which I served as Director, but over the 22 years Indigenous Health Research Program, a highlight of which that I have worked at the Institute. I have seen many changes has been the cross-cultural Spotlight on Science program in those years as we moved from the old building on Bramston that brings Aboriginal and Torres Strait Islander high school Terrace in 1991 to the new Bancroft Centre and under the students for a week research immersion experience. This has leadership of Lawrie Powell embarked on clinical research. been co-sponsored by industry and Education Queensland With the generosity of Chuck Feeney and the support of and has now resulted in 80 students and 14 teachers from Queensland and Federal governments we secured funding all parts of Queensland learning about QIMR research fi rst for the Berghofer Building which opened early in my tenure hand. The Indigenous Health Research Program brought an as Director. That building provided the impetus to further indigenous focus to research studies across all disciplines expand clinical research and the NHMRC funded our Good including cancer, vaccine research, mental health and genetics.
11 DIRECTOR'S REPORT (CONTINUED)
While the CBCRC gave us more space, the hard work and We identifi ed genes that increase the risk of developing ingenuity of our staff gave us the extra grant funding that melanoma and breast cancer, identifi ed a protective action enabled us to fi ll the new building while maintaining our focus against oesophageal cancer by the organisms responsible for on the common but important conditions that affect human stomach ulcers, as well as helping investigate the mechanism health. We saw our grant income from NHMRC increase over of a natural anti-cancer compound that has since been used the last ten years from approximately $5 million to $30 million successfully to treat tumours in animals. today, this year receiving our largest-ever number of project Chuck Feeney, along with the State and Federal governments, grants with 26 successful applications. has now provided funding for a new building, the $180 million At the same time the number of our publications in high impact Smart State Medical Research Centre. This will house our factor journals increased three-fold. This year, we published newest Division, the Mental Health Research Division and our 390 peer reviewed research papers with 50 of these being in new Education Centre, and at the same time provide much the most highly cited journals. The number of senior scientists needed space for our other research programs when it opens who held externally-funded fellowships increased from four to in 2012. Securing the Mental Health Research Division and its 30 and at the same time, our younger scientifi c staff have been inaugural Head, Associate Professor Michael Breakspear, has remarkably successful, perhaps best illustrated by the awards been a wonderful result for the campus and demonstrated how won by QIMR at the gala ASMR - Premier of Queensland annual the Institute and the Royal Brisbane and Women’s Hospital are awards showcase. This year, Associate Professor Maher Gandhi working so well together. In total, 14 of our scientists now also won the Clinical Research Award and the Postgraduate Student hold senior clinical positions, mostly at the RBWH. Award went to his PhD student Kimberly Jones. The High School Education Program currently hosts over The success of our staff continues to be recognised and 1,400 high school students every year for a daylong seminar rewarded. Included among high achievements Professor Peter program and it is our hope that many of these bright students Visscher was honoured by being elected to the Australian will return in later years to undertake research at the Institute Academy of Science, Dr Michelle Wykes awarded a Smart or elsewhere. Our staff and students are to be congratulated Futures Fellowship for her research into malaria infection, and for the fervor with which they welcome and enthuse the school Associate Professor Gail Garvey won the Our Women, Our students by explaining their own research and why they have State award for promoting Indigenous Women. chosen science as a career. Australia is a great country in which to do research and QIMR Our research achievements is one of our nation’s leading institutions. However, we must all work harder to convince governments of the need to invest make QIMR one of the most further in medical research. The value of medical research is best summed up in the statement that a child born today will successful research institutes live on average three months longer than a child born on this day only one year ago. This trend is due to research leading to new public health knowledge, new drugs, diagnostics, in Australia. vaccines and medical and health procedures. This year, we embarked on clinical trials to develop a new The public have been extremely generous in their support of technique for testing potential anti-malaria drugs, used natural QIMR and I thank them most sincerely. I would especially like occurring bacteria to control the spread of Dengue fever, and to thank Chuck Feeney, Marno Parsons, Sean Ryan, Royce identifi ed two new genes that increase the risk of developing Blackburne and Clive Berghofer, and many others for their Alzheimer’s disease. ongoing support. With 1 in 2 Australian suffering from cancer during their lifetime As a non-profi t organisation, all our work is funded by we continue to dedicate half of our research to understanding grants and donations and I strongly believe it is our duty the genetic and environmental causes and developing new as researchers to keep the public informed about our treatments for this horrible disease. achievements.
12 QIMR Annual Report 2009/10 After ten years, it is time to giggivev anothernoot r ppersonrson tththee oopopportunityortu One of the highlights of my to lead the Institute. My plann iiss to ffocusocus my efforteffortss on mmy own research program to developlop vaccines for mmalaria and job has been the opportunity rheumatic heart disease with the support fromom an Australia to meet so many people Fellowship. My relocation to Griffi th Universityity will sstrengthen the already strong bonds that exist between QIMR and the outside the Institute who University. The Institute has been very kind to me and very supportive and the friendships and research collaborations have supported us and that I have here mean a great deal to me. My prayers will always be for the ongoing success of the Institute’s staff and explain to them the nature of students as they work to make this world a healthier place. our research and what we Professor Michael Good AO have discovered. That has Director been a true privilege.
(Left to Right) The Honourable Anna Bligh MP, Helga and Chuck Feeney, Professor Michael Good and Clive Berghofer
13 RESEARCH
CANCER AND CELL BIOLOGY
GENETICS AND POPULATION HEALTH
IMMUNOLOGY
INFECTIOUS DISEASES
MENTAL HEALTH
JOINT PROGRAMS
14 QIMR Annual Report 2009/10 Peer recognition is one of the most satisfying rewards for scientists, and my election as Fellow of the Australian Academy of Science is probably the ultimate form of peer recognition in Australia. It is a refl ection on the fantastic bunch of people that I have had the pleasure and privilege of working with throughout my career.
Professor Peter Visscher, Head of Queensland Statistical Genetics Laboratory
15 CANCER AND CELL BIOLOGY DIVISION
DIVISION CHAIR: PROFESSOR GREG ANDERSON
The Cancer and Cell Biology Division consists of ten laboratories located in the Bancroft Centre and the Clive Berghofer Cancer Research Centre. Research carried out in the Division covers a variety of topics from specifi c investigations of the molecular and genetic aberrations of tumour cells, to clinical and pathological studies of cancers and metabolic disorders. Scientists in the Division are particularly devoted to translating research fi ndings into clinical outcomes.
Tumours studied include melanoma, leukaemia, breast, prostate, liver and colorectal cancer. Research themes cover the normal mechanisms that control cell growth, cell division and inheritance; the DNA damage response and DNA repair; mechanisms of iron homeostasis; development of mouse models to study in vitro functions of cancer genes; developing screening tools for early detection of cancers; devising strategies for cancer treatment; and investigation of liver disease in both the adult and paediatric populations. The Division has strong collaborative links with other QIMR Divisions, the Royal Brisbane and Women’s Hospital and The University of Queensland.
Research highlights for the past year include developing a compound from the rainforest that has shown signifi cant anti-cancer activity in animal cancers; completing a study demonstrating the clinical utility of performing liver biopsies to detect fi brosis in children with cystic brosis;fi demonstrating increased cancer risk in haemochromatosis patients and producing mouse models to investigate colon cancer development, melanoma formation and ataxia with oculomotor apraxia type 2 (AOA2).
16 QIMR Annual Report 2009/10 CANCER AND CELL BIOLOGY DIVISION DRUG DISCOVERY GROUP Laboratory Head: Professor Peter Parsons This Group combines expertise in cancer biology with genomics and drug discovery. Cell communication networks in serious cancers reveal responses that provide opportunities for prevention and treatment.
HIGHLIGHTS
• Identifi ed new markers of melanoma invasion. A new target, alphaB-crystallin was identifi ed. It is lost in perineural invasion of cutaneous squamous cell carcinoma • Identifi ed a target lost in perineural invasion of cutaneous of the head and neck, compared to cutaneous squamous squamous cell carcinoma of the head and neck. cell carcinoma that does not invade neurons. This target was • Developed a compound from the rainforest that has shown previously found to be highly expressed in head and neck signifi cant anti-cancer activity in animal cancers. squamous cell carcinoma. The overall theme of the Drug Discovery Group is to identify Work has focused on a QBiotics compound called EBC- and study the function of genes that are important in the 46 that has very signifi cant anti-cancer activity against development and treatment of certain cancers, with the longer transplanted tumours in animal models, as well as against a term aim of discovering agents that can be aimed at specifi c wide range of spontaneous tumours in companion animals. targets. Several such genes have been identifi ed in melanoma Studies of the mechanism of action have so far revealed the and squamous cell carcinoma of the head and neck and are primary target of the compound and given important clues being followed up at the functional level. about the cell signalling pathways that might be relevant to its action. EBC-46 is a plant product originating from the Recent research has found that MIC-1 is controlled by a Queensland rainforest and this group has developed a viable pathway that is activated in almost all melanomas. Further, method for producing the compound in pure form from it was found that H-cadherin may be controlled by the same cultivated plants. pathway that alters the invasion of melanoma cells.
Oscar pre-treatment; 15 days and 6 weeks post treatment
17 Dr Richard Ruddell, Hepatic Fibrosis Laboratory
CANCER AND CELL BIOLOGY DIVISION HEPATIC FIBROSIS Laboratory Head: Associate Professor Grant Ramm The Hepatic Fibrosis Laboratory investigates the cellular and molecular mechanisms of scar tissue formation in the liver, such as the iron overload disease haemochromatosis, that leads to fi brosis and cirrhosis in adults, and cystic fi brosis and biliary atresia in children. HIGHLIGHTS This year, in a collaboration with paediatric surgeons at • Discovered the role of neutrophils in liver repair. Brown University, Rhode Island, a study found a major role • Completed a study which demonstrated the clinical utility for neutrophils in the resorption of this scar tissue in an animal of performing liver biopsies to detect liver scarring (fi brosis) model that mimics liver disease in children including cystic in children with cystic fi brosis who are suspected of having fi brosis (CF) and biliary atresia. When the bile duct obstruction serious liver disease. is removed in this model, these cells assist in liver repair by producing matrix-degrading metalloproteinase enzymes (MMP- • Demonstrated that current methods to detect liver scarring 8). MMP-8 act as collagenases to digest fi brillar collagens and predict the development of liver disease complications deposited by hepatic stellate cells. are insensitive and non-specifi c. In a recently completed clinical trial, collaborative research with In an animal model that mimics cystic fi brosis liver disease the Royal Children's Hospital demonstrated that liver fi brosis and biliary atresia, a type of blood cell called a neutrophil has identifi ed via liver biopsy, predicts the future development been shown to assist with the repair of injured and scarred liver of clinically signifi cant liver disease (portal hypertension), in tissue. This is achieved through the production of enzymes children with CF. Current clinical modalities used in evaluating called collagenases, which digest scar tissue and allow the liver liver disease in CF, such as clinical examination, blood tests to heal itself. for elevated liver enzymes or liver ultrasound scanning, do not The hepatic stellate cell is one of the principal regulators of liver predict liver fi brosis or the development of portal hypertension. scar (fi brosis) formation via the deposition of fi brillar collagens in Liver biopsy is now proposed as the gold standard to detect chronic liver disease. liver scarring and thus may be adopted clinically to better manage patient care and assist in developing more targeted medical interventions in children with CF.
18 QIMR Annual Report 2009/10 CANCER AND CELL BIOLOGY DIVISION IRON METABOLISM Laboratory Head: Professor Greg Anderson The Iron Metabolism Laboratory focuses on understanding the homeostasis of iron in the body and the natural history of disorders of iron metabolism such as the iron loading disease haemochromatosis.
HIGHLIGHTS
• Identifi ed the iron reductase enzyme Dcytb as a modifi er of to understand how absorption is altered in disorders of iron hereditary haemochromatosis severity. metabolism such as haemochromatosis, thalassaemia and haemolytic anaemia. • Demonstrated increased cancer risk in haemochromatosis patients. Much effort has been directed towards understanding physiological variations in iron absorption at the molecular • Defi ned disease progression and penetrance in hereditary level. Key recent studies have examined how iron absorption haemochromatosis. and its major regulator, hepcidin, are altered in neonates • Examined iron homeostasis in chronic haemolytic anaemia. and during pregnancy, and in chronic haemolytic anaemia and thalassaemia. The Laboratory also maintains a strong • Identifi ed key factors involved in the modulating expression interest in the pathogenesis, penetrance and genetics of the of the iron regulatory hormone hepcidin. iron loading disorder haemochromatosis and has continued Iron is essential for a large number of critical cellular processes to study the natural history of the disease. During the year, a but its concentration in the body must be kept within defi ned series of important new studies have commenced including an limits. Too little iron can result in anaemia while too much can analysis of iron-related oxidative stress in haemochromatosis cause damage to vital organs such as the liver and heart. A to provide an objective endpoint for phlebotomy therapy, central goal of the Iron Metabolism Laboratory is to understand defi ning the role iron plays in lung injury in cystic fi brosis, and the mechanisms of cellular iron transport and the way in developing novel oral iron supplements that deliver iron more which these processes are regulated. A particular theme is effi ciently and with less toxicity than current preparations. to describe the pathways of intestinal iron absorption and
Rat duodenal villi
19 CANCER AND CELL BIOLOGY DIVISION LEUKAEMIA FOUNDATION Laboratory Head: Professor Andrew Boyd
different cancers is being explored using biochemical studies HIGHLIGHTS and animal models. As part of the work on glioma, the • Completed preclinical testing of an antibody against the Laboratory has discovered a key role for Mcl-1 in cell survival EphA3 protein for treatment of leukaemia. and has also explored the loss of a key transcription factor in glioma expression. • Identifi ed a key role for Mcl-1 in cell survival and explored Preclinical studies on antibodies to Eph proteins have the loss of a key transcription factor in glioma expression. continued. In particular, an antibody to EphA3, raised initially • Completed preclinical testing of novel Eph-based therapies against a childhood leukaemia, has been tested in leukaemia for spinal cord injury. and other cancer models. In collaboration with laboratories in Melbourne and a US biotech, one antibody has completed Antibodies to other EphA proteins have been investigated preclinical testing and is expected to go into a clinical trial in a variety of human tumours, complementing studies of within a year. expression in clinical samples. Eph proteins have oncogenic Investigation of EphA4 function has revealed a critical role roles in some cancers, including leukaemia, melanoma and in spinal cord injury. In collaboration with Queensland Brain glioma. In others, they appear to have tumour suppressor Institute, inhibitors of EphA4 in spinal cord injury models in roles, especially those of epithelial cancers. The function in mice and rats are being tested.
The Leukaemia Foundation of Queensland Laboratory is seeking to understand the role of critical cellular proteins in the causation and evolution of leukaemia and other cancers.
Corticospinal nerves in mice regrow past the lesion site following treatment for spinal cord injury.
20 QIMR Annual Report 2009/10 CANCER AND CELL BIOLOGY DIVISION MEMBRANE TRANSPORT Laboratory Head: Associate Professor Nathan Subramaniam This laboratory studies how iron metabolism is regulated by the liver. Identifi cation of the molecules involved in iron metabolism, and defi ning the way they work has major implications for the treatment of iron-related disorders such as hereditary haemochromatosis and anaemia.
HIGHLIGHTS In the fi rst study of its kind, it was shown that deletion of the genes HFE and TFR2, mutations of which cause hereditary • Established that loss of both HFE and transferrin receptor haemochromatosis, lead to severe iron loading typical of 2 genes causes severe iron loading similar to that observed juvenile haemochromatosis. The loss of these genes also in juvenile haemochromatosis. causes the abnormal regulation of the iron hormone hepcidin. • Demonstrated that hepcidin is misregulated in the absence In collaboration with Dr Jon Harris (Queensland University of HFE and transferrin receptor 2 genes. of Technology), it was shown that mutations leading to the macrophage cell iron phenotype of ferroportin disease affect • Showed that chronic infl ammation may not be the primary ability to transport iron and not its localisation. In addition, cause of the anaemia seen in schistosomiasis. mutations which affect the function of ferroportin are • Demonstrated that increased availability of iron may lead to responsible for the phenotypic variability of ferroportin disease. increased disease severity in schistosomiasis. Protein modelling suggested that ferroportin disease mutations cluster in specifi c regions according to phenotype. • Established that mutations leading to the macrophage cell iron phenotype of ferroportin disease affect its iron In collaboration with the Parasite Cell Biology Laboratory, transport activity. a study was conducted into the effect of schistosomiasis infection in the presence of increased iron. These studies • Showed that differences in the functional consequences of suggest that chronic infl ammation may not be the primary mutations in ferroportin are responsible for the phenotypic cause of the anaemia observed in schistosomiasis and that variability of ferroportin disease. increased iron during infection causes increased liver scarring. • Demonstrated that ferroportin disease mutations cluster in A collaborative study with Dr Kerry Richards and Professor specifi c regions according to phenotype. Robin Mortimer (Conjoint Endocrine Laboratory, RBWH) The major focus is aimed at understanding how iron levels showed that the human placenta secretes and internalises the in the body are regulated, the genes involved, their mechanism serum protein transthyretin. This internalisation is increased in of action and the role iron plays in various disorders including the presence of thyroid hormone which enters as a complex cancer. with transthyretin.
Denny Muslim, PhD student, Membrane Transport Laboratory
21 CANCER AND CELL BIOLOGY DIVISION CANCER COUNCIL QUEENSLAND (CCQ) TRANSGENICS Laboratory Head: Associate Professor Graham Kay The CCQ Transgenics Laboratory studies the epigenetic mechanisms that modulate gene expression and the role of tumour suppressor genes in preventing cancer during normal development. HIGHLIGHTS
• Revealed a role for Smchd1 in the control of both Using next generation sequencing to compare changes in autosomal and X-linked gene expression. DNA and chromatin modifi cations in the presence and absence of Smchd1, researchers are now endeavouring to determine • Created a mouse model that contains different the mechanism by which SmchD1 regulates gene expression. combinations of pocket protein loss in their melanocytes. Other studies in the Laboratory are concentrating on the Epigenetic control of gene expression is mediated by role of tumour suppressor genes in the cascade of events mechanisms that modulate access of the transcription leading to cancer with an emphasis on melanoma. One of machinery to the genome. Previously, the Laboratory showed the most frequently mutated tumour suppressor genes in that Smchd1 play an essential role in X-inactivation, an familial melanoma is Cdkn2a, which can act to simultaneously epigenetic process that involves silencing one of the two deregulate both the pocket protein family of proteins (Rb1, X chromosomes in females. Using microarray expression p107 and p130) and the Arf/p53 regulatory pathway. To analysis, results show that Smchd1 is also involved in silencing evaluate the tumour suppressive interactions of each pathway the expression of numerous autosomal genes in both males in melanoma formation, a mouse model was created and females. Some of these genes are regulated in a manner containing different combinations of pocket protein loss, both akin to that involved in X-inactivation, suggesting that Smchd1 alone and in combination with Arf/p53, and the phenotypes of may regulate autosomal and X-linked gene expression through these mouse strains and their melanocytes are being determined. a common mechanism.
Live cell imaging showing single green spot of Smchd1-GFP localising to the inactive X chromosome in female cells.
22 QIMR Annual Report 2009/10 CANCER AND CELL BIOLOGY DIVISION RADIATION BIOLOGY AND ONCOLOGY Laboratory Head: Professor Martin Lavin The focus of this laboratory is DNA damage response and its role in maintaining the integrity of DNA to minimise the risk of cancer and neurodegeneration. HIGHLIGHTS
• Described a novel activity for senataxin defective in ataxia including ataxia with oculomotor apraxia type 1 and 2 (AOA1 with oculomotor apraxia type 2 (AOA2). and AOA2). • Generated a mouse model for AOA2. Progress has been made in describing additional autophosphorylation sites important in the activation of ATM. • Investigated the role for aprataxin defective in ataxia with In collaboration with Thilo Dork (Hannover Medical School), oculomotor apraxia type 1 (AOA1) in oxidative stress. the fi rst Rad50 defi cient patient has been identifi ed. Rad50 • Described the role for aprataxin in DNA double strand represents a member of the Mre11 complex that acts as a break repair. sensor of DNA double strand breaks, and is a new substrate for ATM. Studies are underway to investigate the functional • Developed a sensitive probe for oxidative stress. signifi cance of Rad50 phosphorylation in response to DNA • Generated a mouse model for SMG1 involved in non-sense damage. mediated decay of abnormal mRNAs. The fi rst comprehensive description of the characteristics of The major objective of this laboratory is to investigate the senataxin, the protein defective in AOA2, has been reported. mechanisms that maintain the integrity of the genome to This protein has a role in protecting cells against this form of minimise the risk of cancer and other pathologies. stress and is also involved in transcriptional control and mRNA Over the years, the Laboratory has focused on the human splicing. A mouse model for AOA2 has been generated, which genetic disorder ataxia-telangiectasia (A-T) as a model system will be of great assistance for investigating neurodegeneration. to investigate cancer development and neurogeneration. More In collaboration with Professor Gardiner (UQ), important recently, these studies have been extended to include several progress has been made in developing biomarkers for other disorders that overlap with A-T in their clinical phenotype prostate cancer.
Professor Martin Lavin, Head of Radiation Biology and Oncology Laboratory
23 CANCER AND CELL BIOLOGY DIVISION RBWH GASTROENTEROLOGY Laboratory Head: Professor Barbara Leggett This laboratory identifi es genetic changes which defi ne distinct subtypes of colon cancers and premalignant polyps with the aim of predicting the clinical behaviour of these tumours.
HIGHLIGHTS
• Completed a genome-wide expression profi ling study of 38 serrated colorectal polyps and 100 colorectal cancers. • Established a protocol for genome-wide methylation profi ling and completed a proof of principle pilot study of ten colorectal cancers. • Identifi ed frequent chromosomal instability in tumours with a BRAF mutation that are microsatellite stable. • Commenced a new study to examine molecular changes underlying the development of colorectal polyps. • Initiated a BRAF mutant mouse model to investigate colon cancer development.
Different types of colorectal polyps may progress to cancer and this is accompanied by defi ned molecular changes. A better understanding of the molecular changes that underlie the development of different types of colorectal polyps and cancers will improve patient management and ultimately lead to better therapy options. Recent research efforts have focused on a particularly aggressive form of colorectal cancer that has mutation of the BRAF oncogene in the absence of microsatellite instability. The Laboratory has found that chromosomal instability is common in this cancer type and this may contribute to the worse outcome observed for these patients. A large, genome-wide study is currently underway using expression and methylation microarrays to evaluate key molecular pathways altered in these cancers.
Analysis of methylation status of IGFBP7 and CIMP in serrated polyps showed that IGFBP7 methylation is associated with large, proximal, advanced serrated polyps (ASPs). In addition, IGFBP7 methylation was observed in 68.4% of BRAF mutant/ CIMP positive ASPs. The Laboratory also generated inducible shRNA IGFBP7 knockdown retroviral vectors to analyse IGFBP7 senescence function in vitro. A BRAF mutant mouse model that has inducible colon-specifi c Braf V600E mutant overexpression is being assessed to determine the contribution of BRAF to the initiation or progression of colon cancer.
Immunohistochemical staining of colorectal cancer
24 QIMR Annual Report 2009/10 CANCER AND CELL BIOLOGY DIVISION SIGNAL TRANSDUCTION Laboratory Head: Professor Kum Kum Khanna This laboratory researches signal transduction pathways involved in the detection, signalling or repair of DNA damage and seeks other genes in these pathways which might have similar involvement in cancer susceptibility by preventing the generation of mutations in DNA.
HIGHLIGHTS
• Found that hSSB1 and hSSB2 may have a function in the A novel role was identifi ed for Pin1, a peptidyl-prolyl isomerase maintenance of genomic stability. which is deregulated in many tumours, in cytokinesis. Furthermore, there is evidence that Pin1 regulates the fi nal • Identifi ed a novel role of Pin1 in the regulation of the fi nal stages of cytokinesis by binding to centrosome protein 55 stage of cell division cycle that might provide an explanation kDa (Cep55), an essential component of the cytokinetic ring for the link between dysregulated Pin1 levels and cancer. discovered previously. These data are the fi rst evidence that • Identifi ed DNA damage-induced phosphorylation of Exo-1 Pin1 regulates cytokinesis and may provide a mechanistic and its role in the regulation of DNA damage repair. explanation as to how pathologic levels of Pin1 can stimulate tumour formation. • Characterised centrobin as a novel regulator of the cell division cycle, and in particular mitosis. Centrobin, a recently identifi ed centrosomal protein, was found to have a novel role as a regulator of centrosome and spindle • Demonstrated that cells defi cient in SBP2 accumulate integrity. Centrobin-depleted cells have unfocused spindle oxidative damage that might predispose them to cancer, poles and they fail to satisfy spindle assembly checkpoint. neurodegeneration and premature ageing. Furthermore, interphase microtubules were observed to be In collaboration with Michele Pagano and Weidong Wang, clustered around the centrosome in centrobin-depleted cells integrator subunit 3 (INTS3) was identifi ed as a major partner of compared to more diffused localisation seen in control cells. hSSB1 and hSSB2. The complex also contains many additional The microtubule instability phenotype might be due to an proteins that are suggestive of a role for hSSB1 in damage- indirect effect of centrobin on microtubule growth. induced transcription. Experiments are currently underway to investigate the pathophysiological roles of SSB1 and SSB2, having generated conditional knockout mice for these proteins.
25 CANCER AND CELL BIOLOGY DIVISION SKIN CARCINOGENESIS Laboratory Head: Dr Graeme Walker This laboratory is interested in the interaction of genetic and environmental factors in melanoma development and in particular how ultraviolet radiation (UV) initiates melanoma. HIGHLIGHTS
• Discovered that naevus (mole) development in mice is It was discovered that some of these cytokines also infl uence caused by mutation of the same gene (CDK4) that is melanocytes, which can migrate out of hair follicles to the responsible for melanoma susceptibility in melanoma-prone sunburnt area of skin. These cytokines may be important in the families. development of a melanoma subtype (lentigo maligna) that is caused by chronic sun exposure and proposed emanate from • Investigated how melanocytes move up to the burnt area follicular melanocytes. of skin after sunburn. In contrast, this melanocyte activation may be helpful for The development of naevi (moles) is the strongest risk factor vitiligo (loss of melanocytes). Although not associated with for the development of melanoma. The laboratory has studied excess skin cancer, white patches can create psychological mice that have gene mutations that are important in human and social stigma especially for darker skinned individuals. melanoma. One gene, CDK4, was found to predispose mice Repigmentation involves activation of follicular melanocytes to the developing naevi. This gene regulates cell proliferation and their migration up into and outwards along the epidermis. in general, and investigations are ongoing as to why its Treatments such as phototherapy (UV) and corticosteroids are deregulation has such a special effect on melanocytes. often not successful, and rarely long lasting. Therefore knowing In addition to mechanisms of tumourigenesis, the laboratory which cytokines activate follicular melanocyte precursors may is interested in how melanocytes respond to ultraviolet (UV) be of considerable help to vitiligo patients. radiation. Sun exposure results in infl ammation and the release of molecules (cytokines) that create chemical gradients to attract immune cells into or out of the skin. Multiple-label immunofl uorescence image of a melanoma from a mouse model.
26 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION
DIVISION CHAIR: PROFESSOR EMMA WHITELAW
The Genetics and Population Division encompasses 13 laboratories and over 150 scientists. There continues to be an emphasis on working with large human cohorts and many of these cohorts are being collected at both national and international levels. A number of the laboratories are using classic epidemiological approaches to identify the environmental causes of various cancers, including those of the skin, the pancreas, the ovaries and the oesophagus. Others are involved in fi nding the underlying genetic factors associated with increased susceptibility to cancer, in particular breast, ovarian, endometrial, colorectal cancer and melanoma. Other laboratories are using similar strategies to identify genes that predispose people to migraine, dementia, depression and addiction. Improvements in the technologies available to study DNA both in the germline and in tumour tissues has revolutionised this area of research. The acquisition of a Genome Analyzer II at QIMR has provided us with additional on-site capabilities in this area.
The success of the genome-wide association studies (GWAS) means that studies must now try to understand at a functional level why particular sequence changes in particular parts of the genome predispose to disease. These studies are beginning and a number of laboratories are now investigating this using transcriptome analysis and animal models. The former requires analysis of extremely large datasets and the Division is delighted to welcome Dr Lutz Krause, an experienced bioinformatician. Dr Krause is the recipient of a QIMR Fellowship and moved here from Switzerland in June 2010.
27 Science for me has always been about the search for knowledge, asking new questions and addressing them the best we can. With 10-15% of Australians suffering from asthma, we hope our research will ultimately lead to improved disease prevention and managementgement and allow asthma sufferers to live normal llives.ives.
Dr Manuel Ferreira from the Genetic Epidemiology Laboratory is heading the largest Australian study of asthma genetics.
28 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION CANCER AND POPULATION STUDIES Laboratory Head: Professor Adèle Green The Cancer and Population Studies Group investigate the causes and natural histories of cancers and seek to generate evidence for their prevention. HIGHLIGHTS
• Launched a new study (D-Health) to assess the feasibility This study focuses on the common skin cancers and of conducting a large-scale randomised trial of vitamin D. associated pre-malignant skin conditions. Besides solar radiation, the effects of diet and of human papillomavirus • Completed a study of offi ce-based workers in Brisbane (HPV) infection are also being studied and further investigation showing that the general population is confused about how of the economic burden of skin cancer in the Queensland sun exposure is needed to provide vitamin D. community continues. • Investigated health resource use in relation to oesophageal Since June 2007, the Queensland Pancreatic Cancer cancer and Barrett’s oesophagus. Study has been conducted to understand the genetic and • Showed that persistence of betapapillomavirus infections environmental risk factors of pancreatic cancer. in the skin is a risk factor for actinic keratoses, a potential A new project this year involves middle-aged people with precursor tumour to skin cancer. colorectal cancer. The aim is to investigate the changes • Demonstrated that moderate intake of oily fi sh (average of in employment and work-life while dealing with a life- one serving every fi ve days) and of wine (average of half glass threatening condition and managing treatment demands. per day) may decrease the acquisition of actinic keratoses. This case-control study is the fi rst in Australia and the goal is to enrol 400 men and women with cancer and follow them • Determined that people who have relatively high levels up at one year. of serum selenium have a lower risk of both basal and squamous cell carcinoma in the eight years following blood The highly active QIMR/RBWH Statistics Unit is situated within collection. the Group. The biostatisticians collaborate with scientists and clinicians on projects including development of vaccines and • Showed over a 16 year period that clinical signs of chronic treatment for malaria; human papillomavirus and skin cancer; sun damage to the skin are associated with developing Indigenous health; radiation oncology; and obstetrics and multiple basal cell carcinomas over time. gynaecology. The Cancer and Population Studies Group investigates the role A new study, D-Health, aims to assess the feasibility of of environmental factors and personal characteristics, including conducting a large-scale randomised trial of vitamin D for genetically-determined, in the causation of cancer and its the prevention of chronic disease in the general population. precursors, and in cancer prognosis. D-Health is recruiting approximately 600 people aged A major project continues to be the 20-year follow-up study of 60-85 from across the four eastern states of Australia. almost 1,000 residents of the township of Nambour, Queensland. D-Health is launching in August this year.
29 GENETICS AND POPULATION HEALTH DIVISION CANCER CONTROL GROUP Laboratory Head: Associate Professor David Whiteman The Cancer Control Group conducts research aimed at reducing the burden of cancer. The need for such research is clear, given that almost one in three deaths in Australia is due to cancer. HIGHLIGHTS
• Identifi ed that infection with Helicobacter pylori decreases The Group has long-standing collaborations with researchers the risk of oesophageal adenocarcinoma. at Dartmouth Medical School (USA) and University of Toronto (Canada) to perform pooled analyses of 12 melanoma • Discovered people who experience frequent symptoms of datasets. gastro-oesophageal acid refl ux have seven times higher risk of oesophageal adenocarcinoma. An international consortium headed by Tom Vaughan (Fred Hutchinson Cancer Research Center, Seattle, USA) and • Found that obese people have lower risks of oesophageal David Whiteman (Cancer Control Group, QIMR) was awarded squamous cell carcinoma, the converse of that observed a US$7.6 million grant by the US National Cancer Institute to for oesophageal adenocarcinoma. conduct a genome-wide scan of Barrett’s oesophagus and The Group’s mission is to identify those factors that cause oesophageal adenocarcinoma. cancer, and then to fi nd ways of applying such knowledge The Group’s other major focus is oesophageal cancer. to prevent cancer. Research is conducted into other aspects With QIMR colleagues, the Group has undertaken the of cancer control, including defi ning pathways to diagnosis, largest studies of oesophageal cancers and pre-cancers mapping patterns of care and identifying determinants of yet conducted. These studies have led to new insights about survival from cancer. the causes of these conditions. Analyses will continue for In collaboration with Brisbane pathologists, the current many years, enhanced by the productive collaborations epidemiological study in melanoma has recruited more than with clinicians and researchers across Australia, USA, UK 600 patients. Data analysis will commence in 2011. and Europe.
A photomicrograph of Barrett's oesophagus, the metaplastic precursor for oesophageal adenocarcinoma. 30 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION CANCER GENETICS Laboratory Head: Professor Georgia Chenevix-Trench This laboratory investigates why some people get cancer, and how these cancers develop from a normal cell, particularly breast, ovarian and stomach cancer which are often found together in the same families. HIGHLIGHTS
• Discovered that mutations in the breast cancer These fi ndings are providing novel insights into the aetiology of predisposition gene, BRCA1, appear to alter the pattern of these cancers, and will soon allow risk prediction models to be methylation in breast tumours. developed, particularly in mutation carriers. • Identifi ed the type of mutations in the ATM breast cancer Analysis of GWAS for chemoresponse is also underway, and predisposition gene that are most likely to cause breast the study is expected to identify several novel genes that cancer. predict a patient’s response to treatment. In addition, analysis of expression, copy number and methylation profi les of • Identifi ed the fi rst, validated ovarian cancer susceptibility familial breast tumours has shown that BRCA1-related breast locus. tumours have a distinct methylation profi le. This suggests that The genome-wide association study (GWAS) revolution the BRCA1 gene may play a direct or indirect role in de novo continues, with dozens of genetic variants found to be methylation. identifi ed with cancer risk. The Cancer Genetics Laboratory In addition, detailed analysis of the ATM gene in a large number has played an important role in international consortia that have of breast cancer families, and controls, has shown that rare identifi ed about 20 susceptibility genes for breast cancer, seven evolutionarily unlikely missense substitutions confer increased for ovarian cancer, and nine that modify the risk of cancer in risk of breast cancer. BRCA1 and BRCA2 mutation carriers. Some of these loci, like the one that codes for the telomerase gene, and another at 8q24 near the MYC oncogene, appear to be pan-cancer susceptibility loci that affect risk of many different cancers.
31 GENETICS AND POPULATION HEALTH DIVISION EPIGENETICS Laboratory Head: Professor Emma Whitelaw
The Epigenetics Laboratory aims to understand the basic mechanisms of disease at a molecular level. The Laboratory focuses on chromatin, the proteins that package DNA. HIGHLIGHTS
• Identifi ed a number of novel genes involved in epigenetic The Epigenetics Laboratory suggests that this intangible reprogramming. variation results from the variable establishment of epigenetic modifi cations to the DNA nucleotide sequence in early • Detected hyperactivity in adult mice that were exposed to development. These modifi cations, which involve DNA ethanol in utero. methylation and chromatin remodelling, result in alterations • Began a thorough characterisation of the small RNA in gene expression, which affect the physical form of the population in sperm in the hope of identifying the drivers of organism. non-DNA based transgenerational inheritance. Work from a number of laboratories suggests that these • Developed a mouse model for fetal alcohol spectrum epigenetic states can be infl uenced by the environment, disorder. raising the possibility that they are involved in the developmental origins of some disease states. The Laboratory Biologists across many disciplines have known that there has recently shown that the consumption of 10% ethanol is a surprising degree of variation in physical traits even during the fi rst half of gestation in the mouse alters the DNA among genetically identical individuals and even when the methylation levels at a gene that is particularly sensitive to environmental infl uences, in the strict sense of the word, are epigenetic state. This study has led to the development of controlled. Genetic textbooks acknowledge this fact and refer a mouse model of fetal alcohol spectrum disorder. to it as intangible variation or developmental noise.
32 QIMR Annual Report 2009/10 The Familial Cancer Laboratory examines the genetic changes that make some families more susceptible to colorectal and other cancers.
GENETICS AND POPULATION HEALTH DIVISION FAMILIAL CANCER Laboratory Head: Dr Joanne Young
HIGHLIGHTS
• Demonstrated that approximately half of the patients who Research published by the Laboratory in early 2010 clearly carry Lynch syndrome mutations and who develop breast shows that breast cancers may also be sentinels for Lynch cancer will show DNA mismatch repair defi ciency. syndrome in some families. • Identifi ed a novel syndrome of young-onset (less than 45 Currently, efforts are focused on the signifi cance of skin years old) colorectal cancer associated with sparse polyps cancers and small intestinal cancers in Lynch syndrome; in the patient and their siblings. examining the pathology and molecular features which may be associated with this condition; characterising the types of • Found that in about half of the patients with serrated inheritance of Lynch syndrome mutations in families with these polyposis the polyp which causes cancer is an adenoma. unusual tumours; and looking for evidence of independent • Showed that the smoking paradox in patients with serrated genetic segregation. polyposis differs according to gender. • Discovered that genetic background is important in how the disease is expressed in patients with MUTYH mutations. The Familial Cancer Laboratory concentrates on inherited susceptibility to colorectal and other cancers. This year, the Laboratory has studied some of the cancers which occur outside the colon in patients with a condition called Lynch syndrome. The results of this work can lead to a diagnosis of Lynch syndrome at routine examination, thereby alerting the clinical team that the patient and half of their relatives are at increased risk for cancers and should undergo preventive screening. Similarly to colon and endometrial cancers, breast cancers which arise in Lynch syndrome mutation carriers were found to be more likely to show many infi ltrating lymphocytes, and half of the breast cancers in these patients will demonstrate loss of DNA repair proteins. Though cancer of the colon is most common in Lynch syndrome, there has been debate as to whether cancers of the breast can also occur in this condition. Serrated adenoma and adjacent cancer
33 GENETICS AND POPULATION HEALTH DIVISION GENETIC EPIDEMIOLOGY Laboratory Head: Professor Nick Martin This laboratory investigates the pattern of disease in families to assess the relative importance of genes and environment in a variety of important health problems and to locate the genes responsible using genome-wide association analysis.
HIGHLIGHTS
• Discovered a new gene, IRF4 predisposing to moliness are typed from thousands of twins and their family members and melanoma on chromosome 6. who have previously been measured for hundreds of diverse • Investigated new genes for blood cell characteristics genotypes. including monocyte count, erythrocyte volume and that the There have been major breakthroughs in two of the principal latter also affects iron status. domains of research interest. For melanoma and its most • Showed that top alleles for CD4/CD8 ratio (an important important risk factor, nevus density (moliness), the infl uence of marker of AIDS susceptibility) are also associated with type new genes on chromosomes 9, 20 and 22 have been shown. 1 diabetes, and HIV-1 immune control. Participation in an international consortium found new genes for hair and eye colour, both of which infl uence melanoma risk. • Uncovered a new gene for hair curliness in Europeans, with possible applications for forensics and cosmetics. In the domain of depression, the Laboratory contributed to a large international consortium that has found strong (but not • Found the top gene for fi nger-length ratio, a putative quite signifi cant) evidence for several new genes, and this is marker of prenatal testosterone exposure, is also the top now being combined into a yet larger analysis through the gene affecting age at menarche. Psychiatric Genetics Consortium. • Replicated new gene variants for lipids, smoking, and eye colour. The Genetic Epidemiology Laboratory also played a leading role in initiating the ENIGMA consortium (Enhancing • Published the fi rst genetic study of gambling addiction. NeuroImaging Genetics through Meta-Analysis) to combine This has been an exciting year for the Genetic Epidemiology GWAS studies of brain imaging phenotypes, with a view Laboratory with intensive analysis of genome-wide association to unravelling the genetic infl uences on brain structure and studies (GWAS) on 17,000 study participants, in which half a function as a window into psychiatric diseases – particularly million or more single nucleotide polymorphisms (SNPs) depression.
34 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION GYNAECOLOGICAL CANCER Laboratory Head: Dr Penny Webb This laboratory investigates all aspects of gynaecological cancer from aetiology to diagnosis, patterns of care, quality of life and survival. The main goal is to identify ways to prevent these cancers and to improve outcomes for the women they affect. HIGHLIGHTS
• Showed that high intake of processed meat may be linked conducted ten years earlier. Other ongoing investigations into to elevated risk of ovarian cancer while women who eat risk factors for endometriosis have identifi ed that childhood more poultry and fi sh may have a lower risk. weight and menstrual characteristics are associated with risk. • Identifi ed that women who drink two or more cups of tea Data collection for two national studies (the Ovarian Cancer a day may have a 30% lower risk of getting ovarian cancer Patterns of Care Study and Endometrial Cancer Clinical than women who do not drink tea, and that both black and Follow-Up and Quality of Life Study) is progressing well and green tea seem to confer a similar benefi t. is due for completion in early 2011. Analysis of data from the recently completed Australian National Endometrial Cancer • Found that women with ovarian cancer continue to prioritise Study has begun. tumour response as the most important outcome of chemotherapy despite disease progression over time and Also nearing completion is a pilot study assessing the women's realistic understanding of the low likelihood of cure. feasibility of implementing a home-based walking intervention in women with ovarian cancer who are undergoing adjuvant • Shown that women who maintained or increased their chemotherapy. physical activity after a diagnosis of ovarian cancer have decreased depression and improved quality of life. The Laboratory has continued the contribution to the international Ovarian Cancer Association Consortium The Gynaecological Cancer Laboratory has continued which has recently identifi ed a new gene implicated in the investigations into the causes of ovarian cancer and development of ovarian cancer, and, for the fi rst time, have endometrial cancer through the Australian Ovarian Cancer also contributed data to collaborative studies conducted Study (AOCS) including investigating the role of diet in ovarian through the Epidemiology of Endometrial Cancer Consortium. cancer risk using data from both AOCS and a similar study
35 GENETICS AND POPULATION HEALTH DIVISION INDIGENOUS HEALTH RESEARCH PROGRAM Laboratory Head: Associate Professor Gail Garvey The Program seeks to increase the number of research projects developed in partnership with Aboriginal and Torres Strait Islander communities and to increase the number of Aboriginal and Torres Strait Islander postgraduate students and researchers working on these projects. HIGHLIGHTS
• Conducted a cross-sectional study of Indigenous children The Multicentre Bronchiectasis Study continues to recruit residing in the Torres Strait to assess the prevalence of study subjects. 89 children in Australia and 41 in Alaska have obesity and the metabolic syndrome. been enrolled in the observational study and 45 children in Australia and 37 in New Zealand are enrolled in the • Evaluated and asthma education intervention for randomised controlled trial. Data collection will end in 2011. Indigenous children with asthma. The study on the understanding of dementia was a • Found that Indigenous people’s understanding of dementia collaborative project conducted between QIMR and CRC is poor. Dementia (QUT), Centre for Rural and Remote Health (USQ) • Conducted the Spotlighting Careers in Indigenous Health and Alzheimer’s Australia. This project found that Indigenous and Science Program in August 2009. 15 Indigenous people’s understanding of dementia was poor, which students and two teachers attended the program from highlights the need for culturally appropriate awareness various areas of South East Queensland. campaigns and targeted education interventions on dementia among Indigenous communities. The Program is validating the cultural sensitivity of an existing supportive care needs survey and adapting it for use with Spotlighting Careers in Indigenous Health and Science Australian Indigenous people with cancer. This work has been Program aspires to showcase science and enhance carried out in 2009 and early 2010. A cross-sectional study is students’ understanding of Indigenous health. The program about to commence to assess the baseline support needs of allows students to explore and gain experience in real all adult Indigenous patients hospitalised for their cancer. laboratories and participate in other learning activities specifi c to Indigenous health and culture. In 2009, 15 Indigenous The results from the asthma study and the metabolic syndrome students, one teacher and one Aboriginal Counsellor attended. and obesity study among children and youth of the Torres Strait have been published.
36 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION MOLECULAR CANCER EPIDEMIOLOGY Laboratory Head: Dr Amanda Spurdle This laboratory studies breast, ovarian, endometrial, colon and prostate cancer with a focus on identifying molecular signatures of normal and tumour tissue that can point to the genetic and environmental causes of these cancers.
HIGHLIGHTS
• Developed a quantitative classifi cation scheme for tumour information in this database will assess the predictive colorectal-endometrial cancer mismatch repair gene capacity of tumour features, developing another component of variants, to apply to a large international database. the MMR gene multifactorial classifi cation model.
• Provided information on tumour features in developing a In addition, work is continuing on classifying variants in breast model for the clinical classifi cation of sequence variants in cancer genes BRCA1 and BRCA2, with emphasis on assessing the colorectal-endometrial cancer mismatch repair genes. possible splicing aberrations. The Laboratory’s research has shown that some gene sequence variants predicted to cause • Found that some gene sequence variants predicted to benign protein may actually alter RNA splicing to severely affect cause benign protein changes may alter RNA splicing to protein structure and function. This has important implications severely affect protein structure and function. for bioinformatic components of prediction models, which The Molecular Cancer Epidemiology Laboratory has continued currently do not consider the effect of splicing for variants that lie within the coded protein. work on unclassifi ed variants in mismatch repair (MMR) genes. More that 14,900 variants in an international dataset were The Laboratory has also continued work assessing the role of re-asssessed (identifying error for 3% of entries), and provided common sequence changes in risk and prognosis of breast, a qualitative classifi cation scheme to provide consistent ovarian, endometrial and prostate cancer, in large consortia. evaluation across the dataset. This provided a framework for This has identifi ed further variants that are associated with future research, and also resulted in the reclassifi cation of disease risk and progression, and might be incorporated in variants in 429 families recruited into the study. Analysis of prediction models in the future.
37 GENETICS AND POPULATION HEALTH DIVISION MOLECULAR EPIDEMIOLOGY Laboratory Head: Professor Grant Montgomery The Molecular Epidemiology Laboratory investigates complex diseases using high throughput genomics platforms to identify genes and pathways contributing to disease risk. HIGHLIGHTS
• Discovered novel genetic variants contributing to risk for and implicate several other regions in risk for endometriosis. endometriosis. Replication studies are being completed to confi rm the results and understand the mechanisms. • Discovered age-specifi c effects of IRF4 variants for mole count leading to novel insights in how moles contribute to Current studies of gene expression in melanoma cell lines are melanoma risk. searching for the mechanism for increased risk of moles and melanoma on chromosome 9. Variants in a gene called IRF4 • Discovered new genes for a range of diseases including were recently demonstrated to have age-specifi c effects on coronary heart disease, infl ammatory bowel disease, mole count and predispose to melanoma. A genome-wide nicotine dependence, and eye diseases. search for new genes contributing to melanoma risk was Endometriosis is a common gynaecological disease that recently completed identifying several new leads to follow up. affects up to 10% of women in their reproductive years. It The Laboratory has contributed to new gene discoveries causes pelvic pain, severe dysmenorrhea, and sub-fertility. including genes for coronary heart disease, infl ammatory The Molecular Epidemiology Laboratory is a leading member bowel disease, nicotine dependence, and eye disease through of the International Endogene Consortium in collaboration collaborations with a range of international groups. Follow- with researchers from Oxford University, UK and the Harvard up from these discoveries will lead to greater understanding School of Public Health, USA. Recent analysis of a large of mechanisms increasing disease risk and improve future genome-wide screen of 3,400 endometriosis cases (2,200 diagnosis and treatment. from Australia) identifi ed a novel region on chromosome 7
38 QIMR Annual Report 2009/10 GENETICS AND POPULATION HEALTH DIVISION MOLECULAR PSYCHIATRY Laboratory Head: Dr Corinne Lendon This laboratory seeks to identify and understand the actions of the genes and environmental factors involved in disorders of mental health. These include dementia and cognitive ability, anxiety and depression. HIGHLIGHTS • Completed second phase of genotyping from Longitudinal controls in search for disease associated genes. A genome Ageing Womens (LAW) cohort. wide association studies report of the two candidate genes CRI and CLU1 (in addition to APOE) was published in Nature • Completed European GWAS collaboration, fi ndings Genetics. Evidence was found in support of the role of these published in Nature Genetics 2009. genes in Alzheimer’s disease (AD) in replication studies, and • Completed transcriptomic study that identifi ed IL-33 gene this was convincingly confi rmed by a back-to-back publication in dementia, fi ndings published Molecular Psychiatry 2009. by the UK/US collaboration in the same issue of Nature Genetics. The Dementia Group is headed by Dr Corinne Lendon with The Australian-European collaboration continues and using local researchers and collaborators Dr Antonia Pritchard, GWAS to identify genes predisposing to cognitive decline and Associate Professors Gerard Byrne and Nancy Pachana. probably to late life dementia. This is most timely because biomarkers for presymptomatic testing for dementia are Data collection is complete for the study of cognitive function, becoming a reality. A collection of blood samples is being anxiety and depression in an Australian healthy ageing cohort. prepared to take part in replication of such studies. In addition Candidate gene associations and functional studies are being to searching for genes, the program of functional studies on carried out on RNA. Analyses continue and publications are the differential control of APOE (a proven risk factor of AD) in preparation. As a member of the European Consortium allele and isoform expression is ongoing, using human blood Genome Wide Association Study of Dementia the Laboratory and brain cell models. has completed the fi rst screen of Alzheimer patients and
Normal, healthy brain tissue Brain tissue of Alzheimer's sufferer with amyloid plaques
39 GENETICS AND POPULATION HEALTH DIVISION NEUROGENETICS Laboratory Head: Dr Dale Nyholt The Neurogenetics Laboratory studies the role of genetics in the development and mechanism of the nervous system to identify genes that cause neurological disorders. A particular focus is on migraine, a frequent, debilitating and painful headache disorder that normally affects people during their most productive years. HIGHLIGHTS • Conducted ten large-scale projects examining genetic The Laboratory has contributed to the development of novel markers across the human genome in over 17,000 bioinformatic approaches (powerful gene-based tests) and individuals. sophisticated quantitative genetic studies that have provided novel insight in the genetic architecture of common complex traits. • Confi rmed a genetic association between migraine and anxious depression. Studies examining comorbid migraine and anxious depression were conducted and most recently robustly identifi ed the fi rst • Identifi ed the fi rst locus infl uencing risk of migraine with aura. locus infl uencing susceptibility to common migraine with aura. • Completed the fi rst Australian genome-wide association The fi rst Australian genome-wide association (GWA) study study of the more common forms of migraine. of the more common forms of migraine (migraine with and migraine without aura) has produced some exciting results that In close collaboration with colleagues both within and outside are currently undergoing replication studies by international of QIMR, investigations have been performed on traits including collaborators. Additional large-scale meta-analysis studies are erythrocyte volume, monocyte counts, hair morphology currently underway, where the Australian migraine GWA data (curliness), lymphocyte ratio (and risk of type 1 diabetes is being combined with multiple international migraine case- and HIV-1 immune control), fi nger-length ratio (a putative control cohorts. retrospective biomarker of prenatal testosterone exposure), The next year will produce even more exciting results in which and dizygotic twinning. novel genes and pathways infl uencing migraine susceptibility will be identifi ed.
40 QIMR Annual Report 2009/10 Bright fi eld fl uorescence showing insulin-producing cells in the pancreas
GENETICS AND POPULATION HEALTH DIVISION ONCOGENOMICS Laboratory Head: Professor Nicholas Hayward This laboratory identifi es novel cancer genes and studies the way in which defects in these genes are associated with cancer predisposition or development. HIGHLIGHTS
• Identifi ed key genes that are involved in tumour The Laboratory is looking for ways to control the spread of development in the hormone-producing cells of the these tumour cells by focusing on a gene that has been found pancreas. to be lost from cells as the disease progresses. This year, the key target of this gene has been identifi ed and studies • Identifi ed a small nucleic acid that is switched off in to determine the function of the gene in normal cells and in melanoma, resulting in invasion. melanoma are underway. Future investigations are hoped to • Developed a melanoma specifi c mutation panel that uncover new avenues for possible therapeutic intervention to potentially can predict the response and effectiveness of treat melanoma. emerging therapeutic strategies treating melanoma. Research using gene arrays to profi le copy number (CN) Work to characterise the genetic and molecular changes that changes in oesophageal cancer has been extended to occur in the development of tumours in endocrine organs is include pre-cancerous tissues. Whole genome CN profi les progressing well using new tools and state-of-the-art methods have revealed the most frequent regions of loss involve two that were developed in the last year. Work continues on well-known tumour suppressor genes, disruption of which is the biology of the gene responsible for the disease multiple very frequent in the pre-cancer tissue from cancer patients; endocrine neoplasia type 1 (MEN1), which will help to the surprise was detecting these changes in patients with no understand its normal function and provide clues that may lead history of cancer. The results will be integrated with those of to better treatments for endocrine tumours. others, leading to a possible diagnostic test. These genes are believed to be important in the function of these cells normally, There are currently no effective treatments for advanced and may therefore be important not only in preventing tumours melanoma. Once melanoma cells have spread through the but also in diabetes. body the disease is usually fatal within 6–9 months.
41 GENETICS AND POPULATION HEALTH DIVISION QUEENSLAND STATISTICAL GENETICS Laboratory Head: Professor Peter Visscher Queensland Statistical Genetics (QSTAG) specialises in quantitative and statistical genetics, population genetics, human genetics and bioinformatics to investigate the genetic basis of differences in risk to disease and other phenotypes between individuals. HIGHLIGHTS
• Illuminated the 'missing heritability' problem in complex In collaboration with the Genetic Epidemiology, Neurogenetics, trait genetics. and Molecular Epidemiology Laboratories, a genome-wide association study on iron metabolism phenotypes measured • Developed new statistical methods for the prediction of in blood identifi ed a number of genetic variants that in total genetic risk to common disease. explain a substantial proportion of genetic variation in iron The Laboratory has shown that genetic variation in human status. height, a classical complex trait, is due to many genes with The Queensland Statistical Genetics Laboratory published small effect sizes. This result has implications for the discovery review articles in Nature and Journal of the American Medical of genes affecting all complex traits, including disease. Association.
42 QIMR Annual Report 2009/10 IMMUNOLOGY DIVISION
DIVISION CHAIR: PROFESSOR GEOFF HILL
The Immunology Division has a signifi cant focus on tumour and infectious disease-based immunology. In particular, a central theme of the Division is that of preclinical modelling as a prelude to prospective clinical trials of vaccine and cellular therapies. By expanding this knowledge base, the ultimate aim is to provide improved diagnostics and treatments for infectious diseases and malignancies. The Division’s research continues to provide vital insight into a range of diseases including graft-versus-host disease, breast cancer and melanoma. Early stage preclinical and clinical studies of cellular therapy continue for a number of malignancies including leukaemia, lymphoma, nasopharyngeal carcinoma, breast cancer and melanoma. Studies linking the pathophysiology of EBV infection to autoimmunity (multiple sclerosis) and cancer (lymphoma) are underway. The progressive developmental testing of novel vaccines for infectious agents human cytomegalovirus, Epstein-Barr virus, malaria and streptococcus continues. With over one million people dying every year from malaria and 500,000 of rheumatic heart disease and rheumatic fever (a possible consequence of streptococcus A infection), this work has the potential to save the lives of many people across the globe. In collaboration with an Australian biotech company, a new blood diagnostic kit has been developed that will allow clinicians to easily and effi ciently monitor transplant patients at risk of developing cytomegalovirus disease and improve the outcome of patients post-transplant. A new mouse line has been established to test new vaccines and treatments of chikungunya virus arthritis and a novel way to active T cells to alleviate experimental visceral leishmaniasis has potential applications for a more effi cient treatment.
43 One of the great things about my job is mentoring the next generation of medical researchers. The enthusiasm and energy that talented PhD students like Kimberley bring to the lab is infectious! The future of Australian Health and Medical Research appears to be in very good hands.
Associate Professor Maher Gandhi, Head of Clinical Immunohaematology and Kimberley Jones, PhD student
44 QIMR Annual Report 2009/10 Brendan Parkes and family
IMMUNOLOGY DIVISION BONE MARROW TRANSPLANTATION Laboratory Head: Professor Geoff Hill The Bone Marrow Transplantation Laboratory works towards understanding the mechanisms by which transplant recipients eradicate leukaemia but also develop life-threatening complications, particularly graft-versus-host disease. HIGHLIGHTS • Found that chronic graft-versus-host disease (GVHD) is an (GVHD) and graft-versus-leukaemia effects after haematopoietic IL-17A dependent process. stem cell transplantation. • Demonstrated the ability of the infl ammatory cytokine, In the last year, new work on the previously unknown lymphotoxin, to mediate GVHD. pathogenic pathways of chronic GVHD found that it is an IL-17A dependent process. This opens the way for studies • Discovered a new suppressive pathway (SOCS3) that limits of new inhibitors to prevent and treat this complication that both acute and chronic GVHD, opening the door to new currently lacks any effective therapy. The Laboratory also potential therapeutics. established that soluble lymphotoxin (TNF-related infl ammatory Over 10,000 Australians are diagnosed with a blood cancer cytokine) is involved in acute GVHD, providing a rationale for selecting TNF antagonists for the treatment of disease. each year, accounting for 10% of all cancers and cancer deaths. The transplantation of healthy stem cells from a New studies have progressed on antigen presenting cells and donor of the same genetic background into the recipient their role in GVHD. Using newly generated transgenic lines, with leukaemia (stem cell transplantation) is the most effective effector T cell responses can be imaged in vivo and in real time curative therapy for the majority of these blood cancers. to quantify the important sites of antigen presentation after Unfortunately, this process results in side effects which can bone marrow transplantation. be fatal including infection, a rejection process known as In partnership with the Tumour Immunology Laboratory an graft-versus-host disease and in some patients, the leukaemia experimental treatment was used to help a bone marrow still recurs. transplant overcome a life threatening infection. The research The Bone Marrow Transplantation Laboratory continues to teams are now embarking on a formal prospective clinical trial investigate the mechanisms of graft-versus-host disease to thoroughly test the procedure.
45 IMMUNOLOGY DIVISION CANCER IMMUNOTHERAPY Laboratory Head: Dr Chris Schmidt The focus of research in this laboratory is on understanding how the immune system succeeds in its fi ght against malignancies which is central to the future development of cancer immunotherapies. HIGHLIGHTS
• Established a novel technology for examining antigen- killer T cells effi ciently. The technology will be expanded to specifi c immune responses. include known melanoma antigens. • Commenced the fi rst assessment of anti-tumour immune This will allow refi nement of preliminary studies on the immune responses in patients with minimal residual disease responses against melanoma in patients who have recently following melanoma removal. had most of their tumour removed, and relate the results to their eventual clinical outcome. Few validated cancer targets • Established a bank of matched normal and cancer cell exist for other cancers, and T cells isolated from patients with lines from melanoma patients. prostate cancer and glioblastoma will be tested for responses Two major impediments to successful cancer immunotherapy to proposed antigens using this lentivirus system. are that it is currently not known which molecules on cancer Basic genetic studies in cancer require malignant and matched cells should be targeted by the immune system, nor what kind normal tissue from a large number of patients with well of immune response is required for successful resolution of characterised clinical histories. Previous clinical trials provide metastatic disease. In both cases, a convenient technology for such a patient base, and cell lines have been generated from detecting immune responses to any given protein is essential, their cancers and matched normal cells. This resource will be but currently lacking. made available to researchers through an Enabling Grant from Lentivirus vectors encoding model antigens have been the NHMRC to the Australasian Biospecimens Network, of developed, and found they could stimulate both helper and which the Laboratory is a member.
Computer model of a dendritic cell courtesy of medicagraphics.com
46 QIMR Annual Report 2009/10 The main focus of the Cellular Immunology Laboratory is the cytotoxic T lymphocyte (CTL) and factors controlling its primary function in recognising and killing virus-infected cells.
IMMUNOLOGY DIVISION CELLULAR IMMUNOLOGY Laboratory Head: Associate Professor Scott Burrows
HIGHLIGHTS
• Discovered that polymorphisms in the T cell receptor genes infl uence immune responses in humans. • Discovered strains of Epstein-Barr virus that occur at higher frequencies in multiple sclerosis patients.
T cells play a pivotal role in the immune system by recognising virus-infected tissue through the use of highly specifi c cell surface receptors. These T cell receptors (TCR) recognise viral peptides presented by MHC molecules on the surface of virus- infected cells. For a TCR to be successfully triggered, it must lock onto an exact 3-dimensional structure. In this way, any given TCR must simultaneously recognise both the viral peptide and the MHC presenting it. Such recognition must be sensitive and precise, since a false positive could result in destruction of healthy tissue. This year, the Laboratory has investigated how natural mutations in TCR genes across the human population affect individual responses to viruses. Studies have provided proof of concept that differences in the TCR genes between individuals can infl uence how they respond to viral infection. This year, the controversy over whether there is a link between infection with Epstein-Barr virus (EBV) and the development of multiple sclerosis (MS) has also been investigated. Results have contributed to the mounting evidence in support of a link. Examination of the stains of EBV infecting MS patients versus controls, found that some strains occur at different frequencies in MS patients.
A common mutation within a T cell receptor infl uences recognition of virus-infected cells
47 IMMUNOLOGY DIVISION CLINICAL IMMUNOHAEMATOLOGY Laboratory Head: Associate Professor Maher Gandhi The major research area in this laboratory is the immunobiology of lymphoma. Interests include biomarkers, immuno-evasion, microRNA expression and cellular immunotherapies for virus associated lymphomas. HIGHLIGHTS
• Continued the second year of an NHMRC / NCRIS funded The Laboratory supports a range of translational studies that Phase I clinical trial of adoptive immunotherapy in EBV- will heighten understanding of the biology of lymphoma. Highly positive lymphomas. detailed functional immunoassays are performed and genetic biomarkers on healthy individuals are studied as well as clinical • Performed the fi rst in-depth profi le of viral microRNAs in a samples obtained from lymphoma sufferers. This work has led range of primary samples from histologically diverse EBV- to disease insights and therapeutic advances. positive lymphomas. The transforming abilities of the Epstein-Barr virus (EBV) have • Completed the fi rst year of a multi-centre Phase II been used to establish a model system for investigating key lymphoma trial, specifi cally performing a correlative events in the pathogenesis of lymphoma. laboratory study. Physiologically relevant human models that imitate the various • Identifi ed a previously uncharacterised immune defect that stages of B cell differentiation are lacking. Using high effi ciency leads to fulminant infectious mononucleosis. EBV infection of isolated naive B cells, this laboratory has • Completed specimen collection of a multi-centre Phase II recently demonstrated that the use of EBV infection of isolated study of immune thrombocytopenic purpura. human naive B cells provides a highly relevant in vitro model that mimics the GC reaction. • Characterised the clinical and immunobiological characteristics of a new and highly aggressive EBV-positive From a therapeutic perspective, a novel Phase I clinical trial lymphoma. of autologous EBV-specifi c T cell therapy in patients with relapsed and refractory EBV-positive lymphomas has begun • Demonstrated that EBNA1 is not immunologically silent in collaboration with the Tumour Immunology Laboratory and and can be utilised as a target for vaccines against post- investigators at the Peter MacCallum Cancer Centre. To date, transplantation lymphoproliferative disorders. three patients have been enrolled.
Researchers Dr Jamie Nourse and Kimberley Jones with patient Katie Pulling.
48 QIMR Annual Report 2009/10 IMMUNOLOGY DIVISION DENDRITIC CELLS AND CANCER Laboratory Head: Associate Professor Alejandro López This laboratory explores the function of dendritic cells (DC) in patients with breast cancer and investigates the role of breast cancer stem cells in the generation of tumours. Resulting fi ndings will yield novel DC-based immunotherapy.
HIGHLIGHTS
• Defi ned properties of breast cancer stem cells that differ In collaboration with Professor Brent Reynolds (University from the commonly acknowledged markers. of Florida) the Laboratory has provided further support for a mathematical modelling of how cancer stem cells contribute • Established that the markers commonly associated to tumour growth, specifi cally looking at how symmetric with breast cancer stem cells (BCSC) described distinct division rate of BCSC correlates with tumour growth. subtypes of breast cancer. • Identifi ed molecules that appear to be specifi c for luminal BCSC. • Establishing a correlation between a functional characteristic of BCSC (long-term proliferating cells symmetric division rate) and tumour growth. Defi ning what makes breast cancer stem cells (BCSC) different to other cells contained in a growing cancer would allow a more tailored therapy that specifi cally targets the cells responsible for tumour initiation and growth. Relatives of the adult somatic breast stem cells, BCSC are responsible for the initiation of the tumour and the regrowth after clinical relapses. Research on these cells has been fuelled by the description of two surface markers originally defi ned as expressed by BCSC in a defi ned pattern (named CD24-CD44+). In collaboration with the group of Professor Sunil Lakhani, research has now disclosed that those markers are, instead, specifi c for cells derived from breast cancer of the basal type and not present in other cells originated from cancer of the luminal type. Following an extensive study of cell lines established from breast cancer tissues, the distribution of these two and other markers have been defi ned as present in Primary breast cancer tissue both cells with and without BCSC properties.
49 Researchers at Q-Gen
IMMUNOLOGY DIVISION EPSTEIN-BARR VIRUS BIOLOGY Laboratory Head: Professor Denis Moss This laboratory is committed to understanding the biology and immunology of two clinically important human pathogens, Epstein-Barr virus (EBV) and vaccinia virus, and capturing laboratory fi ndings and using them in human clinical trials. HIGHLIGHTS • Began a peptide-based clinical trial in nasopharyngeal A clinical trial has begun using NPC patients recruited from carcinoma (NPC) patients in collaboration with Princess the Head and Neck Clinic at Princess Alexandra Hospital Alexandra Hospital. in collaboration with Professor Bill Coman and colleagues. This trial involves adoptive transfer of in vitro activated T cells • Defi ned the immune response in healthy individuals and from NPC patients. Activation of T cells involves the use of a NPC patients using the SAVINE vaccine encoded within peptide encoded within a protein associated with NPC. This adenovirus. procedure is conducted within the Q-Gen facility at QIMR, • Screened bioactive compounds for immunological activity. and to date, two patients have been treated. A new formulation (SAVINE) has been designed that includes In collaborative with the Drug Discovery Group, a library of all of the possible immunogenic determinants of proteins compounds derived from natural sources is currently being expressed within NPC biopsies. The EBV Biology Laboratory screened for immunological activity. The overall aim is to is currently performing preclinical testing on this formulation. identify compounds that might have clinical applications, Results indicate that SAVINE, when delivered in a replication- particularly those with immunosuppressive or anti-herpes defi cient adenovirus, is capable of activating immune virus activity. responses from both healthy individuals and NPC patients. These results provide a platform for future clinical trials.
50 QIMR Annual Report 2009/10 IMMUNOLOGY DIVISION IMMUNOLOGY AND INFECTION Laboratory Head: Associate Professor Christian Engwerda This laboratory studies the host immune response during malaria and leishmaniasis, and aims to distinguish host immune responses that control parasite growth from those that contribute to disease. HIGHLIGHTS
• Discovered a novel way to activate the immune system from human visceral leishmaniasis patients in India, during experimental visceral leishmaniasis to improve the in collaboration with Indian scientists. effi cacy of anti-leishmaniasis drugs and improve disease Methods have been developed to prevent experimental outcome. cerebral malaria by expanding regulatory T cells during • Discovered a polymorphism in the galactin-2 gene that infection. The fi ndings from this research have important increases susceptibility to cerebral malaria in highland implications for understanding the pathogenesis of severe Papuan children, but not adults. malaria syndromes in humans. • Discovered a way to expand regulatory T cells in an In collaboration with Professor James McCarthy (Clinical experimental cerebral malaria model to protect from Tropical Medicine, Laboratory, QIMR), a study has begun of disease. T cells from volunteers infected with Plasmodium falciparum, the parasite responsible for most malaria morbidity and • Started studies on volunteers infected with malaria for mortality. This work forms part of a wider program of research analysis of T cell responses during infection. being conducted at QIMR to develop drugs and vaccines to In the past year, the Immunology and Infection Laboratory prevent and treat malaria. continued to identify host immune responses during malaria A satisfying outcome from the Laboratory’s hard work was and leishmaniasis that control infection, and to distinguish the award of a NHMRC New Investigator Project Grant to these from those that cause disease. Discovery of a novel way Ashraful Haque. This is Ash’s fi rst major grant and his fi rst to activate T cells during experimental visceral leishmaniasis step towards establishing an independent research career. has resulted in rapid disease resolution and more effi cient drug Alex Mulherin maintained the perfect record of Honours treatment. This strategy will be tested on cell samples taken students from the Laboratory, achieving First Class awards.
Green fl uorescent malaria parasites sequestered in lung tissue.
51 IMMUNOLOGY DIVISION IMMUNOVIROLOGY Laboratory Head: Professor Andreas Suhrbier The Immunovirology Laboratory is exploiting new knowledge about interactions between viruses and the immune system to develop novel anti-viral and anti-cancer strategies. HIGHLIGHTS
• Developed a mouse model of chikungunya virus arthritis. SerpinB2 is a protein that the body usually makes in very large amounts during infl ammation. What SerpinB2 actually does • Discovered that chikungunya virus persists long term remains controversial. The Laboratory’s research discovered in vivo in macrophages. that a physiological function is regulation of the immune • Discovered that SerpinB2 modulates Th1/Th2 immune response; SerpinB2 suppresses a pro-infl ammatory immunity responses, allowing for the fi rst time an understanding called Th1 immunity. This activity may explain why too little of the role of this protein in diseases like asthma and SerpinB2 results in pre-eclampsia where Th1 responses are pre-eclampsia. excessive, and too much SerpinB2 results in asthma where Chikungunya virus is a mosquito transmitted virus related Th1 responses are insuffi cient. to Ross River virus that has recently emerged in the Indian The Immunovirology Laboratory has continued its collaboration Ocean and India to produce the largest epidemic ever seen with Peplin Ltd., who has developed a new topical treatment for this virus. The disease results in debilitating arthritis for non-melanoma skin cancer (ingenol mebutate, or PEP005). that can persist for months. In collaboration with Dr Pierre The treatment has shown very promising results in human Roques (Commissariat à l'Énergie Atomique, Paris, France), trials. Peplin was recently sold for US$287.5 million to LEO the Laboratory has discovered that the disease is due Pharma, including several patents with QIMR staff as inventors. to recruitment and activation of white blood cells called macrophages, with the virus also able to persist in these cells for extended periods. A mouse model of chikungunya virus arthritis has been developed for testing of new vaccines and treatments for this emerging disease. This model will also help unravel how the virus can evade the immune response for such extended periods.
Professor Andreas Suhrbier, Head of Immunovirology Laboratory
52 QIMR Annual Report 2009/10 IMMUNOLOGY DIVISION MOLECULAR IMMUNOLOGY Laboratory Head: Professor Michael Good The Molecular Immunology Laboratory studies the immune response to pathogens, principally Plasmodium and group A streptococcus (GAS), with the goals of understanding pathogenesis and developing vaccines. HIGHLIGHTS
• Completed preclinical studies of malaria vaccines. • Group A streptococcus (GAS) vaccine entering clinical trials. The Molecular Immunology Laboratory studies the immune response to pathogens with the goals of understanding pathogenesis and developing vaccines. The Laboratory is interested in immunity, pathogenesis and vaccine development for some infectious agents of global importance principally malaria parasites and group A streptococcus (GAS). The low dose malaria vaccine is entering clinical trials in early 2011. This was the culmination of several years of research by Professor Michael Good and his vaccine research team (with Dr Alberto Pinzon-Charry) in collaboration with Professor James McCarthy (Clinical Tropical Medicine Laboratory, QIMR). The molecular mechanism of the vaccine was published in the highly prestigious Journal of Clinical Investigation. The malaria pathogenesis team identifi ed a novel potential treatment to generate long-term protection against malaria. The treatment is novel, as it addresses the immunological changes induced by Plasmodium that prevent natural long- term immunity. The vaccine for GAS is also entering clinical trials in 2010. This project was again the result of several years of research headed by Professor Michael Good, in close collaboration with Dr Michael Batzloff (Bacterial Vaccines Laboratory, QIMR).
Professor Michael Good, Head of Molecular Immunology Laboratory
53 IMMUNOLOGY DIVISION MOLECULAR VACCINOLOGY Laboratory Head: Professor Denise Doolan Research in this laboratory investigates the molecular basis of immunity to disease, with a focus on malaria and model systems that can inform the basic immunology, mechanisms and antigenic targets of immunity, and evaluation of candidate vaccines. HIGHLIGHTS
• Identifi ed 17 novel Plasmodium falciparum sporozoite sporozoite and liver antigens strongly associated with sterile and liver stage antigens strongly associated with sterile protective immunity, novel blood-stage antigens, and cross- protective immunity against malaria. species reactive antigens have been identifi ed. The vaccine • Identifi ed 21 novel P. falciparum blood stage specifi c potential of a subset of these antigens is currently being antigens that may represent good targets for a malaria evaluated. A complementary study using a high throughput vaccine to reduce blood stage parasite burden and approach to identify novel antigens recognised by cell- minimise symptoms. mediated immune responses has been established. • Identifi ed a subset of P. falciparum antigens targeted Laboratory models have been established to assess the by cross-species immunity against malaria, which may immunogenicity and protective effi cacy of candidate malaria represent good targets for a vaccine capable of protecting vaccines, with a particular focus on the liver-stage where against multiple parasite species. clinical symptoms do not occur. Evaluation of candidate vaccines and demonstrated effects on parasite burden have • Developed a high throughput approach to identify, from been carried out. Work is also underway to identify potential the entire proteome of complex pathogens, the antigenic human-use compatible adjuvants capable of augmenting targets of cellular immunity for a rational vaccine design. cell-mediated immunity, since no such adjuvants have been • Developed a sensitive high throughput quantitative method licensed, and have identifi ed one adjuvant that preferentially for assessing Plasmodium parasite burden from very small induces robust CD8+ T cell responses. blood volumes. To understand how an effective immunity can be generated • Identifi ed an adjuvant capable of augmenting cell-mediated by vaccination, investigation of the factors that may modulate immune responses. the function and phenotype of effector T cells, and in particular The Molecular Vaccinology Laboratory uses genome-wide the acquisition of effector function by CD8 T cells, is underway. approaches to identify novel target antigens for malaria vaccine Unexpected insights into the effect of vaccination on immune development, since vaccines to date have been based on function have been obtained that have important implications only a handful of antigens. Using protein microarrays, novel for vaccine development.
Hepa 16 cells treated with IFNg
54 QIMR Annual Report 2009/10 IMMUNOLOGY DIVISION TUMOUR IMMUNOLOGY Laboratory Head: Associate Professor Rajiv Khanna This laboratory seeks a deeper understanding of the mechanisms by which an immune response to tumours may be generated, augmented and applied to the inhibition of tumour growth. HIGHLIGHTS
• Initiated a Phase I clinical trial on nasopharyngeal This therapy is based on a propriety technology (referred to as carcinoma in collaboration with University of Hong Kong. E1-LMPpolyTM) developed by this laboratory. The possibility of expanding this therapy for other EBV-associated cancers, such • Developed novel T cell-based therapy for the treatment of as HL and non-Hodgkin’s lymphomas, is also being explored. cytomegalovirus treatment in stem cell recipients. In addition, a collaborative agreement has been signed with • Completed preclinical studies on a prophylactic vaccine for a UK-based biotech company to jointly develop a therapeutic human cytomegalovirus. vaccine for both NPC and HL. • Determined the infl uence of mRNA structure on the antigen Another aspect of research is focused on developing novel presentation to cytotoxic T cells. immune-based diagnostic tools for human cytomegalovirus, • Developed a novel immune-based diagnostic tool for which is a major cause of morbidity and mortality in transplant human cytomegalovirus. patients. In collaboration with an Australian biotech company, a new whole blood diagnostic kit has been developed that will This laboratory is involved in developing immune-based allow identifi cation and prediction of which transplant patients therapies and novel diagnostic tools for human herpes virus are at the highest risk of developing cytomegalovirus disease associated diseases. These studies are primarily focused after organ transplantation. This diagnostic kit has recently on two viruses, namely Epstein-Barr virus (EBV), which been registered in the European Union as a clinical immune causes glandular fever and Hodgkin’s lymphoma (HL), and monitoring kit. It is anticipated this kit will also available at most cytomegalovirus. EBV is also associated with a number of pathology centres in the United States and Australia within the cancers including nasopharyngeal carcinoma (NPC). next 12–18 months. A large clinical study has been initiated in collaboration with colleagues at the University of Hong Kong to test a killkillerer T cellcell-based-based thetherapyrapy foforr adadvancedvanced NPC patientspatients..
QuantiFERON-CMV (QF-CMV) is a novel whole blood assay that was developed by the scientists at the QIMR and Melbourne-based diagnostic company, Cellestis Limited.
55 INFECTIOUS DISEASES DIVISION
DIVISION CHAIR: PROFESSOR JAMES MCCARTHY
The 13 laboratories that comprise the Infectious Diseases Division study how a range of important pathogenic organisms cause illness, search for better ways to diagnose and treat them, as well as developing vaccines to prevent infections. A major emphasis of work undertaken in the Division is on infections that disproportionately affect people living in the developing world and the tropics. Pathogens studied include viruses such as HIV and mosquito- borne viruses; bacteria such as Streptococci; and parasites such as malaria, intestinal protozoa, worms and scabies. One laboratory in the Division focuses on the application of proteomic technology to biomedical science. In the last 12 months, members of the Division have successfully secured funding for their work from prestigious bodies including the National Institutes of Health (NIH), National Health and Medical Research Council (NHMRC) program and project grant system, as well as the Gates Foundation. Three new laboratories have been added to the Division in the past year, headed by Drs Kathy Andrews (Tropical Parasitology), Katja Fisher (Scabies), and Colleen Olive (Immunity and Vaccinology). The Division has achieved many research milestones, including sequencing of the genome of the Asian blood fl uke (Schistosoma japonicum); successful completion of two PreINDs with the US FDA for fi rst-in man vaccine trials in group A streptococcus and malaria; demonstration that if the Aedes aegypti mosquito is infected with an endosymbiont bacteria called Wolbachia, it can no longer transmit the dengue fever virus; and assisting the World Health Organization identify the best malaria rapid diagnostic tests for use in the effort to control malaria.
56 QIMR Annual Report 2009/10 My research is ever evolving so each day is different. I love to know and understand why something happens and mathematical modelling is the perfect tool for me to explore hypotheses about disease transmission. The collaborations I have with WHO have direct public health impacts, particularly for malaria diagnosis, and it is rewarding to know that this work will help improve the health care of many people.
Dr Michelle Gatton, Head of Malaria Drug Resistance and Chemotherapy Laboratory, Infectious Diseases Division
57
100713_QIMR_AR10_FINAL.indd 57 21/09/10 5:27 PM INFECTIOUS DISEASES DIVISION BACTERIAL PATHOGENESIS Laboratory Head: Professor Kadaba Sriprakash This laboratory undertakes research into streptococci, staphylococci, and other medically important bacteria.
HIGHLIGHTS
• Isolated streptococcal species from school children this occurs, and fully characterising these bacteriophages. in India. Such information may help us to understand the rates at which streptococci undergo large scale genetic drift and help us to • Developed rapid diagnostic tests to distinguish between predict the emergence of new patho-varieties from commensal group A streptococci (GAS) and group G streptococci organisms. (GGS). • Conducted a study analysing GGS isolates collected Many bacteria, some commensal and some disease-causing, from around the world. can inhabit the throat. A molecular approach to identify all major species in these bacterial communities is being The group C and group G streptococci (GGS) are close investigated. The Laboratory’s multi-locus sequence typing genetic relatives of GAS. Traditionally recognised as study using GGS isolates (collected from around the world) commensal organisms, these organisms are emerging as demonstrate that a degree of genetic diversity is present in the signifi cant human pathogens. Despite high rates of rheumatic population. This diversity is driven by lateral transfer of DNA, fever, GAS is rarely isolated from the throats of individuals in not point mutation. Although Streptococcus pyogenes (group the Northern Territory. However, GGS is. Recent research has A streptococcus, GAS) is generally more virulent than demonstrated that DNA can be transferred between group A S. dysgalactiae subsp. equisimilis (group G streptococcus, streptococcus and closely related group G streptococcus. This GGS), the isolation rates of the latter from school children in transfer is mediated by bacteriophages, the equivalent of a India far exceeds that of S. pyogenes. bacterial virus. The Laboratory is investigating how commonly
58 QIMR Annual Report 2009/10 INFECTIOUS DISEASES DIVISION BACTERIAL VACCINES Laboratory Head: Dr Michael Batzloff The focus of this laboratory is the identifi cation, characterisation and evaluation of potential vaccine candidates for group A streptococcus (GAS) specifi cally Streptococcus pyogenes, and other bacterial pathogens. HIGHLIGHTS
• Demonstrated J8-DT mediated protection against group A is antibody mediated. This observation has a large impact on streptococcus is antibody mediated and the lead vaccine vaccine design and adjuvant selection. More recently, the lead candidate can induce a protective immunological memory vaccine candidate has been shown to induce a protective response. immunological memory response which is critical for vaccine effi cacy. • Demonstrated a novel pathway for Burkholderia pseudomallei infection of the nasal cavity leading to direct Burkholderia pseudomallei is another bacterial pathogen that infection of the brain. is a serious problem in tropical countries including northern Australia. In collaboration with Griffi th University through the • Highlighted new interactions with the host tissues, allowing Griffi th Medical Research College, research has demonstrated the identifi cation of target molecules for future vaccine a possible new route of infection resulting in direct infection of research. the brain following intranasal exposure in mice. Traditionally, Over the previous year, the Bacterial Vaccines Laboratory this bacteria was thought to colonise the lung, progress into has made signifi cant progress towards a vaccine for group the blood and then cross the blood-brain barrier. Further A streptococcus and associated diseases. Using a variety investigation of various tissues that the bacteria targets in this of techniques including passive transfer and T cell depletion, new infection pathway has allowed identifi cation of new target it has been demonstrated that J8-DT/alum induced protection proteins for future vaccine development.
An electron micrograph of a pair of bacteria (Streptococcus pyogenes)
59 INFECTIOUS DISEASES DIVISION CLINICAL TROPICAL MEDICINE Laboratory Head: Professor James McCarthy This laboratory undertakes translational research in tropical infectious diseases. A particular focus is the study of drug resistance, identifi cation of new drugs, and the development of novel diagnostic techniques. HIGHLIGHTS • Showed that scabies mite glutathione S-transferase New bioassay methodologies for screening drugs for activity enzymes are involved in the development of resistance to against scabies is ongoing. A trial of scabies infection using the two most commonly used treatments for scabies. a newly developed pig model of human scabies has been • Commenced studies on the clinical pathology and immunology completed. This work lays the foundation for world-fi rst of scabies using a recently developed pig model. prospective studies of scabies immunology. • Initiated scabies drug discovery research by investigating The Laboratory participates in several multicentre national mite-killing properties of natural product extracts and pure and international collaborative research projects. These compounds derived from plants. include: investigating factors infl uencing performance of rapid diagnostic test (RDT) kits for malaria; using serological • Developed a fi eld-based assay to detect glucose 6-phosphate tools to monitor malaria epidemiology; developing a glucose dehydrogenase enzyme defi ciency in malaria patients. 6-phosphate dehydrogenase assay applicable for large • Commenced a clinical study using experimental human scale fi eld study for better management of Plasmodium malaria infection. vivax malaria; and fi eld trials of antihelmintics and diagnostic methods for helminth infections. • Demonstrated that rapid tests for malaria may fail in some circumstances because some parasites lack the target protein. The Laboratory also collaborates with a number of other laboratories at QIMR to research new targets for antimalarial • Completed a large multicentre study of effi cacy of drugs, and investigate the interaction between HIV and malaria. antihelmintics. Translational clinical studies are in various stages of progress. • Successful completion of two Pre-IND applications to the These include work with Professor Michael Good on a US FDA. vaccine for group A streptococcal infection and blood stage This laboratory explored the contribution of glutathione malaria. Exciting projects underway include experimental S-transferases to drug resistance in scabies. In collaboration human malaria infections to test new drugs, and experimental with scientists from the Eskitis Institute (Griffi th University) work hookworm infections to study the relationship between allergy on the acaricidal activity of natural products was undertaken. and helminth infections.
Professor James McCarthy, Head of Clinical Tropical Medicine Laboratory with Dr Cielo Pasay and Mei-Fong Ho
60 QIMR Annual Report 2009/10 INFECTIOUS DISEASES DIVISION HIV MOLECULAR VIROLOGY Laboratory Head: Associate Professor David Harrich The principal focus in this laboratory is detailed analysis of HIV replication. This includes the processes by which HIV is able to convert its genetic material, composed of RNA, into a form compatible with human DNA. Understanding the role of viral and cellular factors in regulating HIV replication is a primary goal.
HIGHLIGHTS
• Isolated and identifi ed several previously unrecognised host The Laboratory studies the HIV life cycle at the molecular proteins that play a vital role in HIV replication. level and seeks to fi nd new means to stop the virus through a detailed analysis of viral interactions with the host cell. Many • Created a mutant form of a viral protein, referred to as host cell proteins are required by the AIDS virus to infect a Nullbasic, to inhibit HIV reproduction in infected cells. cell. A novel assay was used to isolate and identify host cell • Developing a gene therapy approach using Nullbasic proteins used by HIV to facilitate its reproduction. Experiments that could be used for HIV infected people experiencing are under way to determine how these host proteins affect a treatment failure. key HIV process called reverse transcription. Human immunodefi ciency virus (HIV) is the cause of acquired A recent discovery found that the host enzyme PRMT6 is immunodefi ciency syndrome (AIDS). No cure exists for HIV required to stably maintain the HIV Tat protein within a cell. infection. Globally, an estimated 33 million people are living Targetting Tat is critical as it plays key roles in HIV infection with HIV and approximately 2.7 million new infections occur and AIDS. Understanding how these proteins interact at the annually. In total, over 60 million people have been infected by molecular level may reveal a means to stop HIV reproduction in HIV since the beginning of the pandemic resulting in 25 million infected cells. deaths. At the end of 2008, over 17,000 people were living with HIV in Australia. The number of new infections in Australia Recently, the Laboratory showed that a mutant viral protein is now approaching 1,000 annually. There are currently 20 called Nullbasic could potently protect human cells from HIV different drugs available to treat HIV infection, which extend infection. Testing is currently underway for methods to deliver average life expectancy by up to 40 years. Unfortunately, HIV Nullbasic into human cells using a gene therapeutic strategy. is able to rapidly mutate so that some therapies become less effective over time.
Nullbasic causes HIV Rev protein to move out of nucleus into cytoplasm - disrupting HIV growth
61 INFECTIOUS DISEASES DIVISION IMMUNITY AND VACCINOLOGY Laboratory Head: Associate Professor Colleen Olive The Immunity and Vaccinology Laboratory investigates the immunological mechanisms of pathogen recognition and intracellular signalling pathways that culminate in host immunity, with the objectives of developing new vaccines for infectious diseases. HIGHLIGHTS
• Showed that dendritic cells stimulated by different Toll- response to a pathogen and adaptive immunity, and they like receptor agonists induced different signature profi les also have an important role in controlling the type of immunity of cytokines that may infl uence the type of adaptive generated. Research has determined the cytokine signature immunity. profi les of DCs induced by stimulation with various TLR agonists, and identifi ed those which have the potential • Demonstrated that dual stimulation of Toll-like receptors to favour a particular type of immune response. Further enhanced the potency of immune responses. research showed that the immune response can be amplifi ed • Identifi ed a role for different mitogen-activated protein by triggering more than one TLR simultaneously. Research kinases in the regulation of Toll-like receptor signalling in in progress is identifying the cell signalling pathways involved dendritic cells. in TLR signalling in DCs. This may lead to novel ways to manipulate the immune response. Vaccination has long been recognised as a prevention strategy for infectious diseases. However, there remain In collaboration with scientists at the University of California, many pathogens for which suitable vaccines have not been the Laboratory is investigating various chemical approaches developed. One such pathogen, group A streptococcus is in conjunction with liposome technology to engineer TLR- the cause of rheumatic heart disease (RHD) and has been agonist peptide vaccines, which will be evaluated for the focus of research for a number of years. RHD, while protection in animal models of infectious diseases including being a global health problem, is more prevalent in Australia's group A streptococcus. Aboriginal population. Established in February 2010, the Immunity and Vaccinology Laboratory is investigating new approaches to design and deliver high potency tailored peptide vaccines by triggering Toll-like receptor (TLR) signalling in dendritic cells (DCs). DCs are critical to bridging the induction of an innate immune
Jyothy Nair, Research Assistant, Immunity and Vaccinology Laboratory
62 QIMR Annual Report 2009/10 INFECTIOUS DISEASES DIVISION MALARIA BIOLOGY Laboratory Head: Associate Professor Donald Gardiner This laboratory uses transgenic approaches to investigate antimalarial drug targets, mechanisms of antimalarial drug action and antimalarial drug resistance. These studies are essential in the current era of multi-drug resistant malaria parasites. HIGHLIGHTS
• Determined the crystal structure of the Plasmodium The Laboratory is examining the effect of antimalarial falciparum M17 aminopeptidase. drugs on gametocytes and looking at basic gametocyte biology with a particular focus on potential intervention • Published the fi rst study on the effect of antimalarial strategies. A unique technique has been developed that drugs on the transmission stages of the malaria parasite will allow identifi cation of new and novel inhibitors of malaria P. falciparum. transmission. • Undertook three high throughput screens in the USA to In collaboration with colleagues at University of Technology, identify novel antimalarial drugs. Sydney, it has been shown that aminopeptidases are • Identifi ed the fi rst inhibitors of the P. falciparum M18 promising drug targets. Current studies are characterising aminopeptidase. these enzymes and investigating the activity of specifi cally designed inhibitors in vitro and in vivo. Screening of the Malaria remains a leading cause of morbidity and mortality National Institutes of Health (USA) 300,000 compound worldwide, with at least one to two million deaths per library has been completed. annum directly attributable to this disease. The Malaria Biology Laboratory has several ongoing projects which Investigation of the antimalarial activity of antiretroviral focus on rational drug targeting and novel intervention protease inhibitors both alone and in combination with strategies. other drugs continues. Research has presented evidence to suggest that these drugs target an uncharacterised Production of sexual stages or gametocytes is essential for P. falciparum aspartic protease and future plans are to transmission of the malaria parasite through the mosquito determine the function and structure of this enzyme so vector. However, little is known about this life cycle stage. that new potent and specifi c inhibitors can be developed.
Smiley Faced Killers - ring stage parasites of Plasmodium falciparum
63 INFECTIOUS DISEASES DIVISION MALARIA DRUG RESISTANCE AND CHEMOTHERAPY Laboratory Head: Dr Michelle Gatton This laboratory studies the mechanisms and factors infl uencing the development and spread of drug resistance in malaria parasites, and investigates ways to improve the diagnosis, treatment and control of malaria.
HIGHLIGHTS
• Demonstrated that the dormancy of the malaria parasite The Laboratory demonstrated that parasites arrest following artemisinin treatment in vitro is a possible development for up to 20 days (dormancy) following mechanism of artemisinin treatment failure in vivo. artemisinin treatment and that up to 2% of these parasites recover in vitro. Repeated dosing, or combination treatment, • Demonstrated that the amplifi cation of large chromosomal led to a reduction and delay in recovery. Using a mathematical segments occur when parasites develop resistance to model of P. falciparum infection and the dormancy recovery artelinic acid in vitro, but the amplifi cations are unstable rates and profi le, treatment failure rates that mirror those when drug pressure is removed. observed in the fi eld were predicted, indicating that dormancy • Participated in the Round II WHO-Malaria Rapid Diagnostic is a key factor in treatment failure. Tests (RDT) product testing and investigated factors The development of artemisinin resistance is a major infl uencing the performance of malaria RDTs. concern. The resistance mechanism was investigated using laboratory-selected resistant parasites. Amplifi cation events • Investigated the impact of malaria transmission intervention in the chromosomes of resistant parasites were found, strategies in different transmission settings using a and demonstrated to be unstable when drug pressure is mathematical model. withdrawn. The results have practical implications for the • Compared the performance of malaria diagnostics in containment of resistance. Temotu province, Solomon Islands to discover a large Rapid and accurate diagnosis is fundamental to the success proportion of asymptomatic Plasmodium infections with of malaria control and elimination programs. The Laboratory low and submicroscopic parasite densities. participated in the WHO Round II Product Testing of malaria • Developed a real-time web-base surveillance system for RDTs which provides a direct performance comparison of Ross River virus and Barmah Forest virus diseases in malaria RDTs. The results help ensure only quality RDTs are Queensland. deployed in the fi eld. The global diversity of parasite antigens were investigated. Research found parasites in the fi eld lack Artemisinin combination therapy is the recommended fi rst the antigens that are targeted by malaria RDTs, which is an line treatment of P. falciparum malaria, however treatment important fi nding for the selection of effective RDTs for malaria failure is common for artemisinin monotherapy. diagnosis.
64 QIMR Annual Report 2009/10 INFECTIOUS DISEASES DIVISION MOLECULAR GENETICS Laboratory Head: Professor Peter Upcroft This laboratory works on the three most medically important anaerobic protozoan parasites, the sexually transmitted Trichomonas vaginalis, the intestinal parasite Giardia duodenalis and the invasive Entamoeba histolytica. HIGHLIGHTS • Assembled the DNA sequence of the gut protozoan Previously, research showed that the enzyme pyruvate: parasite Giardia into fi ve chromosome linkage groups. ferredoxin oxidoreductase (PFOR), which is involved in metronidazole activation with ferredoxin, was downregulated • Revealed errors in the two longest constructs in the in a metronidazole-resistant line. However, new studies now Giardia genome database and proposed how these show that the C17-resistant lines have both active PFOR should be corrected. and ferredoxin and that reduction of metronidazole can be It has long been thought that the mechanism of action of the achieved in cell free assays with PFOR and ferredoxin purifi ed drug, metronidazole, used to treat infections of anaerobic from the C17-resistant lines. Reduction of metronidazole is organisms was via activation to its toxic form by two parasite followed spectrophotometrically but this is not possible for proteins, pyruvate:ferredoxin oxidoreductase (PFOaR) and C17. Thus, metronidazole and C17 have been separately ferredoxin. The Molecular Genetics Laboratory has shown that reduced in cell free assays and tested on live cells to show that both metronidazole and C17 can be reduced in vitro by Giardia resistant to metronidazole has fully functional PFOR the PFOR-ferredoxin couple. This leaves the possibility that the and ferredoxin. Current investigations have shown that the PFOR-ferredoxin pathway does not activate these drugs in the mechanism of action of metronidazole in anaerobes is via a live parasite or that drug-resistant cells can compartmentalise new mechanism. drugs or exclude them. In response to the Laboratory’s 2006 publication detailing The Giardia DNA sequence was assembled into fi ve chromosome new 5-nitroimidazole (5-NI) drugs which are active against linkage groups. The previous longest contiguous Giardia DNA metronidazole-resistant Giardia, bulk synthesis of one of the sequence was around one million base pairs (1Mb) while the compounds, C17, was arranged allowing detailed research maps now extend this to around 3 Mb. In the process of using a highly active 5-NI compound. With great diffi culty, C17- mapping and assembling the genome into chromosomes, resistant Giardia lines were developed which were also highly errors were revealed in the two longest constructs in the cross-resistant to metronidazole. Over the last year, the focus genome database. Thus, corrections were proposed for these has been how C17 is activated in drug-susceptible isolates errors and the new maps are being incorporated into the and how cells become resistant to C17 and metronidazole. genome database for Giardia.
Dr Kenia Krauer, Senior Research Offi cer, Molecular Genetics Laboratory
65 INFECTIOUS DISEASES DIVISION MOLECULAR PARASITOLOGY Laboratory Head: Professor Don McManus This laboratory researches the biology, pathogenesis and epidemiology of parasitic worms that infect humans with the aim of developing new public health interventions, including vaccines, and diagnostic procedures that will lead to their elimination through integrated control. HIGHLIGHTS
• Published the completed draft genomic sequence for logical vaccine targets. One such protein identifi ed is the Schistosoma japonicum as a cover article in Nature. schistosome-insulin receptor, which has been recently cloned • Identifi ed and cloned the schistosome-insulin receptor as a and characterised from S. japonicum. Formulated with Quil new vaccine target of S. japonicum. A, the vaccine provides more than 70% protection in mice in terms of reduced faecal egg output. This is the highest • Manufactured the fi rst schistosome protein microarray and protective effi cacy reported for any schistosome recombinant probing to identify further targets for vaccine intervention. protein to date. Future plans are to fi eld test the vaccine in The publication of the completed genomic sequence for challenge experiments with water buffaloes and if the vaccine S. japonicum provides a global insight into the host interaction effi cacy is verifi ed, undertake extensive fi eld testing in China of this complex pathogen, revealing that it can exploit host and the Philippines. nutrients, neuroendocrine hormones and signalling pathways The fi rst schistosome protein microarray was manufactured for growth, development and maturation. This is fi rst reported with 172 S. japonicum and 50 S. mansoni cell free expressed for any fl atworm and the genomic information serves as a proteins. The array is being probed with sera from people from valuable platform to facilitate development of new interventions schistosomiasis-endemic areas who are naturally resistant to for schistosomiasis control. schistosome infection, and also with sera taken from animals The Laboratory’s recent published data on apical membrane experimentally protected against schistosomiasis to identify proteins expressed on the surface of the schistosomulum new targets for vaccine intervention. larva and adult worm support the hypothesis that these are Franziska Bieri, PhD student in Molecular Parasitology Laboratory
66 QIMR Annual Report 2009/10 INFECTIOUSININFEF CTTIOOUSUS DDISEASESISSEAE SEES DIDDIVISIONVIV SSIONON MOSQUITOMOSQUITO CCONTROLONTROL LaboratoryLaboratory HHead:ead: DDrr PPetereter RyRyanan Research in this laboratory focuses on the biology and control of mosquito-borne viruses such as dengue, Ross River and Barmah Forest. With the global increase in mosquito-borne diseases such as dengue, new approaches to control are urgently needed. HIGHLIGHTS
• Provided sustainable delivery of health benefi ts to rural household water storage. Households in southern Queensland communities in Vietnam through community-based had a high abundance of different types of containers, dengue control programs, with ongoing costs of between including rainwater tanks, and many of these containers have 0.28 to 0.89 international dollars per person per year. emerged as key habitats for mosquitoes, supporting the belief that some of these areas may be at high risk for invasion of • Identifi ed several new fungi that may be used as biological exotic mosquitoes, including dengue mosquitoes. control agents against Aedes aegypti – the global dengue mosquito. To address this dengue threat, a range of new biological approaches to control Ae. aegypti mosquitoes have been • Demonstrated that household water storage practices investigated, including Wolbachia endosymbionts and encouraged by local, state and federal governments entomopathogenic fungi. can directly increase mosquito productivity in urban areas and may lead to increased risk of dengue and Ross River The Laboratory’s research has shown that mosquitoes that virus transmission. have been infected with Wolbachia have a greatly reduced ability to support infection with dengue virus and this • Identifi ed several mosquito proteins as candidate age demonstrates an alternative approach to control of dengue, biomarkers. without the need for insecticides. • Showed that a Wolbachia endosymbiont blocks replication A range of fungi were evaluated for control of Ae. aegypti. of all four dengue viruses in Aedes aegypti mosquitoes. Infected mosquitoes were less likely to be active and fi nd a The major research focus is the development of contemporary host than were uninfected mosquitoes. This suggests that approaches for the control of the global dengue mosquito – fungus infected Ae. aegypti may have reduced biting Aedes aegypti. Although dengue is a major problem in most behaviour and therefore less likely to transmit pathogens tropical areas, there is also potential for emergence of dengue such as the dengue virus. in cooler sub-tropical areas due to changing patterns of
67 INFECTIOUS DISEASES DIVISION PARASITE CELL BIOLOGY Laboratory Head: Associate Professor Malcolm Jones The Parasite Cell Biology Laboratory researches three specifi c parasites: schistosomes, the hydatid tapeworm Echinococcus granulosus and the malaria parasite Plasmodium, particularly their host interactions which can be exploited in control strategies. HIGHLIGHTS • Completed and published a gene atlas of Schistosoma Through gene knockdown studies using short interfering japonicum. RNAs, it was shown that tetraspanin is integral to the proper formation of the tegument and subsequent survival of the • Deployed gene silencing technologies to interrupt parasite in its human host. This fi nding provides a potential expression of schistosome tetraspanin, a major vaccine mechanism by which a vaccine based on Sm-TSP-2 protects candidate of schistosomiasis, demonstrating major immunised hosts. alteration in tegument architecture as a result of this gene silencing. Recently published genomic sequence datasets for schistosomes has revealed many molecules expressed by • Completed molecular characterisation of families of the schistosome parasites where no functional information proteins controlling uptake of the essential trace element is available. The lack of information extends to ignorance zinc in schistosomes. of where in the complex multicellular schistosome parasites The Parasite Cell Biology Laboratory specialises in cell the genes are expressed. To rectify this defi ciency, techniques biological aspects of the biology of helminth parasites of laser microdissection microscopy and microarray analyses affl icting humans. were combined, to dissect out and defi ne the transcriptome of highly important tissues involved in nutrition and Major progress was achieved in functional studies of reproduction from sections of female Schistosoma japonicum. tetraspanin, a novel surface-associated vaccine target in This approach enabled the basic formulation of a gene atlas Schistosoma mansoni. Schistosomes, or blood fl ukes, reside for schistosome parasites, defi ning the expression repertoire in the blood vessels surrounding the liver and bowel of their of specifi c tissues. This atlas will help clarify roles of specifi c human hosts. The parasites cover themselves in a unique schistosome tissues in host interaction and disease and lead cytoplasmic layer, called the tegument. to better identifi cation of vaccine targets.
Micrograph of a schistosome
686 QIMRQIMR AAnnualn Report 2009/10 INFECTIOUS DISEASES DIVISION PROTEIN DISCOVERY CENTRE Laboratory Head: Professor Jeff Gorman The Protein Discovery Centre aims to discover the identities of proteins involved in or affected by physiological and disease processes and the infl uence of post-translational modifi cations on the ways proteins function and interact. HIGHLIGHTS • Participated in a study that showed that the asparaginyl respiratory syncytial virus (RSV) in collaboration with Dr Kirsten hydroxylase responsible for controlling the transcriptional Spann (Sir Albert Sakzewski Virus Research Centre) and activity of hypoxia inducible factor plays a major role in Dr Peter Collins (National Institute of Allergy and Infectious regulating mammalian metabolism. Diseases, US National Institutes of Health). • Made major contributions to understanding the process of Another major focus has been on regulation of signal activated cartilage development. transcription factors by post-translational modifi cation • Developed a strategy for comprehensively quantifying pathways in collaboration with Drs Murray Whitelaw and Daniel proteomic changes in cells that accompany disease and Peet (The University of Adelaide). Strong collaborations have developmental pathways. also continued with Professor John Bateman (The Murdoch Children’s Research Institute) involving the proteomic analysis • Gained a detailed understanding of how human respiratory of cartilage development and disease. Future expansion of syncytial virus manipulates protein interactions and the PDC research portfolio is anticipated to include prostate metabolic pathways in the infected cell. cancer research in collaboration with Professor Judith The QIMR Protein Discovery Centre (PDC) is a specialty node Clements and her associates (QUT). of the national proteomics consortium, Proteomics Australia. At QIMR, a series of in-house collaborations include The role of the PDC is to provide Australian researchers identifi cation of biomarkers of mosquito age, characterisation collaborative access to specialist proteomics capabilities in of the phenotype of breast cancer cells and the analysis of the the fi elds of analysis of post-translational modifi cation and malarial proteome. infectious disease agents. The PDC obtains substantial funding from the National Collaborative Research Scheme The Centre has invested in the latest mass spectrometry via Bioplatforms Australia and the Queensland Government. hardware including two state-of-the-art LTQ-Orbitrap mass Professor Jeff Gorman was appointed as the convenor of spectrometers from Thermo and two high performance Proteomics Australia in 2009. MALDI-TOF/TOF mass spectrometers from Bruker Daltonics. Additional mass spectrometers include two Bruker Qq-TOF This year, the Centre continued successful involvement in major and one 3D-Ion Trap instruments from Bruker. This equipment activities involving the serious paediatric respiratory pathogen, is complemented with a range of ancillary proteomic equipment.
Professor Jeff Gorman, Head of Protein Discovery Centre and The Honourable Nicola Roxon, MP, Minister for Health and Ageing
69 INFECTIOUS DISEASES DIVISION SCABIES Laboratory Head: Dr Katja Fischer Skin infection with scabies mites is a serious problem among Aboriginal communities, providing sites for colonisation by pathogenic bacteria which lead to serious complications. This laboratory aims to investigate the underlying molecular mechanisms. HIGHLIGHTS
• Created a series of functional knockout mutants of specifi c scabies mite complement inhibitors. • Transferred complement research methodologies to QIMR from a complement laboratory at Lund University in Malmö. • Revealed whole blood bactericidal assays increased bacteria survival rates in the presence of scabies mite molecules under physiological conditions. • Developed a pig model for scabies which will be instrumental in extrapolating in vitro data into an in vivo setting. In collaboration with the Bacterial Pathogenesis Laboratory, • Discovered multiple classes of scabies mite molecules whole blood bactericidal assays revealed increased bacteria that prevent the immune system from killing group survival rates in the presence of scabies mite molecules under A steptococcus bacteria. physiological conditions. Based on high resolution structures generated in collaboration The lack of either an animal model or an in vitro culture has with researchers at Monash University, PhD student Simone limited scabies research previously. The Laboratory has Reynolds has created a series of functional knockout mutants, developed a pig model for scabies which will be instrumental in which will serve as a tool to determine the binding mechanism extrapolating in vitro data into an in vivo setting. between specifi c scabies mite complement inhibitors and In early 2010, the Scabies Laboratory had a change of human complement factors. Laboratory Head. Dr Katja Fischer is now heading the Dr Angela Mika visited a complement laboratory at the Lund Laboratory while Professor Dave Kemp remains as an overall University in Malmö, Sweden to transfer complement research scientifi c advisor, acting as a major resource in supervision, methodologies to QIMR which are instrumental in demonstrating planning and fund raising for projects within the Laboratory. anti-complement activities of scabies mite molecules. Image courtesy of Priscilla Goh Shi Min, Honours student.
70 QIMR Annual Report 2009/10 The Tropical Parasitology Laboratory is working towards a better understanding of parasite biology, in particulary transcriptional regulation. The focus is investigating new antimalarial drugs, drug targets and parasite biology.
INFECTIOUS DISEASES DIVISION TROPICAL PARASITOLOGY Laboratory Head: Dr Kathy Andrews HIGHLIGHTS
• Identifi ed new antimalarial compounds from plants and fungi. back approach, anti-cancer and anti-HIV drugs (and related compounds) are being investigated for their ability to kill malaria • Shown for the fi rst time some HIV protease inhibitors have parasites. antimalarial activity against sexual stage malaria parasites. In collaboration with chemists at the Griffi th University Eskitis Malaria continues to be one of the world’s most devastating Institute, compounds derived from natural sources, such as diseases, particularly in under-developed regions. Around plants and fungi, are being studied for antimalarial activity. This one million people die each year from malaria, with children project has been funded by the Medicines for Malaria Venture under fi ve years of age being a most risk. There is currently no since 2007 and has resulted in the identifi cation of several vaccine for malaria, and prevention and treatment rely on drugs interesting new antimalarial compounds that are being further and public health measures such as bed nets. Unfortunately, investigated. drug resistance is a major problem in the fi ght against malaria which means that new drugs are urgently needed. In parallel to drug discovery approaches, the Laboratory is also using molecular and biochemical approaches to identify To address this, the Tropical Parasitology Laboratory is and validate the targets of antimalarial compounds and to using different approaches to investigate new antimalarial better understand essential processes, such as transcriptional compounds and potential new drug targets. In a piggy regulation, in malaria parasites.
71 MENTAL HEALTH RESEARCH DIVISION CHAIR: PROFESSOR MICHAEL BREAKSPEAR
The Division of Mental Health Research is a new initiative to undertake cutting-edge research into the nature, causes, diagnosis and outcome of the major mental illnesses, with a particular focus on schizophrenia, bipolar disorder, depression and autism. By combining recent advances in neurosciences with QIMR's existing strength in genetics and population health, the Mental Health Research Division has the potential to become one of Australia's leading centres for mental health research.
Through improvements in diagnosis and management, the research aims to reduce the burden of mental illness to society and improve the quality of life for those with a mental illness. By working in collaboration with clinicians and other researchers in Brisbane, the Division will pursue a broad and integrative approach to mental health research. The aim is to work very closely with mental health services to recruit patients into research when they fi rst present for assessment – prior to receiving treatment. The information collected will provide better understanding of the impact these mental illnesses have on brain function and help identify causes of disturbances in basic cognitive processes.
The Division currently encompasses two laboratories – the Systems Neuroscience Group led by Michael Breakspear and the Psychiatric Genetics Laboratory led by ARC Future Fellow Naomi Wray. Systems Neuroscience is a rapidly growing fi eld that seeks the basic principles of brain organisation, dynamics and function across a hierarchy of spatial and temporal scales in health and disease. Family studies show that genetic factors contribute an important risk for all psychiatric disorders. The Psychiatric Genetics Laboratory focuses on combining detailed symptom data with detailed genetic data to unravel the genetic etiology of these disorders.
One of the major events on the near horizon is the establishment of a state-of-the-art brain imaging facility through a collaboration between QIMR, The University of Queensland and the Royal Brisbane and Woman’s Hospital. This will enable translational research into mental health diagnosis and treatment on the Herston campus. Beyond 2010, new laboratories will be established within the Division with the opening of the Smart State Research Centre, building on the existing strengths and new initiatives within QIMR in Mental Health Research.
72 QIMR Annual Report 2009/10 Our research aims to reduce the burden of mental illness to society and improve the quality of life for those with a mental illness. We will utilise the latest brain imaging and computer modelling techniques to help understand the impact these mental illnesses have on brain function and help identify causes of disturbances in basic cognitive processes.
Professor Michael Breakspear, Chair of QIMR Mental Health Division
73
100713_QIMR_AR10_FINAL.indd 73 22/09/10 10:46 AM JOINT RESEARCH
74 QIMRMR AnnualAnnua Report 2009/10 JOINT RESEARCH AUSTRALIAN CENTRE FOR INTERNATIONAL TROPICAL HEALTH (ACITH)
The Australian Centre for International Tropical Health (ACITH) • Dr Peter Ryan, Professor Brian Kay and team with aims to improve the health of populations in Australia and Professor Scott O’Neill (UQ), have shown that the symbiotic bacterium Wolbachia can affect life expectancy, feeding internationally through excellence in education, research behaviour and susceptibility to a range of arboviruses and service including high level representation on major including dengue. With public health researchers in international and tropical health committees, editorial panels Vietnam and the Australian Foundation for Peoples of and review bodies. The Centre also supports postgraduate Asia and the Pacifi c, Professor Brian Kay and Dr Peter coursework and research training in international global and Ryan have now protected over 500,000 people in over tropical health. 50 communes from dengue disease, using a community- driven biological control strategy. In collaboration with ACITH obtains core operating income from the Public Associate Professors Peter Hill and Theo Vos (UQ) and Health Education and Research Program of the Australian three MPH students, the strategy was shown to be low- Government Department of Health and Ageing. This income cost and sustainable. supports staff critical to the public health effort and is matched • Professor Andreas Suhrbier, with Professor Alex Khromykh by funds from the two parent institutions – QIMR and UQ. (UQ), has established patented Replikun technology for ACITH and QIMR have consolidated their international position more effective vaccine delivery. in tropical health with strong grant support from the Gates • Professor Andreas Suhrbier, with Dr Pierre Roques (France) Foundation, NHMRC, NIH and others including The Atlantic and others, has created the fi rst mouse model to understand Philanthropies, several Commonwealth Departments and the the immunopathology and possible treatment modalities for chikungunya virus which swept through the Indian Ocean Queensland Government. Following a 2008 application to islands and India, causing over 1.6 million cases. the Smart State Building Infrastructure Fund for expanded collaborative facilities for JCU, QIMR, QUT and GU, $19.45 • Professors Michael Good and Sri Sriprakash and others million was provided for the Queensland Tropical Health have developed vaccines for malaria and streptococcus which are currently being trialled. Alliance (QTHA) which formally commenced in 2010. • Professor James McCarthy is overseeing the Phase I HIGHLIGHTS malaria trial and made a considerable contribution to the success of Pacifi c Malaria Support Centre. • Professor Don McManus with Professor Gail Williams (UQ) and Yuesheng Li (Hunan, China), has made major • Professor Alex Loukas (now at JCU, Cairns) demonstrated advances with respect to public health policy and practice that celiac disease, among others, could be treated with in China regarding schistosomiasis and hydatid disease. parasites. • With signifi cant collaboration, the genomes of Schistosoma QIMR will continue to support UQ with respect to ACITH japonicum (Professor Don McManus) and Giardia although other funding models will need to be identifi ed. (Professor Peter Upcroft, Dr Jacqui Upcroft) were decoded. The new QTHA model, however, probably offers ACITH greater opportunities to expand its mission as part of this alliance.
75 JOINT RESEARCH AUSTRALIAN CENTRE FOR VACCINE DEVELOPMENT (ACVD) The Australian Centre for Vaccine Development (ACVD) HIGHLIGHTS at QIMR is one of the largest vaccine research centres in Australia. It provides opportunities for its members to develop • Developed an adenoviral vector-based vaccine to prevent collaborative links with national and international academic birth defects in new born babies. institutions and the biotech industry and also provide a • Developed a novel strategy for malaria vaccine based on platform for young Australian and international scientists to Toll-like receptor agonists. learn and develop new techniques in the fi eld of vaccine research. • Developed novel blood test to predict viral diseases in transplant patients. During 2009/10, ACVD and the Emory Vaccine Centre at Emory University in Atlanta (USA) established the Queensland- • Phase I clinical studies aimed at testing novel immune- US Vaccine Technology Alliance with a three-year grant of based therapies for human cancers (nasopharyngeal $1.8 million from the Smart Futures Fund of the Queensland carcinoma, Hodgkin’s lymphoma, post-transplant lymphomas, glioblastoma, and prostate cancer). National and International Research Alliances Program. Additional funding has been provided by QIMR and the Emory • Screened natural compounds for novel adjuvants for University, with total project funding from all sources equalling human vaccine formulations. $8.5 million over three years. Under this collaborative program, • Signed collaborative agreements with major international a number of projects on novel vaccine design have been vaccine development companies to co-develop vaccines funded and training opportunities for postgraduate students for infectious diseases and virus-associated cancers. will be provided. • Described critical characteristics of breast cancer stem cells identifi ed in established breast cancer cell lines. ACVD scientists have made a number of contributions towards vaccine and immunotherapy development. • Identifi ed novel tumour associated antigens in melanoma.
76 QIMR Annual Report 2009/10 JOINT RESEARCH • Tina Skinner-Adams and Michael Williams. Delocalised lipophilic cationic anti-malarial conjugates. COOPERATIVE RESEARCH GMRC staff continue to be successful in attracting external funding. Grants and Fellowships from the ARC and NHMRC CENTRE FOR ABORIGINAL awarded Dr Louisa Gordon and Professor Michael Good, administered through the GMRC, amounted to $4.2 million in HEALTH (CRCAH) 2009/10.
The CRCAH fi nished in December 2009 and its successor, the Lowitja Institute (incorporating the CRC for Aboriginal and Q-PHARM Torres Strait Islander Health) commenced in January 2010. Q-Pharm is a specialist contract research organisation that The Lowitja Institute is a collaborative research organisation conducts early phase clinical trials of pharmaceutical and that brings together Aboriginal organisations, research biotechnology products spanning the areas of therapeutic, institutions and government agencies to facilitate evidence- diagnostic and disease prevention agents. based research into Aboriginal and Torres Strait Islander health. QIMR is a Research Participant and Foundation member. HIGHLIGHTS The Institute will host the Cooperative Research Centre for • Commenced a collaborative study with Professor James Aboriginal and Torres Strait Islander Health (CRCATSIH) and McCarthy on the validation of a human malaria challenge will eventually take over its research program in June 2014, model. thereby providing a permanent organisation for Indigenous health research. Beyond June 2014, the Institute will fund • Completed successful recruitment for an international, research and implement programs in its own right. multicenter infl uenza vaccine study, as lead site. • Continued its leading role in professional education activities with Australian Research Collaborative Service, GRIFFITH MEDICAL British Association of Research Quality Assurance and RESEARCH COLLEGE Queensland Clinical Trials Network. The company offers the best appointed early phase clinical (GMRC) trials facilities in Australasia which include recruitment and outpatient clinics, a specialised 18 bed clinic for the conduct of The Griffi th Medical Research College (GMRC) is a joint the most medically demanding trials and an open plan 24 bed initiative of QIMR and Griffi th University that aims to promote facility for larger healthy volunteer trials. collaboration between researchers of both organisations. The Q-Pharm concluded its eighth year of trading as a private GMRC achieves these aims by providing seed funding for company on 30 June 2010. As in previous years, the collaborative initiatives, supporting research higher degree company’s international client base continued to diversify and students, and promoting professional interaction between staff. accounts for greater than 60% of revenue. Despite challenging This year Professor Michael Good, the founding Director of trading conditions continuing into the 2009/10 fi nancial year, the GMRC stepped down to take up an Australia Fellowship the company has consolidated its place as one of the leading at Griffi th University. Professor Good’s vision and drive were early phase clinical trial organisations in Australasia. instrumental in the founding and promotion of the strategic goals of the GMRC. Professor Alex Loukas also stepped down from the committee after taking up a new position at James Cook University. His place on the Committee was taken by Associate Professor David Whiteman. The GMRC currently includes 66 staff and six students. Biniris (Aust) Pty Ltd continues their generous fi nancial support of GMRC research higher degree students. This year, the GMRC directly awarded funding of $104,500 for three collaborative research projects: • Jeremy Brownlie, Jonathan Darbro and Peter Ryan. Characterisation of fungal pathogen kinetics in Aedes aegypti the global dengue vector. • Jin Gao, Newell Johnson, Peter Parsons and Glen Boyle. Role of transforming growth factor-beta (TGF-beta1) and the matrix metalloproteinases (MMP-2 and -9) cascade in the formation of oral squamous cell carcinoma (OSCC) stem cells via epithelial-mesenchymal transition.
77 CORPORATE
Front row Left to Right: Michael Creevey, IT Manager with members of the IT team: Tomomi Tomlin 78 QIMR Annual Report 2009/10 and Robert Taylor Back Row Left to Right : Archie De Guzman, Luke Lowrey, and Vincent Mar Centre, the new building will serve as the integrating hub for CORPORATE DIVISION the existing buildings and provide an inviting street profi le and The role of the Corporate Division is to ensure the Institute focal point for QIMR. operates effectively and to provide the high level of support The demolition of the Queensland Radium Institute was completed services required to keep QIMR at the forefront of medical on time and all demolition items were removed from site for research. It provides these services in an increasingly recycling as appropriate. Construction has begun and building challenging and complex regulatory and commercial environment. is on schedule for completion on time and within budget. Consisting of Scientifi c Support Services, Finance, Procurement, Grant Management, Human Resources, SYSTEMS Information Technology, Regulatory Affairs, Safety, Records and Information Services, Building Services, External Relations Following a comprehensive review and analysis of existing and Business Development, the dedicated corporate staff are corporate systems, this year saw the implementation of a suite committed to providing its researchers with access to the best of new online systems. staff and students, as well as cutting edge scientifi c equipment, The new systems, which were progressively released over a technologies and processes. period of nine months, streamline the interface for corporate It has been a very productive year for the Corporate Division functions and have made signifi cant impact on the turnaround as we prepare for an anticipated period of rapid growth for time for core services and the level of access to critical the Institute with the construction of the Smart State Medical operating information. Scientists and staff alike have been very Research Centre. The Division’s recent focus has been on positive about the new systems and the effi ciency gains from streamlining and improving QIMR’s systems and processes online access to services. to provide researchers with better quality information at their The new payroll and HR system, Aurion, replaces manual fi ngertips; managing construction of the new facility; and paper processes with secure web access for staff to their raising awareness of QIMR among the general public. HR information and services. The online requisition and ordering system WebGet was designed by QIMR’s IT team to meet the Institute’s specifi c ordering needs. WebGet also SMART STATE MEDICAL provides improved effi ciency of inventory processes and order life cycles. The new fundraising database, The Raiser’s RESEARCH CENTRE Edge, allows the fundraising team to better manage donor The landscape is changing dramatically at QIMR with construction relationships and implement more effective coordination of of a new 13-fl oor research facility underway on the site of fundraising approaches. A new version of the WebReporting the old Queensland Radium Institute (QRI). Set between the Suite was introduced which gives even more real-time on-line existing Bancroft Centre and Clive Berghofer Cancer Research information to scientists to assist with managing their research.
Smart State Medical Research Centre under construction 79 High School students learning about vaccination from Dr Wayne Schroder
QIMR also hosted two well attended public health forums on BIOINFORMATICS skin cancer (in partnership with Melanoma Australia) and men’s The Corporate Division is also supporting QIMR’s new health. Media relations were another priority as refl ected in Bioinformatics Laboratory, with the implementation of a high the increased national and international coverage of QIMR’s performance computer cluster. Bioinformatics is the analysis research programs. of large volumes of research data such as studies of the The department’s education program continues to inspire human genome. This processing capacity will ultimately the scientists of tomorrow with some 1,400 senior students bring QIMR researchers a step closer to understanding the attending the High School Lecture Series in 2009-10. underlying genetic causes of a range of diseases. RESEARCH SUPPORT FUNDRAISING Preparations are underway for the commissioning of the We would like to sincerely thank everyone who has made a SSMRC and the extra demand for services that will follow. donation to QIMR and helped make our important research These include scaling up of the microscopy, DNA sequencing, happen. We rely on community support to maintain our tissue preparation and tissue culture capacity of the Institute. position as a leading medical research institute and to pioneer These service laboratories are getting an upgraded laser for new research. fl ow cytometry that will allow users to perform better protein analysis on live cells and new customised fi lters have been Thank you to our many loyal supporters including our corporate installed to the Deltavision microscope allowing specifi c partners such as Suncorp and Xstrata, and philanthropists proteins and parts of the live cell to be studied. Mr Clive Berghofer, AM and Mr Royce Blackburne.
COMMUNITY ENGAGEMENT The External Relations department’s efforts to raise community awareness of QIMR and the calibre and breadth of its research have included the re-development of the QIMR website. The new site refl ects the new QIMR branding and ensures information is more easily accessible. QIMR was on display for the second consecutive year at the Government House Open Day hosted by QIMR Patron, Queensland Governor Ms Penelope Wensley AO. Some 46,000 people visiting the QIMR display at the Science Pavilion at the 2009 Brisbane Ekka had the opportunity to Mr Sean Ryan, Founder of the Knights of Mr Clive Berghofer AM the Round Table event that has raised over try their hand at some laboratory procedures. $500,000 for QIMR.
80 QIMR Annual Report 2009/10 We also recognise the wonderful contribution made by our monthly donors and the planned givers who kindly made provision for QIMR in their wills. THE ATLANTIC Medical research is an investment with long term potential. PHILANTHROPIES The new treatments we develop can save lives and potentially improve the health of everyone now and in the future. Each The Smart State Medical Research Centre is year QIMR acknowledges some extraordinary people whose only possible thanks to the generous support of support of medical research has been outstanding and The Atlantic Philanthropies (AP). The $27.5 million who share our vision and values. The recipients of 2009-10 Founding Chairman’s grant from Atlantic Ambassador awards were Mrs Norma Schwarz, Mr Bob Rice, Philanthropies is our largest-ever philanthropic gift Ms Robyn Bailey and Mrs Ailsa Zinns. Mrs Fitton and Mr and brings AP’s total commitment to QIMR over the Michael Gambaro were announced as joint winners of the last ten years to $57 million. Mr Charles “Chuck” QIMR Humanitarian Award at the 2009 Derrick-Mackerras Memorial Lecture. Feeney, the Founding Chairman of AP, has been involved in the conceptualisation and planning of the Another important source of funding is generated by individuals new building for some time and played an active role and businesses who organise events for which QIMR is the in encouraging the fi nancial support from both the benefi ciary. We are very appreciative of their support and Federal and State governments. acknowledge their dedicated efforts. They include people such as Sean Ryan (Knights of the Round Table), Sunny Mr Feeney demonstrated his belief in giving while Drescher (Happy Face Cent Auctions), Jones Lang La Salle living when he gave away the vast majority of his and the tenants of the Riverside Centre (Corporate golf day), wealth to start The Atlantic Philanthropies in 1984. our friends at Tattersall’s, employees of Witchery who sell pink Atlantic Philanthropies hopes to inspire individuals ribbons throughout their Queensland stores, the organisers of at widely varying levels of wealth to embrace giving the All British Classic Day and our many friends in Toowoomba while living: to approach philanthropy as a calling to including Fitton Insurance Brokers and all those who contribute which they can, during their lifetimes, actively devote to the success of the Fitton Charity Race Day and Darling their funds, skills and time, and receive enormous Downs Equine Extravaganza. satisfaction in the process. Donna Hancock Acting General Manager/Secretary
Artist’s impression of completed Smart State Medical Research Centre 81 WE THANK AND ACKNOWLEDGE THE SUPPORT OF THE FOLLOWING VALUED FRIENDS AND MAJOR DONORS:
The Atlantic Philanthropies Ryan Saunders Foundation Limited Mr Clive Berghofer AM Mr Kevin and Mrs Dallas Bedford Estate of Mr Peter Lipscombe Mr George Landers Estate of Mr John Francis Pickering Estate of Ms Heather Daphne Livesey Suncorp Metway Queensland Community Foundation Estate of Miss Violet Maud Lingard Selwyn Thomas Fassifern Ozanne and Doreen Elaine Visiting Medical Offi cers (VMO) Committee (AMAQ) Ozanne Trust Estate of Ms Cathryn Janet Christensen Gambaro’s Restaurant Xstrata Copper NOVA 106.9 Estate of Ms Lillian Jenvey Sidney Richard and Beryl Lillian Early Trust Estate of Mr Kevin H Makins Barbara Rhoda Phyllis Dalton Perpetual Charitable Trust Estate of Ms Sheila Beatrice Harrison Mr Tim and Mrs Kym Reid Estate of Mr Camrin Anthony Reeve Mr P R Rowland Roycorp Pty Ltd (Mr Royce Blackburne) Mrs Heather Jordan Port Glaud Limited The Cory Charitable Foundation Estate of Miss Marjorie Grace Dunn All British Classics Car Club Inc BT Investment Management Pty Ltd Mr Stuart Bishop Witchery Spaceframe Buildings Mr Barry and Mrs Maureen Stevenson Qld Ex-Service Women's Association Estate of Ms Flora Ethel Box Jameson Charitable Foundation E M Squires Charitable Trust Mr Rod Wylie Mr Karl Morris Reuben Pelerman Benevolent Foundation Tattersall's Club Mr Dan Holzapfel The Henry Cyril Robjohns and Stella May Robjohns Dr James Aylward Memorial Trust The White Foundation Pty Ltd Biniris Pty Ltd Mr Henry and Mrs Joan Daniel Happy Face Cent Auction (Mrs Sunny Drescher) Community Supporting Police Inc Estate of Mr Geoffrey John Shepherd Fitton Insurance Brokers Mr Douglas and Mrs Helen Cowlishaw Mrs Brenda Holdway G T Burgess Investments Pty Ltd Estate of Ms Margaret Rudder Mrs M J Gibson Mrs Helen Gow Ms Barbara McKay J J Richards and Sons Pty Ltd Mr Damien Cavallucci Mr Kevin and Mrs Elsie Hayes Mr Peter Rasey Mr Ivan Mitchell Estate of Mr Robert Kenneth Gregory Mr Norman and Mrs Marjorie Ongley FGF Developments Pty Ltd Estate of Ms Marjorie Blanche Baxter Mr Leigh Ainsworth Sherrin Investments Pty Ltd Mrs Jacqueline Pascual
82 QIMR Annual Report 2009/10 TRUST REPORT
It has been an important year for the Institute, and for Trust. I would also like to thank our individual and corporate donors Once again, the past 12 months has seen many changes, and for their support of QIMR over the past year. In particular, I these will form the basis of growth and development for many would like to acknowledge the ongoing generosity of Mr Clive years to come. Berghofer. Clive’s support over many years has resulted in the development of new treatment methodologies for many forms The announcement of an increase in recurrent operational of cancer, which will benefi t current and future generations. funding in the recent State Budget was good news for Council and Trust, with the size and capacity of QIMR about to The work of Trust is done by a small number of dedicated increase substantially once the Smart State Research Centre is members, supported by an experienced and competent completed. In particular, it will give Trust the capacity to rebuild staff. During the year, we welcomed Professor John Hay to capital lost in the recent global fi nancial crisis, and will give our ranks, upon his taking the role of Chair of Council. John Council confi dence that it can support an additional 400 of the has been a supportive and valuable member of Trust, and an world’s best scientists in our new facility. inspirational Council Chair. We also farewelled David Stirling who resigned because of work and family commitments. The improved, but still volatile, fi nancial conditions have David has been an important contributor to Trust, particularly resulted in an increase in Trust investment earnings, increasing in the Investment Committee, and his business experience and the value of our reserves from the low point reached during the contribution will be greatly missed. crisis. However, the climate for fundraising and sponsorship is still diffi cult and highly competitive. Against this background, The remaining members of Trust, Rod Wylie and Patricia our External Relations Department has performed very well. I McCormack, have continued to play a vital role, and their would like to congratulate them on a very good year, which has hard work and guidance is appreciated and highly valued. The seen our database resources vastly improved and the launch review and amendment of the Queensland Institute of Medical of our new website. The team is supported by a wonderful Research Act, has not yet occurred, but we are hopeful that band of volunteer fundraisers, who have held boardroom this will occur later in 2010. This will provide a larger base lunches, race days, golf days and other high profi le events, of for Council and Trust, to enable us to further support and which QIMR is a benefi ciary. guide the wonderful efforts of our staff, partners, donors and volunteers to continue QIMR’s vital research. During the year, we identifi ed an opportunity to host a major fundraising event, a two day bike ride, which is planned to take Jane Seawright place in August for the next three years, commencing in 2011. Chair ‘The Ride to Conquer Cancer’ will be our signature event over this period.
83 TRUST MEMBERS Patricia McCormack BA (Psych and IR) FAHRI, MAICD
Jane Seawright Patricia McCormack is a highly BA LLB(Hons) MBus (Marketing) regarded People Management Acting Chair professional with extensive Jane Seawright is a lawyer with experience in all facets of Human extensive experience in marketing Resource Management. She and strategy. She established a established People Focus in 2002 with the aim of providing HR freelance marketing consultancy, services specialising in organisation development and human Seawright Consulting, in 2000 and held the position of resources management. Ms McCormack is a member of the Independent Chair of the Queensland Furnishing Industry QIMR Personnel Administration Committee and the QIMR Superannuation Trust for 13 years. She practices in corporate Marketing Committee. and commercial law, and is also a Law Society-accredited David Stirling mediator and registered adjudicator, pursuant to the Building and Construction Industry Payments Act 2004. She has been David Stirling has had extensive the Convenor and Acting Chair of The Queensland Institute of commercial experience over the past Medical Research Trust since February 2008, and is a member 40 years in the areas of banking, of the QIMR Marketing Committee. merchant banking and investments. Before joining the QIMR Trust, David was Managing Director of a fi nancial Professor John Hay AC BA (Hons) services fi rm and a Partner of an international Chartered (Western Australia and Cambridge), Accounting fi rm. He has been a member of a considerable MA (Cambridge), PhD (Western number of professional organisations including the Institute of Australia), Hon LittD (Deakin), Hon Engineers, Commercial Law Association, Institute of Chartered DLitt. (UWA); Hon DU (QUT); Hon Accounts affi liate, FPA, Securities Institute of Australia and a LLD (Queensland); FAHA; FACE; Fellow of the Australian Institute of Company Directors. David FAIM; FQA (Chair from 24/09/09) is a member of the QIMR Investment Committee.
Professor Hay was Vice Chancellor of The University of Queensland from 1996-2007. In that time he led the Rodney Wylie development of many major new research institutes including the Institute for Molecular Bioscience, the Australian Institute OBE B Comm BA FCA FAICD of Bioengineering and Nanotechnology and the Queensland Rod Wylie is a Brisbane-based Brain Institute. He was also instrumental in securing funding for Chartered Accountant with the Translational Research Institute to be built at the Princess substantial experience in investment, Alexandra Hospital. He has led both Deakin University and The company management and University of Queensland to be named Australian universities corporate governance issues across of the year by the Good Universities Guide. Professor Hay a wide range of organisations, in many cases with nationwide is Chair of nine boards, including QIMR to which he was and international activities. He has been involved through appointed by the Queensland Government in September 2009. Board/Council membership in the administration of a number of professional and community non-profi t groups. Mr Wylie chairs the QIMR Investment Committee and is a member of the QIMR Finance and Audit Committee and QIMR Personnel Administration Committee.
84 QIMR Annual Report 2009/10
100713_QIMR_AR10_FINAL.indd 84 21/09/10 5:19 PM POSTGRADUATE TRAINING
QIMR’s postgraduate students have continued to make an impressive impact on the wider scientifi c community this year receiving numerous notable awards
Today’s students are the scientists of the future so Kimberley Jones was awarded the ASMR Medal as winner postgraduate students are an important part of the research of the Australian Society of Medical Research Postgraduate effort at QIMR and the mentoring of students remains a high Student Category; Kate Markey, won the Young Researcher priority. The excellent research facilities, support services, Award from the Australian Academy of Sciences to attend the extensive network of international and national research 2010 Meetings of Nobel Laureates in Lindau, Germany and collaborations and internationally-ranked quality of QIMR Karin Verweij won a prize for the best poster presentation at the scientists combine to provide an outstanding environment for International Congress on Twin Studies in Seoul, South Korea. advanced training in health and biomedical research. QIMR students also did very well in receiving travel awards to Overall, 2009-2010 was an excellent year for students at attend international conferences including Miriam Mosing and QIMR with a total of 24 PhD students, four Research Masters Karin Verweij who won Behaviour Genetics Association travel and 14 Honours students successfully graduating from their Fellowships and Daniel Worthley who won a Royal Australian degree programs. During the year, the Institute admitted College of Physicians Overseas Travelling Fellowship. 26 new PhD, two Research Masters and 21 Honours students; The Higher Degrees Committee (HDC) evaluates students PhD admissions in particular were greatly increased from prior to their acceptance as candidates at the Institute, only 14 in 2008-2009. QIMR also hosted 52 visiting students monitors their progress during their candidature, provides during the year, many from overseas; again a considerable education programs and offers a number of travel awards, increase from the 28 students who visited the Institute in the Honours and PhD Top-Up Scholarships to the top students. previous year. The highly successful QIMR Summer Vacation As in previous years, HDC members have devoted Scholarship program again attracted a signifi cant number of considerable time to the review of students during their applications and the 14 successful Vacation Scholars gained study program with more than 33 reviews conducted in valuable experience working with QIMR scientists between 2009-2010. December 2009 and February 2010.
85 Being a PhD student at QIMR has been extremely rewarding. I’ve been very well supported by my supervisors and the other members of the lab. The expertise and technology available within the lab, and the institute as a whole, has been critical for the success of my PhD project. QIMR has provided me with signifi cant ppersonal support in terms of top-up scholarshipsholarships and travel funding.
Kate Markey, PhD student, Bone Marrow Transplantation Laboratory, Immunology Division
86 COMPLETED STUDENTS 2009-2010
STUDENT UNIVERSITY QIMR SUPERVISOR THESIS PHD Julie BALEN School of Population Health, UQ, Don McManus Determinants of Schistosoma japonicum and soil-transmitted helminth infections, and associated morbidity in Hunan province, China: an epidemiological assessment Daniel BUCHANAN Medicine UQ, Joanne Young and George Mellick Genetic risk factors in Parkinson's disease Melissa BURKE School of Population Health, UQ, Don McManus/Geoff Gobert Transcriptomics of Schistosoma japonicum-induced immunopathology Enda BYRNE School of Medicine, UQ, Peter Visscher and Allan McRae Mitochondrial and autosomal genetic analyses in the Australian Population Justin CHAPLIN QUT, Grant Montgomery Molecular genetics of reproductive disorders Teong CHUAH UQ, Martin Lavin Amber GLANFIELD Public Health, University of Queensland, Malcolm Jones Iron Biology of schistosomes: molecular characterization and vaccine potential of iron homeostasis proteins Davina GORTON School of Veterinary and Biomedical Sciences, James Dr Colleen T cell and B cell Responses in a rat Model of Rheumatic Heart Olive (co-supervisor) Cook University, Disease Matthew JONES UQ School of Medicine Primary Supervisor KK Khanna; Co- Understanding the role of tousled-like kinases in cell cycle supervisors: D. Krause progression Marina KVASKOFF School of Population Health, University of Queensland and Ecole Endometriosis and naevus-associated gene variants in relation to risk Doctorale ED420, Université de Paris XI, France, David Whiteman of cutaneous melanoma Nelson LEE Medicine, UQ, James McCarthy and Qin Cheng Towards the Optimisation of Malaria Rapid Diagnostic Tests Hong Yon LIM School of Molecular and Microbial Sciences, UQ, Kathy Andrews Identifi cation of P. falciparum histone deacetylase 1 (PfHDAC1) interacting proteins Penelope MCBRIDE UQ, Adele Green Cutaneous squamous cell carcinoma & its determinants Luke MEREDITH GMRC, Griffi th University, David Harrich The role of viral and cellular factors in regulating HIV-1 reverse transcription Daniel MORGAN School of Medicine, UQ, Emma Whitelaw Epigenetic Modifi ers of Transgene Silencing Nirmala PANDEYA School of Population Health, University of Queensland, David Risk factors for cancers of the oesophagus: histological subtypes, Whiteman temporal effects and bias Naomi RICHMOND- QUT, Adele Green The Epidemiology of Basal Cell Carcinoma SINCLAIR Kienan SAVAGE UQ School of Medicine Primary Supervisor KK Khanna; Co- BRCA1, KAP1 and DNA damage response supervisors: G.Chenevix-Trench & D.J. Richard Meru SHEEL Life Science, QUT, Michael Batzloff Immunogenicity and protective effi cacy of an anti-Streptococcus pyogenes vaccine candidate in multiple animal species Nadia WHITELAW School of Medicine, UQ, Emma Whitelaw The characterisation of three MOMMEs Daniel WORTHLEY School of Medicine, The University of Queensland, Barbara DNA methylation throughout the human colorectum: person, place Leggett and pathology Hong YOU School of Population Health, UQ, Don McManus/Geoff Gobert/ Cloning, characterisation and vaccine effi cacy of schistosoma Wenbao Zhang japonicum insulin receptors Christine ZHANG Griffi th University, Grant Montgomery Molecular genetics of endometriosis Gu ZHU Medicine UQ, Nick Martin The Quantitative Genetics of Nevus Count and Other Pigmentary Characteristics of the Skin Brendan ZIETSCH Psychology, UQ,Nick Martin Causes of covariation between personality, psychiatric symptoms, and sexual behaviour BSC HONOURS Michelle BAUER Cell and Molecular Biosciences , QUT, David McMillan Evaluation of a multi-epitope group A streptococcal vaccine Priscilla GOH SHI MIN Moleculas Biosciences, University of Queensland, Dr Katja Fischer The role of peritrophins in scabies mite immunity and Dr Angela Mika Thomas HARDING Cell and Molecular Biosciences , QUT, David McMillan Characterisation of the arsenic resistance locus in group G streptococcus Krystal LIANOS B. Appl Sc Hons, Life Sciences, QUT, Emma Whitelaw Dicer effects on epigenetically-sensitive alleles Laken MCGARVEY School of Chemistry and Molecular Biosciences, UQ, Don Gene Expression Profi ling and Flow Cytometry of the Lungs of Naïve McManus/Geoff Gobert and Rechallenged Mice During Migration of Schistosoma japonicum Schistosomula Rachael MCGEORGE Griffi th University, Tina Skinner-Adams Examining the Antimalarial Activity of the HIV Protease Inhibitors Sean MORGAN Cell and Molecular Biosciences , QUT, David McMillan Multilocus Sequence Typing of invasive group G streptococcal isolates from Fiji Alex MULHERIN SBMS, UQ, Christian Engwerda Defi ning the role of dendritic cells in the activation of T cells in response to Leishmania donovani infection. Nurual OSMAN UQ, McDonald/Hill Chronic GVHD Jillian PACKHAM Nan Yang Singapore, Don Gardiner Functional Studies of Ring Exported Protein 1 (REX1) in Plasmodium falciparum Meera PERUMALPILLAI- School of Chemical and Molecular Biosciences, University of Proteomic analyses of egg secretions of schistosomes MCGARRY Queensland, Malcolm Jones Ben RUTHERFORD QUT, Leon Hugo and Peter Ryan Development of Proteomic Techniques for Analysis of Ae. aegypti Proteome
87 COMPLETED STUDENTS 2009-2010 CONTINUED
STUDENT UNIVERSITY QIMR SUPERVISOR THESIS Leigh SCHULTE School of Chemical and Molecular Biosciences, University of Molecular characterization of zinc transporters of schistosomes Queensland, Malcolm Jones Hong YON LIM School of Molecular and Microbial Sciences, University of Identifi cation of P. falciparum histone deacetylase 1 (PfHDAC1) Queensland, Kathy Andrews interacting proteins MASTERS Abraham JOHN MSc Honours, School of Biomolecular and Physical Sciences , Role of ATM (ataxia telangiectasia mutated) in iron metabolism Griffi th University, Nathan Subramaniam Mariska MIRANDA School of Chemistry and Molecular Biosciences, The University of Investigating the role of IGFBP7 in serrated neoplasia of the colon Queensland, Kevin Spring Klara UNOSSON Linköpings University, Sweden, Christian Engwerda Defi ning early immune events following Plasmodium berghei infection. Renate ZELGER Universitäftür Bodenkultur Wien, Don Gardiner Protein traffi cking within the malaria parasite
STUDENT AWARDS 2009-2010
RECIPIENT BESTOWER DATE AWARD REASON Enda Byrne QIMR Jan-10 Dr. Diana Cavaye scholarship Top-up scholarship Australian Centre for Patrick Driguez Aug-09 ACVD Josephine Mackerras Training Scholarship Excellence in PhD research Vaccine Development ACVD Oct-09 Josephine Mackerras Training Scholarship Imogen Gillions QIMR Jul-10 QIMR PhD TopUp Award Australian Society of Kimberley Jones Jun-10 Winner, Post-Graduate Student Category Medical Research Australian Neuroscience Muhsin Karim Jul-09 MC Ainsworth Scholarship in Neurosciences Best Postgraduate Essay Society Best student oral presentation award in the 5th Griffi th University Nov-09 Yi Lu International Student Research Forum Australian Twin Registry Jun-10 Travel award Council of the Lindau Chosen Attended Lindau Meetings of Nobel Meetings of Nobel Jun-10 Young researcher award Laureates Laureates Transplantation Society of Jun-10 Young investigator High ranking abstract at annual meeting Australia and NZ Kate Markey Transplantation Society of Jun-10 KHA Laboratory Award Highest ranking abstract at annual meeting Australia and NZ Australian Society of Award to present at World Transplant May-10 Travel award Immunology Congress, Vancouver The Transplantation Top student abstract submitted to World Jun-10 Travel award Society Transplant Congress ANZ Trustees PhD scholarship in Medical Nico Martin ANZ Banking Corporation Jun-09 Postgraduate Stipend Research Brian Morrison QIMR Jan-10 QIMR PhD TopUp Award Relinquished ANZ Banking Corporation Jun-09 NZ Trustees PhD Scholarship Postgraduate Stipend Miriam Mosing Behavior Genetics Jun-10 BGA Travel Fellowships 2010 BGA Seoul Conf Travel Associaton Australasian Flow Michelle Neller Nov-09 Best Student Presentation Cytometry Group Shu Qin Toh QIMR Mar-10 Honours Scholarships The East Coast Protein Jul-09 Runner Up PhD Talk Prize 2009 Meeting The East Coast Protein Jul-09 Student Travel Award 2009 Simone Reynolds Meeting The ASP and ARC/ NHMRC Network for Jul-09 Student Travel Award 2009 Parasitology RBWH Research Royal Brisbane and Women’s Hospital Research Celestine Rickman Oct-09 RBWH Research Week Foundation Foundation Basic Sciences Prize, $1000. Brisbane Immunology Aug-09 Peter Doherty Medal Best student presentation Group Renne Robb Australian Center for Merit award to attend World Transplant Jul-09 Josephine Mackerras Training Scholarship Vaccine Design Congress
88 QIMR Annual Report 2009/10 STUDENT AWARDS 2009-2010 CONTINUED
RECIPIENT BESTOWER DATE AWARD REASON Behavior Genetics Jun-10 BGA Travel Fellowships 2010 BGA Seoul Conf Travel Association Psychology UQ Jun-10 Annandale Bequest Awardee 2010 Seoul ICTS/BGA Conf Travel Psychology, UQ Jun-10 International Conf Travel Seoul ICTS/BGA Conf Travel Karin Verweij ANZ Trustees PhD scholarship in Medical ANZ Banking Corporation Jan-10 Postgraduate Stipend Research International Congress on Jun-10 Best Poster Presentation, Seoul Meeting RUNNER UP -ICTS Seoul Twin Studies (ICTS) Australasian HIV/AIDS Kylie Warren Sep-09 Best student oral presentation conference Familial Cancer Poster: BRCA2 sequence variants causing Phillip Whiley Conference 2009 Aug-09 Poster Prize missense alterations and spli Committee RBWH Research Royal Brisbane and Women’s Hospital Research Oct-09 RBWH Research week Foundation Foundation Clinical Sciences Prize, $1000. Royal Australasian College of Physicians Cottrell RACP Jan-10 Fellowship Fellowship, $60,000. Royal Australasian College of Physicians IMS Daniel Worthley RACP Jan-10 Travelling Fellowship Overseas Travelling Fellowship, $15,000. NHMRC/CJ Martin Biomedical Overseas NHMRC Jan-10 Fellowship: to Columbia University, NY, US: Postdoctoral Training Fellowship $429,022. NHMRC Jan-10 NHMRC/R.G. Menzies Fellowship: Postdoctoral Training Fellowship
QIMR AWARDS 2009-2010
THE DERRICK-MACKERRAS MEMORIAL LECTURE RALPH DOHERTY QIMR SCIENCE PRIZE Each year, an eminent person is invited to deliver the Derrick- The prestigious Ralph Doherty Science Prize for outstanding Mackerras Memorial lecture, named after the founding Director achievement and leadership in medical research was given to and Deputy Director of QIMR. This year, the Honourable Barry Professor Nick Hayward for his leadership in the fi eld of Jones, AO, gave the lecture titled: My life and times: the factors melanoma genetics and his dedication to QIMR as a researcher, that made me an advocate for science. mentor and ambassador for science in the public arena.
BANCROFT MEDAL POSTDOCTORAL PRIZE The Bancroft Medal is awarded annually to those who have This year’s winner of the QIMR Postdoctoral Prize was Dr made an outstanding contribution to the Institute. This year’s Manuel Ferriera of the Genetic Epidemiology Laboratory for his recipient was Ms Joy Black. Joy has been an outstanding published work on bipolar disorder, autism and schizophrenia employee with QIMR for the last 23 years. As Executive risk. These papers reshaped the research landscape not just Assistant to the Director, Joy has been at the forefront of in psychiatry but for other complex diseases as well and will contact with staff, students, external stakeholders, dignitaries infl uence the research agenda for years to come. and the public and has performed her role with enthusiasm, dignity and hard work. HUMANITARIAN AWARD
FELLOWS OF THE INSTITUTE This annual award has been designed to recognise people within the community who tangibly and actively raise Each year, outstanding individuals are named as Fellows of the awareness and/or revenue for the Institute and our research Institute and this year, Dr Peter Roeser and Professor Peter program. This year we awarded two individuals with the Brooks were named. Humanitarian Award in honour of their signifi cant contributions Dr Roeser was awarded the fellowship in recognition of towards our vision to improve human health and longevity. his contribution as Chair of the QIMR Clinical Trial Protocol They are Del Fitton and Michael Gambaro. Del Fitton is a QIMR Committee since 2003 and his work to ensure that QIMR Ambassador who has raised over $200,000 for QIMR since maintains its high reputation in translational research. 1998 as founder and driving force behind the Darling Downs Equine Extravaganza. Professor Peter Brooks was awarded the fellowship for his contribution to QIMR as NHMRC nominee on the Michael Gambaro has supported QIMR for many years through QIMR Council, Chair of the Appointments and Promotions the Knights of the Round Table event and has helped raise Committee and the Medical Advisory Board and his work in over $1 million for charities in Queensland including QIMR. cementing research partnerships between UQ and QIMR.
89 OTHER AWARDS 2009-2010
BESTOWER RECIPIENT DATE AWARD REASON OF AWARD Dr Barrie Anthony University of Salford, UK June 2010 Hugh Mulligan prize for work of outstanding Excellence in PhD research merit on a thesis for a PhD or MSc in the fi eld of parasitology, bacteriology or tropical medicine Dr Beben Benyamin Heart Foundation November 2009 Best student oral presentation award in the 5th International Student Research Forum Prof Michael Breakspear QLD Offi ce and Health and June 2010 Health Research Fellowship Successful Application Medical Research Dr Manuel Ferreira QIMR Derek Mackerras October 2009 QIMR Postdoctoral Prize Winner Awards Assoc Prof Maher Gandhi Australian Society of Medical June 2010 Winner, Clinical Researcher Category Research Assoc Prof Gail Garvey Queensland Government November 2009 Our Women Our State Awards Promoting Indigenous Women in Science Award Prof Michael Good Australian Museum September CSIRO Eureka Prize for Leadership in Science Leadership in Science 2009 NHMRC December 2009 NHMRC Australia Fellowship Queensland Government June 2010 2010 Queensland Great A renowned national and international health leader who has made a life-long contribution Dr Darren Gray Griffi th University August 2009 Griffi th University Postdoctoral Fellowship Three year fellowship Dr Motoko Koyama Transplantation Society of June 2010 Young investigator award High ranking abstract at Australia and NZ annual meeting Dr Marina Kvaskoff des Labaoratoires SVR December 2009 Jean Darier Award For an epidemiological study project in Dermatology Fondation de France October 2009 Laureate Postdoctoral Award Research excellence Dr Yuesheng Li Australian Research Council January 2010 Future Fellowship Four year fellowship Assoc Prof J. Alejandro Griffi th University July 2009 Graduate Certifi cate of Higher Education López Dr Stuart Macgregor Australian Academy of March 2010 Ruth Stephens Gani Medal Science Prof Don McManus World Health Organisation August 2009 Expert Advisory Panel on Parasitic Diseases WHO Panel Membership (Schistosomiasis) UNICEF/UNDP/World bank/ November 2009 Member of the Disease Reference Group on Member of Reference Group WHO Special Programme Zoonoses and Marginalized Infectious Diseases for Research and Training in of Poverty Tropical Diseases (TDR) Joint International Tropical December 2009 Member of the Scientifi c Program Committee Member of the Scientifi c Medicine Committee Regional Network for Asian November 2009 Elected as Board Member Board Membership Schistosomiasis and Other Helminth Zoonoses (RNAS+) International Association of December 2009 Awarded Cerifi cate of Merit Excellence in hydatid Hydatidology research American Society May 2010 Conferred with honorary membership of Tropical Medicine and Hygiene Assoc Prof Colleen Olive DEEDI May 2010 Queensland International Fellowship Dr Nirmala Pandeya National Health and Medical January, 2010 Post doctoral fellowship Research excellence Research Council Dr Alberto Pinzon-Charry The Australian Institute of November 2009 2009 Queensland Young Tall Poppy Science For excellence in research Policy and Science Award and public engagement Dr Celestine Rickman RBWH Research Foundation October 2009 Royal Brisbane and Women’s Hospital Research RBWH Research Week Foundation Basic Sciences Prize, $1000. Dr Richard Ruddell Australian Liver Foundation January 2010 Career Development Research Fellowship 3yr Fellowship Dr Tina Skinner-Adams CASS Foundation Oct 2009 Travel Award Travel USA Dr Brett Stringer 2nd Eph/Ephrins and Cancer June 2010 Travel Award Outstanding Abstract Prize Meeting Dr Patricia Valery Australian Society January 2009 Queensland Premier’s Award for Health and Presentation on education for Medical Research Medical Research (Senior Researcher category) – intervention for childhood selected as a fi nalist asthma Prof Peter Visscher Australian Academy March 2010 Fellow of Science Dr Logan Walker Genesis Oncology Trust, NZ December 2009 John Gavin Postdoctoral Research Fellowship Competitive post-doctoral fellowship application Assoc Prof David Whiteman Australian Research Council September Future Fellowship Research excellence 2009 Dr Michelle Wykes Queensland State February 2010 Smart Futures Fellowship Government Dr Zhen Zhen Zhao Cancer Council Queensland June 2009 Travel Award BIT’s 2nd Annual World Cancer Congress 90 GRANTS AND FUNDING Major new Grants Awarded 2009-2010 (over $100,000)
SOURCE CHIEF INVESTIGATORS AND PROJECT TITLE TERM PERIOD TOTAL FUNDING
ALF ALF - Hospitality Industry Career Development Fellowship 3 yrs 2010 - 2012 $270,000
ARC RICHARD D: The role of human single-stranded binding protein 4 yrs 2010 - 2013 $686,400
ARC NYHOLT D: Elucidating the molecular mechanisms underlying migraine 4 yrs 2010 - 2013 $686,400
ARC WRAY N: Dissecting the shared genetic architecture of psychiatric & 4 yrs 2010 - 2013 $686,400
ARC LI Y:Development of new interventions and treatment 4 yrs 2010 - 2013 $686,400
ARC WHITEMAN D: Studies in Cancer Control 4 yrs 2010 - 2013 $891,200
ANDREWS K: New Drugs for Malaria that Target Histone Deacetylases (Adminsitered by ARC 4 yrs 2010 - 2013 $154,000 Griffi th University) GORDON L: Work Life after a diagnosis of breast, prostate and colorectal cancer ARC 3 yrs 2010 - 2012 $240,000 (Administered by Griffi th University) KHANNA K: Functional characterization of SSB2: a novel single stranded ARC 3 yrs 2010 - 2012 $310,000 DNA binding protein (Administered by Griffi th University) LAVIN M et al: To investigate the role of the protein kinase SMG-1 in the stress response ARC 3 yrs 2010 - 2012 $285,000 (Administered by University of Queensland) LAVIN M: Characterisation of the novel mitochondrial protein ARC 3 yrs 2010 - 2012 $300,000 (CABC1/ADCK3) (Administered by University of Queensland)
ARC MARTIN N: Identifying genes for cognition (Administered by University of Queensland) 3 yrs 2010 - 2012 $328,000
CCQ SCHMIDT C: Analysis of the ant-tumour immune response and its target antigens 2 yrs 2010 - 2011 $192,500
CCQ BOYLE G: Functional interplay between hSSBI and the NRM Complex 2 yrs 2010 - 2011 $100,000
CCQ MacDONALD K: Analysis of a novel regulatory T cell induced by allore activity 2 yrs 2010 - 2011 $200,000
CCQ RICHARD D: Functional interplay between hSSBI and the NRM Complex 2 yrs 2010 - 2011 $200,000
DEEDI KHANNA R: Australia - US Vaccine Alliance 4 yrs 2009 - 2012 $1,272,000
GOT WALKER L: The role of germline DNA copy number variation in familial breast cancer risk 2 yrs 2010 - 2011 NZ$140,000
LFA CHARMSAZ S: EphA proteins may be therapy targets for Leukaemia 3 yrs 2010 - 2012 $120,000
SUBRAMANIAM N: Study of alcohol and iron interactions, non HFE haemochromatosis and LRC hepatic fi brosis (Administered by University 3 yrs 2010 - 2012 $202,592 of Queensland)
NBCF CHEVENIX-TRENCH G:Towards targeted treatments for advanced basal breast cancer 2 yrs 2010 - 2011 $199,996
NHF BATZLOFF M et al: Protection mediated by a vaccine candidate for rheumatic heart disease 2 yrs 2010 - 2011 $129,000
NHMRC MOUNSEY K: Molecular mechanisms of ivermectin resistance in the ectopar 2 yrs 2010 - 2011 $142,500
NHMRC Practioner Fellowship (Administered by University of Tasmania) 5 yrs 2010 - 2014 $271,133
NHMRC MACGREGOR S: Statistical Methods for Gene Mapping 4 yrs 2010 - 2013 $417,000
McMANUS D: Impact of the Three Gorges Dam on transmission and future control of NHMRC 5 yrs 2010 - 2014 $1,347,500 human schistosomiasis in China GARDINER D et al: Traffi cking of the major virulence protein tp the host cell surface in NHMRC 3 yrs 2010 - 2012 $188,500 malaria parasite infceted erythrocytes (administered by LaTrobe University)
NHMRC FISCHER K: Functional Analysis of Novel Scabies Mite Serpins 3 yrs 2010 - 2012 $321,518
NHMRC HAYWARD N: Ongogenic fusions in melanoma 3 yrs 2010 - 2012 $417,375
ANDERSON G et al: Assessment of oxidant stress and mitochondrial dysfunction in younf NHMRC 3 yrs 2010 - 2012 $580,500 adults with iron loading diseases
NHMRC ANDERSON G et al: Red cell disorders and the regulation of iron homeostasis 3 yrs 2010 - 2012 $583500
FERREIRA M et al: Finding the genetic causes of asthma: the Australian Asthma Genetics NHMRC 3 yrs 2010 - 2012 $1,659,013 Consortium VISSCHER P et al: Explaining the Dark Matter of Genome-wide Association Studies for NHMRC 2 yrs 2010 - 2011 $264,750 Complex Disease
NHMRC MULVENNA J: Unravelling the tetraspanin web in the schistosome tegument 3 yrs 2010 - 2012 $288,750
GATTON M et al: Development & application of theoretical models of Plasmodium NHMRC 3 yrs 2010 - 2012 $304,125 transmission to guide Malaria elimination CHEVENIX-TRENCH G et al: Identifi cation of the gene for a novel syndrome of gastric NHMRC 3 yrs 2010 - 2012 $364,875 adenocarcinoma and promal polyposis of the stomach
91 GRANTS AND FUNDING CONTINUED
SOURCE CHIEF INVESTIGATORS AND PROJECT TITLE TERM PERIOD TOTAL FUNDING
NHMRC BURROWS S et al: Investigations into the biology and functionality of the T Cell Receptor 3 yrs 2010 - 2012 $409,125
NEALE R et al: Does vitamin D supplementation reduce mortality for for older Adults - a NHMRC 3 yrs 2010 - 2012 $427,700 pilot trial MONTGOMERY G et al: Defi ning the mechanism of melanoma & naevus risk on NHMRC 3 yrs 2010 - 2012 $505,300 Chromosome 9p21 SUBRAMANIAM N et al: Examining the relationship between MATRIPTASE-2 & HEM- NHMRC 3 yrs 2010 - 2012 $514,500 OJUVELIN, two essentials regulators of iron homeostasis NHMRC ENGWERDA C et al: Tissue specifi c antigen presenting cell functions during infection 3 yrs 2010 - 2012 $535,500 NHMRC SUHRBIER A: The role of macrophage SerpinB2 in infl ammation 3 yrs 2010 - 2012 $563,500 HAQUE A: IL-2/anti-IL-2 complexes in immunity to blood stage malaria infection and NHMRC 3 yrs 2010 - 2012 $565,500 prevention of cerebral immunopathology OLIVE C et al: A dual antigen sythentic peptide subunit vaccine approach to prevent NHMRC 3 yrs 2010 - 2012 $582,450 streptococcal associated cardiovascular disease NHMRC NEALE R et al: Patterns of care and quality of life in patients with pancreatic cancer 3 yrs 2010 - 2012 $655,213 SUHRBIER A: Inhibition of interferon-alpha/beta by chikungunya virus and the induction of NHMRC 3 yrs 2010 - 2012 $683,875 arthritis WRAY N et al: Towards an etiological understanding of the comorbidity of psychotic NHMRC 3 yrs 2010 - 2012 $845,938 disorders NYHOLT D: Elucidating the molecular mechanisms underlying migraine and endometriosis NHMRC 5 yrs 2010 - 2014 $618,750 via genetic dissection WRAY N: Dissecting the shared genetic architecture of psychiatric & psychological traits NHMRC 5 yrs 2010 - 2014 $560,000 with application to prediction of genetic risk MONTGOMERY G: Identifi cation of rare autosomal copy number variant (CNV) events from NHMRC 5 yrs 2010 - 2014 $677,500 SNP and CNV probes KHANNA K: Functional analysis of hSSB1 and hSSB2, two newly discovered single- NHMRC 5 yrs 2010 - 2014 $766,250 stranded DNA binding proteins VISSCHER P: Quantify and partition the contribution of common variants, rare variants and NHMRC 5 yrs 2010 - 2014 $766,250 CNV to genetic risk of disease susceptibility HILL G: Immunological therapies for cancer,chronic infection & autoimmunity (Administered NHMRC 5 yrs 2010 - 2014 $2,026,000 by University of Queensland) LAVIN M et al: Rad50 protects the integrity of the genome to minimise disease risk NHMRC 3 yrs 2010 - 2012 $505,500 (Administered by University of Queensland) LAVIN M: Role of Senataxin in protecting against neurodegeneration (Administered by NHMRC 3 yrs 2010 - 2012 $520,500 University of Queensland) NIAID DOOLAN D: Proteome-wide cellular immunity approach to P. falciparum 4 yrs 2009 - 2013 US$2,479,629 NIH-WU MARTIN N et al: Genetic Epidemiology of Acoholism AND Comorbidity - Project 7 5 yrs 2009 - 2014 US$1,264,016 RAMM G et al: Continuation, Expansion & merging of the Biliary Atresia Research NIH-WU 5 yrs 2009 - 2014 US$162,000 Consortium RISS SCHMIDT C: Dendritic Cell Immunotherapy for Glioblastoma 1 yrs 2009 - 2010 $100,000 TGEN HAYWARD N: Identifi cation of novel melanoma risk genes using high throughput genomics 1 yrs 2009 - 2010 $293,020 UNI MELB YOUNG J: UniMelb Colobrative Research - Colorectal Cancer 2 yrs 2009 - 2011 $146,000
LEGEND FOR SOURCE OF FUNDS
ALF Australian Leukaemia Foundation NHF National Heart Foundation
ARC Australian Research Council NHMRC National Health and Medical Research Council
CCQ Cancer Council Queensland NIAID National Institute of Allergy and Infectious Disease
DEEDI Dept of Employment, Economic Development & Innovation NIH-WU National Institutes of Health
GOT Genesis Oncology Trust RISS NCRIS - Research Infrastructure Support Services Limited
LFA Leukaemia Foundation Australia TGEN Translational Genomics Research Institute
LRC Leukaemia Research Centre Uni Melb University of Melbourne
NBCF National Breast Cancer Foundation
92 QIMR Annual Report 2009/10 QIMR PATENTS
TITLE INVENTOR(S) APPLICATION NUMBER Patent Families Managed By QIMR
Novel molecules Toni Antalis; John Hooper PCT/AU1998/000085
Immunogenic agent and pharmaceutical composition for use against Michael Good; Mary Stevenson PCT/AU2004/000870 homologous and heterologous pathogens G-CSF derivative for inducing immunological tolerance Geoff Hill; Kellie MacDonald; Edward Morris PCT/AU2004/001116
Polytope vaccines Andreas Suhrbier; Scott Thomson; PCT/AU1995/000461 Rajiv Khanna; Scott Burrows; Barbara Coupar; Denis Moss Synthetic peptides and vaccines comprising the same Juan Cooper; Wendy Relf; Michael Good; Allan Saul PCT/AU1995/000681
Cytotoxic T-cell epitopes Denis Moss; Scott Burrows; Rajiv Khanna; PCT/AU1995/000140 Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier EBV CTL epitopes Rajiv Khanna; Beverley Kerr; Ihor Misko; PCT/AU1997/000328 Denis Moss; Scott Burrows CTL epitopes from EBV Martina Sherritt; Scott Burrows; Rajiv Khanna PCT/AU1998/000531
EBV peptide epitopes, polyepitopes and delivery system therefor Rajiv Khanna; Jaikumar Duraiswamy PCT/AU2003/001451
Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising Rajiv Khanna; Rebecca Elkington; Susan Walker PCT/AU2002/000829 same and diagnostic and prophylactic and therapeutics uses therefor
Human cytomegalovirus immunotherapy Rajiv Khanna PCT/AU2005/001798
Peptide compounds Istvan Toth; William Gibbons PCT/GB1993/001558
Novel human ssDNA binding proteins and methods of cancer diagnosis Kum Kum Khanna; Derek Richard; PCT/AU2008/000181 Malcolm White Therapeutic antibodies, antibody fragments and antibody conjugates Michael Good; Michael Batzloff; US 11/950,217 Manisha Pandey Synthetic chimeric peptides Katin Nordstrom; Michael Good; US12/333,222 Michael Batzloff Cancer drug targets and methods of diagnosis Andrew Boyd; Bryan Day; Brett Stringer PCT/AU2009/000672
Human cytomegalovirus immunotherapy Rajiv Khanna 61/347,352
QIMR Patent Families Managed Outside QIMR
Materials and methods relating to stem cell mobilization by multi-pegylated Geoff Hill PCT/US2009/062471 granulocyte colony stimulating factor Detection of genes Catherine Hyland PCT/AU1994/000506
Receptor ligand system and assay Andrew Boyd US 1998/104340
Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis Andrew Boyd PCT/AU2004/000142
A method of treatment Andrew Boyd PCT/AU1999/000931
Differentiation modulating agents and uses therefore Johannes Prins PCT/AU2005/000008
Treatment for EBV associated disease Denis Moss PCT/AU2006/001854
Vaccine Michael Batzloff US 2003/706275
Melanoma-associated MHC Class 1 Associated oligopeptide and its use Chris Schmidt PCT/EP2006/008533
Method for screening for anticancer agents Kum Kum Khanna PCT/GB2008/003390
A novel growth factor and a genetic sequence encoding same Nicholas Hayward PCT/AU1996/000094
Patent Families Resulting from Industry Sponsored Contract Research Performed at QIMR
Treatment of virally induced lesions Andreas Suhrbier PCT/AU2008/000596
Use of angeloyl-substituted ingenones in combination with other agents to Andreas Suhrbier; Peter Parsons PCT/AU2006/001700 treat cancer Treatment of solid tumours Andreas Suhrbier PCT/AU2005/001827
Chaperonin 10 modulators of toll-like receptors inducible cytokine and Andreas Suhrbier PCT/AU2005/000041 cytokine secretion Treatment of prostate cancer Peter Parsons PCT/AU2001/000966
Therapeutic agents I Andreas Suhrbier; Peter Parsons PCT/AU2001/000679
Therapeutic agents II Andreas Suhrbier; Peter Parsons PCT/AU2001/000680
Therapeutic agents III Andreas Suhrbier; Peter Parsons PCT/AU2001/000678
93 QIMR PATENTS CONTINUED
TITLE INVENTOR(S) APPLICATION NUMBER Patents Families Managed by QIMR as Trustee for the CRC-Vaccine Technology
T helper epitopes David Jackson PCT/AU2000/000070
Novel immunogenic lipopeptides comprising T-helper and cytotoxic T David Jackson PCT/AU2003/001019 lymphocyte (CTL) epitope Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes David Jackson PCT/AU2003/001018
Truncated LHRH formulations David Jackson PCT/AU2005/001383
Immunogenic molecules David Jackson PCT/AU2006/000162
Trade Marks Managed by QIMR
MARK STATUS AUSTRALIAN TRADE MARK NUMBER Queensland Institute of Medical Research Registered/Protected 1233303
QIMR Registered/Protected 1233307
Hexagons device Registered/Protected 1233317
Dividends Defeating Disease Registered/Protected 1116557
OFFICIAL COMMITTEES 2009-2010
QIMR COUNCIL Animal Ethics Committee Dr Andrew Redmond The Smart State Medical Research (AEC) Steering Committee ProfessorJohn Hay Dr Christopher Schmidt (Chair from 24/09/09) Scientifi c Sub-Committee (AEC) Dr Tom Sculley Professor John Hay (Chair) (From 24/09/09) Mr Christopher Coyne Professor Kadaba Sriprakash (Acting Chair to 23/09/09) Human Research Ethics Committee Mr Chris Coyne (Chair) Dr Brett Stringer (HREC) (To 24/09/09) Professor Emeritus Bryan Campbell Dr Marion Woods Dr Ian Wilkey (Chair) Mr Rod Wylie Professor Judith Clements Mrs Rebecca Lacey – Secretary (To Dr Roger Allison Mr John Parnell Mr Paul Fennelly 25/06/10) Ms Madeline Brennan Mr Alan Stockman Professor Lyn Griffi ths Mrs Gwen Eardley Clinical Trial Protocol Committee Ms Rosemary Hood Assoc Professor Paula Marlton (CTPC) Mr Angus Edmonds Dr Rick Andrew Dr Jeannette Young Dr Peter Roeser (Chair) Ms Clare Endicott (To 01/11/09) Ms Karen Thompson Dr Graham Radford-Smith (Deputy COMMITTEES REPORTING Mr Colin Forrest (From 15/06/10) Ms Donna Hancock Chair) (To 30/06/10) TO COUNCIL Mrs Mary Mackenzie Ms Beatrix Wanrooy - Secretariat Dr Geoff Beadle Mr David Russell Finance and Audit Committee Professor Andrew Boyd Dr Christopher Schmidt COMMITTEES REPORTING Mr Paul Fennelly (Chair) Dr Suzanne Elliott TO THE DIRECTOR Dr Katharine Trenholme Professor Emeritus Bryan Campbell Mr Paul Fahey (To 26/03/10) Dr Tom Sculley Senior Executive Team Mr Rod Wylie Professor James McCarthy Dr Julie-Anne Tarr (To 30/06/10) Professor John Hay (ex offi cio) (To 18/12/09) Dr Agnieszka Mitchell Professor Michael Good (Chair) (From 24/09/09) Dr Agnieszka Mitchell (ex offi cio) Dr Michael Moore Professor Adèle Green Appointments and Promotions Ms Rebecca Lacey – Secretary (To Professor Denis Moss Professor Andrew Boyd Committee 25/06/10) Dr Lesley Ross-Lee Ms Donna Hancock Professor Judith Clements (Chair) Dr Christopher Schmidt Scientifi c Sub-Committee (HREC) Professor Brian Kay Professor Graham Brown Dr Joanna Youngson Dr Katharine Trenholme (Chair) Professor Martin Lavin Professor Julie Campbell Mrs Rebecca Lacey – Secretary (To Dr Ian Wilkey (Deputy Chair) Dr Agnieszka Mitchell Professor Lyn Griffi ths 25/06/10) (01/02/10 to 31/03/10) Mr Paul Fahey (To 25/03/10) Professor James McCluskey Professor Emma Whitelaw Assoc Professor Gail Garvey Council Personnel Administration Dr Jurgen Michaelis Committee Assoc Professor David Whiteman Dr Helen Leonard Professor Joe Trapani Mr Paul Fennelly (Chair) (01/02/10 to 30/06/10) Dr Agnieszka Mitchell Professor Michael Good Mr Chris Coyne Dr Julie-Anne Tarr (ex offi cio) (To 30/06/10) (To 18/12/09) Ms Patricia McCormack Ms Nerida Fox – Secretary Mr Rod Wylie
94 QIMR Annual Report 2009/10 Safety Committee Professor Grant Montgomery Seminars Committee Dr Joanna Youngson Dr Helen Leonard (Chair) Ms Michelle Neller Professor Martin Lavin (Chair) Ms Mandie Quince – Secretary Dr Glen Boyle (Deputy Chair) Dr Chris Peatey Professor Michael Good IT Committee Dr Michael Batzloff Dr Peter Ryan (To 30/06/10) Dr Dale Nyholt (Chair) Dr Anita Burgess (From 20/05/10) Dr Kevin Spring Professor Geoff Hill Mr Harry Beeby Mr Ron Buttenshaw Dr Katherine Trenholme Professor Grant Montgomery Dr Glen Boyle Mr Paul Collins (To 10/12/09) Professor Emma Whitelaw Assoc Professor Scott Burrows Dr Juan Cooper (To 21/01/10) Dr Patricia Valery Ms Jann O’Keefe (To 11/12/09) Dr Juan Cooper (To 21/01/10) Ms Gwen Cuthbert Dr Margie Wright Ms Deborah Bishop Mr Michael Creevey Ms Nicci Wayte (To 01/05/10) (From 18/01/10) Mr Macky Edmundson (From 13/11/09) (From 15/04/10) Dr Terry Walsh Consumer and Community Mr Mark Feodoroff (To 01/04/10) Dr Geoff Gobert Dr Andrea Whittaker Participation Committee Ms Michelle Gatton Mr Andrew King (From 30/06/10) Professor Adèle Green (Chair) Ms Donna Hancock Dr Agnieszka Mitchell Professor Gail Williams Ms Deborah Bishop (To 01/05/10) Ms Heather Matthews Professor Denis Moss Ms Simone Cross Dr Agnieszka Mitchell Ms Michelle Richards Joint Consultative Committee Mr Ken Dutton-Regester Mr Mark Spanevello Dr Christine Rzepczyk Mr Trevor Greenaway (Chair) Assoc Professor Gail Garvey Assoc Professor Nathan Mr Alan Stockman Ms Pauline Buratowski Ms Sara-Jane Georgeson Subramaniam (To 30/06/10) Dr Joanna Youngson Ms Melina Georgousakis Professor Peter Upcroft (To 08/03/10) Dr Anita Burgess (From 20/05/10) (To 19/01/10) Mr Christopher Ward Dr Julie-Anne Tarr (To 18/12/09) Mr Paul Collins (To 20/05/10) Ms Imogen Gillions (To 24/12/09) Ms Donna Hancock Professor Michael Good Ms Vivienne Johnson Ms Jann O’Keefe (To 11/12/09) (From 14/04/10) (To 30/06/10) Professor Denis Moss Records and Information Professor Peter Upcroft Dr David McMillan Dr Arne Mould Committee Ms Jo Chow – Secretary Dr Penny Webb Dr Amanda Spurdle (To 12/03/10) ProfessorMartin Lavin (Chair) Professor Emma Whitelaw Ms Jann O’Keefe (To 11/12/09) Ms Jaclyn Hawdon – Secretary (From Dr Suyinn Chong Dr Julie-Anne Tarr (To 18/12/09) Ms Natasha Stevens 11/02/10) Dr Deepak Darshan QPSU Representative Ms Sarah Tennant Dr Katja Fischer Equipment Committee QNU Representative Dr Vicki Whitehall Mr Owen Griffi ths Professor Andrew Boyd (Chair) Medical Advisory Board Mr Simon Jaremczuk Professor Greg Anderson COMMITTEES Professor Andrew Boyd REPORTING TO SET Mr Jason Jeffery (To 15/01/10) Dr Juan Cooper (To 21/01/10) (Deputy Chair) Ms Nelly Kremko Mr Michael Creevey Dr Paul Bartley Strategic Science Committee (To Dr Rachel Neale (from 12/11/09) 30/06/10) Dr Geoff Beadle Dr Wayne Schroeder Mr Macky Edmundson Professor Martin Lavin (Chair) Dr Ian Bunce (from 21/01/10) Dr Daniel Wallace Professor Greg Anderson Dr Don Cameron Professor James McCarthy Dr Michelle Wykes Assoc ProfessorGail Garvey Professor Adèle Green Mr Chris Ward (To 24/12/09) Professor Michael Good Professor Michael Good QIMR TRUST Dr Emma Whitelaw (To 30/06/10) Professor Adele Green Ms Jane Seawright (Acting Chair) Mrs Joanna Youngson Professor Barbara Leggett Professor Geoff Hill ProfessorJohn Hay Higher Degrees Committee Dr Joseph McCormack Professor James McCarthy (From 24/09/09) Assoc Professor Nathan Dr Paul Sandstrom Professor Emma Whitelaw Ms Patricia McCormack Subramaniam (Chair) Dr Mark Smithers Ms Mandie Quince – Secretary Mr David Stirling (To January 2010) Dr John Varghese Mr Rod Wylie Dr Penny Webb Clinical and Translational Dr Michael O’Rourke Committee (To 30/06/10) (Chair from August 2010) COMMITTEES REPORTING TO Professor Andrew Boyd (Chair) Dr Glen Boyle (From 10/08/09) Mentoring Committee TRUST/COUNCIL Assoc ProfessorGail Garvey Ms Simone Cross Assoc Professor David Whiteman (Chair) Investment Committee Professor Michael Good Professor Joy Cumming Professor Georgia Mr Rod Wylie (Chair) Professor Denise Doolan Chenevix-Trench Professor Adele Green Mr Bruce Phillips (From 10/08/09) Professor Nick Hayward Professor Geoff Hill Mr David Stirling Professor Michael Good Assoc Professor Rajiv Khanna Dr Corinne Lendon (To 18/01/10) (To 30/06/10) Professor Emma Whitelaw Dr Alex Loukas (To 31/12/09) Marketing Committee Dr Judith Greer Dr Agnieszka Mitchell Ms Patricia McCormack Scientifi c Advisory Board Dr Sergei Kozlov Professor Denis Moss Ms Jane Seawright Professor Graham Brown (Chair) Assoc Professor Alan Lawson Dr Grant Ramm Professor Dallas English Dr Kelli MacDonald Dr Chris Schmidt Professor Douglas Hilton Dr David McMillan (From 10/08/09) Assoc Professor Nathan Subramaniam ProfessorJoe Trapani
95 2009-2010 SCIENTIFIC PUBLICATIONS
Agrawal A, Lynskey MT, Bucholz Viel A, Bernard L, Radice P, Szabo Arnold JM, Choong DY, Thompson single nucleotide polymorphisms in KK, Madden PAF, Martin NG, Heath CI, Foretova L, Zikan M, Claes K, ER; kConFab, Waddell N, ovarian cancer survival. International AC. Using twin data to address the Greene MH, Mai PL, Rennert G, Lindeman GJ, Visvader JE, Journal of Gynecological Cancer. relationship between early cannabis Lejbkowicz F, Andrulis IL, Ozcelik Campbell IG, Chenevix-Trench 20(4):529-536. 2010 use and elevated mood (mania). H, Glendon G; OCGN, Gerdes AM, G. Frequent somatic mutations of Behavior Genetics 39(6):632-633. Thomassen M, Sunde L, Caligo MA, GATA3 in non-BRCA1/BRCA2 familial Bonthuis M, Hughes MC, Ibiebele 2009 Laitman Y, Kontorovich T, Cohen S, breast tumors, but not in BRCA1-, TI, Green AC, van der Pols JC. Kaufman B, Dagan E, Baruch RG, BRCA2- or sporadic breast tumors. Dairy consumption and patterns Agrawal A, Sartor CE, Lynskey MT, Friedman E, Harbst K, Barbany- Breast Cancer Research & Treatment. of mortality of Australian adults. Grant JD, Pergadia ML, Grucza R, Bustinza G, Rantala J, Ehrencrona 119(2):491-6. 2010 European Journal of Clinical Nutrition. Bucholz KK, Nelson EC, Madden H, Karlsson P, Domchek SM, 64(6):569-77. 2010 PAF, Martin NG, Heath AC. Evidence Nathanson KL, Osorio A, Blanco Azzato EM, Tyrer J, Fasching Becherel OJ, Jakob B, Cherry for an Interaction Between Age at I, Lasa A, Benítez J, Hamann U, PA, Beckmann MW, Ekici AB, First Drink and Genetic Infl uences Hogervorst FB, Rookus MA, Collee Schulz-Wendtland R, Bojesen AL, Gueven N, Fusser M, Kijas on DSM-IV Alcohol Dependence JM, Devilee P, Ligtenberg MJ, van SE, Nordestgaard BG, Flyger, H; AW, Peng C, Katyal S, McKinnon Symptoms. Alcoholism-Clinical and der Luijt RB, Aalfs CM, Waisfi sz Milne, RL; Arias, JI; Menendez, P; PJ, Chen J, Epe B, Smerdon SJ, Experimental Research. 33(12):2047 Q, Wijnen J, van Roozendaal CE; Benitez, J; Chang-Claude, J; Hein, Taucher-Scholz G, Lavin MF. -2056. 2009 HEBON, Peock S, Cook M, Frost R; Wang-Gohrke, S; Nevanlinna, CK2 phosphorylation-dependent D, Oliver C, Platte R, Evans DG, H; Heikkinen, T; Aittomaki, interaction between aprataxin and Ahlbom A, Feychting M, Green A, Lalloo F, Eeles R, Izatt L, Davidson K; Blomqvist, C; Margolin, S; MDC1 in the DNA damage response. Kheifets L, Savitz D, Swerdlow A. R, Chu C, Eccles D, Cole T, Mannermaa, A; Kosma, VM; Kataja, Nucleic Acids Research. 38(5):1489- Mobile Phone Use and Brain Tumors Hodgson S; EMBRACE, Godwin V; Beesley, J; Chen, XQ; Chenevix- 503. 2010. - A Review of the Epidemiological AK, Stoppa-Lyonnet D, Buecher Trench, G; Couch, FJ; Olson, Beckham SA, Boyd SE, Reynolds Evidence. Epidemilogy. B, Léoné M, Bressac-de Paillerets JE; Fredericksen, ZS; Wang, XS; S, Willis C, Johnstone M, Mika 20(6):S241-S241, Suppl. S. 2009 B, Remenieras A, Caron O, Lenoir Giles, GG; Severi, G; Baglietto, L; A, Simerská P, Wijeyewickrema GM, Sevenet N, Longy M, Ferrer Ainger SA, Wong SS, Roberts Southey, MC; Devilee, P; Tollenaar, SF, Prieur F; GEMO, Goldgar D, LC, Smith AI, Kemp DJ, Pike RN, DW, Leonard JH, Sturm RA. The RAEM; Seynaeve, C; Garcia- Fischer K. Characterization of a Miron A, John EM, Buys SS, Daly Closas, M; Lissowska, J; Sherman, role of MC1R in melanogenesis of MB, Hopper JL, Terry MB, Yassin serine protease homologous to house ME; Bolton, KL; Hall, P; Czene, melanocytic cells in co-culture with Y; Breast Cancer Family Registry, dust mite group 3 allergens from K; Cox, A; Brock, IW; Elliott, GC; keratinocytes. Journal of Investigative Singer C, Gschwantler-Kaulich D, the scabies mite Sarcoptes scabiei. Reed, MWR; Greenberg, D; Anton- Dermatology. 129(12):2920-2920. Staudigl C, Hansen TO, Barkardottir Journal of Biological Chemistry. Culver, H; Ziogas, A; Humphreys, 2009 RB, Kirchhoff T, Pal P, Kosarin K, 4;284(49):34413-22. 2009 M; Easton, DF; Caporaso, Offi t K, Piedmonte M, Rodriguez Anderson GJ, Vulpe CD. Mammalian NE; Pharoah, PDP. Kathleen Beesley VL, Janda M, Eakin EG, GC, Wakeley K, Boggess JF, Basil J, iron transport. Cellular and Molecular Cuningham Fdn Consortium. Auster JF, Chambers SK, Aitken JF, Schwartz PE, Blank SV, Toland AE, Life Sciences 66(20):3214-61. 2009 Dunn J, Battistutta D. Gynecological Montagna M, Casella C, Imyanitov Association Between a Germline OCA2 Polymorphism at Chromosome cancer survivors and community Anderson GJ. Things that go BMP EN, Allavena A, Schmutzler RK, 15q13.1 and Estrogen Receptor- support services: referral, awareness, in the liver: bone morphogenetic Versmold B, Engel C, Meindl A, Negative Breast Cancer Survival. utilization and satisfaction. Psycho- protein 6 and the control of body iron Ditsch N, Arnold N, Niederacher Journal of the National Cancer oncology 19(1):54-61. 2010 homeostasis. Hepatology. 50(1):316- D, Deissler H, Fiebig B, Suttner Institute 102(9):650-662. 2010 9. 2009 C, Schönbuchner I, Gadzicki D, Beesley VL, Clavarino AM, Webb Caldes T, de la Hoya M, Pooley Baade PD, Youlden DR, Valery PC, PM, Wyld DK, Francesconi AB, Anderson S, Panizza B. Are cell KA, Easton DF, Chenevix-Trench G; Hassall T, Ward L, Green AC, Aitken Horwood KR, Doecke JD, Loos CA, salvage and autologous blood CIMBA. Common variants in LSP1, JF. Trends in incidence of childhood Green AC. Ranked importance of transfusion safe in endonasal 2q35 and 8q24 and breast cancer cancer in Australia, 1983-2006. outcomes of fi rst-line versus repeated surgery? Otolaryngology - Head and risk for BRCA1 and BRCA2 mutation British Journal of Cancer. 102(3): chemotherapy among ovarian cancer Neck Surgery. 142(3 Suppl 1):S3-6. carriers. Human Molecular Genecist. 620-626. 2010. patients. Support Care Cancer. (Epub 18(22):4442-56. 2009 Review. 2010 ahead of print) 2009 Baglietto L, Lindor NM, Dowty Andrews DM, Estcourt MJ, Antonsson A, Green AC, Mallitt JG, White DM, Wagner A, Gomez Bellingham M, Fowler PA, Andoniou CE, Wikstrom ME, Khong KA, O'Rourke PK, Pawlita M, Garcia EB, Vriends AH; Dutch Amezaga MR, Whitelaw CM, A, Voigt V, Fleming P, Tabarias H, Waterboer T, Neale RE. Prevalence Lynch Syndrome Study Group, Rhind SM, Cotinot C, Mandon- Hill GR, van der Most RG, Scalzo and stability of antibodies to the BK Cartwright NR, Barnetson RA, Pepin B, Sharpe RM, Evans NP. AA, Smyth MJ, Degli-Esposti MA. and JC polyomaviruses: a long-term Farrington SM, Tenesa A, Hampel Foetal Hypothalamic and Pituitary Innate immunity defi nes the capacity longitudinal study of Australians. H, Buchanan D, Arnold S, Young J, Expression of Gonadotrophin- of antiviral T cells to limit persistent Journal of General Virology. 91 Walsh MD, Jass J, Macrae F, Antill Releasing Hormone and Galanin infection. Journal of Experimental (Pt 7):1849-53. 2010 Y, Winship IM, Giles GG, Goldblatt Systems is Disturbed by Exposure Medicine. 207(6):1333-1343. 2010 Apte SH, Groves P, Olver S, Baz J, Parry S, Suthers G, Leggett B, to Sewage Sludge Chemicals via Andrews KT, Tran T, Bozdech Z, A, Doolan DL, Kelso A, Kienzle N. Butz M, Aronson M, Poynter JN, Maternal Ingestion. Journal of IFN-gamma inhibits IL-4-induced type Skinner-Adams T, Lucke A, Boyle Baron JA, Le Marchand L, Haile R, Neuroendocrinology. 22 (6): 2 cytokine expression by CD8 T cells G, Fairlie D. Pharmacodynamics of Gallinger S, Hopper JL, Potter J, 527-533. 2010 in vivo and modulates the anti-tumor de la Chapelle A, Vasen HF, Dunlop Hydroxamate-based HDAC Inhibitors Benyamin B, Ferreira MA, response. Journal of Immunology. MG, Thibodeau SN, Jenkins in Plasmodium Falciparum. American Willemsen G, Gordon S, 185(2):998-1004. 2010 MA.Risks of Lynch syndrome cancers Journal of Tropical Medicine and Middelberg RP, McEvoy BP, for MSH6 mutation carriers. Journal Hygiene. 81(5):158 Suppl. S. 2009 Arden KE, Faux CE, O'Neill NT, Hottenga JJ, Henders AK, National Cancer Institute 102(3):193- McErlean P, Nitsche A, Lambert Campbell MJ, Wallace L, Frazer Antoniou AC, Sinilnikova OM, 201. 2010 SB, Nissen MD, Sloots TP, Mackay IH, Heath AC, de Geus EJ, McGuffog L, Healey S, Nevanlinna IM. Molecular characterization and Batra Jyotsna, Tan Olivia L, O’Mara Nyholt DR, Visscher PM, Penninx H, Heikkinen T, Simard J, Spurdle distinguishing features of a novel Tracy, Zammit Rebecca, Nagle BW, Boomsma DI, Martin NG, AB, Beesley J, Chen X; Kathleen human rhinovirus (HRV) C, HRVC- Christina M, Clements Judith Montgomery GW, Whitfi eld JB. Cuningham Foundation Consortium QCE, detected in children with fever, A, Kedda, Mary-Anne, Spurdle Common variants in TMPRSS6 for Research into Familial Breast cough and wheeze during 2003. Amanda B. Kallikrein-related are associated with iron status and Cancer, Neuhausen SL, Ding YC, Journal of Clinical Virology. 47(3):219- peptidase 10 (KLK10) expression and erythrocyte volume. Nature Genetics. Couch FJ, WangX, Fredericksen Z, 23. 2010 Peterlongo P, Peissel B, Bonanni B, 41(11):1173-5 2009
96 QIMR Annual Report 2009/10 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
Brennan RM, Burrows JM, to Streptococcus pyogenes among Burrows SR, Chen Z, Archbold GE, Molina DM, Burk CR, Waisberg Bell MJ, Bromham L, Csurhes Mumbai school children. Journal of JK, Tynan FE, Beddoe T, Kjer- M, Jasinskas A, Tan XL, Doumbo PA, Lenarczyk A, Sverndal J, Medical Microbiology. 59(2):220-223. Nielsen L, Miles JJ, Khanna R, S, Doumtabe D, Kone Y, Narum Klintenstedt J, Pender MP, Burrows 2010 Moss DJ, Liu YC, Gras S, Kostenko DL, Liang XW, Doumbo OK, Miller SR. Strains of Epstein-Barr virus L, Brennan RM, Clements CS, LH, Doolan DL, Baldi P, Felgner PL, Branstrom R, Chang YM, Kasparian infecting multiple sclerosis patients. Brooks AG, Purcell AW, McCluskey Pierce SK. A prospective analysis N, Affl eck P, Tibben A, Aspinwall Multiple Sclerosis. 16(6):643-51. 2010 LG, Azizi E, Baron-Epel O, J, Rossjohn J. Hard wiring of T of the Ab response to Plasmodium cell receptor specifi city for the falciparum before and after a malaria Bishop DT, Demenais F, Iles MM, Battistuzzi L, Bruno W, Chan M, major histocompatibility complex is season by protein microarray. Harland M, Taylor JC, Corda Cuellar F, Debniak T, Pjanova D, underpinned by TCR adaptability. Proceedings of the National Acedemy E, Randerson-Moor J, Aitken Ertmanski S, Figl A, Gonzalez M, Hayward NK, Hocevar M, Kanetsky Proceedings of the National Academy of Sciences of the United States of JF, Avril MF, Azizi E, Bakker B, PA, Leaf SL, van Nieuwpoort FA, of Science USA. 107(23):10608-13 America. 107(15):6958-6963. 2010. Bianchi-Scarra G, Bressac-de Heisele O, Palmer J, Peric B, Puig 2010 Paillerets B, Calista D, Cannon- Cronin-Fenton DP, Murray LJ, S, Ruffi n AD, Schadendorf D, Gruis Albright LA, Chin AWT, Debniak T, Byrne EM, McRae AF, Duffy DL, NA, Brandberg Y, Newton-Bishop Whiteman DC, Cardwell C, Webb Galore-Haskel G ,Ghiorzo P, Gut J. Melanoma risk factors, perceived Zhao ZZ, Martin NG, Wright MJ, PM, Jordan SJ, Corley DA, Sharp L, I, Hansson J, Hocevar M, Hoiom threat and intentional tanning: an Montgomery GW, Visscher PM. Lagergren J; Barrett's Esophagus, V, Hopper JL, Ingvar C, Kanetsky international online survey. European Association study of common Adenocarcinoma Consortium PA, Kefford RF, Landi MT, Lang J, Journal of Cancer Prevention. mitochondrial variants and cognitive (BEACON) Investigators. Lubinski J, Mackie R, Malvehy J, 19(3):216-226. 2010 ability. Behaviour Genetics. 39(5):504- Reproductive and sex hormonal Mann GJ, Martin NG, Montgomery 12. 2009 factors and oesophageal and gastric GW, van Nieuwpoort FA, Novakovic Brennan RM, Burrows JM, junction adenocarcinoma: a pooled S, Olsson H, Puig S, Weiss M, van Bell MJ, Bromham L, Csurhes Byrne EM, McRae AF, Duffy DL, analysis. European Journal of Cancer. Workum W, Zelenika D, Brown PA, Lenarczyk A, Sverndal J, Zhao ZZ, Martin NG, Whitfi eld 46(11):2067-76. 2010 KM, Goldstein AM, Gillanders EM, Klintenstedt J, Pender MP, Burrows JB, Visscher PM, Montgomery SR. Strains of Epstein-Barr virus Boland A, Galan P, Elder DE, Gruis GW. Family-based mitochondrial Curley C, Kennedy G, Haughton infecting multiple sclerosis patients. NA, Hayward NK, Lathrop GM, association study of traits related A, Love A, McCarthy C, Boyd, A. Multiple Sclerosis. 16(6):643-651. 2010 Barrett JH, Bishop JA. Genome- to type 2 diabetes and the Acute myeloid leukemia, the 3q21q26 metabolic syndrome in adolescents. syndrome and diabetes insipidus: wide association study identifi es three Brown IS, Whiteman DC, Lauwers Diabetologia. 52(11):2359-68. 2009 loci associated with melanoma risk. GY. Foveolar type dysplasia in Barrett A case presentation. Asia-Pacifi c Journal of Clinical Oncology 6(2):77- Nature Genetics 41:920-925. 2009 esophagus. Modern Pathology. Chavchich M, Gerena L, Peters 23(6):834-843. 2010. 79. 2010 Birley AJ, James MR, Dickson J, Chen NH, Cheng Q, Kyle DE. PA, Montgomery GW, Heath AC, Buchanan DD, Sweet K, Drini Role of pfmdr1 Amplifi cation and Currie BJ, McCarthy JS. Martin NG, Whitfi eld JB. ADH M, Jenkins MA, Win AK, Gattas Expression in Induction of Resistance Permethrin and Ivermectin for single nucleotide polymorphism M, Walsh MD, Clendenning M, to Artemisinin Derivatives in Scabies. New England Journal of associations with alcohol metabolism McKeone D, Walters R, Roberts Plasmodium falciparum. Antimicrobial Medicine. 362(8):717-725. 2010 A, Young A, Hampel H, Hopper Agents and Chemotherapy. in vivo. Human Molecular Genetics. Davis RA, Carroll AR, Andrews 18(8):1533-42. 2009 JL, Goldblatt J, George J, Suthers 54(6):2455-2464. 2010 GK, Phillips K, Young GP, Chow E, KT, Boyle GM, Tran TL, Healy Black M, Trent A, Tirrell M, Olive C. Parry S, Woodall S, Tucker K, Muir Chen X, Webb TI, Lynch JW. PC, Kalaitzis JA, Shivas Advances in the design and delivery A, Field M, Greening S, Gallinger The M4 transmembrane segment RG. Pestalactams A-C: novel of peptide subunit vaccines with a S, Green J, Woods MO, Spaetgens contributes to agonist effi cacy caprolactams from the endophytic focus on Toll-like receptor agonists. R, de la Chapelle A, Macrae F, differences between alpha1 and fungus Pestalotiopsis sp. Organic & Expert Review of Vaccines (2): 157- Walker NI, Jass JR, Young JP. alpha3 glycine receptors. Molecular Biomolecular Chemistry 8(8):1785- 173. 2010 Phenotypic diversity in patients with Membrane Biology 26(5):321-32. 2009 1790. 2010 multiple serrated polyps: a genetics Doherty JA, Rossing MA, Bolderson E, Richard DJ, Zhou clinic study. International Journal of Clements ACA, Magalhaes RJS, BB, Khanna KK. Recent advances Colorectal Disease 25 (6): 703-712. Tatem AJ, Paterson DL, Riley TV. Cushing-Haugen KL, Chen C, Van in cancer therapy targeting proteins 2010 Clostridium diffi cile PCR ribotype Den Berg DJ, Wu AH, Pike MC, involved in DNA double-strand break 027: assessing the risks of further Ness RB, Moysich K, Chenevix- Buchanan DD, Roberts A, Walsh repair. Clinical Cancer Reseach. worldwide spread. Lancet Infectious Trench G, Beesley J, Webb PM, MD, Parry S, Young JP. Lessons 15(20):6314-20. 2009 Diseases. 10(6):395-404. 2010 Chang-Claude J, Wang-Gohrke S, from Lynch syndrome: a tumor Goodman MT, Lurie G, Thompson Bolderson E, Tomimatsu N, biology-based approach to familial Clements ACA, Deville MA, PJ, Carney ME, Hogdall E, Richard DJ, Boucher D, Kumar R, colorectal cancer. Future Oncology Ndayishimiye O, Brooker S, Kjaer SK, Hogdall C, Goode EL, Pandita TK, Burma S, Khanna KK. 6 (4): 539-549. 2010 Fenwick A. Spatial co-distribution of Cunningham JM, Fridley BL, Phosphorylation of Exo1 modulates neglected tropical diseases in the East Vierkan, RA, Berchuck A, Moorman Burke ML, McManus DP, Ramm African Great Lakes region: revisiting homologous recombination repair of GA, Duke M, Li Y, Jones MK, PG, Schildkraut JM, Palmieri RT, the justifi cation for integrated control. DNA double-strand breaks. Nucleic Gobert GN. Co-ordinated gene Cramer DW, Terry KL, Yang HP, Tropical Medicine & International Acids Research. 38(6):1821-31. 2010 expression in the liver and spleen Garcia-Closas M, Chanock S, Health. 15(2):198-207. 2010 during Schistosoma japonicum Lissowska J, Song HL, Pharoah Bonthuis M, Hughes MC, Ibiebele infection regulates cell migration. Coventry WL, James MR, Eaves PDP, Shah M, Perkins B, McGuire TI, Green AC, van der Pols JC. PLoS Neglected Tropical Diseases. V, Whittemore AS, Di Cioccio, Dairy consumption and patterns LJ, Gordon SD, Gillespie NA, 4(5):e686. 2010 Ryan L, Heath AC, Montgomery RA Gentry-Maharaj A, Menon U, of mortality of Australian adults. Gayther SA, Ramus SJ, Ziogas Burke ML, McManus DP, Ramm GW, Martin NG, Wray NR. Do European Journal of Clinical Nutrition. A, Brewster W, Anton-Culver H, GA, Duke M, Li Y, Jones MK, 5HTTLPR and stress interact in risk 64(6):569-77. 2010 Pearce CL, Australian Ovarian Gobert GN. Temporal expression for depression and suicidality? Item Boyle RK, Waters BA, O'Rourke PK. of chemokines dictates the hepatic response analyses of a large sample. Cancer Study Mana, Australian Measures of blood loss and red cell infl ammatory infi ltrate in a murine American Journal of Medical Genetics Cancer Study Ovarian Canc. transfusion targets for caesarean model of schistosomiasis. PLoS B Neuropsychiatric Genetics. Ovarian Cancer Assoc Consortium. delivery complicated by placenta Neglected Tropical Diseases. 153B(3):757-65. 2010 ESR1/SYNE1 Polymorphism praevia. Australian & New Zealand 4(2):e598. 2010 and Invasive Epithelial Ovarian Journal of Obstetrics & Gynaecology Coyne T, Ibiebele TI, Baade PD, Cancer Risk: An Ovarian Cancer Burger DC, Lawrance IC, Bampton 50(3): 242-245. 2010 McClintock CS, Shaw JE. Metabolic Association Consortium Study. PA, Prosser R, Croft A, Gilshenan syndrome and serum carotenoids: Cancer Epidemiology Biomarkers & Bramhachari PV, Kaul SY, McMillan K, Radford-Smith GL, Florin TH. fi ndings of a cross-sectional study in Prevention. 19(1):245-250. 2010 DJ, Shaila MS, Karmarkar MG, Anti-tumour necrosis factor-alpha Queensland, Australia. British Journal Sriprakash KS. Disease burden treatment for perianal Crohn's disease of Nutrition. 102(11):1668-77. 2009 Dong Y, Tan OL, Loessner D, due to Streptococcus dysgalactiae in Australia. Medical Journal of Stephens C, Walpole C, Boyle subsp equisimilis (group G and C Australia 192(7):375-377. 2010 Crompton PD, Kayala MA, Traore GM, Parsons PG, Clements JA. streptococcus) is higher than that due B, Kayentao K, Ongoiba A, Weiss Kallikrein-Related Peptidase 7
97 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
Promotes Multicellular Aggregation via Park JY, Spurdle A, Clements J, Ferreira MA, Oates NA, van Vliet J, Jones MK. Tissue specifi c profi ling the alpha(5)beta(1) Integrin Pathway Dickinson JL, Maier C, Vogel W, J, Zhao ZZ, Ehrich M, Martin NG, of females of Schistosoma japonicum and Paclitaxel Chemoresistance in Dörk T, Rebbeck TR, Cooney KA, Montgomery GW, Whitelaw E, by integrated laser microdissection Serous Epithelial Ovarian Carcinoma. Cannon-Albright L, Chappuis PO, Duffy DL. Characterization of the microscopy and microarray analysis. Cancer Research. 70(7):2624-2633. Hutter P, Zeegers M, Kaneva R, methylation patterns of MS4A2 in PLoS Neglected Tropical Diseases. 2010 Zhang HW, Lu YJ, Foulkes WD, atopic cases and controls. Allergy. 30;3(6):e469. 2009 English DR, Leongamornlert DA, 65(3):333-7. 2010 Doyle AE, Biederman J, Ferreira Tymrakiewicz M, Morrison J, Gobert GN, Tran MH, Moertel L, MAR, Wong P, Smoller JW, Faraone Ardern-Jones AT, Hall AL, O'Brien Ferreira MA, Zhao ZZ, Thomsen Mulvenna J, Jones MK, McManus SV. Suggestive Linkage of the Child LT, Wilkinson RA, Saunders EJ, SF, James M, Evans DM, Postmus DP, Loukas A. Transcriptional Behavior Checklist Juvenile Bipolar Page EC, Sawyer EJ, Edwards SM, PE, Kyvik KO, Backer V, Boomsma changes in Schistosoma mansoni Disorder Phenotype to 1p21, 6p21, Dearnaley DP, Horwich A, Huddart DI, Martin NG, Montgomery GW, during early schistosomula and 8q21. Journal of the American RA, Khoo VS, Parker CC, Van As Duffy DL. Association and interaction development and in the presence of Academy of Child ad Adolescent N, Woodhouse CJ, Thompson A, analyses of eight genes under asthma erythrocytes. PLoS Neglected Tropical Psychiatry. 49(4):378-387. 2010 Christmas T, Ogden C, Cooper CS, linkage peaks. Allergy. 64(11):1623- Diseases. 4(2):e600. 2010 8. 2009 Driguez P, Doolan DL, Loukas Southey MC, Lophatananon A, Liu Gordon LG, Obermair A. Potential A, Felgner PL, McManus DP. JF, Kolonel LN, Le Marchand L, Flanagan JM, Cocciardi S, Waddell hospital cost-savings attributed Schistosomiasis vaccine discovery Wahlfors T, Tammela TL, Auvinen N, Johnstone CN, Marsh A, to improvements in outcomes for using immunomics. Parasites & A, Lewis SJ, Cox A, FitzGerald Henderson S, Simpson P, da Silva colorectal cancer surgery following Vectors. 28;3:4. 2010 LM, Koopmeiners JS, Karyadi DM, L, Khanna K, Lakhani S, Boshoff self-audit. BMC Surgery. 27;10:4. 2010 Kwon EM, Stern MC, Corral R, C, Chenevix-Trench G, kConFab Dry JR, Pavey S, Pratilas CA, Gordon LG, Scuffham PA, van Joshi AD, Shahabi A, McDonnell Investigators. DNA Methylome of Harbron C, Runswick S, Hodgson der Pols JC, McBride P, Williams SK, Sellers TA, Pow-Sang J, Familial Breast Cancer Identifi es D, Chresta C, McCormack R, Byrne GM, Green AC. Regular sunscreen Chambers S, Aitken J, Gardiner Distinct Profi les Defi ned by Mutation N, Cockerill M, Graham A, Beran use is a cost-effective approach to RA, Batra J, Kedda MA, Lose F, Status. American Journal of Human G, Cassidy A, Haggerty C, Brown skin cancer prevention in subtropical Polanowski A, Patterson B, Serth Genetics. 86(3):420-433. 2010 H, Ellison G, Dering J, Taylor BS, J, Meyer A, Luedeke M, Steffl ova settings. Journal of Investigative Stark M, Bonazzi V, Ravishankar K, Ray AM, Lange EM, Farnham Flesch IEA, Woo WP, Wang Y, Dermatology. 129(12):2766-71. 2009 S, Packer L, Xing F, Solit DB, Finn J, Khan H, Slavov C, Mitkova Panchanathan V, Wong YC, La Grealy R, Griffi ths LR. Current status RS, Rosen N, Hayward NK, French A, Cao G; UK Genetic Prostate Gruta NL, Cukalac T, Tscharke of pharmacogenomics testing for anti- T, Smith PD. Transcriptional Pathway Cancer Study Collaborators/ DC. Altered CD8(+) T Cell tumor drug therapies: approaches to Signatures Predict MEK Addiction British Association of Urological Immunodominance after Vaccinia non-melanoma skin cancer. Molecular and Response to Selumetinib Surgeons' Section of Oncology; Virus Infection and the Naive Diagnosis and Therapy. 13(2):65-72. (AZD6244). Cancer Research. UK ProtecT Study Collaborators; Repertoire in Inbred and F-1 Mice. Review. 2009 70(6):2264-2273. 2010. PRACTICAL Consortium, Easton Journal of Immunology 184 (1): 45- DF. Identifi cation of seven new prostate 55. 2010 Duffy DL, Iles MM, Glass D, Zhu Griffi ths, LR; Cox, HC; Bellis, C; cancer susceptibility loci through a G, Barrett JH, Höiom V, Zhao ZZ, Fischer K, Langendorf CG, Irving Nyholt, D; Macgregor, S; Lea, RA; genome-wide association study. Nature Sturm RA, Soranzo N, Hammond JA, Reynolds S, Willis C, Beckham Charlesworth, J; Dyer, T; Blangero, Genetics. 41(10):1116-21. 2009 C, Kvaskoff M, Whiteman DC, S, Law RH, Yang S, Bashtannyk- J. A genome-wide linkage analysis of migraine in the descendents of the Mangino M, Hansson J, Newton- Falchi M, Bataille V, Hayward NK, Puhalovich TA, McGowan S, bounty mutineers implicates the 13q Bishop JA; GenoMEL, Bataille V, Duffy DL, Bishop JA, Pastinen T, Whisstock JC, Pike RN, Kemp DJ, chromosomal region. Cephalalgia Hayward NK, Martin NG, Bishop Cervino A, Zhao ZZ, Deloukas P, Buckle AM. Structural mechanisms 29:83-83, Special Issue Suppl 1. 2009 DT, Spector TD, Montgomery Soranzo N, Elder DE, Barrett JH, of inactivation in scabies mite serine GW. IRF4 variants have age- Martin NG, Bishop DT, Montgomery protease paralogues. Journal of Hacker E, Hayward NK, Dumenil specifi c effects on nevus count and GW, Spector TD. Genome-wide Molecular Biology. 390(4):635-45. 2009 T, James MR, Whiteman DC. predispose to melanoma. American association study identifi es variants Gamboa D, Ho MF, Bendezu J, The association between MC1R Journal Human Genetics. 87(1):6-16. at 9p21 and 22q13 associated with Torres K, Chiodini PL, Barnwell genotype and BRAF mutation status 2010 development of cutaneous nevi. JW, Incardona S, Perkins M, Bell in cutaneous melanoma: fi ndings Nature Genetics. 41(8):915-9. 2009 Duffy DL, Zhao ZZ, Sturm D, McCarthy J, Cheng Q. A Large from an Australian population. Journal of Investigative Dermatology. RA, Hayward NK, Martin NG, Ferreira MA, Mangino M, Brumme Proportion of P. falciparum Isolates 130(1):241-8. 2010 . Montgomery GW. Multiple CJ, Zhao ZZ, Medland SE, in the Amazon Region of Peru Lack pigmentation gene polymorphisms Wright MJ, Nyholt DR, Gordon pfhrp2 and pfhrp3: Implications for Hacker E, Muller HK, Hayward N, account for a substantial proportion S, Campbell M, McEvoy BP, Malaria Rapid Diagnostic Tests. Plos Fahey P, Walker G. Enhancement of risk of cutaneous malignant Henders A, Evans DM, Lanchbury One 5(1):article -e8091. 2010 of DNA repair using topical T4 melanoma. Journal of Investigative JS, Pereyra F; International HIV Gardiner DL, Skinner-Adams TS, endonuclease V does not inhibit Dermatology. 130(2):520-8. 2010 Controllers Study, Walker BD, Haas Brown CL, Andrews KT, Stack CM, melanoma formation in Cdk4(R24C/ DW, Soranzo N, Spector TD, de Dunn LA, Burgess AG, Krauer KG, McCarthy JS, Dalton JP, Trenholme R24C)/Tyr-Nras(Q61K) mice following Bakker PI, Frazer IH, Montgomery Eckmann L, Vanelle P, Crozet MD, KR. Plasmodium falciparum: new neonatal UVR. Pigment Cell & GW, Martin NG. Quantitative trait Gillin FD, Upcroft P, Upcroft JA. A molecular targets with potential for Melanoma Research. 23(1):121-8. 2010 loci for CD4:CD8 lymphocyte ratio new-generation 5-nitroimidazole can antimalarial drug development. Expert are associated with risk of type 1 Hansell NK, Agrawal A, Whitfi eld induce highly metronidazole-resistant Review of Anti-Infective Therapy diabetes and HIV-1 immune control. JB, Moreley KI, Gordon SD, Lind Giardia lamblia in vitro. International 7(9):1087-98. 2009 American Journal Human Genetics. PA, Pergardia ML, Montgomery Journal of Antimicrobial Agents. 86(1):88-92. 2010 GW, Madden PA, Todd RD, Heath 36(1):37-42. 2010 Garvey G, Rolfe IE, Pearson SA, Treloar C. Indigenous Australian AC, Martin NG. Linkage Analysis Ferreira MA, Hottenga JJ, Edo De Bock C, Lin Z, Mekkawy medical students' perceptions of of Alcohol Dependence Symptoms Warrington NM, Medland SE, AH, Byrne JA, Wang Y. Interaction their medical school training. Medical in the Community. Alcoholism Willemsen G, Lawrence RW, between urokinase receptor and Education. 43(11):1047-55. 2009 Clinical and Experimental Research. Gordon S, de Geus EJ, Henders heat shock protein MRJ enhances 34(1)158-163(6). 2010 AK, Smit JH, Campbell MJ, cell adhesion. International Journal of Georgousakis MM, Hofmann A, Wallace L, Evans DM, Wright MJ, Haque A, Good MF. Malaria vaccine Oncology. 36(5):1155-63. 2010 Batzloff MR, McMillan DJ, Nyholt DR, James AL, Beilby JP, Sriprakash KS. Structural optimisation research: lessons from 2008/9. Future Eeles RA, Kote-Jarai Z, Al Olama Penninx BW, Palmer LJ, Frazer of a conformational epitope improves Microbiology. 4:649-54. Review. 2009 AA, Giles GG, Guy M, Severi G, IH, Montgomery GW, Martin NG, antigenicity when expressed as a Haque A, Stanley AC, Amante Muir K, Hopper JL, Henderson BE, Boomsma DI. Sequence variants recombinant fusion protein. Vaccine. FH, Rivera FD, Zhou Y, Kuns Haiman CA, Schleutker J, Hamdy in three loci infl uence monocyte 27(48):6799-806. 2009 RD, Yardley V, Sakaguchi S, Hill FC, Neal DE, Donovan JL, Stanford counts and erythrocyte volume. Gobert GN, McManus DP, GR, Engwerda CR. Therapeutic JL, Ostrander EA, Ingles SA, John American Journal of Human Genetics. Glucocorticoid-Induced TNF EM, Thibodeau SN, Schaid D, 85(5):745-9. 2009 Nawaratna S, Moertel L, Mulvenna
98 QIMR Annual Report 2009/10 Receptor-Mediated Amplifi cation of Body composition, smoking, and Jahanshad N, Lee AD, Barysheva Johnston SE, Beraldi D, McRae AF, CD4+ T Cell Responses Enhances spontaneous dizygotic twinning. M, McMahon KL, de Zubicaray GI, Pemberton JM, Slate J. Horn type AntiparasiticImmunity. Journal of Fertility and Sterility. 93(3):885-893. Martin NG, Wright MJ, Toga AW, and horn length genes map to the Immunology. 184(5):2583-92 2010 Thompson PM. Genetic infl uences same chromosomal region in Soay on brain asymmetry: A DTI study of sheep. Heredity. 104(2):196-205. 2010 Harris JL, Jakob B, Taucher-Scholz Hogg K, Etherington SL, Young JM, 374 twins and siblings. Neuroimage G, Dianov GL, Becherel OJ, Lavin McNeilly AS, Duncan WC. Inhibitor 52(2):455-469. 2010 Jones K, Nourse J, Corbett G, MF. Aprataxin, poly-ADP ribose of Differentiation (Id) Genes Are Gandhi MK. Sodium valproate in polymerase 1 (PARP-1) and apurinic Expressed in the Steroidogenic Cells Janda M, Baade PD, Youl PH, combination with ganciclovir induces endonuclease 1 (APE1) function of the Ovine Ovary and Are Aitken JF, Whiteman DC, Gordon L, lysis of EBV-infected lymphoma cells together to protect the genome Differentially Regulated by Members Neale RE. The skin awareness without impairing EBV-specifi c T-cell against oxidative damage. Human of the Transforming Growth study: Promoting thorough skin self- immunity. International Journal of Molecular Genetics 1;18(21):4102- Factor-beta Family. Endocrinology. examination for skin cancer among Laboratory Hematology. 32(1):E169- 17. 2009 151(3):1247-1256. 2010 men 50 years or older. Contemporary E174,Part 1. 2010 Clinical Trials. 31(1):119-130. 2010 Harty MW, Muratore CS, Hu WB, Clements A, Williams Jordan SJ, Siskind V, C Green Papa EF, Gart MS, Ramm GA, G, Tong SL. Dengue fever and Jeffery JA, Thi Yen N, Nam VS, A, Whiteman DC, Webb PM. Gregory SH, Tracy TF. Neutrophil El Nino/Southern Oscillation in Nghia le T, Hoffmann AA, Kay BH, Breastfeeding and risk of epithelial Depletion Blocks Early Collagen Queensland, Australia: a time series Ryan PA. Characterizing the Aedes ovarian cancer. Cancer Causes Degradation in Repairing Cholestatic predictive model. Occupational and aegypti population in a Vietnamese Control. 21(1):109-16. 2010 Rat Livers. American Journal of Environmental Medicine. 67(5):307- village in preparation for a Wolbachia- Patholog.176(3):1271-1281. 2010 311. 2010 based mosquito control strategy to Joyce P, Kuwahata M, Turner eliminate dengue. PLoS Neglected N, Lakshmanan P. Selection Healy PC, Loughrey T, Williams ML, Hugo LE, Cook PE, Johnson Tropical Diseases. 3(11):e552. 2009 system and co-cultivation medium Parsons PG. Synthesis, structure and PH, Rapley LP, Kay BH, Ryan are important determinants cytotoxicity studies of four-coordinate PA, Ritchie SA, O'Neill SL. Field Jeffery JM, Urquhart AJ, of Agrobacterium-mediated bis (cis-bis (diphenylphosphino) Validation of a Transcriptional Assay Subramaniam VN, Parton RG, transformation of sugarcane. Plant ethene) gold(I) complexes, for the Prediction of Age of Uncaged Khanna KK. Centrobin regulates the Cell Reports (2):173-183. 2010 [Au(dppey)(2)]X. Journal of Inorganic Aedes aegypti Mosquitoes in Northern assembly of functional mitotic spindles. Biochemistry. 104(6):625-631. 2010 Australia. PLOS Neglected Tropical Oncogene. 29(18):2649-58. 2010 Jones K, Nourse J, Corbett G, oate in Diseases. 4(2):article -e608. 2010 Gandhi MK. Sodium valpr Herath NI, Boyd AW. The role of Johnatty SE, Couch FJ, combination with ganciclovir induces Eph receptors and ephrin ligands Hunt NH, Grau GE, Engwerda C, Fredericksen Z, Tarrell R, Spurdle lysis of EBV-infected lymphoma in colorectal cancer. International Barnum SR, van der Heyde H, AB, Beesley J, Chen X; kConFab cells without impairing EBV-specifi c Journal of Cancer. 126(9):2003-11. Hansen DS, Schofi eld L, Golenser Investigators; AOCS Group; T-cell immunity. International Journal Review. 2010 J. Murine cerebral malaria: the Swedish BRCA1 and BRCA2 of Laboratory Hematology. 32(1 Pt whole story. Trends in Parasitology. Study Collaborators, Gschwantler- 1):e169-74. 2010 Herath NI, Purdie DM, Kew MC, 26(6):272-274. 2010 Kaulich D, Singer CF, Fuerhauser Smith JL, Young J, Leggett C, Fink-Retter A, Domchek SM, Kaminen-Ahola N, Ahola A, Maga BA, MacDonald GA. Varying Hurst TP, Kay BH, Brown MD, Nathanson KL, Pankratz VS, M, Mallitt KA, Fahey P, Cox TC, etiologies lead to different molecular Ryan PA. Melanotaenia duboulayi Lindor NM, Godwin AK, Caligo Whitelaw E, Chong S. Maternal changes in Australian and South Infl uence Oviposition Site Selection MA, Hopper J, Southey MC, Giles ethanol consumption alters the African hepatocellular carcinomas. by Culex annulirostris (Diptera: GG, Justenhoven C, Brauch H, epigenotype and the phenotype of International Journal of Oncology. Culicidae) and Aedes notoscriptus Hamann U, Ko YD, Heikkinen T, offspring in a mouse model. PLoS 35(5):1081-9. 2009 (Diptera: Culicidae) but Not Culex Aaltonen K, Aittomäki K, Blomqvist Genetics. 6(1):e1000811. 2010 quinquefasciatus (Diptera: Culicidae). Herath NI, Doecke J, Spanevelle C, Nevanlinna H, Hall P, Czene K, Kay BH, Tuyet Hanh TT, Le NH, Quy Environmental Entomology. Liu J, Peock S, Cook M, Platte R, MD, Leggett BA, Boyd AW. 39(2):545-551. 2010 TM, Nam VS, Hang PV, Yen NT, Hill Epigenetic silencing of EphA1 Gareth Evans D, Lalloo F, Eeles R, PS, Vos T, Ryan PA. Sustainability expression in colorectal cancer is Ibiebele TI, Parekh S, Mallitt KA, Pichert G, Eccles D, Davidson R, and cost of a community-based correlated with poor survival. British Hughes MC, O'Rourke PK, Webb Cole T, Cook J, Douglas F, Chu C, strategy against Aedes aegypti Journal of Cancer 100:1095-1102. PM; Australian Ovarian Cancer Study Hodgson S, Paterson J, Hogervorst in northern and central Vietnam. 2009 Group and the Australian Cancer FB, Rookus MA, Seynaeve C, American Journal of Tropical Medicine Study. Reproducibility of food and Wijnen J, Vreeswijk M, Ligtenberg and Hygiene. 82(5):822-30. 2010 Hill GR, Tey SK, Beagley L, Crough nutrient intake estimates using a M, van der Luijt RB, van Os TA, T, Morton JA, Clouston AD, semi-quantitative FFQ in Australian Gille HJ, Blok MJ; HEBON, Issacs Keightley MC, Brown P, Jabbour Whiting P, Khanna R. Successful adults. Public Health Nutrition. C, Humphreys MK, McGuffog L, HN, Sales KJ. F-Prostaglandin immunotherapy of HCMV disease (12):2359-65. 2009 Healey S, Sinilnikova O, Antoniou receptor regulates endothelial cell using virus-specifi c T cells expanded AC, Easton DF, Chenevix-Trench function via fi broblast growth factor-2. from an allogeneic stem cell Ibiebele TI, Van der Pols JC, G. Breast Cancer Association BMC Cell Biology 11:article 8. 2010 transplant recipient. American Journal Hughes MC, Marks GC, Green Consortium and Consortium of Keller MC, Medland SE, Duncan of Transplantation. 10(1):173-9. 2010 AC. Dietary fat intake and risk of Investigators of Modifi ers of BRCA1/2. LE. Are Extended Twin Family skin cancer : a prospective study in No evidence that GATA3 rs570613 Hinoue T, Weisenberger Daniel Designs Worth the Trouble? A Australian adults. International Journal SNP modifi es breast cancer risk. J, Pan Fei, Campan Mihaela, Comparison of the Bias, Precision, and of Cancer. 125(7):1678-84. 2009. Breast Cancer Research and Kim Myungjin, Young Joanne, Accuracy of Parameters Estimated Treatment. 117(2):371-9. 2009 Whitehall Vicki L, Leggett Barbara Idaghdour Y, Czika W, Shianna KV, in Four Twin Family Models. Behavior A, Laird Peter W. Analysis of the Lee SH, Visscher PM, Martin HC, Johnatty SE, Beesley J, Chen X, Genetics. 40(3):377-393. 2010 Association between CIMP and Miclaus K, Jadallah SJ, Goldstein Spurdle AB, Defazio A, Webb PM, Kolahdooz F, van der Pols JC, BRAF in Colorectal Cancer by DNA DB, Wolfi nger RD, Gibson G. Australian Ovarian Cancer Study Bain CJ, Marks GC, Hughes Methylation Profi ling. PLos One 4(12) Geographical genomics of human Group, Australian Cancer Study MC, Whiteman DC, Webb PM; e8357. 2009 leukocyte gene expression variation in (Ovarian Cancer), Goode EL, Rider Australian Cancer Study (Ovarian southern Morocco. Nature Genetics. DN, Vierkand RA, AndersonS, Ho V, Whiteman D, Miller M, Raulli Cancer) and the Australian Ovarian 42(1):62-U79. 2010 Wu AH, Pike M, Van Den Berg D, A, Ombiga J, Boyd P. Esophageal Cancer Study Group. Meat, fi sh, Moysich K, Ness R, Doherty J, cancer in Indigenous Australians in Jabbar A, Kyngdon CT, Gauci CG, and ovarian cancer risk: Results from Rossing MA, Pearce CL, Chenevix- Far North Queensland. Journal of Walduck AK, McCowan C, Jones 2 Australian case-control studies, a Trench G. Polymorphisms in the Gastroenterology and Hepatology. MK, Beveridge I, Lightowlers MW. systematic review, and meta-analysis. FGF2 gene and risk of serous ovarian 24(10):1683-6. 2009 Localisation of three host-protective American Journal of Clinical Nutrition. cancer: results from the ovarian oncospheral antigens of Taenia ovis. 91(6):1752-63. 2010. cancer association consortium. Hoekstra C, Willemsen G, van International Journal for Parasitology. Twin Research and Human Genetics. Beijsterveldt T, Lambalk CB, 40(5):579-589. 2010 Montgomery GW, Boomsma DI. 12(3):269-75. 2009
99 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
Kominami K, Nagasaka T, Cullings association between the ADAM 12 6(5):article e1000934. 2010 McDonald CJ, Jones MK, Wallace HM, Hoshizima N, Sasamoto H, and SH3PXD2A (SH3MD1) genes and DF, Summerville L, Nawaratna S, Young J, Leggett BA, Tanaka Alzheimer's disease. Neuroscience Liu JZ, Medland SE, Wright MJ, Subramaniam VN. Increased iron N, Matsubara N. Methylation in Letters 468 (1):1-2. 2010 Henders AK, Heath AC, Madden stores correlate with worse disease p14(ARF) is frequently observed PA, Duncan A, Montgomery GW, outcomes in a mouse model of Lavin MF, Masci PP. Prothrombinase in colorectal cancer with low-level Martin NG, McRae AF. Genome- schistosomiasis infection. PLoS One complexes with different physiological microsatellite instability. Journal of wide association study of height 5(3):e9594. 2010 roles. Journal of Thrombosis and International Medical Research. 37: and body mass index in Australian Haemotosis. 102(3):421-3. 2009 McEvoy BP, Visscher PM. Genetics 1038-1045. 2009 twin families. Twin Research and Human Genetics. 13(2):179-93. 2010 of human height. Economics & Leggett Barbara A. Family-based Kozlov S, Waters NC, Chavchich Human Biology. 7(3):294-306. 2009 screening for colorectal cancer: The M. Leveraging cell cycle analysis in Liu JZ, McRae AF, Nyholt DR, Australian perspective. Journal of McEvoy BP, Montgomery GW, anticancer drug discovery to identify Medland SE, Wray NR, Brown KM; Gastroenterology and Hepatology McRae AD, Ripatti S, Perola M, novel plasmodial drug targets. AMFS Investigators, Hayward NK, Review 24Suppl3:S29-S32. 2009. Montgomery GW, Visscher PM, Spector TD, Cherkas L, Ahmadi Infectious Disorders Drug Targets. KR, Boomsma D, Willemsen 10(3):165-90. 2010 Leggett B, Whitehall V. Role of the Martin NG, Macgregor S. A versatile gene-based test for genome-wide G, Hottenga JJ, Pedersen NL, serrated pathway in colorectal cancer Magnusson PK, Kyvik KO, Krauer KG, Burgess AG, Dunn LA, association studies. American Journal pathogenesis. Gastroenterology. Christensen K, Kaprio J, Heikkila Upcroft P, Upcroft JA. Sequence of Human Genetics. 87(1):139-145. 2010 138(6):2088-100. Review. 2010 K, Palotie A, Widen E, Muilu J, map of the 2 Mb Giardia lamblia Syvanen AC, Liljedahl U, Hardiman assemblage A chromosome. Journal Lim YC, Roberts T, Harding A, Day Loser R, Gut J, Rosenthal PJ, O, Cronin S, Peltonen L, Martin NG, of Parasitology. 96(3):660-2. 2010 B, Kozlov S, Walker D, Lavin M. Frizler M, Gutschow M, Andrews Low dose radiation responses and KT. Antimalarial activity of azadipeptide Visscher PM. Geographical structure and differential natural selection Kuns RD, Morris ES, Macdonald knockdown of ATM kinase activity nitriles. Bioganic & Medicinal among North European populations. KP, Markey KA, Morris HM, in glioma stem cells. Acta medica Chemistry letters 20(1):252-255. 2010 Genome Research. 19(5):804-14. 2009 Raffelt NC, Banovic T, Don AL, Nagasakiensia. 53(supl.):37043. 2009 Loughrey BT, Williams ML, Rowe V, Burman AC, Clouston Macgregor S, Bellis C, Lea RA, Cox Lind PA, Luciano M, Horan MA, Carruthers TJ, Parsons PG, AD, Farah C, Besra GS, Illarionov H, Dyer T, Blangero J, Visscher PM, Marioni RE, Wright MJ, Bates TC, Healy PC. Synthesis, Structure, PA, Smyth MJ, Porcelli SA, Hill Griffi ths LR. Legacy of mutiny on the Rabbitt P, Harris SE, Davidson Y, and Selective Cytotoxicity of GR. Invariant natural killer T cell- Bounty: founder effect and admixture Deary IJ, Gibbons L, Pickles A, Organometallic Cp*Ru-II O-Alkyl- natural killer cell interactions dictate on Norfolk Island. European Journal Ollier W, Pendleton N, Price JF, N-phenylcarbamate Sandwich transplantation outcome after alpha- of Human Genetics. 18(1):67-72. 2010 galactosylceramide administration. Payton A, Martin NG. No association Complexes. Australian Journal of Blood. 113(23):5999-6010. 2009 between Cholinergic Muscarinic Chemistry 63(2):245-251. 2010 Macgregor S. Optimal selection Receptor 2 (CHRM2) genetic of markers from DNA pooling Lu Y, Dimasi DP, Hysi PG, Hewitt Labadie K, Larcher T, Joubert C, variation and cognitive abilities in experiments. Behaviour Genetics. AW, Burdon KP, Toh T, Ruddle Mannioui A, Delache B, Brochard three independent samples. Behavior 40(1):46-7; discussion 48. 2010 P, Guigand L, Dubreil L, Lebon Genetics. 39(5):513-23. 2009 JB, Li YJ, Mitchell P, Healey PR, P, Verrier B, de Lamballerie X, Montgomery GW, Hansell N, McGowan S, Oellig CA, Birru Lind PA, Luciano M, Wright MJ, Suhrbier A, Cherel Y, Le Grand R, Spector TD, Martin NG, Young TL, WA, Caradoc-Davies TT, Stack Montgomery GW, Martin NG, Roques P. Chikungunya disease Hammond CJ, Macgregor S, Craig CM, Lowther J, Skinner-Adams T, Bates TC. Dyslexia and DCDC2: Mucha A, Kafarski P, Grembecka in nonhuman primates involves JE, Mackey DA. Common genetic normal variation in reading and J, Trenholme KR, Buckle AM, long-term viral persistence in variants near the Brittle Cornea spelling is associated with DCDC2 Gardiner DL, Dalton JP, Whisstock macrophages. Journal of Cllinical Syndrome locus ZNF469 infl uence polymorphisms in an Australian JC. Structure of the Plasmodium Investigation.120(3):894-906. 2010 the blinding disease risk factor central population sample. European Journal corneal thickness. PLoS Genetics. falciparum M17 aminopeptidase and Lahmann PH, Wills RA, Coory M. of Human Genetics. 18(6):668-73. 2010 6(5):e1000947. 2010 signifi cance for the design of drugs targeting the neutral exopeptidases. Trends in birth size and macrosomia Lind PA, Macgregor S, Vink JM, Lutzky VP, Corban M, Heslop L, Proceedings of the National Academy in Queensland, Australia, from 1988 Pergadia ML, Hansell NK, de Morrison LE, Crooks P, Hall DF, of Sciences of the United States of to 2005. Paediatric & Perinatal Moor MH, Smit AB, Hottenga JJ, Epidemiology. 23(6):533-41. 2009 Coman WB,Thomson SA, Moss DJ. America. 107(6): 2449-2454. 2010 Richter MM, Heath AC, Martin Novel approach to the formulation of NG, Willemsen G, de Geus EJ, Lambert JC, Heath S, Even G, an Epstein-Barr virus antigen-based McManus DP, Gray DJ, Li Y, Feng Z, Vogelzangs N, Penninx BW, Campion D, Sleegers K, Hiltunen nasopharyngeal carcinoma vaccine. Williams GM, Stewart D, Rey- Whitfi eld JB, Montgomery GW, M, Combarros O, Zelenika D, Journal of Virology. 84(1):407-17. 2010 Ladino J, Ross AG. Schistosomiasis Boomsma DI, Madden PA. A in the People's Republic of China: the Bullido MJ, Tavernier B, Letenneur genomewide association study of era of the Three Gorges Dam. Clinical L, Bettens K, Berr C, Pasquier Lutzky VP, Davis JE, Crooks P, nicotine and alcohol dependence in Microbiological Reviews. 23(2):442- F, Fievet N, Barberger-Gateau P, Corban M, Smith MC, Elliott M, Australian and dutch populations. 66. 2010 Engelborghs S, De Deyn P, Mateo Morrison L, Cross S, Tscharke D, Twin Research & Human Genetics. Panizza B, Coman W, Bharadwaj I, Franck A, Helisalmi S, Porcellini McManus DP. Refl ections on the 13(1):10-29. 2010 M, Moss DJ. Optimization of E, Hanon O, de Pancorbo MM, biochemistry of Echinococcus: past, LMP-specifi c CTL expansion for Lendon C, Dufouil C, Jaillard C, Lindor NM, RabeKG, Petersen GM, present and future. Parasitology. potential adoptive immunotherapy in Leveillard T, Alvarez V, Bosco P, Chen H, Bapat B, Hopper J, Young 136(12):1643-52. 2009 Mancuso M, Panza F, Nacmias J, Jenkins M, Potter J, Newcomb P, NPC patients. Immunology and Cell B, Bossu P, Piccardi P, Annoni G, Templeton A, LeMarchand L, Grove Biology. 87(6):481-8. 2009 McMillan DJ, Vu T, Bramhachari PV, Kaul SY, Bouvet A, Shaila MS, Seripa D, Galimberti D, Hannequin J, Burgio MR, Haile R, Green J, McCarron JK, Stringer BW, Day Karmarkar MG, Sriprakash KS. D, Licastro F, Soininen H, Ritchie Woods MO, Seminara D, Limburg BW, Boyd AW. Ephrin expression Molecular markers for discriminating K, Blanche H ,Dartigues JF, Tzourio PJ, Thibodeau SN. Parent of origin and function in cancer. Future Streptococcus pyogenes and S. C, Gut I, Van Broeckhoven C, effects on age at colorectal cancer Oncology. 6(1):165-76. 2010. dysgalactiae subspecies equisimilis. Alperovitch A, Lathrop M, Amouyel diagnosis. International Journal of European Journal of Clinical P, European Alzheimers Dis Cancer. 127(2):361-366. 2010 McCarthy JS, Good MF. Whole Microbiology & Infections Diseases. Initiative. Genome-wide association parasite blood stage malaria vaccines: Liu F, Wollstein A, Hysi PG, 29(5):585-9. 2010 study identifi es variants at CLU and A convergence of evidence. Human Ankra-Badu GA, Spector TD, CR1 associated with Alzheimer's Vaccine. 6(1):114-23 Malintan NT, Nguyen TH, Han L, Park D, Zhu G, Larsson M, Duffy disease. Nature Genetics. 41 Latham CF, Osborne SL, Wen McCutcheon VV, Heath AC, Nelson (10):1094-U68 2009. DL, Montgomery GW, Mackey PJ, Lim SJ, Sugita S, Collins BM, EC, Bucholz KK, Madden PAF, DA, Walsh S, Lao O, Hofman Meunier FA. Abrogating Munc18- Laumet G, Petitprez V, Sillaire A, A, Rivadeneira F, Vingerling JR, Martin NG. Clustering of Trauma 1-SNARE complex interaction has Ayral AM, Hansmannel F, Chapuis Uitterlinden AG, Martin NG, and Associations with Single and limited impact on exocytosis in PC12 J, Hannequin D, Pasquier F, Hammond CJ, Kayser M. Digital Co-Occurring Depression and Panic cells. Journal of Biological Chemistry. Scarpini E, Galimberti D, Lendon Quantifi cation of Human Eye Color Attack over Twenty Years. Twin 284(32):21637-46. 2009 C, Campion D, Amouyel P, Highlights Genetic Association of Research and Human Genetics. Lambert JC. 2010. A study of the Three New Loci. PLOS Genetics 13(1):57-65. 2010
100 QIMR Annual Report 2009/10 Mallitt KA, O’Rourke P, Bouwes involved in neoplastic transformation Mounsey KE, Pasay CJ, Arlian LG, Tey SK, Kennedy G, Gandhi MK. Bavinch JN, Abeni D, de Koning of serous ovarian cancer. BMC Morgan MS, Holt DC, Currie BJ, Fulminant infectious mononucleosis MNC, Feltkamp MCW, Green AC, Cancer. 23;9:378. 2009 Walton SF, McCarthy JS. Increased and recurrent Epstein-Barr virus Quint WGV, Michael KM, Pawlita transcription of Glutathione reactivation in an adolescent. Clinical M, Pfi ster H, Weissenborn S, Mika A, Boenisch MJ, Hopff S-transferases in acaricide exposed Infectious Diseases. 50(6):e34-7. 2010 Waterboer T, Neale RE and the EPI- D, Luthje S. Membrane-bound scabies mites. Parasites & Vectors. HPV-UV-CA group. An analysis of guaiacol peroxidases from maize 3:43. 2010 Nyholt DR. Letter to the Editor: clustering of beta papillomavirus DNA (Zea mays L.) roots are regulated Further evidence is required to and Antibodies. Journal of General by methyl jasmonate, salicylic acid, Mujaj S, Manton K, Upton Z, confi rm association between Virology. 91(Pt 8):2062-7. 2010 and pathogen elicitors. Journal of Richards S. Serum-Free Primary CACNA1C gene variants and bipolar Experimental Botany. 61(3):831-841. Human Fibroblast and Keratinocyte affective disorder. Psychological Markey KA, Burman AC, Banovic T, 2010 Coculture. Tissue Engineering Part Medicine. 40(4):702; author reply Kuns RD, Raffelt NC, Rowe V, Olver A.16(4):1407-1420. 2010 703-4. 2010 SD, Don AL, Morris ES, Pettit AR, Miller SM, Hansell NK, Ngo TT, Wilson YA, Robb RJ, Randall LM, Liu GB, Pettigrew JD, Martin NG, Mulvenna J, Moertel L, Jones MK, O'Leary CA, Duffy D, Biros I, Corley Korner H, Engwerda CR, Clouston Wright MJ. Genetic contribution to Nawaratna S, Lovas EM, Gobert S. Linkage confi rms canine pkd1 AD, Macdonald KP, Hill GR. Soluble individual variation in binocular rivalry GN, Colgrave M, Jones A, Loukas orthologue as a candidate for bull lymphotoxin is an important effector rate. Proceedings of the National A, McManus DP. Exposed proteins terrier polycystic kidney disease. molecule in GVHD and GVL. Blood. Academy of Sciences of the United of the Schistosoma japonicum Animal Genetics. 40(4):543-546. 2009 115(1):122-32. 2010 States of America. 107(6):2664-2668. tegument. International Journal of 2010 Parasitology. 40(5):543-454. 2010 O'Mara TA, Clements JA, Spurdle Mao X, Peng H, Ling J, Friis T, AB. The Use of Predictive or Whittaker AK, Crawford R, Xiao Mitchell D, Olive C. Regulation of Mulvenna J, Sripa B, Brindley PJ, Prognostic Genetic Biomarkers in Y. Enhanced human bone marrow Toll-like receptor-induced chemokine Gorman J, Jones MK, Colgrave Endometrial and Other Hormone- stromal cell affi nity for modifi ed poly(L- production in murine dendritic cells ML, Jones A, Nawaratna S, Laha T, Related Cancers: Justifi cation for lactide) surfaces by the upregulation by mitogen-activated protein kinases. Suttiprapa S, Smout MJ, Loukas A. Extensive Candidate Gene Single of adhesion molecular genes. Molecular Immunology. The secreted and surface proteomes Nucleotide Polymorphism Studies Biomaterials 30(36):6903-11. 2009 47(11-12):2065-73. 2010 of the adult stage of the carcinogenic of the Matrix Metalloproteinase human liver fl uke Opisthorchis viverrini. Family and their Inhibitors. Cancer Medland SE, Neale MC. An Mitchell, PB, Frankland A, Hadzi- Proteomics. 10(5):1063-78. 2010 Epidemiology Biomarkers & integrated phenomic approach Pavlovic D, Roberts G, Wright A, Prevention.18 (9): 2352-2365. 2009 to multivariate allelic association. Loo C, Malhi GS, Breakspear M. Nagamine Y, Pong-Wong R, European Journal of Human Genetics. A comparison of the phenomenology Visscher PM, Haley CS. Detection Olsen CM, Carroll HJ, Whiteman DC. (2):233-9. 2010 and illness course of major depressive of multiple quantitative trait loci and Familial melanoma: a meta-analysis episodes in major depressive disorder their pleiotropic effects in outbred and estimates of attributable fraction. Medland SE, Nyholt DR, Painter and bipolar I and bipolar II disorders. pig populations. Genetics Selection Cancer Epidemiology Biomarkers and JN, McEvoy BP, McRae AF, Zhu G, Bipolar Disorders. 12:38-38.Suppl. Evolution. 41: article - 44. 2009 Prevention. 19(1):65-73. 2010 Gordon SD, Ferreira MA, Wright 1. 2010 MJ, Henders AK, Campbell MJ, Naidu D, Scott J, Ong D, Ho CTC. Olsen CM, Carroll HJ, Whiteman DC. Duffy DL, Hansell NK, Macgregor Moreira LA, Iturbe-Ormaetxe I, Validity, reliability and reproducibility of Estimating the attributable fraction S, Slutske WS, Heath AC, Jeffery JA, Lu GJ, Pyke AT, Hedges three methods used to measure tooth for Cancer : A meta-analysis of nevi Montgomery GW, Martin NG. LM, Rocha BC, Hall-Mendelin widths for Bolton analyses. Australian and melanoma. Cancer Prevention Common variants in the trichohyalin S, Day A, Riegler M, Hugo LE, Orthodontic Journal. 25(2):97-103. 2009 Research (Phila Pa). 3(2):233-45. 2010 gene are associated with straight hair Johnson KN, Kay BH, McGraw EA, van den Hurk AF, Ryan PA, O'Neill Neale RE, Hamilton AR, Janda Osborne NJ, Gurrin LC, Allen KJ, in Europeans. American Journal of M, Gies P, Green AC. Seasonal Constantine CC, Delatycki MB, Human Genetics 85(5):750-5. 2009 SL. A Wolbachia Symbiont in Aedes aegypti Limits Infection with Dengue, variation in measured solar ultraviolet McLaren CE, Gertig DM, Anderson Medland SE, Zayats T, Glaser B, Chikungunya, and Plasmodium. Cell. radiation exposure of adults in GJ, Southey MC, Olynyk JK, Powell Nyholt DR, Gordon SD, Wright MJ, 139(7):1268-1278. 2010 subtropical Australia. Photochemistry LW, Hopper JL, Giles GG, English Montgomery GW, Campbell MJ, & Photobiology. 86(2):445-8. 2010 DR. HFE C282Y Homozygotes Are Henders AK, Timpson NJ, Peltonen Morrow BJ, Keddie DJ, Gueven at Increased Risk of Breast and N, Lavin MF, Bottle SE. A novel Nelson EC, Agrawal A, Pergadia Colorectal Cancer. Hepatology. L, Wolke D, Ring SM, Deloukas P, ML, Wang JC, Whitfi eld JB, Martin NG, Smith GD, Evans DM. A profl uorescent nitroxide as a 51(4):1311-1318. 2010 sensitive probe for the cellular redox Saccone FS, Kern J, Grant JD, variant in LIN28B is associated with Schrage AJ, Rice JP, Montgomery Osorio A, Milne RL, Pita G, 2D:4D fi nger-length ratio, a putative environment. Free Radical Biology and Medicine. 49(1):67-76. 2010 GW, Heath AC, Goate AM, Peterlongo P, Heikkinen T, Simard retrospective biomarker of prenatal Martin NG, Madden PAF. H2 J, Chenevix-Trench G, Spurdle testosterone exposure. American Mosing MA, Gordon SD, Medland haplotype at chromosome 17q21.31 AB, Beesley J, Chen X, Healey S, Journal of Human Genetics. SE, Statham DJ, Nelson EC, Heath protects against childhood sexual Neuhausen SL, Ding YC, Couch 86(4):519-25. 2010 AC, Martin NG, Wray NR. Genetic abuse-associated risk for alcohol FJ, Wang X, Lindor N, Manoukian Medland SE, Zhu G, Martin NG. and Environmental Infl uences on the consumption and dependence. S, Barile M, Viel A, Tizzoni L, Estimating the heritability of hair Co-morbidity between depression, Addiction Biology. 15(1):1-11. 2010 Szabo CI, Foretova L, Zikan curliness in twins of European panic disorder, agoraphobia and M, Claes K, Greene MH, Mai P, social phobia: A Twin Study. Netzel-Arnett S, Bugge TH, Rennert G, Lejbkowicz F, Barnett- ancestry. Twin Research and Human Hess RA, Carnes K, Stringer Genetics. 12(5):514-8. 2009 Depression and Anxiety. 26(11):1004- Griness O, Andrulis IL, Ozcelik 1011. 2009 BW, Scarman AL, Hooper JD, H, Weerasooriya N, Gerdes AM, Meredith LW, Ducloux C, Isel Tonks ID, Kay GF, Antalis TM. Thomassen M, Cruger DG, Caligo C, Marquet R, Harrich D. A U5 Mosing MA, Zietsch BP, Shekar SN, The Glycosylphosphatidylinositol- MA, Friedman E, Kaufman B, repressor of reverse transcription is Wright MJ, Martin NG. Genetic and Anchored Serine Protease PRSS21 Laitman Y, Cohen S, Kontorovich required for optimal HIV-1 infectivity environmental infl uences on optimism (Testisin) Imparts Murine Epididymal T, Gershoni-Baruch R, Dagan and replication. Retrovirology 6: article and its relationship to mental and self- Sperm Cell Maturation and Fertilizing E, Jernstrom H, Askmalm MS, O14, Suppl 2009 rated health: a study of aging twins. Ability. Biology of Reproduction. Arver B, Malmer B, Domchek SM, Behavioral Genetics. 39(6):597-604. 81(5):921-932. 2009 Nathanson KL, Brunet J, Cajal Meredith LW, Sivakumaran H, 2009 Nourse JP, Crooks P, Van DN, TRY, Yannoukakos D, Hamann U, Major L, Suhrbier A, Harrich D. Hogervorst FBL, Verhoef S, Garcia Potent inhibition of HIV-1 replication Mounsey KE, Holt DC, McCarthy Jones K, Ross N, Gandhi MK. JS, Currie BJ, Walton SF. EBV MicroRNA Expression in EBG, Wijnen JT, van den Ouweland by a Tat mutant. PLoS One. A, Easton DF, Peock S, Cook 4(11):e7769. 2009 Longitudinal Evidence of Increasing Virus Driven B-Cell Differentiation In Vitro Tolerance of Scabies and Lymphomagenesis. Blood. M, Oliver CT, Frost D, Luccarini Merritt MA, Parsons PG, Newton Mites to Ivermectin in Scabies- 114(22):43-4. 2009 C, Evans DG, Lalloo F, Eeles R, TR, Martyn AC, Webb PM, Green Endemic Communities. Archives of Pichert G, Cook J, Hodgson S, AC, Papadimos DJ, Boyle GM. Dermatology. 145(7):840-841. 2009. Nourse JP, Jones K, Dua U, Morrison PJ, Douglas F, Godwin Expression profi ling identifi es genes Runnegar N, Looke D, Schmidt C, AK, Sinilnikova OM, Barjhoux L,
101 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
Stoppa-Lyonnet D, Moncoutier V, Pandeya N, Webb PM, Sadeghi Peatey CL Skinner-Adams TS Goodman MT, Schildkraut JM, Giraud S, Cassini C, Olivier-Faivre S, Green AC, Whiteman DC, Dixon MW McCarthy JS Gardiner Chenevix-Trench G, Berchuck A, L, Revillion F, Peyrat JP, Muller D, Australian Cancer Study. Gastro- DL Trenholme KR. Effect of Sellers TA. Australian Canc Study Fricker JP, Lynch HT, John EM, oesophageal refl ux symptoms and the antimalarial drugs on Plasmodium Ovarian Canc, Australian Ovarian Buys S, Daly M, Hopper JL, Terry risks of oesophageal cancer: are the falciparum gametocytes. Journal of Canc Study Grp. Polymorphism in MB, Miron A, Yassin Y, Goldgar D, effects modifi ed by smoking NSAIDs Infectious Diseases. 200(10):1518- the GALNT1 Gene and Epithelial Singer CF, Gschwantler-Kaulich or acid suppressants? Gut. 59(1):31- 21. 2009 Ovarian Cancer in Non-Hispanic D, Pfeiler G, Spiess AC, Hansen 8. 2010 White Women: The Ovarian TV, Johannsson OT, Kirchhoff T, Peatey CL Andrews KT Eickel Cancer Association Consortium. Offi t K, Kosarin K, Piedmonte Pandey M Batzloff MR Good MF. N MacDonald T Butterworth Cancer Epidemiology Biomarkers & M, Rodriguez GC, Wakeley K, Mechanism of protection induced AS Trenholme KR Gardiner DL Prevention. 19(2):600-604. 2010 Boggess JF, Basil J, Schwartz PE, by group A Streptococcus vaccine McCarthy JS Skinner-Adams TS. Blank SV, Toland AE, Montagna M, candidate J8-DT: contribution of B Antimalarial asexual stage-specifi c Phillipps KSM, Wykes MN, Liu XQ, Casella C, Imyanitov EN, Allavena and T-cells towards protection. and gametocytocidal activities of Brown M, Blanchfi eld J, Toth I. A A, Schmutzler RK, Versmold B, PLoS One. 4(4):e5147. 2009 HIV protease inhibitors. Antimicrobial novel synthetic adjuvant enhances Engel C, Meindl A, Ditsch N, Agents and Chemotherapy. dendritic cell function. Immunology Pandey M Sekuloski S Batzloff 54(3):1334-7. 2010 128(1):e582-e588, Part 2. 2009 Arnold N, Niederacher D, Deissler MR. Novel strategies for controlling H, Fiebig B, Varon-Mateeva R, Streptococcus pyogenes infection Pereria TN, Walsh M, Rowsell D, Plasmeijer EI, Neale RE, de Schaefer D, Froster UG, Caldes and associated diseases: from Shepherd R, Lewindon PJ, Ramm Koning MNC, Quint WGV, McBride T, de la Hoya M, McGuffog L, potential peptide vaccines to antibody GR. The role of monocyte chemotaxis P, Feltkamp MCW, Green AC. Antoniou AC, Nevanlinna H, Radice immunotherapy. Immunology and Cell protein-1 and the ductular reaction Persistence of Betapapillomavirus P, Benitez J. KConFab, OCGN, Biology, 87(5):391-9. 2009 in initiating fi brogenesis in paediatric Infections as a Risk Factor for Actinic SWE-BRCA, HEBON, EMBRACE, cholestatic liver disease. Journal of Keratoses Precursor to Cutaneous GEMO, Breast Cancer Family Papp LV Holmgren A Khanna KK. Gastroenterology and Hepatology. Squamous Cell Carcinoma. Cander Registry, CIMBA. Evaluation of a Selenium and Selenoproteins in 24:A304-A304 Suppl. 2. 2009 Research 69 (23): 8926-8931. 2009 candidate breast cancer associated Health and Disease. Antioxidants & SNP in ERCC4 as a risk modifi er in Redox Signaling. 12(7):793-795. 2010 Pergadia ML, Agrawal A, Loukola Plasmeijer EI Green AC de BRCA1 and BRCA2 mutation carriers. A, Montgomery GW, Broms U, Koning MNC O'Rourke P Quint Papp LV Lu J Bolderson E Boucher Results from the Consortium of Saccone SF, Wang JC, Todorov AA, GV Feltkamp MCW Neale RE. D Singh R Holmgren A Khanna KK. Investigators of Modifi ers of BRCA1/ Heikkila K, Statham DJ, Henders Transmission of betapapillomaviruses SECIS-binding protein 2 promotes BRCA2 (CIMBA). British Journal of AK, Campbell MJ, Rice JP, Todd between domestic partners in an cell survival by protecting against Cancer. 101(12): 2048-2054. 2009 RD, Heath AC, Goate AM, Peltonen Australian community. Journal of oxidative stress. Antioxidants and L, Kaprio J, Martin NG, Madden Clinical Virology 47 (3): 216-218. 2010. Painter JN Willemsen G Nyholt Redox Signalling. 12(7):797-808. 2010 PAF. Genetic Linkage Findings D Hoekstra C Duffy DL Henders Posthuma D, de Koning DJ, Parriott SK, Suttiprapa S, Laha T, for DSM-IV Nicotine Withdrawal AK Wallace L Healey S Cannon- Dolan C, Goddard ME, Visscher Sripa B, Loukas A, Brindley PJ. in Two Populations. American Albright LA Skolnick M Martin NG PM. A Note on Permutation Tests Recombinant Expression and Journal of Medical Genetics Part Boomsma DI Montgomery GW. for Genetic Association Analysis of Purifi cation of Caspase 9 of B – Neurophychiatric Genetics. A genome wide linkage scan for Quantitative Traits When Variances Opisthorchis Viverrini. American 150B(7):950-959. 2009 dizygotic twinning in 525 families of Are Heterogeneous. Genetic Journal of Tropical Medicine and mothers of dizygotic twins. Human Perttila J, Merikanto K, Epidemiology. 33(8):710-716. 2009 Hygiene. 81(5):1130, Suppl. S. 2009 Reproduction. 25(6):1569-80. 2010 Naukkarinen J, Surakka I, Martin Powell LW Overview: Liver disease Pasay C, Mounsey K, Arlian L, NW, Tanhuanpaa K, Grimard V, Palath V, Vekhande R, Lee A, and transplantation. Journal of Morgan M, Holt D, Currie B, Taskinen MR, Thiele C, Salomaa Williams J, Zhang L, List AF, Boyd Gastroenterology and Hepatology. Walton S, McCarthy J. Role of V, Jula A, Perola M, Virtanen A, Lackmann M, Scott AM, Cilloni Suppl 3:S97-S104. 2009 elevated transcription of Glutathione I, Peltonen L, Olkkonen VM. D, Yarranton GT, Bebbington C. S-transferases (GSTS) in Pyrethroid OSBPL10, a novel candidate gene for Poynter JN, Haile RW, Siegmund A Recombinant Human Antibody Resistant Scabies Mites. American high triglyceride trait in dyslipidemic KD, Campbell PT, Figueiredo JC, to EphA3 with Pro-Apoptotic and Journal of Tropical Medicine and Finnish subjects, regulates cellular Limburg P, Young J, Le Marchand Enhanced ADCC Activity Shows Hygiene. 81(5):8, Suppl. S. 2009 lipid metabolism. Journal of Molecular L, Potter JD, Cotterchio M, Casey Selective Cytotoxicity against Myeloid Medicine. 87(8):825-835. 2009 G, Hopper JL, Jenkins MA, Leukemia Cells and CD123-Positive Pearson MS Bethony JM Pickering Thibodeau SN, Newcomb PA, Leukemic Stem Cells. Blood. Pettigrew CA, French JD, Saunus DA de Oliveira LM Jariwala A Baronlo JA. Colon Canc Family 114(22):688-688. 2009 JM, Edwards SL, Sauer AV, Smart Santiago H Miles AP Zhan B Jiang Registry. Associations between D Ranjit N Mulvenna J Tribolet CE, Lundstrom T, Wiesner C, Pampillo M, Camuso N, Taylor Smoking, Alcohol Consumption, and L Plieskatt J Smith T Bottazzi Spurdle AB, Rothnagel JA, Brown JE, Szereszewski JM, Ahow MR, Colorectal Cancer, Overall and by ME Jones K Keegan B Hotez MA. Identifi cation and functional Zajac M, Millar RP, Bhattacharya Tumor Microsatellite Instability Status. PJ Loukas A. An enzymatically analysis of novel BRCA1 transcripts, M, Babwah AV. Regulation of Cancer Epidemiology Biomarkers & inactivated hemoglobinase from including mouse Brca1-Iris and GPR54 Signaling by GRK2 and beta- Prevention. 18(10):2745-2750. 2009 Necator americanus induces human pseudo-BRCA1. Breast Arrestin. Molecular Endocrinology. neutralizing antibodies against Cancer Research and Treatment. Price MA, Zachariae R, Butow 23(12):2060-2074. 2009 multiple hookworm species and 119 (1): 239-247. 2010 PN, Defazio A, Chauhan D, Espie Pandian JD, Dalton K, Scott J, protects dogs against heterologous Phelan CM, Tsai YY, Goode EL, CA, Friedlander M, Webb PM, Read SJ, Henderson RD. hookworm infection. Federation of Vierkant RA, Fridley BL, Beesley J, Australian Ovarian Canc Study Grp, Cardiovascular autonomic function American Societies for Experimental Chen XQ, Webb PM, Chanock S, Australian Ovarian Cancer Study tests to provide normative data from Biology Journal (FASEB J) 23(9):3007- Cramer DW, Moysich K, Edwards Qual. Prevalence and predictors of a healthy older population. Journal of 19. 2009 RP, Chang-Claude J, Garcia-Closas insomnia in women with invasive Clinical Neuroscience. 17(6):731-735. ovarian cancer: Anxiety a major Pearson MS Pickering DA Tribolet M, Yang H, Wang-Gohrke S, Hein 2010 R, Green AC, Lissowska J, Carney factor. European Journal of Cancer. L Cooper L Mulvenna J Oliveira 45(18):3262-3270. 2009 Pandeya N, Williams GM, Green LM Bethony JM Hotez PJ Loukas ME, Lurie G, Wilkens LR, Ness RB, AC, Webb PM, Whiteman DC. Do A. Neutralizing antibodies to the Pearce CL, Wu AH, Van Den Berg Pritchard AL Ratcliffe L Sorour low control response rates always hookworm hemoglobinase Na-APR-1: DJ, Stram DO, Terry KL, Whiteman E Haque S Holder R Bentham affect the fi ndings? Assessments of implications for a multivalent vaccine DC, Whittemore AS, DiCioccio RA, P Lendon CL. Investigation of smoking and obesity in two Australian against hookworm infection and McGuire V, Doherty JA, Rossing dopamine receptors in susceptibility case-control studies of cancer. schistosomiasis. Journal of Infectious MA, Anton-Culver H, Ziogas A, to behavioural and psychological Australia New Zealand Journal of Diseases. 201(10):1561-9. 2010 Hogdall C, Hogdall E, Kjaer SK, symptoms in Alzheimer's disease. Public Health. 33(4):312-9. 2009 Blaakaer J, Quaye L, Ramus SJ, International Journal of Geriatric Jacobs I, Song HL, Pharoah PDP, Psychiatry. 24(9):1020-5. 2009 Iversen ES, Marks JR, Pike MC, Gayther SA, Cunningham JM,
102 QIMR Annual Report 2009/10 Prodoehl MJ, Hatzirodos N, Irving- Rebbeck TR Mitra N Domchek Roque JB, O'Leary CA, Kyaw- Suhrbier A. A physiological function Rodgers HF, Zhao ZZ, Painter JN, SM Wan F Chuai S Friebel TM Tanner M, Latter M, Mason K, of infl ammation-associated SerpinB2 Hickey TE, Gibson MA, Rainey Panossian S Spurdle A Chenevix- Shipstone M, Vogelnest L, Duffy DL. is regulation of adaptive immunity. WE, Carr BR, Mason HD, Norman Trench G, kConFab Singer CF Haplotype sharing excludes canine Journal of Immunology 184(5):2663- RJ, Montgomery GW, Rodgers Pfeiler G Neuhausen SL Lynch HT orthologous Filaggrin locus in atopy in 70. 2010 RJ. Genetic and gene expression Garber JE Weitzel JN Isaacs C West Highland White Terriers. Animal Sedegah M, Kim Y, McGrath S, analyses of the polycystic ovary Couch F Narod SA Rubinstein WS Genetics. 40(5):793-794. 2009 Ganeshan H, Lejano J, Abot S, syndrome candidate gene fi brillin-3 Tomlinson GE Ganz PA Olopade Ross AG, Hou XY, Chen SX, Banania G, Belmonte M, Sayo and other fi brillin family members in OI Tung N Blum JL Greenberg R McManus DP, Li YS. A 36-Year- R, Farooq F, Doolan DL, Peters human ovaries. Molecular Human Nathanson KL Daly MB. Old Chinese Man with High Fever, B, Bruder J, King CR, Soissons Reproduction. 15 (12): 829-841. 2009 Modifi cation of ovarian cancer risk Abdominal Pain, Watery Diarrhea, and L, Diggs C, Ockenhouse CF, by BRCA1/2-interacting genes in Myalgia. Clinical Infectious Diseases. Hollingdale M, Sette A, Richie TL. Purcell SM, Wray NR, Stone JL, a multicenter cohort of BRCA1/2 50(9): 1256-+. 2010 Identifi cation of HLA restricted Visscher PM, O'Donovan MC, mutation carriers. Cancer Research. Sullivan PF, Sklar P, Ruderfer CD8+T-cell epitopes on the 69(14):5801-10. 2009 Rulli NE, Guglielmotti A, Mangano DM, McQuillin A, Morris DW, Plasmodium Falciparum AMA1 G, Rolph MS, Apicella C, Zaid O'Dushlaine CT, Corvin A, Holmans Reid DW, Anderson GJ, Lamont IL. A, Suhrbier A, Mahalingam S. protein. American Journal of Tropical PA, Macgregor S, Gurling H, Role of lung iron in determining the Amelioration of Alphavirus-Induced Medicine and Hygiene. 81(5):743, Blackwood DHR, Corvin A, bacterial and host struggle in Arthritis and Myositis in a Mouse Suppl. S. 2009 Craddock NJ, Gill M, Hultman CM, cystic fi brosis. American Journal Model by Treatment With Bindarit, an Selonen V, Hanski IK, Painter JN. Kirov GK, Lichtenstein P, Muir WJ, of Physiology – Lung Cellular Inhibitor of Monocyte Chemotactic Gene fl ow and natal dispersal in Owen MJ, Pato CN, Scolnick EM, and Molecular Physiology. Proteins. Arthritis and Rheumatism. the Siberian fl ying squirrel based on St Clair D, Craddock NJ, Holmans 297(5):L795-L802. 2009 60(8):2513-2523. 2009 PA, Williams NM, Georgieva L, direct and indirect data. Conservation Nikolov I, Norton N, Williams H, Reid H, Vallely A, Taleo G, Tatem Ruyssers NE, De Winter BY, De Genetics. 11 (4): 1257-1264. 2010 AJ, Kelly G, Riley I, Harris I, Henri I, Toncheva D, Milanova V, Hultman Man JG, Ruyssers ND, Van Gils AJ, Serewko-Auret MM Mould Arne Iamaher S, Clements ACA. Baseline Loukas A, Pearson MS, Weinstock CM, Lichtenstein P, Thelander EF, W Loffl er KA Duncan R Kay GF spatial distribution of malaria prior to JV, Pelckmans PA, Moreels TG. Sullivan P, Kenny E, Quinn EM, Gill Hayward NK. Alternations in Gene an elimination programme in Vanuatu. Schistosoma mansoni proteins M, Corvin A, Choudhury K, Datta Expression in MEN1-Associated Malaria Journal. 9: article 150. 2010 attenuate gastrointestinal motility S, Pimm J, Thirumalai S, Puri V, Insulinoma Development. Pancreas disturbances during experimental Krasucki R, Lawrence J, Quested Richards AA Colgrave ML Jialiang 00. 2010 colitis in mice. World Journal of D, Bass N, Crombie C, Fraser G, Z Webster J Simpson F Preston E Gastroenterology.16(6): 03-712. 2010 Schistosoma japonicum Genome Kuan SL, Walker N, Blackwood Wilks D Hoehn KL Stephenson M Sequencing and Functional DHR, Muir WJ, McGhee KA, Macdonald GA Prins JB Cooney Sachdev PS, Lammel A, Trollor Analysis Consortium, Liu F, Zhou Y, Pickard B, Malloy P, Maclean AW, GJ Xu A Whitehead JP. Sialic JN, Lee T, Wright MJ, Ames D, Wang ZQ, Lu G, Zheng H, Brindley Van Beck M, Wray NR, Macgregor Acid Modifi cation of Adiponectin Is Wen W, Martin NG, Brodaty H, PJ, McManus DP, Blair D, Zhang S, Visscher PM, Pato MT, Medeiros Not Required for Multimerization or Schofi eld PR, OATS Res Team. A QH, Zhong Y, Wang S, Han ZG, H, Middleton F, Carvalho C, Morley Secretion but Determines Half-Life in Comprehensive Neuropsychiatric Chen Z. The Schistosoma japonicum C, Fanous A, Conti D, Knowles JA, Circulation. Molecular Endocrinology. Study of Elderly Twins: The Older genome reveals unique features Ferreira CP, Macedo A, Azevedo 24(1):229-39. 2009 Australian Twins Study. Twin Research of host-parasite interplay. Nature MH, Kirby AN, Ferreira MAR, and Human Genetics. 12 (6): 573- 460:345-352 (featured on front cover) Daly MJ, Chambert K, Kuruvilla Rist M Smith C Bell MC Burrows 582. 2009 F, Gabriel SB, Ardlie K, Moran JL, SR Khanna R. Cross-recognition of Shah SP, Kobel M, Senz J, Morin Daly MJ, Scolnick EM.. Common HLA DR4 alloantigen by virus-specifi c Samaratunga H, Duffy D, Yaxley RD, Clarke BA, Wiegand KC, Leung polygenic variation contributes to risk CD8+T cells: a new paradigm for J, Delahunt B. Any proportion of G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones of schizophrenia and bipolar disorder. self-/nonself-recognition. Blood. ductal adenocarcinoma in radical S, Varhol R, Swenerton KD, Miller Nature. 460(7256):748-752. 2009 114(11):2244-53. 2009 prostatectomy specimens predicts extraprostatic extension. Human D, Clement PB, Crane C, Madore Radford-Smith G, Croft A, Doecke Rizzi SC Upton Z Bott K Dargaville Pathology. 41 (2): 281-285. 2010 J, Provencher D, Leung P, DeFazio J, Walsh A. Outcomes of salvage TR. Recent advances in dermal A, Khattra J, Turashvili G, Zhao YJ, therapy for acute severe ulcerative wound healing: biomedical device Sandbacka M, Painter J, Zeng T, Glover JNM, Vanderhyden colitis Cyclosporin versus Infl iximab. approaches. Expert Review of Puhakka M, Halttunen M, Laivuori B, Zhao CQ, Parkinson CA, Infl ammatory Bowel Diseases. 15(12): Medical Devices. 7(1):143-54. 2010 H, Aittomaki K. Does the Y Jimenez-Linan M, Bowtell DDL, S43-S44, Suppl. S. 2009 chromosome have a role in Mullerian Mes-Masson AM, Brenton JD, Roddam AW, Appleby P, Neale R, aplasia?. Fertility and Sterility. Aparicio SA, Boyd N, Hirst M, Ramm GA. Chemokine (C-C motif) Dowsett M, Folkerd E, Tipper S, 94(1):120-125. 2010 Gilks CB, Marra M, Huntsman DG. receptors in fi brogenesis and hepatic Allen NE, Key TJ. Association Mutation of FOXL2 in Granulosa-Cell Sartor CE Grant JD Bucholz KK regeneration following acute and between endogenous plasma Tumors of the Ovary. New England Madden PA Heath AC Agrawal chronic liver disease. Hepatology. hormone concentrations and Journal of Medicine. 360(26):2719- A Whitfi eld JB Statham DJ 50(5):1664-1668. 2009 fracture risk in men and women: 2729. 2009 the EPIC-Oxford prospective cohort Martin NG Lynskey MT. Common Ramm GA Ruddell RG study. Journal of Bone and Mineral genetic contributions to alcohol Shanks GD, MacKenzie A, Subramaniam VN. Identifi cation of Metabolism. 27(4):485-493. 2009 and cannabis use and dependence Mclaughlin R, Waller M, Dennis ferritin receptors: their role in iron symptomatology. Alcoholism: P, Lee SE, Brundage JF. Mortality homeostasis hepatic injury and Rogers C, Kvaskoff M, DiSipio T, Clinical and Experimental Research. Risk Factors During the 1918-1919 infl ammation. Gastroenterology. Youlden D, Whiteman D, Eakin E, 1,34(3):545-54. 2010 Infl uenza Pandemic in the Australian 137(5):1849-51. 2009 Youl PH, Aitken J, Fritschi L. Army. Journal of Infectious Diseases. Schira MM, Tyler CW, Spehar Prevalence and determinants of 201(12):1880-1889. 2010 B, Breakspear M. Modeling Randall LM Kenangalem E Lampah sunburn in Queensland.Health Magnifi cation and Anisotropy in the Sheel M Pandey M Good MF DA Tjitra E Mwaikambo ED Handojo Promotion Journal of Australia. Primate Foveal Confl uence. PLOS Batzloff MR. Correlation between T Piera KA Zhao ZZ de Labastida 20(2):102-6. 2009 Rivera F Zhou Y McSweeney KM Computational Biology. 6(1):article bioluminescence and bacterial burden Le L Amante FH Haque A Stanley Rolfe MI, Mengersen K, Beadle G, -e1000651. 2010 in passively protected mice challenged AC Woodberry T Salwati E Granger Vearncombe K, Andrew B, with a recombinant bioluminescent Schira MM, Tyler CW, Breakspear DL Hobbs MR Price RN Weinberg Johnson HL, Walsh C. Latent class M49 group A streptococcus strain. M, Spehar B. The Foveal Confl uence JB Montgomery GW Anstey NM piecewise linear trajectory modelling Clinical and Vaccine Immunology in Human Visual Cortex. Journal of Engwerda CR. Age-Related for short-term cognition responses 17(1):127-33 2010 after chemotherapy for breast cancer Neuroscience. 29(28):9050-9058. 2009 Susceptibility to Severe Malaria Shekar SN Duffy DL Youl P Baxter patients. Journal of Applied Statistics. Associated with Galectin-2 in Highland Schroder WA Le TT Major L Street AJ Kvaskoff M Whiteman DC 37(5):725-738. 2010 Papuans. Journal of Infectious S Gardner J Lambley E Markey K Green AC Hughes MC Hayward Diseases. 202(1):117-124. 2010 MacDonald KP Fish RJ Thomas R NK Coates M Martin NG. A
103 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
population-based study of Australian risk for Barrett's esophagus. Clinical Neck Journal for the Sciences and Carcinogenic Human Liver Fluke twins with melanoma suggests a Gastroenterology & Hepatology. Specialties of the Head and Neck. Opisthorchis viverrini Correlates with strong genetic contribution to liability. 7(8):840-8. 2009 (6):802-806. 2009 Elevated Levels of Interleukin-6. Journal of Investigative Dermatology. Hepatology. 50(4):1273-1281. 2009 129(9):2211-9. 2009 Smout MJ, Laha T, Mulvenna J, Song HL, Ramus SJ, Tyrer J, Bolton Sripa B, Suttiprapa S, Jones A, KL, Gentry-Maharaj A, Wozniak Stark MS, Tyagi S, Nancarrow DJ, Shi JX, Levinson DF, Duan JB, Brindley PJ, Loukas A. A granulin- E, Anton-Culver H, Chang-Claude Boyle GM, Cook AL, Whiteman DC, Sanders AR, Zheng YL, Pe'er like growth factor secreted by the J, Cramer DW, DiCioccio R, Dork Parsons PG, Schmidt C, Sturm RA, I, Dudbridge F, Holmans PA, carcinogenic liver fl uke Opisthorchis T, Goode EL, Goodman MT, Hayward NK. Characterization of the Whittemore AS, Mowry BJ, Olincy viverrini promotes proliferation Schildkraut JM, Sellers T, Baglietto Melanoma miRNAome by Deep A, Amin F, Cloninger CR, Silverman of host cells. PLoS Pathogens. L, Beckmann MW, Beesley J, Sequencing. PLoS One. 5(3):e9685. JM, Buccola NG, Byerley WF, Black 5(10):e1000611. 2009 Blaakaer J, Carney ME, Chanock S, 2010 DW, Crowe RR, Oksenberg JR, Chen ZH, Cunningham JM, Dicks Mirel DB, Kendler KS, Freedman Skaar JR, Richard DJ, Saraf A, E, Doherty JA, Durst M, Ekici AB, Steer AC, Batzloff MR, Mulholland R, Gejman PV. Common variants on Toschi A, Bolderson E, Florens L, Fenstermacher D, Fridley BL, Giles K, Carapetis JR. Group A chromosome 6p22.1 are associated Washburn MP, Khanna KK, Pagano G, Gore ME, De Vivo I, Hillemanns streptococcal vaccines: facts versus with schizophrenia. Nature. M. INTS3 controls the hSSB1- fantasy. Current Opinion in Infectious 460(7256):753-757. 2009 mediated DNA damage response. P, Hogdall C, Hogdall E, Iversen Diseases. 22(6):544-552. 2009 Journal of Cell Biology. 187(1):25-32. ES, Jacobs IJ, Jakubowska A, Li D, Simerska P McGeary RP Abdel- 2009 Lissowska J, Lubinski J, Lurie G, Steer AC, Magor G, Jenney AWJ, Aal AB Moyle PM Olive C Good McGuire V, McLaughlin J, Medrek Kado J, Good MF, McMillan D, M.F Toth I. Vaccine delivery utilizing Skinner-Adams TS, Andrews K, Moorman PG, Moysich K, Narod Batzloff M, Carapetis JR. emm and liposaccharides. Advances in KT, Gardiner DL, McCarthy JS. S, Phelan C, Pye C, Risch H, C-Repeat Region Molecular Typing Experimental Medicine and Biology Understanding the Antimalarial Runnebaum IB, Severi G, Southey of Beta-Hemolytic Streptococci in 611:345-346. 2009 Action of the HIV Protease Inhibitors. M, Stram DO, Thiel FC, Terry KL, a Tropical Country: Implications for American Journal of Tropical Medicine Vaccine Development. Journal of Singh, S, van Hauten, P, Jones, K, Tsai YY, Tworoger SS, Van Den and Hygiene. 81(5):299,Suppl. S. 2009 Clinical Microbiology. 47 (8): 2502- Grimmett, K, Mills, AK, Gandhi, MK. Berg DJ, Vierkant RA, Wang- 2509. 2009 Selective accumulation of virus- Skinner-Adams TS, Stack CM, Gohrke S, Webb PM, Wilkens LR, specifi c CD8(+) T cells within Trenholme KR, Brown CL, Wu AH, Yang HN, Brewster W, Stringer BW, Day BW, Spanevello the peripheral blood stem cell Grembecka J, Lowther J ,Mucha Ziogas A, Houlston R, Tomlinson MD, Reynolds BA, Carter JC, Cox compartment. Blood. 114 (9): 2001- A, Drag M, Kafarski P, McGowan S, I, Whittemore AS, Rossing MA, JM, Ellis VJ, Brown CL, Walker 2003. 2009 Whisstock JC, Gardiner DL, Dalton Ponder BAJ, Pearce CL, Ness RB, DG, Lickliter JD, Boyd AW. ELK4 JP. Plasmodium falciparum neutral Menon U, Kjaer SK, Gronwald J, Neutralisation sensitises high- Sinilnikova OM, Antoniou AC, aminopeptidases: new targets for Garcia-Closas M, Fasching PA, grade Glioma to apoptosis through Simard J Healey, S Léoné M, Sinnett anti-malarials. Trends in Biochemical Easton DF, Chenevix-Trench G, downregulation of the antiapoptotic D, Spurdle AB, Beesley J Chen X, Science. 35(1):53-61. 2010 Berchuck A, Pharoah PDP, Gayther protein MCL-1. Neuro-oncology. kConFab, Greene MH, Loud JT, SA. Australian Canc Ovarian Study; 11 (6): 959-960. 2009 Lejbkowicz F, Rennert G, Dishon Slutske WS, Zhu G, Meier Australian Ovarian Canc Study Grp; S, Andrulis IL, OCGN, Domchek MH, Martin NG. Genetic and Ovarian Canc Assoc Consortium. Sturm RA, Larsson M. Genetics SM, Nathanson KL, Manoukian Environmental Infl uences on A genome-wide association study of human iris colour and patterns. S, Radice P, Konstantopoulou I, Disordered Gambling in Men identifi es a new ovarian cancer Pigment Cell & Melanoma Research. Blanco I, Laborde AL, Durán M, and Women. Archives of General susceptibility locus on 9p22.2. Nature 22(5):544-562. 2009 Osorio A, Benitez J, Hamann U, Psychiatry. 67(6):624-630. 2010 Genetics. 4 (9) 996-U60. 2009 Hogervorst FB, van Os TA, Gille Subramaniam VN. Regulation of Iron HJ, HEBON, Peock S, Cook M, Slutske WS, Blaszczynski A, Martin Spurdle AB. Clinical relevance of rare Homeostasis: Is it All in the HBD? Luccarini C, Evans DG, Lalloo F, NG. Sex Differences in the Rates of germline sequence variants in cancer Gastroenterology. 136(4):1449-51. Eeles R, Pichert G, Davidson R, Recovery, Treatment-Seeking, and genes: evolution and application 2009 Cole T, Cook J, Paterson J, Brewer Natural Recovery in Pathological of classifi cation models. Current Suhrbier A, Mahalingam S. The C, EMBRACE,Hughes DJ, Coupier Gambling: Results From an Australian Opinion in Genetics & Development. immunobiology of viral arthritides. I, Giraud S, Coulet F, Colas C, Community-Based Twin Survey. 20(3):315-23. 2010 Pharmacology and Therapeutics 2009 Soubrier F, Rouleau E, Bièche I, Twin Research and Human Genetics. Spurdle AB, Lakhani SR, Da Lidereau R, Demange L, Nogues 12(5):425-432. 2009 Summers KM, Bokil NJ, Lu FT, Silva LM, Balleine RL, kConFab C, Lynch HT, GEMO, Schmutzler Low JT, Baisden JM, Duffy D, Smeesters PR, McMillan DJ, Investigators Goldgar DE. Bayes RK, Versmold B, Engel C, Meindl Radford DJ. Mutations at KCNQ1 Sriprakash KS, Georgousakis MM. analysis provides evidence of A, Arnold N, Sutter C, Deissler H, and an Unknown Locus Cause Long Differences among group A pathogenicity for the BRCA1 c.135- Schaefer D, Froster UG, GC- QT Syndrome in a Large Australian streptococcus epidemiological 1G>T (IVS3-1) and BRCA2 c.7977- HBOC, Aittomäki K, Nevanlinna H, Family: Implications for Genetic Testing. landscapes: consequences for M 1G>C (IVS17-1) variants displaying McGuffog L, Easton DF, Chenevix- American Journal of Medical Genetics. protein-based vaccines? Expert in vitro splicing results of equivocal Trench G, Stoppa-Lyonnet D, Part A.152A(3):613-621. 2010 Review of Vaccines. 2009 clinical signifi cance. Human Mutation. Consortium of Investigators of 31(2):E1141-5. 2010 Modifi ers of BRCA1/2. The TP53 Smeesters PR, McMillan DJ, Sun C, Zhu G, Wong TY, Hewitt AW, Ruddle JB, Hodgson L, Arg72Pro and MDM2 309G>T Sriprakash KS. The streptococcal M Spurdle AB, Fahey P, Chen X, Montgomery GW, Young TL, polymorphisms are not associated with protein: a highly versatile molecule. McGuffog L, kConFab, Easton Hammond CJ, Craig JE, Martin breast cancer risk in BRCA1 and Trends in Microbiology. 18(6):275- D, Peock S, Cook M, EMBRACE NG, He M, Mackey DA. Quantitative BRCA2 mutation carriers. British 282. 2010. Simard J, INHERIT Rebbeck TR, genetic analysis of the retinal vascular Journal of Cancer. 101(8):1456-60. MAGIC Antoniou AC, Chenevix- Smith KJ, O’Brien SM, Green AC, caliber: the Australian Twins Eye Study. 2009 Trench G. Pooled analysis indicates Webb PM, Whiteman DC, Study Hypertension. 54(4):788-95. 2009 that the GSTT1 deletion GSTM1 Sivakumaran H, van der Horst A, of Digestive Health. Current and deletion and GSTP1 Ile105Val Fulcher AJ, Apolloni A, Lin MH, past smoking signifi cantly increase Sun XP, Barlow EA, Ma SD, polymorphisms do not modify breast Jans DA, Harrich D. 2009. Arginine risk for Barrett’s esophagus. Clinical Hagemeier SR, Duellman SJ, cancer risk in BRCA1 and BRCA2 Methylation Increases the Stability of Gastroenterology and Hepatology. Burgess RR, Tellam J, Khanna R, mutation carriers. Breast Cancer Human Immunodefi ciency Virus Type 7(8):840-8. 2009 Kenney SC. Hsp90 inhibitors block Research and Treatment. 122(1):281- 1 Tat. Journal of Virology 83 (22): outgrowth of EBV-infected malignant 5. 2010 11694-11703. 2009 Solares CA, Brown I, Boyle GM, cells in vitro and in vivo through an Parsons PG, Panizza B. Neural cell EBNA1-dependent mechanism. Sripa B, Mairiang E, Thinkhamrop Smith KJ, O'Brien SM, Green AC, adhesion molecule expression: no Proceedings of the National Academy B, Laha T, Kaewkes S, Sithithaworn Webb PM, Whiteman DC; Study correlation with perineural invation in of Sciences of the United States of P, Tessana S, Loukas A, Brindley PJ, of Digestive Health. Current and cutaneious squamous cell carcinoma America.107(7):3146-3151. 2010 Bethony JM. Advanced Periductal past smoking signifi cantly increase of the head and neck. Head and Fibrosis from Infection with the
104 QIMR Annual Report 2009/10 Suraweera A, Lim Y, Woods R, independently of IL-17A during Tonks ID, Mould AW, Schroder WA, Upcroft JA Dunn LA Wal T Tabrizi S Birrell GW, Nasim T, Becherel, OJ carcinogenesis and metastasis. Cotterill A, Hayward NK, Walker Delgadillo-Correa MG Johnson PJ Lavin MF. Functional role for senataxin Procedings of the National Academy GJ, Kay GF. Dual loss of rb1 and Garland S Siba P Upcroft P. defective in ataxia oculomotor apraxia of Sciences of the United States of Trp53 in the adrenal medulla leads to Metronidazole resistance in type 2 in transcriptional regulation. America. 107(18):8328-8333. 2010 spontaneous pheochromocytoma. Trichomonas vaginalis from highland Human Molecular Genetics. Neoplasia. 12(3):235-43. 2010 women in Papua New Guinea. Sexual 18(18):3384-96. 2009 Teng RW, McManus D, Aylward J, Health. 6(4):334-8. 2009 Ogbourne S, Armstrong D, Mau SL, Tonks ID, Mould AW, Schroder WA, Tabakoff B, Saba L, Printz M, Johns J, Bacic A. Biotransformation Hacker E, Bosenberg M, Hayward Upcroft JA. History of Parasitology at Flodman P, Hodgkinson C, of ingenol-3-angelate in four plant cell NK, Walker GJ, Kay GF. Melancyte QIMR. In: “The History of Parasitology Goldman D, Koob G, Richardson suspension cultures. Biocatalysis and homeostasis in vivo tolerates rb1 loss in Australia” Ed. Beveridge I. and HN, Kechris K, Bell RL, Hubner N, Biotransformation. 27 (3): 186-194. 2009 in a developmentally independent O’Donoghue P.J. Australian Society Heinig M, Pravenec M, Mangion J, fashion. Pigment Cell & Melanoma for Parasitology publication. Raw Legault L, Dongier M, Conigrave Thara R, Srinivasan T, John S, Research. Short Communication 2010 Publishing Blackburn Victoria KM, Whitfi eld JB, Saunders J, Nancarrow D, Chant D, Holliday Australia 2009. Grant B, Hoffman PL. WHO ISBRA E, Mowry B. Design and clinical Toth I, Moyle PM, Simerska P, Study State Trait Marker. Genetical characteristics of a homogeneous Fujita Y, Olive C, Good M.F. Vaccine Utzinger J, Raso G, Brooker genomic determinants of alcohol schizophrenia pedigree sample from delivery: synthesis and investigation S, de Savigny D, Tanner M, consumption in rats and humans. Tamil Nadu, India. Australian and New of a highly pure multi-epitopic Ornbjerg N, Singer BH, N'Goran BMC Biology 7: article 70. 2009 Journal of Psychiatry. 43 (6): 561- lipopeptide vaccine candidate. EK. Schistosomiasis and neglected 570. 2009 Advances in Experimental Medicine tropical diseases: towards integrated Tallis C, Boyd P, Ombiga J, and Biology 611: 347-349 2009. and sustainable control and a word of Terry S, O'Rourke P, Chin B. Thorgeirsson TE, Gudbjartsson DF, caution. Parasitology. 136(13):1859- Blinded randomised trial of effi cacy, Surakka I, Vink JM, Amin N, Geller Tran MH, Freitas TC, Cooper L, 1874. 2009 acceptance and adherence of F, Sulem P, Rafnar T, Esko T, Walter Gaze S, Gatton ML,Jones MK, standard bowel preparation of S, Gieger C, Rawal R, Mangino M, Lovas E, Pearce EJ ,Loukas A. Valdez CA, Tripp JC, Miyamoto "glycoprep" and "fl eet" versus Prokopenko I, Magi R, Keskitalo Suppression of mRNAs encoding Y, Kalisiak J, Hruz P, Andersen "colocap balance (TM)" in bowel K, Gudjonsdottir IH, Gretarsdottir tegument tetraspanins from YS, Brown SE, Kangas K, Arzu preparation for colonoscopy. Journal S, Stefansson H, Thompson JR, Schistosoma mansoni results in LV, Davids BJ, Gillin FD, Upcroft of Gastroenterology and Hepatology. Aulchenko YS, Nelis M, Aben KK, impaired tegument turnover. PLoS JA, Upcroft P, Fokin VV, Smith 24: A254-A254, Suppl. 2. 2009 den Heijer M, Dirksen A, Ashraf Pathogens. 6(4):e1000840. 2010 DK, Sharpless KB, Eckmann L. H, Soranzo N, Valdes AM, Steves Synthesis and Electrochemistry of Treloar SA, Bell TA, Nagle CM, Tang J, Harper SJ, Wei T, Clover C, Uitterlinden AG, Hofman A, 2-Ethenyl and 2-Ethanyl Derivatives Purdie DM, Green AC. Early GRG. Characterization of hydrangea Tonjes A, Kovacs P, Hottenga JJ, of 5-Nitroimidazole and Antimicrobial menstrual characteristics associated chlorotic mottle virus, a new member Willemsen G, Vogelzangs N, Doring Activity against Giardia lamblia. with subsequent diagnosis of of the genus Carlavirus. Archives of A, Dahmen N, Nitz B, Pergadia ML, Journal of Medicinal Chemistry. endometriosis. American Journal Virology. 155(1) 7-12. 2010 Saez B, De Diego V, Lezcano V, 52(13):4038-4053. 2009 or Obstetrics and Gynecology. Garcia-Prats MD, Ripatti S, Perola 202(6):534. 2010 Tavtigian SV, Oefner PJ, Babikyan M, Kettunen J, Hartikainen AL, Valery PC Masters IB Taylor B D, Hartmann A, Healey S, Le Pouta A, Laitinen J, Isohanni M, Laifoo Y O'Rourke PK Chang AB. Calvez-Kelm F, Lesueur F, Trenholme KR, Brown CL, Skinner- An education intervention for childhood Huei-Yi S, Allen M, Krestyaninova Adams TS, Stack C, Lowther J, Byrnes GB, Chuang SC, Forey M, Hall AS, Jones GT, van Rij AM, asthma by Aboriginal and Torres Strait N, Feuchtinger C, Gioia L, Hall To J, Robinson MW, Donnelly Islander health workers: a randomised Mueller T, Dieplinger B, Haltmayer SM, Dalton JP, Gardiner DL. J, Hashibe M, Herte B, McKay- M, Jonsson S, Matthiasson SE, controlled trial. Medical Journal of Chopin S, Thomas A, Vallee MP, Aminopeptidases of malaria parasites: Australia. 192(10):574-9. 2010 Oskarsson H, Tyrfi ngsson T, new targets for chemotherapy. Voegele C, Webb PM, Whiteman Kiemeney LA, Mayordomo JI, DC, Sangrajrang S, Hopper JL, Infectious Disorders Drug Targets. Van de Horst A Khanna KK. Lindholt JS, Pedersen JH, Franklin 10(3):217-25. 2010 The peptidyl-prolyl isomerise Pin1 Southey MC, Andrulis IL, John WA, Wolf H, Montgomery GW, EM, Chenevix-Trench G. Australian regulates cytokinesis through Cep55. Heath AC, Martin NG, Madden PAF, Turner MS, Andersson P, Bell JM, Cancer Research. 69(16):6651-9. 2009 Canc Study, BCFR, Kathleen Giegling I, Rujescu D, Jarvelin MR, Turnidge JD, Harris T, Giffard PM. Cuningham Fdn Consortium. Rare, Salomaa V, Stumvoll M, Spector Plasmid-borne blaSHV genes in Van der Horst A Simmons J Khanna Evolutionarily Unlikely Missense TD, Wichmann HE, Metspalu A, Klebsiella pneumoniae are associated KK. Cep55 stabilization is required for Substitutions in ATM Confer Samani NJ, Penninx BW, Oostra with strong promoters. Journal normal execution of cytokinesis. Cell Increased Risk of Breast Cancer. BA, Boomsma DI, Tiemeier H, of Antimicrobial Chemotherapy Cycle. 8(22):3742-9. 2009 American Journal of Human Genetics. van Duijn CM, Kaprio J, Gulcher 64(5):960-4. 2009 Van der Pols JC Gunnell D Williams 85(4):427-446. 2009 JR, McCarthy MI, Peltonen L, Umapathy A, Whitehall V, Tran K, GM Holly JM Bain C Martin RM. Thorsteinsdottir U, Stefansson K. Taylor BV, Lucas RM, Dear K, Grieu F, Hewitt C, Evans TJ, Ismail Childhood dairy and calcium intake ENGAGE Consortium. Sequence Kilpatrick TJ, Pender MP, van der T, Li W, Collins P, Ravetto P, Fox S, and cardiovascular mortality in variants at CHRNB3-CHRNA6 and Mei IAF, Chapman C, Coulthard Salto-Tellez M, Soong R, Scott R, adulthood: 65-year follow-up of the CYP2A6 affect smoking behavior. A, Dwyer T, McMichael AJ, Valery Leggett B, Dobrovic A, Iacopetta B. Boyd Orr cohort. Heart. 95(19):1600- Nature Genetics. (5): 448-U135. 2010 PC, Williams D, Ponsonby AL. A multicentre study to evaluate k-ras 6. 2009 Latitudinal variation in incidence and Thurber E, Sturm EC, Douglas G, mutation testing methodologies Vearncombe KJ, Rolfe M, Wright type of fi rst central nervous system Leonard JH, Sturm RA. Induction in the clinical setting. Journal of M, Pachana NA, Andrew B, Beadle demyelinating events. Multiple of spheroid cultures from adherent Gastroenterology and Hepatology. G. Predictors of Cognitive Decline Sclerosis. 16(4):398-405. 2010 melanoma cell lines to study the 24:A240-A240. Suppl 2. 2009 After Chemotherapy in Breast Cancer heterogenous nature of melanoma Teng L, Buck M, Scells B, Clarke Ungerer JPJ, Pretorius CJ, Dimeski Patients. Journal of the International tumours. Journal of Investigative RA, Samaratunga MLTH, Yaxley G, O'Rourke PK, Tyack SA. Falsely Neuropsychological Society. Dermatology. 129 (12): 2920-2920. J, Gianduzzo T, Coughlin G, elevated troponin I results due to 15(6):951-962. 2009 2009 Lavin MF, Gardiner RA. Molecular outliers indicate a lack of analytical Verderio P Pizzamiglio S Southey & metabonomic profi ling of Tong ENC, Clements ACA, Haynes robustness. Annals of Clinical MC Spurdle AB Hopper JL Chen ejaculate fl uid in prostate cancer MA, Jones MA, Morton AP, Biochemistry. 47: 242-247 Part 3. X Beesley J, Australian Ovarian detection. British Journal of Urology Whitby M. Improved hospital-level 2010 Cancer Study Group KConFab International. 105:004 Suppl 1. 2010 risk adjustment for surveillance of Upcroft JA, Krauer KG, Burgess Schmutzler RK Engel C Burwinkel healthcare-associated bloodstream Teng MWL, Andrews DM, AG, Dunn LA, Chen N, Upcroft P. B Bugert P Ficarazzi F Manoukian infections: a retrospective cohort McLaughlin N, von Scheidt B, Sequence map of the 3-Mb S Barile M Wappenschmidt B study. BMC Infectious Diseases. Ngiow SF, Moller A, Hill GR, Giardia duodenalis assemblage Chenevix-Trench G Radice P 9:article 145. 2009 Iwakura Y, Oft M, Smyth MJ. IL-23 A chromosome. Chromosome suppresses innate immune response Research. 17(8):1001-14. 2009
105 2009–2010 SCIENTIFIC PUBLICATIONS CONTINUED
Peterlongo P. A BRCA1 promoter Walker LC, Thompson BA, a case series from the colon cancer papilloma viruses in plucked hairs variant (rs11655505) and breast Waddell N, kConFab Investigators, family registry. Clinical Cancer depend on cellular DNA input. Journal cancer risk. Journal of Medical Grimmond SM, Spurdle AB. Use Research. 16(7):2214-24. 2010 of Virological Methods. 161(2):280- Genetics. 47(4):268-70. 2010 of DNA-damaging agents and RNA 283. 2009 Walsh MD, Buchanan DD, Walters pooling to assess expression profi les R, Roberts A, Arnold S, McKeone Verweij KJH, Zietsch BP, Bailey associated with BRCA1 and BRCA2 Whiley PJ Pettigrew CA Brewster D, Clendenning M, Ruszkiewicz JM, Martin NG. Shared etiology mutation status in familial breast BL Walker LC, kConFab AR, Jenkins MA, Hopper JL, of risky sexual behaviour and cancer patients. PLoS Genetics. Investigators Spurdle AB Brown Goldblatt J, George J, Suthers GK, adolescent misconduct: Genetic and 6(2):e1000850. 2010 MA. Effect of BRCA2 sequence environmental infl uences. Behavior Phillips K, Young GP, Macrae F, variants predicted to disrupt exonic Genetics. 39(6): 687-687. 2009 Walker LC, Whiley PJ, Couch FJ, Drini M, Woods MO, Parry S, Jass splice enhancers on BRCA2 Farrugia DJ, Healey S, Eccles JR, Young JP. Analysis of families transcripts. BMC Medical Genetics. Verweij KJ, Zietsch BP, Lynskey DM, Lin F, Butler SA, Goff SA, with Lynch syndrome complicated 11:80. 2010 MT, Medland SE, Neale MC, Thompson BA, Lakhani SR, Da by advanced serrated neoplasia: the Martin NG, Boomsma DI, Vink JM. Silva LM, kConFab Investigators importance of pathology review and Whisstock JC, McGowan S, Genetic and environmental infl uences Tavtigian SV Goldgar DE Brown pedigree analysis. Familial Cancer. Trenholme KR, Gardiner DL, Dalton on cannabis use initiation and MA Spurdle AB. Detection of splicing 8(4):313-323. 2009 JP. Reply to Klemba: Intracellular problematic use: a meta-analysis of processing of the membrane-bound aberrations caused by BRCA1 and Walsh MJ, Lewindon PJ, Shepherd twin studies. Addiction. 105(3):417- BRCA2 sequence variants encoding PfA-M1 neutral aminopeptidase, 30. 2010 RW, Greer RM, Williamson R, a target for new antimalarials. missense substitutions: implications Pereira TN, Frawley K, Bell S, Smith for prediction of pathogenicity. Human Proceedings of the National Academy Visscher PM, Montgomery GW. JL, Ramm GA. Detection and follow- of Sciences of the United States of Mutation. 31(6):E1484-505. 2010 up of hepatic fi brosis in cystic fi brosis: Genome-wide Association Studies America. 106(22):E56-E56. 2009 a role for diagnostic liver biopsy and Human Disease: From Trickle Wallace AE, Sales KJ, Catalano and serum markers in evaluating to Flood. Journal of the American RD, Anderson RA, Williams ARW, Whitehall V, Tran K, Umapathy A, outcomes of cystic fi brosis liver Medical Association. 302(18):2028-9. Wilson MR, Schwarze J, Wang Grieu F, Hewitt C, Evans TJ, Ismail disease. Journal of Gastroenterology 2009 HW, Rossi AG, Jabbour HN. T, Li WQ, Collins P, Ravetto P, and Hepatology. 24:A225-A225, Prostaglandin F-2 alpha-F-Prostanoid Leggett B, Salto-Tellez M, Soong Visscher PM, Hill WG. The limits Suppl. 2. 2009 Receptor Signaling Promotes R, Fox S, Scott RJ, Dobrovic A, of individual identifi cation from Iacopetta B. A multicenter blinded Neutrophil Chemotaxis via Chemokine Wang X Pankratz VS Fredericksen sample allele frequencies: theory and study to evaluate KRAS mutation (C-X-C Motif) Ligand 1 in Endometrial Z Tarrell R Karaus M McGuffog L statistical analysis. PLoS Genetics testing methodologies in the 5(10) e1000628. 2009 Adenocarcinoma. Cancer Research. Pharaoh PD Ponder BA Dunning 6 (14) 5726-5733. 2009 AM Peock S Cook M Oliver C clinical setting. Journal Molecular Visscher PM, Goddard ME. Frost D, EMBRACE Sinilnikova Diagnostics. 11(6):543-52. 2009 Wallace DF, Harris JM, Systems genetics: the added value OM Stoppa-Lyonnet D Mazoyer esting the divergent Subramaniam VN. Functional Whiteman DC. T of gene expression. HFSP Journal. S Houdayer C, GEMO Hogervorst pathway hypothesis for melanoma: analysis and theoretical modeling 4(1):6-10. 2010 FB Hooning MJ Ligtenberg MJ, recent fi ndings and future challenges. of ferroportin reveals clustering of HEBON Spurdle A Chenevix- Vounatsou P, Raso G, Tanner M, mutations according to phenotype. Expert Review of Anticancer Therapy. Trench G, kConFab Schmutzler 10(5):615-8. 2010 N'Goran EK, Utzinger J. Bayesian American Journal of Physiology - RK Wappenschmidt B Engel C geostatistical modelling for mapping Cell Physiology. 298(1):C75-84. 2010 Meindl A Domchek SM Nathanson Whiteman DC, Parmar P, Fahey P, schistosomiasis transmission. KL Rebbeck TR Singer CF Wallace DF, Summerville L, Moore SP, Stark M, Zhao ZZ, Parasitology. 136(13):1695-1705. 2009. Gschwantler-Kaulich D Dressler C Crampton EM, Frazer DM, Montgomery GW, Green AC, Fink A Szabo CI Zikan M Foretova Vu LH, van der Pols JC, Whiteman Anderson GJ, Subramaniam VN. Hayward NK, Webb PM for the L Claes K Thomas G Hoover RN DC, Kimlin MG, Neale RE. Knowledge Combined deletion of Hfe and Australian Cancer Study. Helicobacter Hunter DJ Chanock SJ Easton DF and Attitudes about Vitamin D and transferrin receptor 2 in mice leads pylori infection and esophageal Antoniou AC Couch FJ. Common Impact on Sun Protection Practices to marked dysregulation of hepcidin cancer: exploring potential variants associated with breast among Urban Offi ce Workers in and iron overload. Hepatology. environmental and genetic modifi ers cancer in genome-wide association Brisbane Australia. Cancer of the effect. Gastroenterology. Dec,50(6):1992-2000. 2009 studies are modifi ers of breast cancer Epidemiology Biomarkers & 139(1):73-83. 2010 risk in BRCA1 and BRCA2 mutation Prevention. 19(7):1784-9. 2010 Wallace DF Trinder D Subramaniam VN. Hepcidin carriers. Human Molecular Genetics. Whitfi eld JB, Dy V, McQuilty R, Wainwright CE, France MW, regulation by HFE and TFR2: is 19(14):2886-97. 2010 Zhu G, Heath AC, Montgomery GW, Martin NG. Genetic effects O'Rourke P, Anuj S, Kidd TJ, it enough to give a hepatocyte Warrilow D Tachedjian G Harrich Nissen MD, Sloots TP, Coulter C, a complex? Gastroenterology. on toxic and essential elements in D. Maturation of the HIV reverse humans: arsenic cadmium copper Ristovski Z, Hargreaves M, Rose 137(3):1173-5,discussion 1175. 2009 transcription complex: putting the lead mercury selenium and zinc in BR, Harbour C, Bell SC, Fennelly KP. jigsaw together. Reviews in Medical Wallace GL, Lee NR, Prom- erythrocytes. Environmental Health Cough-generated aerosols of Virology. 19(6):324-37 2009. Pseudomonas aeruginosa and other Wormley EC, Medland SE, Lenroot Perspectives. 118(6):776-82. 2010 RK, Clasen LS, Schmitt JE, Neale Waterboer T, Neale R, Michael Gram-negative bacteria from Whitfi eld, JB. Molecular biology MC, Giedd JN. A Bivariate Twin KM, Sehr P, de Koning MNC, patients with cystic fi brosis. Thorax. and genetics in clinical chemistry Study of Regional Brain Volumes and Weissenborn SJ, Sampogna F, 64(11):926-931. 2009. and laboratory medicine. Clinical Verbal and Nonverbal Intellectual Skills Abeni D, Green AC, Bavinck JNB, Chemistry and Laboratory Medicine. Waldron M, Heath AC, Martin NG. During Childhood and Adolescence. Pawlita M. EPI HPV UV CA Grp. 48(4):431-434. 2010 Alcohol dependence predicts Behavior Genetics. 40(2): 125-134, Antibody responses to 26 skin delayed marriage in men: Findings in Sp. Iss. SI. 2010. human papillomavirus types in the Wieser T, Dresler K, Evers S, Gaul Australian twins. Behavior Genetics. Netherlands, Italy and Australia. Walsh MD, Buchanan DD, C, Konig D, Holzl D, Berger K, 39(6):688-689. 2009 Journal of General Virology. 90:1986- Nyholt D, Deufel T. No Infl uence of Cummings MC, Pearson SA, Arnold 1998, Part 8. 2009 Waldron M, Martin NG, Heath AC. ST, Clendenning M, Walters R, 5-HTTLPR Gene Polymorphism on Parental Alcoholism and Offspring McKeone DM, Spurdle AB, Hopper Webbink D, Martin NG, Visscher Migraine Symptomatology, Comorbid Behavior Problems: Findings in JL, Jenkins MA, Phillips KD, PM. Does education reduce the Depression, and Chronifi cation. Australian Children of Twins. Twin Suthers GK, George J, Goldblatt probability of being overweight?. Headache. 50(3):420-430. 2010 Research and Human Genetics. J, Muir A, Tucker K, Pelzer E, Journal of Health Economics. Williams A, O'Rourke P, Keogh S. 29(1):29-38. 2010 12(5):433-440. 2009 Gattas MR, Woodall S, Parry S, Making choices: why parents present Macrae FA, Haile RW, Baron JA, Walker G, Gabrielli B, Box N, Weissenborn SJ, Neale R, de to the emergency department for Potter JD, Le Marchand L, Bapat Takahiro K, Muller HK. Kit signalling Koning MNC, Waterboer T, Abeni non-urgent care. Archives of Disease B, Thibodeau SN, Lindor NM, in melanoma and the melanocyte D, Bavinck JNB, Wieland U, Pfi ster in Childhood. 94(10):817-820. 2009 McGuckin M,A Young JP. Lynch proliferative response to UVR. HJ. EPI-HPV-UV-CA Grp. Prevalence syndrome-associated breast cancers: Journal of Investigative Dermatology. and multiplicity of cutaneous beta clinicopathologic characteristics of 29(12):2922-2922. 2009.
106 QIMR Annual Report 2009/10 Wilson R, Diseberg AF, Gordon L, Worthley DL, Hewett DG, Spring K, Yang YR, Liu TX, Bai XL, Boufana Zhang WB, Zhang ZZ, Yimit T, Zivkovic S, Tatarczuch L, Mackie Whitehall VL, Leggett BA. Proximal B, Craig PS, Nakao M, Ito A, Shi BX, Aili H, Tulson G, You H, Li EJ, Gorman JJ, Bateman JF. serrated polyps: inconspicuous but Zhang JZ, Giraudoux P, McManus J, Gray DJ, McManus DP, Wang Comprehensive Profi ling of Cartilage not inconsequential. Re: Protection DP. Natural Infection of the Ground JC. A Pilot Study for Control of Extracellular Matrix Formation from right- and left-sided colorectal Squirrel (Spermophilus spp.) with Hyperendemic Cystic Hydatid Disease and Maturation Using Sequential neoplasms after colonoscopy: Echinococcus granulosus in China. in China. PLOS Neglected Tropical Extraction and Label-free Quantitative population-based study. Journal of PLOS Neglected Tropical Diseases. Diseases. (10):article e534. 2009 Proteomics. Molecular & Cellular the National Cancer Institute in press 3(9):article e518. 2009 (letter) 2010 Proteomics. 9(6):1296-1313. 2010 Zhong J, Khanna R. Ad-gBCMVpoly: Yang J, Wray NR, Visscher PM. A novel chimeric vaccine strategy for Wray NR, Visscher PM. Narrowing Wood MJ, Skoien R, Powell LW. Comparing apples and oranges: human cytomegalovirus-associated the boundaries of the genetic The global burden of iron overload. equating the power of case-control diseases. Journal of Clinical Virology. architecture of schizophrenia. and quantitative trait association Hepatology International. 3(3):434- Schizophrenia Bulletin 36(1):14-23. 2010 46 Suppl 4:S68-72. 2009 444. 2009 studies. Genetic Epidemiology. Wray NR, Goddard ME. Multi-locus 34(3):257-7. 2010 Zhong W, Skwarczynski M, Fujita Wooldridge L, Clement M, models of genetic risk of disease. Y, Simerska P, Good MF, Toth I. Lissina A, Edwards ESJ, Ladell Genome Medicine. 2(2):10. 2010 Yang JZ, Zhao ZY, Li YS, Krewski Design and Synthesis of Lipopeptide- K, Ekeruche J, Hewitt RE, Laugel D, Wen SW. A multi-level analysis Carbohydrate Assembled Multivalent B, Gostick E, Cole DK, Debets R, Wray NR, Yang J, Goddard of risk factors for Schistosoma Vaccine Candidates Using Native Berrevoets C, Miles JJ, Burrows ME, Visscher PM. The genetic japonicum infection in China. Chemical Ligation. Australian Journal SR, Price DA, Sewell AK. MHC interpretation of area under the ROC International Journal of Infectious of Chemistry. 62(9):993-999. 2009 Class I Molecules with Superenhanced curve in genomic profi ling. PLoS Diseases. 13 (6):E407-E412. 2009 Genetics. 6(2):e1000864. 2010 CD8 Binding Properties Bypass the Zhou Y, Zheng HJ, Chen YY, You H, Zhang W, Jones MK, Zhang L, Wang K, Guo J, Huang Requirement for Cognate TCR Wray NR, James MR, Gordon SD, Gobert GN, Mulvenna J, Rees G, Z, Zhang B, Huang W, Jin K, Dou Recognition and Nonspecifi cally Dumenil T, Ryan L, Coventry WL, Spanevello M, Blair D ,Duke M, Activate CTLs. Journal of Statham DJ, Pergadia ML, Madden TH, Hasegawa M, Wang L, Zhang Brehm K, McManus DP. Cloning Immunology. 184(7):3357-3366. 2010 PA, Heath AC, Montgomery GW, Y, Zhou J, Tao L, Cao ZW, Li YX, Martin NG. Accurate Large-Scale and characterisation of Schistosoma Vinar T, Brejova B, Brown D, Li M, Worthley DL, Johnson DF, Eisen Genotyping of 5HTTLPR and Flanking japonicum insulin receptors. PLoS Miller DJ, Blair D, Zhong Y, Chen DP, Dean MM, Heatley SL, Tung JP, Single Nucleotide Polymorphisms in One. 5(3):e9868. 2010 Z, Hu W, Wang ZQ, Zhang QH, Scott J, Padbury RT, Harley HA, an Association Study of Depression Song HD, Chen SJ, Xu XN, Xu You H, Zhang WB, Moertel Bardy PG, Angus PW, Mullighan Anxiety and Personality Measures. B, Ju C, Huang YC, Brindley PJ, L, McManus DP, Gobert GN. CG. Donor mannose-binding lectin Biological Psychiatry. 2009 McManus DP, Feng Z, Han ZG, Transcriptional profi les of adult defi ciency increases the likelihood 66(55):468-76 Lu G, Ren SX, Wang YZ, Gu WY, male and female Schistosoma of clinically signifi cant infection after Kang H, Chen J, Chen XY, Chen Wright JM Webb RI O'Donoghue japonicum in response to insulin liver transplantation. Clinical Infectious ST, Wang LJ, Yan J, Wang BY, Lv P Upcroft P Upcroft JA. reveal increased expression of genes Diseases. 48(4):410-7. 2009 XY, Jin L, Wang BF, Pu SY, Zhang Hydrogenosomes of Laboratory- involved in growth and development. XL, Zhang W, Hu QP, Zhu GF, Wang Induced Metronidazole-Resistant International Journal for Parasitology. Worthley DL, Leleu R, Whitehall J, Yu J, Wang J, Yang HM, Ning V, Conlon M, Christophersen C, Trichomonas vaginalis Lines are Down 39(14): 1551-1559. 2009 Sized While Those from Clinically ZM, Beriman M, Wei CL, Ruan YJ, Belobrajdic D, Mallitt K, Ogino S, Metronidazole-Resistant Isolates Zaman M, Abdel-Aal AM, Phillipps Zhao GP, Wang SY, Liu F, Wang ZQ, Irahara N, Leggett B, Young G. Are Not. Journal Of Eukaryotic KSM, Fujita Y, Good MF, Toth I. Zheng HJ, Zhang QH, Wang SY, A human, double-blind, placebo- Microbiology. 57 2: 171-176. 2009 Structure-activity relationship of Han ZG. Schistosoma Japonicum controlled, cross-over trial of lipopeptide Group A streptococcus Genome Seque. The Schistosoma prebiotic, probiotic and synbiotic Wykes MN Good MF. What have (GAS) vaccine candidates on toll-like japonicum genome reveals features supplementation: effects on luminal, we learnt from mouse models for the receptor 2. Vaccine. 28(10):2243- of host-parasite interplay. Nature. infl ammatory, epigenetic and epithelial study of malaria? European Journal of 2248. 2010 460(7253):345-U56. 2009 biomarkers of colorectal cancer. Immunology. 39(8):2004-7. 2009 Journal of Gastroenterology and Zietsch BP, Verweij KJ, Bailey JM, Wynn KK Crough T Campbell Zhan B, Perally S, Brophy PM, Xue Hepatology. 24:A239-A239, Suppl. S McNeil K Galbraith A Moss J, Goud G, Liu S, Deumic V, de Wright MJ, Martin NG. Genetic and 2. 2009 DJ Silins SL Bell S Khanna Oliveira LM, Bethony J, Bottazzi environmental infl uences on risky ME, Jiang D, Gillespie P, Xiao sexual behaviour and its relationship Worthley DL, Whitehall VL, R. Narrowing of T-cell receptor beta variable repertoire during SH, Gupta R, Loukas A, Ranjit with personality. Behavioral Genetics. Bampton P, Prosser R, Simms symptomatic herpesvirus infection in N, Lustigman S, Oksov Y, Hotez 40(1):12-21. 2010 L, Ogino S, Irahara N, Radford- transplant patients. Immunology and P. Molecular cloning biochemical Smith G, Legget BA. Chronic Zou YY, Su ZX, Yang J, Zeng YW, Cell Biology. 88(2):125-35. 2010 characterization and partial protective colitis is associatied with signifi cant Gu X. 2009. Uncovering Genetic immunity of the heme-binding hypomethylation of LINE-1 within Yang J Benyamin B McEvoy BP Regulatory Network Divergence glutathione S-transferases from the colorectal mucosa. Journal of Gordon S Henders AK Nyholt DR Between Duplicate Genes Using the human hookworm Necator Gastroenterology and Hepatology. Madden PA Heath AC Martin NG Yeast eQTL Landscape. Journal americanus. Infection & Immunity. 24: A242-A242, Suppl. 2. 2009 Montgomery GW Goddard ME of Experimental Zoology Part B 78(4):1552-63. 2010 Visscher PM. Common SNPs explain – Molecular and Developmental Worthley DL ,Whitehall VL, a large proportion of the heritability Zhan L, Leow AD, Jahanshad Evolution. 312B(7):722-733. 2009 Buttenshaw RL, Irahara N, Greco for human height. Nature Genetics. N, Chiang MC, Barysheva M, SA, Ramsnes I, Mallitt KA, Le Leu 42(7):565-9. 2010 Lee AD, Toga AW, McMahon RK, Winter J, Hu Y, Ogino S, Young Yang YR Gray DJ Ellis MK Yang GP, Leggett BA. DNA methylation KL, de Zubicaray GI, Wright MJ, SK Craig PS McManus DP. within the normal colorectal mucosa Thompson PM. How does angular Human cases of simultaneous is associated with pathway-specifi c resolution affect diffusion imaging echinococcosis and tuberculosis predisposition to cancer. Oncogene. measures?. Neuroimage. 49(2):1357- - signifi cance and extent in China. 1371. 2010 29(11):1653-62. 2010 Parasites & Vectors. 2(1):53. 2009 Worthley Daniel L, Leggett Barbara Zhang N, Fu ZX, Linke S, Chicher Yang YR, Craig PS, Ito A, J, Gorman JJ, Visk D, Haddad A. Colorectal Cancer : Molecular Giraudoux P, Zhang JZ, McManus GG, Poellinger L, Peet DJ, Powell Features and Clinical Opportunities. DP. A rodent species (spermophilus F, Johnson RS. The Asparaginyl Clinical Biochemists Reviews. 31 2010 dauricus) infected with Echinococcus Hydroxylase Factor Inhibiting HIF-1 Granulosus in Ningxia China: A potentially new mode of hydatid alpha Is an Essential Regulator transmission. American Journal of Metabolism. Cell Metabolism. of Tropical Medicine and Hygiene. 11(5):364-378. 2009 81(5):55, Suppl S. 2009
107 INVITED LECTURES AND PRESENTATIONS 2009-2010
PROFESSOR GREG ANDERSON
Mechanisms of iron homeostasis in the perinatal period Department of Biochemistry, University of Otago, Dunedin, New Zealand, December 2009
Body iron absorption and traffi cking Laboratory for Nonoscience and Technology, Chinese Academy of Sciences, Beijing, China, April 2010
Body iron absorption and traffi cking Institute of Molecular Neurobiology and Neuropharmacology, Hebei Normal University, Shijiazhuong, China, April 2010 Adaptations in iron homeostasis in early post natal life Veterans Affairs Longbeach Healthcare System, Long Beach, CA, USA, April 2010
The molecular basis of intestinal iron absorption and its FASEB - Experimental Biology 2010, Anaheim, CA, USA, April 2010 regulation New aspects of the absorption of iron - an essential CAS Institute for Nutritional Sciences, Shanghai, China, June 2010 trace element The molecular basis of body iron traffi cking School of Chemical and Molecular Biosciences, University of Queensland, Brisbane, March 2010
DR KATHY ANDREWS
Targeting histone deacetylases for malaria therapy Department Seminar, University of Florida, USA, November 2009
Malaria drug discovery: from trees to targets Queensland Institutes of Health Forum, Townsville, November 2009
Negotiating the Global Research Environment Women in Research Leadership program, Brisbane, June 2010
DR SIMON APTE
Analyzing CD8+ T cell function with fl ow cytometry Australasian Flow Cytometry Group conference, Brisbane, November 2009
IFNg and IL-4 as master regulators of CD8 T cell function University of Melbourne, Melbourne, VIC, February 2010 and phenotype DR JULIE BALEN
Global public health: what a human security framework Infectious Diseases, Security and Ethics, University of Sydney, February 2010 can bring to the discourse DR BEBEN BENYAMIN
For genes affecting iron status in general populations: Australian Medical Bioinformatics Resources (AMBeR) Scientifi c Meeting, Brisbane, August 2009 a GWAS approach Genetics of iron status The Centers for Disease Control and Prevention (CDC), Division of Blood Disorder’s 2009 Iron Overload Conference, USA, September 2009 Panel member The Centers for Disease Control and Prevention (CDC), Division of Blood Disorder’s 2009 Iron Overload Conference, USA, September 2009 MS GABRIELLA BLOKLAND
Quantifying the heritability of task-related brain activation UQ Psychiatry Research Seminar, Brisbane, November 2009 and performance during the N-back working memory task: A twin fMRI study. PROFESSOR ANDREW BOYD
Eph receptors in cancer and development. Cell Signalling in Cancer and Development, Adelaide, November 2009
Novel approaches to glioma therapy QBI Retreat, Noosa Heads, October 2009
EphA3 as a target for leukaemia therapy New Directions in Leukaemia Research, Twin Waters, March 2010
Eph receptors in cancer Curie Institute, Paris, December 2009
The role of EphA4 in spinal cord development Frontiers in Spinal Cord Research, Brisbane, September 2009
PROFESSOR MICHAEL BREAKSPEAR
Multistability of Brain Rhythms Brain Connectivity Workshop, Berlin, Germany, June 2010
The Nonlinear Brain Opening Symposium of the Laboratory for Social and Neural Systems Research, Zurich, Switzerland, June 2010 Nonlinear Brain Dynamics Human Brain Mapping, Barcelona, Spain,June 2010
Multistable and Hierarchical Cortical Dynamics Computational Neurosciences meeting, Max Planck Institute for Complex Systems, Dresden, Germany, November 2009 Modelling Nonlinear Brain Dynamics Brain Modes Meeting, Bristol, UK, December 2009
Multistable and Hierarchical Cortical Dynamics Computational Medicine Meeting, Chinese Academy of Sciences, Beijing, November 2009
Computational Models of the Brain Winter School in Computational Biology, Brisbane, July 2009
Brain Network Perturbation in Schizophrenia Royal Brisbane and Women's Hospital Health Care Symposium, Brisbane, October 2009
On Criticality and Perception in the Human Brain Australian Society for Cognitive Sciences, Sydney, September, 2009
MS REBEKAH BRENNAN
Sequence polymorphism in the human TCR loci and its Frontiers in Immunology Research Network, Kona, Hawaii, July 2009 infl uence on herpes virus infection
108 QIMR Annual Report 2009/10 INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED
ASSOCIATE PROFESSOR SCOTT BURROWS
Allelic polymorphism in the T-cell receptor loci and its Australasian Society for Immunology, Gold Coast, December 2009 impact on antiviral immunity The Specifi city/Degeneracy of T Cell Recognition “Eijkman Lecture”, Infection & Immunity Center, Utrecht, The Netherlands, May 2010
Allelic polymorphism in the T-cell receptor loci and its 7th International Congress on Autoimmunity, Ljubljana, Slovenia, May 2010 functional and structural impact on antiviral immunity Allelic polymorphism in the T-cell receptor loci and its 4th MASIR Conference (Measuring Antigen-Specifi c Immune Responses), Mykonos, Greece, functional and structural impact on antiviral immunity June 2010 PROFESSOR GEORGIA CHENEVIX-TRENCH
Chemoresponse in ovarian cancer AACR, USA, April 2010
DR QIN CHENG
Update on HRP2 antigen polymorphism, including gene WHO Technical Consultation on Parasitological Confi rmation of Malaria Diagnosis, deletions, and its effect on RDT performance and product Geneva, Switzerland, October 2009 testing/lot testing of malaria RDTs Parasite densities and fever in malaria infections in Temotu, WHO Technical Consultation on Parasitological Confi rmation of Malaria Diagnosis, Solomon Islands Geneva, Switzerland, October 2009 P. falciparum pyrogenic threshold in naive individuals WHO Technical Consultation on Parasitological Confi rmation of Malaria Diagnosis, Geneva, Switzerland, October 2009 Selection of malaria RDTs in South America 58th ASTMH annual meeting, Washington DC, USA, November 2009
DR SUYINN CHONG
Maternal ethanol consumption alters the epigenotype and Griffi th Medical Research College Retreat, Brisbane, June 2009 phenotype of offspring in a mouse model Epigenetics and the determination of phenotype Epigenetics 2009 Australian Scientifi c Conference, Melbourne, January 2009
Maternal ethanol consumption alters the epigenotype and Queensland Brain Institute Symposium: Epigenomics, Behaviour & Disease, Brisbane, March 2010 the phenotype of offspring in a mouse model PROFESSOR DENISE DOOLAN
Genome Credentialing and Malaria Vaccine Development “Malaria Vaccine – Fact or Fantasy?” Symposium. 2009 Joint Meeting of the Australian Society for Parasitology and the ARC/NHMRC Research Network for Parasitology. Sydney, July 2009 qRT-PCR evaluation of malaria immunity in infants. AgeMal Consortium, Barcelona, Spain, September 2009
Immunomics & Malaria Vaccine Development University of Melbourne, Melbourne, October 2009
The Search for the Holy Grail – a universal cross-species Pfi zer Australia, Melbourne, October 2009 malaria vaccine. Attenuated whole organism sporozoite vaccines for malaria 58th American Society of Tropical Medicine and Hygiene Meeting. Washington, DC, USA., symposium: Plasmodium immunomics. November 2009 Immunomics & Malaria Vaccine Development La Jolla Institute of Allergy and Immunology., November 2009
Protein arrays for malaria vaccine development. Australian Society of Immunology Conference. Gold Coast, December 2009
MR PATRICK DRIGUEZ
Development and Immunoscreening of an Immunomics Hunan Institute of Parasitic Diseases, Yueyang, Jiangxi Provincial Institute of Parasitic Diseases, Protein Microarray to Investigate Asian Schistosomiasis Nanchang, Nanjing Medical University, Nanjing and National Institute of Parasitic Diseases, Shanghai, China, May 2010 ASSOCIATE PROFESSOR CHRISTIAN ENGWERDA
Changes in malaria-specifi c CD4+ T cell responses ARC/NHMRC Research Network for Parasitology Conference, Sydney July 2009 following vaccination and co-infection T cells mediate parasite tissue sequestration during Australian Society for Immunology, Gold Coast, December 2009 experimental cerebral malaria The pathogenesis of experimental cerebral malaria: The Institute of Immunology and Infection Research, School of Biological Sciences, University of role of the host immune response Edinburgh, Edinburgh, UK, November 2009 DR MANUEL FERRIERA
Association Mapping WEHI - Postgraduate Teaching Course - seminar series, Melbourne May 2010
DR KATJA FISCHER
Detecting Complement Defi ciencies Workshop at the 12th European Meeting on Complement in Human Disease, Visegrad, Hungary, September 2009 Scabies mite inactivated serine protease paralogs inhibit Sixth General International Meeting of the International Proteolysis Society, Surfers Paradise, the human complement system October 2009
109 INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED
ASSOCIATE PROFESSOR MAHER GANDHI
The B and T of EBV Mater Medical Research Institute, Brisbane, November 2009
EBV as a model of immunity Pathology Dept, Royal Brisbane Hospital, Brisbane, July 2009
Chronic Myeloid Leukaemia Human Immunology Society, Brisbane May 2010
EBV-positive Lymphomas British Society of Immunology, Wales, June 2010
DR MICHELLE GATTON
An overview of Round 2 Malaria RDT product testing WHO Specimen Bank Steering Committee, Bangkok, Thailand, February 2010 results Analyzing the bench performance of malaria RDTs 58th ASTMH annual meeting, Washington DC, USA, November 2009
An overview of the VEDS System for mosquito-borne Communicable Diseases Unit, Queensland Health, Brisbane, Australia, June 2010 disease surveillance ASSOCIATE PROFESSOR DON GARDINER
Aminopeptidase inhibitors Scripps Research Centre, Jupiter, USA, November 2009
ASSOCIATE PROFESSOR GAIL GARVEY
Closing the divide: Understanding the reasons for poorer National Maori Cancer Forum 2009 – Revolution of cancer care for Maori and Whanau, NZ, August cancer outcomes in Indigenous Queenslanders. 2009 Improving the health of Aboriginal and Torres Strait Islander Queensland Health, Brisbane, May 2010 children through research DR GEOFF GOBERT
Microarray Studies of the Schistosoma japonicum lifecycle Veterinary Research Institute, Xinjiang Academy of Animal Science, Urumqi and College of Veterinary Medicine, South China Agricultural University, Guangzhou, China, July 2010 PROFESSOR MICHAEL GOOD
The Future of Infectious Diseases 50th Australian Medical Student’s Association (AMSA) National Convention, Brisbane, July 2009
Malaria Vaccine: Fact or Fantasy? 2009 Australian Parasitology Conference, Sydney, July 2009
Prevention and early intervention approaches to tackle Social Development Committee Inquiry into Chronic Diseases, Parliament House, Brisbane, chronic diseases August 2009 Vaccines for the developing world – status of rheumatic fever Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute, Sydney, August 2009
Recent developments in QIMR Research Kowloon Rotary Club, Hong Kong, October 2009
Progress on the NPC Immunotherapy Study Dynasty Club, Hong Kong, October 2009
Developing vaccines for the world’s poorest. Do hidden The Nancy Millis Lecture, La Trobe University, Melbourne, October 2009 molecules hold the key? QIMR and the Leukaemia Foundation Leukaemia Foundation of Queensland Annual State Conference, Brisbane, October 2009
Developing vaccines for the world’s poorest Warren Jones Oration, Fremantle Hospital Medical Research Foundation, Perth, October 2009
The challenges of developing vaccines for the world’s School of Biomolecular and Physical Sciences, Griffi th University, Nathan Campus, Brisbane, poorest November 2009 Enduring lessons from a student’s life QUT IHBI Postgraduate Student Conference, Brisbane, November 2009
The immunological challenges of developing vaccines for School of Chemistry and Molecular Biosciences 5th Annual Research Students Symposium, University variant organisms. Do hidden molecules hold the key? of Queensland, Brisbane, November 2009 The importance of clinical leadership in improving health care NHMRC NICS Implementation Fellows Graduation, Brisbane, November 2009
Suppressed immune responses and hidden epitopes: the 10th FIMSA Immunology Training Course, Tangalooma, December 2009 keys to unlocking the challenges to the next generation of vaccines From a mug punter to directing medical research – has ASI 2009, Gold Coast, December 2009 anything changed? The importance of science education The importance of science education, Brisbane, February 2010
The Inaugural Eureka Moments Address Australian Museum, Sydney, March 2010
Our progress towards making a malaria vaccine Rotary District 9600 Conference, Caloundra, March 2010
Address to Graduands The University of South Australia Graduation Ceremony, Adelaide, March 2010
Malaria vaccines: Lessons from immune escape instruct Keystone Symposium (Malaria: New Approaches to Understanding Host-Parasite Interactions), new strategies Colorado, USA, April 2010 Graduation Address University of Sydney Faculty of Medicine, Sydney, May 2010
110 QIMR Annual Report 2009/10 PROFESSOR JEFFREY GORMAN
Proteomic dissection of RSV-host cell interactions Laboratory of Infectious Diseases Seminar at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD US, April 2010 Human respiratory syncytial virus proteins suppress host Lorne Protein Structure and Function Conference, Lorn, Australi, Feb 2010 cell innate antiviral responses via interferon-dependent and -independent pathways Human respiratory syncytial virus proteins suppress host ComBio2009, Christchurch, New Zealand, 2009 cell innate antiviral responses via interferon-dependent and -independent pathways Human respiratory syncytial virus proteins suppress host Australian Peptide Conference, Couran Cove, Australi, 2009 cell innate antiviral responses PROFESSOR ADÈLE GREEN
Insights from epidemiological studies European Society of Photobiology, Wroclaw, Poland, September 2009
Causes and preventability of skin cancer Children's Cancer Institute, Sydney, NSW, August 2009
Causes & preventability of skin cancer ARC Epidemiology Unit, University of Manchester, Manchester, UK, March 2010
Current evidence on skin cancers and their prevention Division of Genetics and Molecular Medicine, King's College, London, UK, May 2010
Prevention of skin cancer: Insights from 'Down Under' AACR: Cancer Prevention Research Annual Conference, Houston, USA, December 2009
The Epidemiology of Melanoma in Young People 6th International Conference on Teenage And Young Adult Cancer Medicine, London, UK, June 2010
DR ASHRAFUL HAQUE
Parasite load & T cells: inter-dependent factors causing Australian Society for Immunology,Gold Coast 2009 Experimental Cerebral Malaria Designing the perfect adjuvant for a malaria vaccine Australian Vaccine and Immunotherapeutics Development Meeting, Melbourne, May 2010
What molecule from which cell-type? Federation of the Immunological Societies of Asia-Oceania (FIMSA) Advanced Immunology training course, Moreton Island, December 2009 Year 12 Explore, Dream, Discover Careers Dinner All Saints School, Gold Coast, July 2009
In vivo modelling of multi-organ, parasite-driven pathology Sanger Research Institute, Cambridge, UK, April 2010 in severe malaria An inter-dependent relationship between CD8+ T cells and Woods Hole Immunoparasitology Meeting, Woods Hole, MA, USA, April 2010 antigen loaddrives cerebral immune path DR DAVID HARRICH
A U5 repressor of reverse transcription is required for Retrovirology Meeting, Montpelier, France, September 2009 optimal HIV-1 infectivity and replication PROFESSOR NICHOLAS HAYWARD
Low penetrance melanoma predisposition genes in relation Society of Melanoma Research Congress, Boston, USA, November 2009 to skin phenotypes and sunlight exposure Identifying low penetrance melanoma predisposition Clinical Oncological Society of Australia Conference, Gold Coast, November 2009 genes: is it all about skin phenotypes? What's next for fi nding high penetrance genes in International Melanoma Genetics Consortium Meeting, Leeds, UK, June 2010 melanoma families? PROFESSOR GEOFF HILL
Ian McKenzie Lecture Transplantation Society of Australia and NZ annual meeting, Canberra, June 2010
IL-17 and antigen presentation in transplantation Australasian vaccines and immunotherapeutics annual meeting, Melbourne, May 2010
NKT cells in transplantation Australian Society of Immunology annual meeting, plenary lecture annual meeting plenary lecture, Gold Coast, December 2009 NKT cells in transplantation Haematology Society of Australia and NZ annual meeting, plenary lecture, Adelaide, October 2009
New roles for the stem cell donor Australian Bone Marrow Donor Registry meeting, Sydney, August 2009
ASSOCIATE PROFESSOR MALCOLM JONES
Laser Microdissection and tissue-specifi c transcriptomes Schistosomiasis Molecular Toolbox Workshop, San Francisco, USA, September 2009 of schistosomes Aspects of the host-parasite interface of schistosomes Department of Parasitology, Veterinary School, South China , Agricultural University, Guangzhou, China, July 2009 Aspects of the host-parasite interface of schistosomes Xinjiang Veterinary Institute, Urumchi, Xinjiang Province China, July 2009
Aspects of the host-parasite interface of schistosomes Xinjiang Medical College, Urumchi, Xinjiang Province China, July 2009
111 INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED
PROFESSOR BRIAN KAY
Surveillance and control of dengue vectors Second Dengue Program Managers Meeting, WHO, Hanoi, Vietnam, December 2009
Community-based Mesocyclops and Popcorn Wolbachia 41st Asia-Pacifi c Academic Consortium on Public Health conference, Taipei, Taiwan, December 2009
Exciting progress in dengue vector control Emerging Infectious Diseases: The Global Perspective, Canberra, November 2009
PROFESSOR KUM KUM KHANNA
DNA damage as a cause and cure for cancer Peter MacCallum Cancer Institute Seminar, Melbourne, July 2009
Defective cellular responses to DNA damage and its link Seminar at Mater Medical Research Institute, Brisbane, July 2009 with cancer Checkpoint responses to DNA damage. International Symposium in the Institute of Molecular and Cellular Biology, Singapore, September 2009 Cell Cycle Characterization of novel players involved in Genome Indo-US Bilateral workshop on Epigenetics and Genome Stability, Hyderabad, India, December 2009 Maintenance Centrobin as a regulator of microtubule and centrosome Hunter Valley Cell Biology Conference, NSW, Australia, March 2010 integrity Overview of research in Signal Transduction laboratory Seminar at Eskitis Institute for Cell and Molecular Therapies, Griffi th University, April 2010
Pathways relevant to development of targeted therapies Seminar at Pfi zer Biopharmaceuticals, Pine River, New York, USA, April 2010 for Breast cancer Coping with DNA damage to maintain genomic stability; Seminar at University of Texas Southwestern Medical Centre, Dallas, USA, April 2010 functional characterization of novel repair proteins PROFESSOR MARTIN LAVIN
Rare Autosomal Recessive Ataxias: Cancer Predisposition University of Qld Centre for Clinical Research, July 2009 and Neurodegeneration Upregulation of PCA3 and BMMC1 in prostate cancer URS 2009, August 2009
Role of Rad50 in the DNA Damage Response NUI Galway, Ireland, September 2009
DNA Damage Signalling through the MRN Complex Telomere Biology and DNA Repair, Australia, October 2009
Snake Venom Proteins with potential as Therapeutic Agents Venomics Program UQ, Brisbane, October 2009
Senataxin, defective in ataxia oculomotor apraxia type 2, ASMR AGM, Australia, November 2009 is involved in transcription and the defense against oxidative DNA damage Workshop on “Irradiation of Living Cells with High Monash Centre for Synchrotron Science (MCSS), Australia, December 2009 Resolution X-Ray Microbeam” Fara (A) Friedrich Ataxia National Research Review University of Melbourne, December 2009 Meeting Venomics: Pre-clinical evaluation of snake venom with University of Queensland, Brisbane February 2010 Therapeutic Potential Senataxin, defective in AOA2, protects against oxidative Ataxia Investigators Meeting, USA, March 2010 stress and transcription dysregulation Ataxia oculomotor apraxia and other autosomal 53rd Ataxia National Foundation Annual Membership Meeting, USA, March 2010 recessive ataxias A varied phenotype with Rad50 defi ciency Memorial Sloan Kettering Meeting, USA, March 2010
Faculty Retreat UQ CCR Retreat, Australia, May 2010
PROFESSOR BARBARA LEGGETT
Molecular Pathogenesis of Colorectal polyps Mater Medical Research Institute, Brisbane, July 2009
Serrated Neoplasia CaSS/Pathology Queensland GIT Pathology Course, Brisbane, October 2009
Family based screening for colorectal cancer Australian Gastroenterology Week, Sydney, October 2009
Serrated Neoplasia GE Society of Queensland, Brisbane, March 2010
DR CORINNE LENDON
Dementia Research In SEQ Queensland Dementia Clinical Network Forum, 2009
ASSOCIATE PROFESSOR J. ALEJANDRO LÓPEZ
Células Madres Cancerígenas en Cáncer del Seno Invited Speaker, Chile, September 2009
Breast Cancer Stem Cells for Immunotherapy ASI Annual Meeting, Gold Coast December 2009
Clickers on Academic Performance in Bio-medical Griffi th University Seminar, Brisbane, July 2010 Sciences. Have We Got The Picture?
112 QIMR Annual Report 2009/10 DR KELLI MACDONALD
G-CSF promotes type-17 differentiation and scleroderma European Society of Bone Marrow Transplantation, Vienna, Austria, March 2010
PROFESSOR NICHOLAS MARTIN
Genetics of brain structure and function International Congress of Psychiatric Genetics (ISPG), San Diego, USA, November 2009
Progress in the genetics of moliness and melanoma GenoMel consortium meeting, Leiden, The Netherlands, December 2009
Genetics of visible traits VisiGen consortium meeting, Rotterdam, The Netherlands, December 2009
Genetics of moliness and melanoma Melanoma Research Alliance, Las Vegas, USA, February 2010
Twin studies and the GWAS revolution in mental health Central Institute of Mental Health Research, Mannheim, Germany, March 2010 research Global CNV burden and IQ Behavior Genetics Association, Seoul, Korea, June 2010
The role of twin studies in elucidating disease etiology INVITED PLENARY: International Congress of Twin Studies, Seoul, Korea, June 2010
DR BRIAN MCEVOY
Will redheads be extinct in 100 years? QIMR High School lecture Series, September 2009
PROFESSOR DON MCMANUS
Pathways to improved, sustainable morbidity control and NHMRC: Global Health - addressing the health needs of the Asia/Pacifi c region, workshop, prevention of schistosomiasis in the Peoples’s Republic Canberra, May 2010 of China Schistosomiasis work in China and developing a Pan Pacifi c Veterinary Conference 2010, Brisbane, April 2010 transmission blocking vaccine for use in water buffaloes Echinococcosis and Schistosomiasis Disease Reference Group Conference on Zoonoses and Marginalized Infectious Diseases of Poverty, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Cairo,Egypt, April 2010 Transmission blocking vaccine for schistosomiasis japonica 2nd World Congress of Vaccine, Beijing, China, March 2010 in China Dog vaccination for echinococcosis World Congress of the International Association of Hydatidology, Colonia del Sacramento, Uruguay, December 2009 Transmission Blocking Veterinary Vaccines for Zoonotic S. American Society for Tropical Medicine and Hygiene 58th Annual Meeting, Washington, USA, japonicum November 2009 Schistosomiasis Control The Ninth Regional Network Meeting for Asian Schistosomiasis and Other Helminth Zoonoses (RNAS+), Vientiane, Lao, PDR, October 2009 Asian Schistosomiasis WHO/TDR Regional Consultation Conference on Infectious Diseases of Poverty in Western Pacifi c Countries Vientiane, Lao, PDR, October 2009 Echinococcosis and Zoonotic Schistosomiasis Disease Reference Group Conference on Zoonoses and Marginalized Infectious Diseases of Poverty, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Liverpool, UK, November 2009 Schistosome vaccines Joint Meeting of the Australian Society for Parasitology and the ARC/NHMRC Research Network for Parasitology, Sydney,July 2009 DR DAVID MCMILLAN
Genetic variation in group G Streptococci School of Veterinary and Microbiological Sciences, James Cook University, July 2009
DR ALLAN MCRAE
Using sequence data to unravel the genetic architecture of Australasian Conference on Statistical Methods for Genomic Data Analysis, Brisbane, October 2009 complex traits Gene mapping with sequence data Winter School in Mathematical and Computational Biology, Brisbane, July 2009
DR SARAH MEDLAND
Common variants in the Trichohyalin gene are associated 6th World Congress of Hair Research, Townsville, June 2010 with straight hair in Europeans DR ANGELA MIKA
Scabies mite proteases and serpins inhibit human Clinical Research Centre, Lund University, University Hospital, Malmö, Sweden, September 2009 complement and promote streptococcal growth PROFESSOR GRANT MONTGOMERY
Genomics and genetic architecture in common COMBIO, New Zealand, December 2009 complex disease Genome-wide association studies and beyond Otago Genomics 2010, New Zealand, February 2010
Genome wide associations studies for disease traits International Symposium on Genomics for Animal Health, France, June 2010
113 INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED
MR BRIAN MORRISON
Breast Cancer Stem Cells and Therapy: Characteristics of Griffi th Gold Coast Health and Medical Research Conference, Gold Coast, December 2009 Mammospheres Generated From Cell Lines PROFESSOR DENIS MOSS
A case for the ascent of non-furry immunology AVID conference, Melbourne, June 2010
DR DEREK NANCARROW
Whole genome approach to biomarker discovery for Frontiers in Barrett’s Oesophagus and Oesophageal Cancer, Sydney, November 2009 Barrett’s oesophagus and adenocarcinoma MS MICHELLE NELLER
Ex vivo analysis of effective T cell responses against Australasian Flow Cytometry Group 32nd Annual Meeting,Brisbane, November 2009 advanced melanoma. ASSOCIATE PROFESSOR COLLEEN OLIVE
Targeting dendritic cells with Toll-like receptor agonists to Seventh World Congress on Vaccines, Immunisation and Immunotherapy, Berlin, Germany, May 2010 enhance and modulate immune responses - implications for peptide vaccines DR CATHERINE OLSEN
Divergent causal pathways to melanoma Skin Cancer College of Australia and New Zealand Skin Cancer Conference 2010, Gold Coast, April 2010 DR JODIE PAINTER
Genome-wide linkage scan for dizygotic twinning 13th International Congress on Twin Studies, Korea, June 2010
Application of GWA data to address issues of genetic 57th annual conference of the Genetics Society of Australasia, Canberra, July 2010 loading in complex human diseases. DR CHRIS PEATEY
The effect of antimalarial drugs on P. falciparum American Society of Tropical Medicine, Washington, November 2009 gametocytes PROFESSOR LAWRIE POWELL
Iron and non-alcoholic fatty liver disease APASL, Beijing, China, March 2010
ASSOCIATE PROFESSOR GRANT RAMM
Mechanisms Underlying Liver Fibrosis: Role of the 50th Anniversary of Australian Gastroenterology Week, Sydney, October 2009 Chemokine C-C Motif System DR PETER RYAN
Emerging threats and opportunities in dengue vector Queensland Institutes of Health Meeting, Cairns 2009 control in Queensland DR CHRISTOPHER SCHMIDT
Characteristics of immunotherapeutic dendritic cells Tumour Immunology Workshop at the Annual Meeting of the Australasian Society for Immunology, Gold Coast, December 2009 T cells kill cancer Volunteers of the Cancer Council Queensland, Brisbane, November 2009
Characteristics of immunotherapeutic dendritic cells Ludwig Cancer Research Institute Translational Oncology Conference, Melbourne, November 2009
Immunological Monitoring of Immunotherapy Trials 3rd Australasian Vaccines & Immunotherapeutics Development Meeting, Melbourne, May 2010
DR TINA SKINNER-ADAMS
Examining the Antimalarial activity of the HIV Protease University of Florida, Gainsville, November 2009 Inhibitors DR AMANDA SPURDLE
Update on the moderate-risk study, assessing risk ENIGMA (Evidence-based Network for the Interpretation of Germline, London, UK, May 2010 associated with the BRCA1 R1699Q va Inclusion of MSI in a multifactorial model for mismatch InSIGHT, Paris, France, May 2010 repair gene variants SNPs in irradiation-responsive genes and modifi cation of Consortium for Investigators of Modifi ers of BRCA1 and BRCA2 Biannual meeting, Cambridge, UK, breast cancer risk in BRCA1/2 mutation carriers. April 2010 Candidate breast cancer predisposition SNPs and Consortium for Investigators of Modifi ers of BRCA1 and BRCA2 Biannual meeting, New York City, modifi cation of breast cancer risk in BRCA1/2 mutation USA, November 2009 carriers: results from phase 7 B-list.
114 QIMR Annual Report 2009/10 Assessing risk associated with the BRCA1 R1699Q ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) Consortium variant. Meeting, New York City USA, November 2009 Translational research capabilities of ANECS Australian & New Zealand Gynaecological Oncology Group Annual Meeting, Noosa, Qld, February 2010
DR BRETT STRINGER
EphA3 regulates high-grade glioma stem/progenitor cell 2nd Eph/Ephrins and Cancer Meeting, Winston-Salem, North Carolina, June 2010 proliferation and differentiation. ASSOCIATE PROFESSOR NATHAN SUBRAMANIAM
Non-HFE Haemochromatosis USA Centers for Disease Control Iron Overload Conference, Atlanta, USA, September 2009
Identifi cation of novel genes in iron metabolism: 5th Indo-Australian Biotech Conference, Hyderabad, India, September 2009 implications for iron defi ciency and overload DR ANGELA TRIEU
Protein arrays for malaria vaccine development Australian Society of Immunology Conference. Gold Coast, December 2009
DR PATRICIA VALERY
Adapting an existing Supportive Care Needs tool to be Cancer Care Coordination Conference, Clinical Oncological Society of Australia, Gold Coast, used with Indigenous cancer patients March 2010 Closing the divide: Understanding the reasons for poorer National Maori Cancer Forum 2009 – Revolution of cancer care for Maori and Whanau, NZ, cancer outcomes in Indigenous Queenslanders. August 2009 DR ANNA VINKHUYZEN
Reconsidering the Heritability of General Intelligence in Behavior Genetics Association Conference, Korea, June 2010 Adults, Taking into Account Assortative Mating and Cultural Transmission PROFESSOR PETER VISSCHER
Risk prediction for complex disease Seminar, University of Central Otago, New Zealand, March 2010
The genetic basis of complex traits Seminar at the University of Queensland, Brisbane, August 2010
Genome wide association studies and the problem of Seminar at the WEHI, Melbourne, May 2010 missing heritability Genetic of schizophrenia 2nd Schizophrenia International Research Society Conference, Italy, 2010
Prediction of individual risk to disease from genetic data Australian Pharmacogenomics Summit, Sydney, July 2009
The missing heritability problem Australasian Conference on Statistical Methods for Genomic Data Analysis, Brisbane, October 2009
Quantitative genetics of human height German Biotechnology Consortium, Germany, October 2009
Genetics of human height Seminar at Washington University, USA, November 2009
The Queensland Statistical Genetics laboratory Diamantina Institute retreat, Brisbane, December 2009
The genetic basis of quantitative trait variation Australian Academy of Science New Fellows lecture, May 2010
Quantitative genetics of human height Invited talk, statistical genetics symposium, Auckland, New Zealand, May 2010
Genome-wide association studies and the missing heritability Invited speaker, European Society of Human Genetics conference, Gothenburg, Sweden, June 2010
Genome-wide association studies and the missing heritability Seminar, Cardiff University, UK, June 2010
Human quantitative genetics Invited lecturer, Statistical Genetics Summer School, Seattle, USA, June 2010 inexpensive whole genome association using pooled Invited Oral Presentation: Australasian Conference on Statistical Methods for Genomic Data Analysis. whole blood Brisbane, October 2009 Legacy of Mutiny on the Bounty: Founder Effect and Oral presentation, International Genetic Epidemiology Society conference, USA, November 2009 Admixture on Norfolk Island DR GRAEME WALKER
Kit signaling drives melanocyte proliferation in response to DNA University of Colorado, Denver, CO, USA, September 2009 damage and the development of some forms of melanoma”. DR DANIEL WALLACE
Hepcidin, the iron regulator, will this eliminate venesections? AGM of the Haemochromatosis Society of Australia Inc, Brisbane August 2009
DR PENNY WEBB
Confounding QUT Public health students, Brisbane. August 2009
PROFESSOR EMMA WHITELAW
Intangible Variation Gordon Conference on Epigenetics, New Hampshire, USA, August 2009
A screen for modifi ers of epigenetic reprogramming University College, London, London UK
The role of epigenetic modifi ers in intangible variation in Peterhouse College,Cambridge, UK, September 2009
115 INVITED LECTURES AND PRESENTATIONS 2009-2010 CONTINUED
The role of epigenetics in the determination of phenotype Mental Health Research Institute, Melbourne, November 2009
A screen for epigenetic modifi ers International Human Epigenome Consortium, Paris, France, January 2010
An ENU screen for epigenetic modifi ers in the mouse Review of Australian Phenomics Network, Canberra, March 2010
A new model of fetal alcohol spectrum disorder in the mouse Symposium on Epigenetics of Brain Development, Montreal, Canada, March 2010
A random mutagenesis screen for epigenetic modifi ers Division Seminar, WEHI, Melbourne, April 2010
Epigenetics and Transgenerational Effects Keystone Symposium on Epigenetics, Singapore, April 2010
Environmental Infl uences on the Epigenome Lund University, Lund, Sweden, May 2010
Transgenerational epigenetic inheritance Stockholm University, Stockholm, Sweden, May 2010
Epigenetics 101 James Cook University, Townsville, May 2010
ASSOCIATE PROFESSOR DAVID WHITEMAN
Plenary lecture: Blue Sky Epidemiology Public Health Association of Australia Annual Conference, Canberra, September 2009
Obesity and Cancer Royal Brisbane and Women's Hospital Annual Conference, Brisbane, October 2009
Lifestyle factors and oesophageal cancer Australian Gastroenterology Week, Sydney, October 2009
Cancer registration UICC Cancer Epidemiology Course, Port Moresby, Papua New Guinea, November 2009
Research and clinical frontiers in oesophageal cancer Cancer Council NSW Oesophageal Cancer Workshop, Sydney, November 2009
Towards the control of melanoma American Association for Cancer Research Frontiers in Cancer Prevention Research, Houston, USA, December 2009 Genes, sunlight and the origins of cutaneous melanoma 6th Annual Congress of the European Association for Dermatologic Oncology, Athens, Greece, June 2010
Screening for melanoma: The Australian Perspective 6th Annual Congress of the European Association for Dermatologic Oncology, Athens, Greece, June 2010
Blue Sky Epidemiology Murdoch Children’s Research Institute, Melbourne, February 2010
DR JOHN WHITFIELD
Markers of Alcohol Sensitivity AACB Annual Scientifi c Meeting, Brisbane, September 2009
DR MICHELLE WYKES
Malaria impedes short and long term immunity via ASP & ARC/NHMRC Research Network for Parasitology Annual Conference, Sydney July 2009 dendritic cells Malaria impedes short and long term immunity via Brisbane Immunology Group Meeting, Gold Coast, August 2009 Dendritic cells B cell assays 10th FIMSA Immunology Training Course, Tangalooma, December 2009
Chair, “Humoral Immunity” session Australian Society of Immunology Conference, Gold Coast, December 2009
Malaria impedes short and long term immunity via Australian Society of Immunology Conference, Gold Coast, December 2009 dendritic cells DR JOANNE YOUNG
Molecular Pathology of Colorectal Cancers COSA Meeting, Gold Coast, November 2009
A Tribute to Jeremy Jass Collaborative Group of the Americas, Honolulu, October 2009
Familial Serrated Neoplasia Gut Club of NZ, Auckland, NZ, March 2010
Serrated Neoplasia in the Family Cancer Clinic University of WA, Perth, February 2010
Serrated Polyposis: an Update Ohio State University, Columbus, May 2010
DR LI YUESHENG
Human immunity and schistosomiasis Howard Hughes Medical Institute Annual Meeting for Research Washington DC, USA, September 2009
DR WENBAO ZHANG
Dog vaccine against Echinococcus granulosus World Congress of the International Association of Hydatidology, Colonia del Sacramento, USA, December 2009
116 QIMR AnnualAnnual Report 20092009/10 QIMR STAFF 2009-2010
DIRECTOR F Smith BAppSc AO BSc(Med) MBBS(Hons) PhD MD DSc M Spanevello BAppSc(Hons) PhD M F Good (to Jun 10) FASM FAFPHM FRACP(Hon) FAIM S Stein (to Feb 10) BAppSc DEPUTY DIRECTOR B Stringer BMedSc MBBS PhD A Green MBBS MSc PhD AC T Yeadon BSc(Hons) PhD GENERAL MANAGER MEMBRANE TRANSPORT D Hancock (Acting) BComm MBA MAICD V Subramaniam BSc MSc PhD J Tarr (to Dec 09) BA LLM PhD JD P Lusby BAppSc(Hons) GradDipComm ASSISTANT DIRECTORS C McDonald BSc (Hons) PhD A Boyd (UQ) BMedSc(Hons) MBBS PhD FRACP L Ostini BSc GradDipCBioChem M Lavin (UQ) BSc(Hons) PhD D Wallace BSc(Hons) MSc PhD EXECUTIVE SECRETARY TO THE DIRECTOR CCQ TRANSGENICS J Black G Kay BSc(Hons) PhD ADMINISTRATIVE SUPPORT TO THE DIRECTOR D Carrie BSc T Checkley A Mould BSc(Hons) PhD CANCER AND CELL BIOLOGY DIVISION Z Pang BBiotech MBiotech Division Chair: G Anderson I Tonks BSc(Hons) PhD DRUG DISCOVERY GROUP RADIATION BIOLOGY AND ONCOLOGY P Parsons BSc(Hons) PhD M Lavin BSc PhD G Boyle BSc(Hons) PhD O Becherel BSc MSc PhD J Johns BSc(Hons) M Buck DipMedTech L Maslovskaya PhD P Chen BSc MSc PhD J Pedley BSc J Cullen BSc(Hons) PhD C Pierce BBioMedSc(Hons) S Earl (to Aug 09) BBiotech(Hons) PhD HEPATIC FIBROSIS A Farrell NCEA CAppSc G Ramm BSc(Hons) PhD M Gatei BSc PhD M Bertrand-Philippe (to Dec 09) MSc PhD U Ho BSc(Hons) D Hoang-Le BSc(Hons) A Kijas BBiotech(Hons) PhD T Pereira BSc(Hons) PhD S Kozlov MSc PhD L Ramm BSc J Luff CertVetNurs D Rowsell BSc(Hons) T Roberts BSc(Hons) PhD R Ruddell BSc(Hons) PhD S Stirling BSc(Hons) PhD R Shepherd MBBS MD A Suraweera (to Jul 09) PhD BSc(Hons) M Walsh (to Mar 10) BSc(Hons) PhD M Trabi (to Dec 09) BSc(Hons) PhD IRON METABOLISM RBWH GASTROENTEROLOGY G Anderson BSc(Hons) MSc PhD B Leggett BSc(Hons) PhD K Boorman BVsc K Banducci (to Sep 09) BAppSc(Hons) D Darshan MBBS MAppSc PhD T Dumenil BAppSc MAppSc J Dixon BA(Hons) RN MPh P Faleiro BSc D Frazer BAppSc(Hons) PhD W Fernando (to Jan 10) BTech J Ghazali BNurs S Greco BSc N Houston BSc MEnvSt CT (ASC) S Nayler BAppSc(Hons) L Rawlings D Mckeone AssocDipLabTech D Reid BMedSc MBChB MRCP FRACP C Rickman (to Jan 10) BSc(Hons) V Shaw J Robinson (to Nov 09) BSc(Hons) PhD T Steele BSc(Hons) K Spring BSc PhD S Wilkins BSc(Hons) SIGNAL TRANSDUCTION LEUKAEMIA FOUNDATION K Khanna BSc MSc PhD A Boyd BMedSc(Hons) MBBS PhD FRACP F Al-Ejeh BBio(Hons) PhD S Charmsaz (to Mar 10) MBiotech BBiotech A Bain BSc BSc(Hons) B Day BAppSc BSc(Hons) PhD E Bolderson BSc(Hons) PhD C De Bock (to Dec 09) BSc MSc PhD D Boucher DipHlth MRadBiol PhD K Ensbey BSc BBehavSc J Jeffery BSc(Hons) PhD N Herath BSc(Hons) PhD S Miles AssocDipAppBiol P Jamieson BA BSc(Hons) M Miranda BSc E Lau (to Aug 09) BSc PostGradDipSc J Pagan BSc(Hons) PhD K Miller BSc L Papp BSc(Hons) PhD
117 QIMR STAFF 2009-2010 CONTINUED
M Parish N Pandeya BSc GradDipAppSc MMedSc PhD D Richard BSc(Hons) PhD S Perry BAppSc BEnvironHlth MEnvirCommHlth W Shi BMed MSc PhD V Siskind BSc PhD A Urquhart BSc(Hons) PhD CANCER GENETICS A Wiegmans BSc(Hons) GradDipBiotech GradDipIPL G Trench BSc PhD A Van Der Horst (to Jul 09) PhD BBioMedSc S Andrews (to Mar 10) BSc SKIN CANCER CARCINOGENESIS J Beesley BSc(Hons) PhD G Walker BSc GradDipCBioChem MSc PhD X Chen BMed B Ferguson BSc S Healey BAppSc BSc DipEd H Handoko BSc MSc PhD H Holland BA BHlthSc(Hons) GENETICS AND POPULATION HEALTH S Johnatty MSc PhD Division Head: E Whitelaw S Kugler BSc(Hons) BIOINFORMATICS I Makunin MSc PhD L Krause MBioinf PhD H Mariasegaram BSc(Hons) PhD CANCER AND POPULATION STUDIES A Marsh BSc(Hons) A Green MBBS MSc PhD AC N Waddell (to Sep 09) BSc(Hons) PhD L Braatvedt BSc MSpeechPath EPIGENETICS R Cicero BA E Whitelaw BSc(Hons) PhD T Corish CertGenNurs A Ahola (to Mar 10) MSc P Fahey (to Apr 10) BSc DipMedStats MMedStats A Chapman (to May 10) BSc(Hons) MSc PhD L Gordon BEcon MPH PhD S Chong BAppSc(Hons) PhD R Grealy BBiomedSc(Hons) A Combes BSc (Hons) PhD L Green RN T Epp BSc(Hons) MSc PhD N Hirst BEcon BCom S Harten BAppSc(Hons) PhD M Hughes BSc MMedSc N Kaminen-Ahola (to Dec 09) MSc PhD C Jaremczuk BA GradDipProfPsych E Lambley BSc(Hons) J Jetann (to Aug 09) BNurs D Morgan (to Aug 09) BSc(Hons) T Luong AssocDipArtsPho H Oey BSc (Hons) PhD K Mallitt (to Apr 10) BSc(Hons) J Sutton Cert2ComAnimal L Marquart BSc BEcon N Whitelaw (to Jun 10) BSc(Hons) PhD P McBride BMedSc MBBS S Young (to Jan 10) BAppSc(Hons) A McMurtrie BNurs N Youngson BSc(Hons) PhD F Millar BNurs FAMILIAL CANCER E Minehan RN J Young GradDipBiotech MAppSc PhD R Neale BVSc PhD D Buchanan BSc(Hons) P O'Rourke BA(Hons) BSc(Hons) GradCertEd PhD M Clendenning BSc(Hons) PhD N Richmond BAppSc(Hons) B Nagler DipAssSci BSc M Russell BSc DipNutr MMedStats E Pavluk BSc DipEd GradDipZoo D Simmonds (to Dec 09) BNurs MPH S Pearson AssDipBioLabTec J Van Der Pols BSc MSc PhD A Roberts BSc(Hons) T Vu BSc M Walsh BSc A Ward RN R Walters BAppSc B Waters (to Oct 09) BAppSc MPh L Young CANCER CONTROL GROUP GENETIC EPIDEMIOLOGY D Whiteman BMedSc MBBS(Hons) PhD N Martin BSc PhD FASSA FAA I Antonsson MBBS(Hons) PhD H Beeby BSc(Hons) C Baxter BA M Caffrey H Carroll (to Feb 10) DipObsGynae AdvDipNat MBBS MPH J Cochrane (to Feb 10) BBus M Davis MD MPH M De Nooyer BBehavSc BPsych(Hons) K Harrap BInfoTech A Dormer AssocDipArts C Hill BNurs D Duffy MBBS PhD L Jackman DipBusAdmin G Dwyer BHlthSc P Lahmann DipOecTroph PhD A Eldridge RN D Lancini J Evans AssDipBus A McMurtrie BNurs M Ferguson S O'Brien BNurs MPH M Ferreira PhD C Olsen BSc(Hons) PhD S Fox BSc
118 QIMR Annual Report 2009/10 N Garden BBehavSc(Hons) B Alexander BNurs RN S Gordon BEng(Hons) PhD V Beesley BHlthSc(Hons) PhD M Grace RN CoronCareCert S Brown BA RN L Grey BSc J Griffi th S Hancock BHlthSc BA BBusMgt T Ibiebele BSc MPh PhD K Hanigan BSc F Kolahdooz (to Jul 09) MSc BSc N Hansell BA(Hons) PhD T Lawton D Hickey AssocDipArts M Malt BBus EN N Huang DipHortSc BAgSc MAppSc K Martin BHealthAdmin RN L Hume (to Oct 09) BA MA PhD M Mosey BSc (Nursing) M James BSc(Hons) MSc PhD C Nagle PhD BAppSc MPH K Johnson BPsychSc(Hons) B Ranieri M Ikonomopoulou (to Jan 10) BSc MSc PhD D Roffe RN K Krishnaprasad BEng H Steane C Laizans K Van Dooran BSc A Lin BMedSc J White RN E Mallon (to Feb 10) INDIGENOUS HEALTH K McAloney BComm G Garvey BEd MEd S McCoombe (to Jun 10) V Clements (to Oct 09) MAppEpi J Medhurst DipHort BBus V Harrhy (to Sep 09) RN S Medland BA(Hons) PhD C Jacka R Middelberg (to May 10) PhD V Logan E Miller (to Jul 09) BBehavSc(Hons) S Moore BHlthSc MPH CertNurs N Moghbelpour BSc GradDipPsych MInterPubHlth T O'Brien BJournalism J Moir BA BSc P Valery BMed MPH PhD J Morrissey L Whop BAppSc L Nunn DipTeach S Woolford MHumServs GradDipRehab MOLECULAR CANCER EPIDEMIOLOGY H Park GradCertDisStud A Spurdle BSc MSc PhD D Park BAppSc H Baxter R Parker BPsych(Hons) K Ferguson C Pink F Lose BSc(Hons) PhD C Pretsel (to Apr 10) M O'Brien (to Dec 09) AssDipComWel DipSocWelfare BSocSc S Rodda M Parsons BBioTechInv MArts C Paterson (to May 10) BSc S Shekar BSc(Hons) BLaws PhD S Rounsevell BSc (IT) Grad Cert Bus P Shertock B Thompson BForSc BSc(Hons) L Simms BSc(Hons) L Walker BSc MSc PhD C Singer BA MInfMgtSys S Webb (to Mar 10) BNurs D Smyth BEng(Hons) P Whiley BAppSc BBus BSc(Hons) A Somerville BA MOLECULAR EPIDEMIOLOGY D Statham (to Feb 10) BA(Hons) G Montgomery BAgSc(Hons) PhD L Sullivan BA L Bowdler BAppSc H Taylor N Campbell (to Dec 09) MSc BSc A Toivanen BPsych(Hons) M Campbell (to May 10) BAppSc A Vanderstaay BSc A Caracella BSc K Watson J Chaplin (to Jan 10) BMath BSc K White (to Dec 09) AdvCertArts B Chapman BAppSc J Whitfi eld BSc(Hons) MSc PhD FRACB FRCPath S Crooks BSc GradDipCMicrBio L Winkler A Henders BSc(Hons) J Wood M Lin (to Jan 10) BMed MSc M Wright BSc(Hons) PhD P Lind BSc(Hons) PhD O Zheng DipInfoTech J McAloney G Zhu BMedSc MPH PhD J Painter BSc(Hons) PhD B Zietsch (to Dec 09) BPsychSc(Hons) PhD K Patel (to Mar 10) BSc(Hons) PostGradCertImm GYNAECOLOGICAL CANCER M Richter BAppSc P Webb MA PhD S Smith BBioSc(Hons)
119 QIMR STAFF 2009-2010 CONTINUED
S Thomas (to Feb 10) BSc M Bell BSc(Hons) L Wallace BBioMedSc GradDipGenCouns R Brennan BSc(Hons) R Zhang (to Jan 10) BSc(Hons) J Burrows BSc GradDipTeach Z Zhao MDentalSc PhD J Miles BSc(Hons) PhD MOLECULAR PSYCHIATRY M Neller BAppSc(Hons) C Lendon (to Jan 10) BSc(Hons) PhD S Silins (to Dec 09) BSc(Hons) PhD A Pritchard (to Sep 09) BMedSc(Hons) CLINICAL IMMUNOHAEMATOLOGY NEUROGENETICS M Gandhi MBChB PhD FRACP FRCP FRCPath D Nyholt BSc(Hons) PhD P Crooks BSc(Hons) ONCOGENOMICS E Han BMed MMed N Hayward BSc MSc PhD K Jones (to Jul 09) BSc L Aoude BA BEng J Nourse BSc DipSc MSc EMP Research Offi cer PhD M Auret BSc(Hons) PhD N Ross BSc (Hons) V Bonazzi PhD F Vari BSc(Hons) PhD M Gartside BAppSc DENDRITIC CELLS AND CANCER K Loffl er BSc(Hons) PhD A Lopez MD D Nancarrow BSc MSc PhD B Morrison BA MSc L Packer BSc(Hons) EBV BIOLOGY J Palmer RN D Moss BSc(Hons) PhD A Poh BSc(Hons) V Lutzky MSc PhD M Stark BAppSc(Hons) M Martinez DipAppSc J Symmons BBus L Morrison CertBioLabTech S Tyagi MSc PhD N Stevens BSc GradDipMedSc S Woods BSc(Hons) PhD IMMUNOLOGY & INFECTION QLD STATISTICAL GENETICS C Engwerda BAgSc(Hons) PhD P Visscher BSc MSc PhD FAA F Amante BSc(Hons) PhD B Benyamin BAgSc(Hons) MAg PhD S Best BSc (Hons) S Lee BAg MAg PhD P Bunn J Liu BEcon BSc(Hons) J De Labastida Rivera BSc GradDipBiotech MBiotech S MacGregor BSc MSc PhD K Evans (to Jul 09) BMedChem PhD B McEvoy BA(Hons) PhD A Haque BA(Hons) PhD A McRae BSc(Hons) PhD M Sheel BSc(Biotech) PhD J Powell BSc MSc IMMUNOVIROLOGY A Vinkhuyzen MSc A Suhrbier BA(MA)(Hons) PhD J Yang BSc PhD I Anraku BSc(Hons) PhD IMMUNOLOGY DIVISION S Cozzi-Boyle BAppSc(Hons) PhD Division Chair: G Hill J Gardner BAppSc ANTIGEN PRESENTATION AND IMMUNOREGULATION C James BBiotech MA K MacDonald BSc(Hons) MSc PhD T Le BAppSc GradDipBiotech BONE MARROW TRANSPLANTATION L Major BAppSc(Hons) PhD G Hill MBChB MD BHB FRCPA FRACP W Schroder BSc(Hons) PhD T Banovic (to Jul 09) MMedSc MD MOLECULAR IMMUNOLOGY A Don BSc(Hons) AO BSc(Med) MBBS(Hons) PhD MD DSc M F Good (to Jun 10) FASM FAFPHM FRACP(Hon) FAIM M Koyama MD PhD P Anderson (to Dec 09) R Kuns BSc(Hons) BSc(Vet) V Kienzle BSc(Hons) S Olver BSc(Hons) X Liu BMed MMedSc N Raffelt BSc(Hons) V McPhun BSc MSc A Varelias BAppSc PhD D Mitchell (to Feb 10) BSc(Hons) Y Wilson BAppSc(Hons) A Pinzon-Charry MD&S PhD CANCER IMMUNOTHERAPY M Wykes BSc(Hons) PhD C Schmidt BSc(Hons) PhD MOLECULAR VACCINOLOGY X Huang BMed PhD D Doolan BSc(Hons) MPh PhD C Lanagan BBioSc S Apte BSc(Hons) PhD L O'Connor AssocDegAppSc K Buttigieg (to Jul 09) BBioTech CELLULAR IMMUNOLOGY F Caldas Cardoso BSc MSc PhD S Burrows BSc PhD P Day (to Feb 10) J Arnold BSc(Hons) PhD
120 QIMR Annual Report 2009/10 B Douradinha Mateus MSc Biotech PhD HELMINTH BIOLOGY P Groves BAppSc A Loukas (to Dec 09) BSc(Hons) PhD J Roddick BSc(Hons) A Aziz (to Dec 09) A Trieu BBiotech(Hons) PhD L Cooper (to Nov 09) BAppSc AssocDipCLT TUMOUR IMMUNOLOGY S Gaze (to Dec 09) BSc MSc PhD R Khanna BSc MSc PhD H McSorley (to Dec 09) MSc PhD L Beagley BSc M Meuleman (to Dec 09) T Crough BSc(Hons) J Mulvenna (to Dec 09) BComm BSc(Hons) PhD D Elhassen BSc MSc PhD M Pearson (to Dec 09) BSc MSc PhD L Heslop BBiomedSc(Hons) M Smout (to Dec 09) BSc(Hons) D Hoang-Le BSc(Hons) L St Pierre (to Dec 09) BSc(Hons) PhD L Jones M Tran (to Jan 10) BSc GradDipCBioChem PhD J Peet BAppSc(Hons) L Tribolet (to Dec 09) BAppSc PostGradDipBio C Smith BSc(Hons) PhD HIV MOLECULAR VIROLOGY J Tellam BSc(Hons) MSc PhD D Harrich BSc PhD N Tellam BSc A Apolloni BSc PhD J Zhong BSc PhD D Sivakumaran BSc(Hons) PhD INFECTIOUS DISEASES DIVISION D Warrilow BSc(Hons) PhD Division Chair: J McCarthy T Wei BAgSc MAgSc PhD AMI MALARIA DRUG RESISTANCE IMMUNITY AND VACCINOLOGY Q Cheng MBBS MMed PhD C Olive BSc(Hons) PhD L Bain BSc J Raju BBio MSc M Gatton BSc(Hons) PhD N Willemsen (to Jun 10) BAppSc (Hons) PhD K Gresty BSc(Hons) MALARIA BIOLOGY D Kerlin BSc(Hons) MInfTech PhD D Gardiner BAppSc PhD A Pelecanos BSc(Hons) BBioinformatics K Anderson CBLT W Sharrock BSc(Hons) R McGeorge BForensicSc BCCJ F Teuscher BPharm PhD E Saig (to Apr 10) BMedSc MMolBio N Walpole Cert3AnimalServ Cert3BusAdmin T Skinner-Adams BSc(Hons) PhD BACTERIAL PATHOGENESIS K Trenholme BSc MSc PhD K Sriprakash MPharm PhD MOLECULAR GENETICS M Bauer BBio BAppSc(Hons) P Upcroft BSc(Hons) PhD M Georgousakis (to Jan 10) BSc(Hons) PhD A Burgess BSc MSc PhD D McMillan BSc(Hons) PhD L Dunn BSc(Hons) PhD J Shera BSc(Hons) K Krauer BSc PhD T Vu BAppSc(Hons) BAppSc J Upcroft BSc(Hons) PhD D Smyth BSc(Hons) PhD MOLECULAR PARASITOLOGY BACTERIAL VACCINES D McManus BSc(Hons) DSc PhD M Batzloff BSc(Hons) PhD B Anthony BSc(Hons) MSc PhD J Hartas BAppSc M Burke BBiomedSc PhD G Magor (to Jun 10) BSc(Hons) M Duke AssocDipFarmMgt J Malcolm BSc(Hons) M Ellis BSc(Hons) MSc PhD M Pandey BSc MSc PhD G Gobert BSc(Hons) PhD S Sekuloski BSc(Hons) PhD D Gray (to Sep 09) BSc MSc GradCertPublicHlth PhD CLINICAL TROPICAL MEDICINE Y Li MD PhD J McCarthy MBBS MD FRACP J Li BPharm PhD A Butterworth BSc(Hons) L McGarvey BSc(Hons) W Chung (to Feb 10) BSc (Hons) PhD L Moertel (to Dec 09) BBiomedSc(Hons) PhD L Hannon (to Feb 10) BSc (Hons) H You BSc MSc PhD M Ho BSc(Hons) W Zhang BSc PhD D Jones BAppSc DipAppSc RN MOSQUITO CONTROL M Kuwahata (to Apr 10) BA BAppSc MSc P Ryan BSc(Hons) MAppSc PhD K Mounsey BSc (Hons) PhD J Darbro BA MSc PhD M Pasay BSc MSc PhD P Fraley A Robertson (to Jan 10) BSc(Hons) R Hugo BSc(Hons) PhD Y Wang BBioSc T Hurst BSc(Hons) PhD
121 QIMR STAFF 2009-2010 CONTINUED
J Jeffery (to Jan 10) BA BSc(Hons) PhD C Groennou B Kay BSc(Hons) PhD FAA D Gunn A Kho BSc(Hons) S Hunting W Lee (to May 10) BMultimedia BA T Laing BA G Lu BAgSc MAgSc MVetSc PhD D Meaclem K Marshall M Randle Cert 3Admin&Fin DipBasicOps DipBasicMgt J Monkman BSc(Hons) G Sriprakash B Trewin BSc(Hons) BUILDING SERVICES PARASITE CELL BIOLOGY A Stockman HigherCertEng HigherNatDipEng NatEngCert M Jones BSc(Hons) PhD M Bugden Trade Cert A Glanfi eld BSc(Hons) PhD K Eaton (to Jan 10) E Lovas (to Dec 09) BAppSc(Hons) J Fahrner Cert3Kennel&Cat M Perumalpillai-McGarry BSc G Madders Electrical Mech L Schulte BSc(Hons) A McKee AdvDipElect&Eng PROTEIN DISCOVERY CENTRE D Patrick AdvDipEng AssocDipElecEng J Gorman BSc PhD R Tyrrell Fitter J Chicher BSc MSc REGULATORY AFFAIRS K Dave BSc(Hons) MSc PhD A Mitchell BSc(Hons) PhD A Diseberg BSc(Hons) S Chow BA BSc MPh M Hastie BAppSc(Hons) PhD R Lacey (to Jun 10) M Headlam BSc PhD H Phillips (to Apr 10) BSc(Hons) MSc B Jayakody Arachchige BSc SAFETY H Jiang (to Oct 09) BSc MSc PhD J Leonard BSc MSc PhD AdvDipOHS M Plan BAgSc PostGradDipAgSt PhD J Hawdon BSc(Hons) E Redhead BSc(Hons) L Richards BSc PosGradDipSc C Wright BSc(Hons) EXTERNAL RELATIONS GROUP SCABIES V Johnson BA MBus GradCertMktg K Fischer PhD V Torres Cert3BusAdmin D Kemp BSc(Hons) PhD FAA A Van Der Beek (to Dec 09) BBus M Johnstone BSc(Hons) PhD FUNDRAISING A Mika BSc MSc PhD T Scanlan D Pickering BAppSc(Hons) H Astbury GradCertBus Y Zhou BMed DipAppSc A Dignan TROPICAL PARASITOLOGY A Hall BBus K Andrews BSc(Hons) GradCertEd PhD A McGaw L Melville (to Dec 09) BA BSc M O'Hara T Tran BSc(Hons) J Stockman MENTAL HEALTH DIVISION SCIENCE COMMUNICATION Division Chair: M Breakspear BSc(Hons) GradDipScComm GradDipSecEd S Tennant MEnvSc&Law MENTAL HEALTH D Bishop BA BCrA Cert4Train&Assess M Breakspear BA(Hons) MBBS(Hons) PhD S Cross BSc(Hons) MSc DipEd N Quirk (to Dec 09) S Georgeson BBehSc J Roberts Bsc(Hons) J Gill (to Mar 10) BComm PSYCHIATRIC GENETICS S Matthews BSc N Wray BSc(Hons) MSc PhD J O'Keefe (to Apr 10) BSc DipBusComm E Byrne BA(Hons) M Quince DipBus CORPORATE DIVISION GRAPHIC SUPPORT GENERAL MANAGER H Matthews BA(Hons) GradCertPhtgrphy D Hancock (Acting) BComm MBA MAICD M Kersting BFA J Tarr (to Dec 09) BA LLM PhD JD G Melissari (to Oct 09) ASSISTANT SECRETARY SCIENTIFIC SERVICES GROUP N Fox J Cooper (to Jan 10) BSc MSc PhD GradCertMgt EXECUTIVE SECRETARY TO THE GENERAL MANAGER ANALYTICAL FACILITY B Wanrooy H Edmundson BSc MAppSc ADMINISTRATION P Collins BSc(Hons) B Wanrooy C Green Cert3BusAdmin
122 QIMR Annual Report 2009/10 ANIMAL FACILITY BUSINESS DEVELOPMENT S Cassidy Cert4TrainAsses CertAnimalCare G Haaima BSc(Hons) PhD MBA C Alexander J Fox BSc PhD A Allester (to Nov 09) R Parlett BBiotech(Hons) PhD L Billing FINANCE J Bonnily G Cunningham BBus Cert3AnimalTec Cert3ComAnimal T Booth BCom CPA S Buckland Cert3ChildStud J Lin BLit GradDipMan MComm C Cross C McNally A Cross Cert3ComAnimal K Moran C Dickfos CertLabCare AssocDipAppSc M Stromberg A Dorrington (to Dec 09) A Valentine N Felder GRANTS B Fewster D Evans L Gunn L Casey BSc GradDipTh A Hale K Dry DipMgt D Mcneilly Cert3LabAnmlTec B Dunphy BBus A O'Regan Cert3ComAnimal J Whybird BBus GradDipAdVocEd T Scown CertAnimTech HUMAN RESOURCES AND PAYROLL I Shiels BVSc PhD MACVSc T Greenaway BComm GradDipPsych CULTURE MEDIA SERVICES M Anderson Cert2BusAdmin S Gregg CertAnimTech P Buratowski FLOW CYTOMETRY S Field Cert1WorkplaceT BA GradDipBus G Chojnowski BAppSc E Horsfi eld (to Jan 10) Cert3Bus DipBus G Chapman BSc MSc PhD DipTexChem L Lane P Hall BSc S Pekhu D Sivakumaran BSc(Hons) PhD M Weaver AdvDipBus GLASSWARE SERVICES INFORMATION TECHNOLOGY G Cuthbert Cert3HlthServ BNurs MACS GradDipCommComp C Ward (to Dec 09) V Mathews AssocDipAppBiol L Thompson M Creevey BEng L Thompson (to Jan 10) A De Guzman BBus MInfTech S Watkins M Feodoroff (to Apr 10) BInfo HISTOTECHNOLOGY D James C Winterford AssDipAppBiol S Jaremczuk BBioSc MInfoSys MBA MCITP AAIM MACS R Collins CertBioLabTech D Johnstone DipInfoTech D Harbrow BSc MSc P Kaim (to Jun 10) BAppSc S Park DipClinPath X Lin BEng MEng PhD GradDipIT G Rees CertDiagCytlgy AssDipCLT DipOHS V Mar COBC CCSA HP-UX Q-GEN S McDonagh BSc J Youngson BSc PhD X Nguyen K Miller DipLabTech CertLabTech A Nutley-Govaerts BAppSc M Peters BAppSc A Stevens P Toh (to Jan 10) BSc T Tomlin BEng J Uksanovic-Barnjak DipLabTech DipVetFoodSc L Ward BInfoTech STORES PURCHASING A Kent S Wood CertTrsWareDist A Girle Cert3IT CertTrsWareDist M Eaton CertTrsWareDist M Mcdade A Hough DipBus A Reeves DipVisArts RECORDS AND INFORMATION SERVICES CORPORATE SERVICES GROUP N Kremko CHIEF COMMERCIAL MANAGER A Crace (to Dec 09) D Hancock BComm MBA O Griffi ths BA BUSINESS ANALYST L O'Mahoney P Verso BBus DipConsLandMgt
123 RESEARCH STUDENTS
HONOURS STUDENTS SUPERVISOR C Jekimovs BAppSc(Hons) K Khanna B Botterill BAppSc M Jones J Johnson BSc(Hons) BBusMgt G Trench S Goh BSc K Fischer K Jones BSc M Gandhi L Grant BAppSc M Gandhi B Kendall MBBS D Whiteman Y Grewal BIT DipIT G Gorman S Lane MBBS(Hons) A Boyd E Heng DipMolBio BSc M Lavin E Leddy BAppSc(Hons) N Subramaniam C Ho BSc E Whitelaw Y Leow BAppSc MSc M Jones B Hoad BBioMedSc K Khanna H Leow BSc(Hons) MSc J McCarthy C Huang BSc E Whitelaw Y Lim BSc(Hons) M Lavin C Mirciov BSportSc G Anderson M Lin BSc MA DipEng D Harrich S Mustafah DipScBio BSc C Engwerda A Lord BSc(Hons) M Breakspear N Osman BBioMedSc G Hill Y Lu BEcon(Hons) MSc P Visscher C Perry BAppSc D McManus H Luong BMed BPed MMedSc G Montgomery E Sedlacek BSc A Spurdle K Markey BEng(Hons) G Hill A Tabib BBioMedSc G Gorman Nico Martin MSc BSc N Martin S Toh BSc M Jones J McCarron BAppSc(Hons) A Boyd A Woods BSc K Andrews A Molehin MRes D McManus A Yeo BSs M Lavin B Morrison MSc BA A Lopez P Yeo DipScBio BSc C Engwerda M Mosing MPsych BPsych DipPsych N Martin H Zowawi BAppSc K Sriprakash S Mujaj BSc(Hons) M Gandhi MASTERS SCHOLARS SUPERVISOR D Muslim BSc(Hons) BBioSc N Subramaniam R Barr MBBS BAppSc BEcon P Parsons S Nawaratna MPh MBBS(Hons) M Jones C Biondi GradCertPubHlth PhD P Webb S Nayler BAppSc(Hons) M Lavin L Desbarrieres BSc C Engwerda BAppSc GradDipHlthMgt A Neill P Webb MPH MNurs V Mathai MBBS MPH MHM P Webb P Nguyen MPH BMed P Ryan K Oftedal BSc(Hons) K Khanna D Pattinson BSc(Hons) D Doolan PHD SCHOLARS SUPERVISOR C Peatey BSc (Hons) D Gardiner N Abdul Murad MMSc BSc M Lavin K Phillipps BBiotech(Hons) M Good S Ahmad BSc(Hons) MSc G Anderson Y Poo BSc(Hons) A Suhrbier B Appleyard MPH BSc(Hons) J McCarthy A Redmond MBBS D Doolan GradDipPubHlth MSPh S Arabshahi A Green BSc M Reiter BSc(Hons) C Schmidt A Bain BSc(Hons) BSc M Renteria Rodriguez BSc N Martin F Bieri MSc D McManus N Ross BSc (Hons) M Gandhi G Blokland MSc N Martin M Rubinov BMedSc MBBS M Breakspear C Bond Bphysio MSc B Leggett M Sa'Ariwijaya MSc BSc(Hons) M Lavin R Brennan BSc(Hons) S Burrows S Schussek MSc D Doolan S Charmsaz MBiotech BBiotech A Boyd M Sikulu BSc MSc K Sriprakash T Chuah MBBS BMedSc M Lavin J Simmons Bbiotech(Hons) K Khanna V Dasari BSc MSc R Khanna K Smith MBChB D Whiteman BMarineSc(Hons) BA FRCPA FRACP H Driguez D McManus S Tey R Khanna BAdvSc MBBS(Hons) M D'Souza Bbiotech MMolBiol P Parsons A Thrift BAppSc(Hons) D Whiteman K Dutton-Regester BAppSc(Hons) N Hayward P Tran MPH BMed P Ryan W Fernando BTech MMolBiol B Leggett C Verweij BPsych MSc N Martin I Gillions BAppSc(Hons) A Lopez K Warren BMedSc(Hons) D Harrich C Gordon BSc(Hons) D McManus M Wood RACP MBBS G Ramm D Hall MBBS BSc(Hons) P Parsons R Zhang BSc(Hons) E Whitelaw
124 QIMR Annual Report 2009/10 VISITING SCIENTISTS
CANCER & CELL BIOLOGY DIVISION J Doecke PhD BSc(Hons) I Ferriera R Aizawa MD E Fearnley MAppEpi PhD BEnvHlth S Gaze PhD MSc BSc S Allan MBBS C Filippich BAppSc C Keane MBBCh MRCPI FRCPATH J Aylward PhD MSc BSc J Flanagan PhD BSc(Hons) BAppSc A Kelso BSc(Hons) PhD G Beadle FRACP MBBS T Flatscher-Bader PhD BSc(Hons) N Kienzle PhD MA BSc R Buttenshaw CertChem S Freeman RN H Mcsorley PhD MSc D Chin PhD N Gillespie PhD BA(Hons) I Misko PhD BSc(Hons) R Clarke BSc(Hons) PhD D Goldgar PhD MD BA T Mynott PhD BAgSc(Hons) M Coulthard PhD FJFICM FRACP MBBS J Gratten PhD BSc(Hons) D Nguyen-Van MD MSc PhD M Cummings FIAC PhD FRCPA MBBS E Hacker PhD M Pender MD PhD FRACP MBBS L Fletcher PhD BSc(Hons) A Hadley BMed(Hons) V Pousada Da MSc BSc Hora F Gardiner MD FRACS FRCS MBBS P Hatemi PhD MA BSBA A Rickinson BA MA PhD A Hallahan DipPaed MBBS BSc FRACP A Heath PhD BA T Sculley J Hancock BSc(Hons) J Jayanthan BSc(Hons) L Smallwood BSc(Hons) MBBS PhD M Heritage PhD BBiomedSc(Hons) S Jordan MBBS(Hons) PhD T Woodberry PhD BAppSc(Hons) P Inglis MBBS FRACP N Kaminen-Ahola PhD MSc K Wynn PhD BAppSc W Ingram PhD BSc(Hons) P Keith BSc H Xu PhD MMed BMed T Ishii M Keller V Jain A Knaapila INFECTIOUS DISEASES DIVISION L Jaskowski AssDipCLT S Lakhani Bsc MBBS MD FRCPath FRCPA R Anders PhD BAgSc M Kim A Lane DipClinSci P Bartley MBBS(Hons) BMedSc P Lewindon MBBS FRACP FRCP M Larsson PhD BSocSc G Birrell MSc PhD C Loo PhD MBBS BMedSc M Lynskey PhD MSc BSc(Hons) D Mackey C Brown PhD BSc(Hons) G MacDonald FRACP MBBS(Hons) PhD P Madden PhD MSc BSc M Chavchich MSc PhD D MacFarlane MBBS FRACP N Malik BSc(Hons) C Chuah BBiotech(Hons) P Masci MBiochem MSc BSc B Mason A Clements BVetSci (Hons) MVetMed PhD C McDermott S Miller BSc M Conrad BBiol MSc T Murphy MSc BSc G Miller J Croese S Ogbourne PhD BSc(Hons) F Milne D Gray BSc MSc GradPhil PhD C Peng MMed B Mowry MBBS BA(Hons) MD FRANZCP C Gray BSc(Hons) PhD L Powell FRCP PhD FRACP MD MRACP A Nelson BA A Henningham S Reece FRACGP MD FRCS FRACS N Ketheesan GradCertEd PhD MSc MD MBBS E Nelson MD BA A Loukas PhD BSc(Hons) R Shepherd MBBS MD P Pakkiri MMedPath MBChB(Hons) H Mcwilliam BSc C Smart PhD BSc(Hons) H Rangappa MPH MBBS K Mounsey BSc (Hons) PhD J Smith PhD BSc MSc L Reid MMSc BSc J Mulvenna PhD BSc(Hons) BComm L Teng C Rosty MD PhD H Nguyen BEng BIntStud A Umapathy BSc(Hons) I Rowlands M Nguyen BSc(Hons) S Vuckovic PhD MSc BSc S Sadeghi MD DipPubHlth PhD V Pallaval PhD D Walker MBBS(Hons) BMedSc K Sanderson BAppSc G Raso PhD MSc D Watters BSc(Hons) PhD J Saunus BSc(Hons) PhD T Seidens BSc V Whitehall PhD BSc(Hons) R Shepherd BSc(Hons) PhD D Shanks MPh MD BSc K Zhao PhD MSc BSc P Simpson PhD BSc W Slutske BA PhD BSc P Smeesters PhD BMed H Smith BSc K Spann PhD BSc(Hons) AssocDipMusic GENETICS AND POPULATION L St Pierre BSc(Hons) PhD HEALTH DIVISION S Srinivasan BSc(Hons) N Waters R Arden BA(Hons) R Sturm PhD BSc(Hons) G Williams PhD MSc BSc(Hons) R Ataee Pharm D D Tam MBBS BPhar C Willis PhD MSc BSc C Bain MSc MPh MBBS BSc S Treloar PhD Y Yang MMed BMed T Bates A Vargas MBBS Calderson P Yonglitthipagon BSc J Batra PhD N Waddell PhD V Zhang BSc(Hons) S Broadley BSc(Hons) ChB MRCP PhD FRACP CCST N Wayte BSc(Hons) L Zhang PhD K Buchanski BSc B Zietsch PhD L Clemens- MSc PhD MENTAL HEALTH DIVISON Daxinger IMMUNOLOGY DIVISION F Freyer PhD W Coventry N Anstey PhD FRACP DTM & H MSc A Cronin BEng MMan MBBS MBBS(Hons) CORPORATE DIVISION L Da Silva MD N Davis-Poynter PhD M Mcintyre AssDipAssSc A De Witt BNurs K Ellem R Sutharsan PhD BSc
125 ACRONYMS
AASLD American Association ARC Australian Research CT Computed axial tomography GMRC Griffi th Medical for the Study of Liver Diseases Council Research College CTL Cytotoxic T lymphocyte ACITH Australian Centre for ASARCO American Smelting GU Griffi th University CVD Cardiovascular disease International and Tropical Health and Refi ning Company GVHD Graft-versus-host DC Dendritic cells ACVD Australian Centre for ASIP Agouti signalling protein disease Vaccine Development DNA Deoxyribonucleic acid A-T Ataxia-telangiectasia GVL Graft-versus-leukaemia AHMRC Aboriginal Health and EBV Epstein-Barr virus Medical Research Council ATM Ataxia-telangiectasia GWAS Genome-wide mutated ENU N-ethyl-N-nitrosourea association study AIDS Acquired Immune EVC Defi ciency Syndrome BCC Basal cell carcinoma Emory Vaccine Centre HCC Hepatocellular carcinoma FACS Fluorescence-activated AMATA Australasian Microarray BRCA Breast cancer gene HCMV Human cytomegalovirus cell sorter and Associated Technologies CDKN2A Cyclin-dependent HDC Higher Degrees Committee Association kinase inhibitor 2A FAS Fetal alcohol syndrome HGSA Human Genetics Society ANU Australian National CF Cystic fi brosis GAS Group A streptococcus of Australasia University CMR Centre for Magnetic GC Germinal cell HIF Hypoxia inducible factor AOA1 Ataxia with oculomotor Resonance apraxia type 1 G-CSF Granulocyte colony HIV Human immunodefi ciency CNV copy number variant stimulating factor virus AOCS Australian Ovarian GFP Green fl uorescent protein Cancer Study CRCAH Cooperative Research HL Hodgkin’s lymphoma Centre for Aboriginal Health GGS Group G streptococcus APC Antigen presenting cells HLA Human leukocyte antigen CSIRO Commonwealth GITR Glucocorticoid-induced APHA HPS Hyperplastic polyposis Australian Private Scientifi c and Industrial tumor necrosis factor receptor Hospitals Association Research Organisation syndrome GMP Good manufacturing API IL-2 Interleukin 2 Antiretroviral protease CSLD Chronic suppurative lung practice inhibitors disease
126 QIMR Annual Report 2009/10 IMB Institute of Molecular MLPA Multiplex ligation- PDC Protein discovery centre SMIPP Scabies mite inactivated Bioscience dependent probe amplifi cation protease paralogue PET Positron emission tomography JCC Joint Consultative MLST Multilocus sequence SNP Single nucleotide Committee typing PFOR Pyruvate ferredoxin polymorphisms oxidoreductase JCU James Cook University MRC Medical Research Council SPH School of Population PHERP Public Health Education Health LAW cohort Longitudinal mRNA Messenger ribonucleic and Research Program Ageing Women’s cohort acid TCR T-cell receptor PTEN Phosphatase and tensin LDRL Liver Disease Review MS Multiple sclerosis homologue TLR Toll-like receptor Letters MYH MutY homologue PTLD Post-transplant TNF Tumour necrosis factor MALVAC Malaria Vaccine lymphoproliferative disease Advisory Committee NCI National Cancer Institute UK The United Kingdom QTL Quantitative trait locus MBL Mannose-binding lectin NCRIS National Collaborative UNESCO United Nations Research Infrastructure Strategy QUT Queensland University of Educational, Scientifi c and MCP-1 Monocyte chemotaxis Technology Cultural Organization protein-1 NHMRC National Health and Medical Research Council RBWH Royal Brisbane and UQ The University of MDR Multi-drug resistant Women’s Hospital Queensland NIAID National Institute of MEGA Epidemiology Molecular, Allergy and Infectious Disease RDT Rapid diagnostic test UV Ultra violet Environmental, Genetic & Analytic Epidemiology NIH National Institute of Health RISS Research Infrastructure VIPBG Virginia Institute for Support Services Psychiatric and Behavioural MGE Mobile genetic elements NKT-cell Natural Killer T-cell Genetics RNA Ribonucleic acid MHC Major histocompatibility NPC Nasopharyngeal WEHI Walter and Eliza Hall complex carcinoma RSV Respiratory synctival virus Institute
MIC-1 Macrophage inhibitory PACMISC Pacifi c Malaria RT-PCR Reverse transcription WHO World Health Organization cytokine 1 Initiative Support Centre polymerase chain reaction YSA Young Scientist of Australia PCA3 Prostate cancer gene 3 SCC Squamous cell carcinoma
127 Administrative Support ORGANISATIONAL STRUCTURE
General Manager
Corporate Services Scientifi c Services External Relations
Building Services Administrative Support Purchasing Stores Science Communication
Business Development Safety Regulatory Affairs Animal Welfare Graphic Support
HR & Payroll Flow Cytometry Fundraising
Records & Information Glassware Services
Information Technology Histotechnology
Finance DNA & Peptide Facility
Grants Culture & Media Services
Animal Facility
Q-Gen
300 Herston Road, Herston QLD 4006, Australia T: (+61) 7 3362 0222 E: [email protected] www.qimr.edu.au Project Manager Sarah Tennant Compilation Deborah Bishop Editing Sarah-Jane Matthews Design Rowland Graphic Support Madeleine Kersting Photography Heather Matthews, Tony Phillips Published September 2010 Copies can be obtained by phoning 1800 993 000 or [email protected] Online version available at www.qimr.edu.au
128 QIMR Annual Report 2009/10 DEPUTY DIRECTOR DIRECTOR
Assistant Strategic Science Director Committee (Advisory)
Assistant Clinical & Translational Research Committee Director (Advisory)
Senior Executive Team (Advisory)
Infectious Diseases Immunology Cancer & Cell Biology Genetics & Population Mental Health Research Division Head Division Head Division Head Studies Division Head Division Head
Bacterial Vaccines Cellular Immunology Iron Metabolism Cancer Genetics Systems Neuroscience
Malaria Drug Resistance Molecular Vaccinology Leukaemia Foundation Indigenous Health Psychiatric Genetics
Cancer & Population Malaria Biology Immunology & Infection CCQ Transgenics Studies
Clinical Protein Discovery Centre Immunohaematology Signal Transduction Oncogenomics
Radiation Biology HIV Molecular Virology Molecular Immunology & Oncology Genetic Epidemiology
Bone Marrow Infl ammatory Bowel RBWH Foundation Disease Parasite Cell Biology Transplantation Conjoint Gastroenterology
Molecular Epidemiology Scabies Tumour Immunology Drug Discovery Group
Neurogenetics Tropical Parasitology Dendritic Cells & Cancer Hepatic Fibrosis
Gynaecological Cancer Group Clinical Tropical Medicine EBV Biology Membrane Transport
Molecular Cancer Epidemiology Molecular Parasitology Cancer Immunotherapy
Familial Cancer Mosquito Control Immunovirology
Qld Statistical Genetics Immunity & Vaccinology Molecular Genetics
Cancer Control Group Antigen Presentation Bacterial Pathogenesis & Immunoregulation
Skin Cancer Carcinogenesis
Epigenetics ANNUAL REPORT 2009-10
300 Herston Road, Herston QLD 4006, Australia P: (+61) 7 3362 0222 F: (+61) 7 3362 0111 www.qimr.edu.au [email protected]